<SEC-DOCUMENT>0001520138-19-000217.txt : 20190701
<SEC-HEADER>0001520138-19-000217.hdr.sgml : 20190701
<ACCEPTANCE-DATETIME>20190701130159
ACCESSION NUMBER:		0001520138-19-000217
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		59
FILED AS OF DATE:		20190701
DATE AS OF CHANGE:		20190701

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOVIE INC.
		CENTRAL INDEX KEY:			0001580149
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				462510769
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-231136
		FILM NUMBER:		19932360

	BUSINESS ADDRESS:	
		STREET 1:		2120 COLORADO AVE.
		STREET 2:		SUITE 230
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90404
		BUSINESS PHONE:		310-444-4300

	MAIL ADDRESS:	
		STREET 1:		2120 COLORADO AVE.
		STREET 2:		SUITE 230
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOANTIBIOTICS, INC.
		DATE OF NAME CHANGE:	20130625
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>bivi-20190628_s1a1.htm
<DESCRIPTION>FORM S-1 AMENDMENT NO. 1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>As filed with the U.S. Securities
and Exchange Commission on July 1, 2019</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Registration No. 333-231136</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 3pt solid; font: 3pt/107% Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 3pt/107% Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 3pt; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM S-1/A</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>Amendment No. 1</B> </P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REGISTRATION STATEMENT&nbsp;UNDER&nbsp;THE
SECURITIES ACT OF&nbsp;1933</B></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>BioVie
Inc.</B></FONT><BR>
<FONT STYLE="font-size: 9pt">(Exact Name of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>46-2510769</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">(State
    or other jurisdiction of</FONT><FONT STYLE="font-size: 9pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">incorporation or organization)</FONT></FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">(Primary
    Standard Industrial</FONT><FONT STYLE="font-size: 9pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Classification Code Number)</FONT></FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">(I.R.S.
    Employer</FONT><FONT STYLE="font-size: 9pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Identification No.)</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>2120 Colorado Avenue, #230, </B> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>Santa Monica, California 90404</B> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(310) 444-4300</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&rsquo;s Principal Executive Offices)</P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>Terren S. Peizer</B> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>Chief Executive Officer</B> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>c/o BioVie Inc.</B> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>2120 Colorado Avenue, #230</B> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>Santa Monica, California 90404</B> </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: center"><B>(310) 444-4300</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)</P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Copies to:</B></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><BR>
        Mitchell Nussbaum, Esq.</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Norwood P. Beveridge, Jr., Esq.</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Lili Taheri, Esq.</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Loeb &amp; Loeb LLP</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>345 Park Avenue</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>New York, NY 10154</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Phone: (212) 407-4000</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Fax: (212) 407-4990</B></P></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 49%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><BR>
        Alan Annex, Esq.</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Jason Simon, Esq.</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Greenberg Traurig LLP</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>200 Park Avenue</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>New York, NY 10166</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Phone: (212) 801-9200</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Fax: (212) 801-6400</B></P></TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Approximate date of commencement of
proposed sale to public:<BR>
As soon as practicable after the effective date hereof.</B></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415
under the Securities Act of 1933, check the following box.&nbsp;</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for
the same offering.&nbsp;</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 9pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Large&nbsp;accelerated&nbsp;filer&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%; width: 164px"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Accelerated&nbsp;filer&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Non-accelerated&nbsp;filer&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Smaller&nbsp;reporting&nbsp;company
    </FONT></TD>
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt">&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Emerging
    growth company </FONT></TD>
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"> <FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt">&#9744;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Title of each class of</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>securities to be registered</B></P></TD>
    <TD STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed maximum aggregate offering&nbsp;</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>price(1)</B></FONT></TD>
    <TD STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount of registration fee(2)</B></FONT></TD>
    <TD STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 60%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Class A common stock, par value $0.0001 per share</FONT></TD>
    <TD STYLE="width: 1%; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 17%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,250,000</FONT> </TD>
    <TD STYLE="width: 1%; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 17%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,090.70</FONT> </TD>
    <TD STYLE="width: 1%; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 95%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes shares of our Class A common stock that the underwriters have the option to purchase to cover over-allotments, if any.&nbsp;Pursuant to Rule 416 under the Securities Act of 1933, as amended (or the Securities Act), the securities being registered hereunder include such indeterminate number of additional shares of common stock as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="width: 95%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calculated
    pursuant to Rule&nbsp;457(o) based on an estimate of the proposed maximum aggregate offering price. Previously paid. </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The registrant hereby amends this
registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file&nbsp;a
further amendment which specifically states that this registration statement shall thereafter become effective in accordance with
Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such
date as the Commission, acting pursuant to Section&nbsp;8(a), may determine.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font: 10pt/107% Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 3pt solid; font: 3pt/107% Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><B>The information contained
in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement
filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #B10021"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 34%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>PRELIMINARY PROSPECTUS</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 32%; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>SUBJECT TO COMPLETION</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 32%; text-align: right; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>DATED
    JULY 1, 2019</B></FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 14pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 14pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>$15,000,000 Shares</B> </P>

<P STYLE="font: 14pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Class A Common Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; color: red">&nbsp;<IMG SRC="image_001.jpg" ALT="CzAwX4YXEAAAOf2 (1)" STYLE="height: 50px; width: 145px"></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 18pt"><B>BioVie
Inc.</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 1pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">This is a firm commitment public offering of shares of Class
A common stock (&ldquo;common stock&rdquo;) of BioVie&nbsp;Inc. Prior to this offering, there has been a limited public market
for our common stock on the OTCQB Marketplace under the ticker BIVI. We are selling&nbsp;up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
of common stock. There are no selling shareholders in this offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> On June 26, 2019, the last
reported sale price for our common stock as reported on the OTCQB Marketplace was $11.88 per share, after giving effect to
our planned 1:125  reverse stock split. The final public offering price will be determined through negotiation between us
and the lead underwriters in the offering and the recent market price used throughout this prospectus may not be indicative
of the final offering price. We have applied to list our common stock on The NASDAQ Capital Market under the symbol
&ldquo;BIVI,&rdquo; which listing is a condition to this offering. No assurance can be given that our application will be
approved.&nbsp;This offering will only occur if NASDAQ approves the listing of our common stock on NASDAQ. If NASDAQ does not
approve the listing of our common stock, we will not proceed with this offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Investing in our common stock is highly speculative and
involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page&nbsp;5.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per Share</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 78%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial public offering price</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discounts and commissions (1)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to us, before expenses</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    discounts and commissions do not include a non-accountable expense allowance equal to 1.0% of the public offering price
    payable to the underwriters. We refer you to the &ldquo;Underwriting&rdquo; section of this prospectus beginning on page 53
    for additional information regarding the underwriters&rsquo; compensation.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have granted a 45-day option to the
representative of the underwriters to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional
shares of common stock solely to cover over-allotments, if any.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The underwriters expect to deliver the
shares to purchasers on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2019.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ThinkEquity</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>a division of Fordham Financial Management,
Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2019&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-bottom: Black 1.5pt solid"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE>
</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_011.jpg" ALT=""></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_012.jpg" ALT=""></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>BIV201 (continuous infusion terlipressin)
is an investigational therapy</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>
<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-bottom: Black 1.5pt solid"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE>
</DIV>
    <!-- Field: /Page -->
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I><IMG SRC="image_013.jpg" ALT=""></I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;<IMG SRC="image_014.jpg" ALT=""></I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-bottom: Black 1.5pt solid"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="toc"></A>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 90%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page </B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">Prospectus Summary</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right; line-height: 107%">1</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">Risk Factors</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">5</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">Cautionary Note Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">21</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">Use of Proceeds</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">22</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Dividend Policy</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right; line-height: 107%">22</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">Capitalization</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">23</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Dilution</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">24</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">25</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Business</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">30</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Management</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">37</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Executive Compensation</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">44</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">Principal Stockholders</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">46</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">Certain Relationships and Related Party Transactions</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">48</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">Description of Capital Stock</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">50</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_015">Underwriting</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">53</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_016">Experts</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">61</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_017">Legal Matters</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">61</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_018">Where You Can Find More Information</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">61</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_019">Index to Financial Statements</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">You should rely only on the information
contained in this prospectus. We have not authorized any other person to provide you with information different from or in addition
to that contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on
it. We are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. You should
assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus.
Our business, financial condition, results of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In this prospectus, we rely on and refer
to information and statistics regarding our industry. We obtained this statistical, market and other industry data and forecasts
from publicly available information. While we believe that the statistical data, market data and other industry data and forecasts
are reliable, we have not independently verified the data.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this prospectus, unless the
context indicates or otherwise requires, &ldquo;the Company,&rdquo; &ldquo;our Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo;
and &ldquo;our&rdquo; refer to BioVie Inc., a Nevada corporation, and its consolidated subsidiaries.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-bottom: Black 1.5pt solid"><TR><TD STYLE="text-align: center; width: 100%"><FONT STYLE="font-size: 10pt">i</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_001"></A>Prospectus
Summary</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This summary highlights certain information
appearing elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information that you should
consider before investing in shares of our common stock and it is qualified in its entirety by, and should be read in conjunction
with, the more detailed information appearing elsewhere in this prospectus. Before you decide to invest in our common stock, you
should read the entire prospectus carefully, including &ldquo;Risk Factors&rdquo; beginning on page 5  and the financial
statements and related notes included in this prospectus.</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> <I>A 1:125 reverse stock split of
our common stock will be effected prior to the closing of this offering. All share amounts in this prospectus have been retroactively
adjusted to give effect to this reverse stock split (subject to rounding up fractional shares), except for the financial statements
and notes thereto.</I> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This prospectus includes trademarks,
service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this prospectus
are the property of their respective owners.</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Company</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">We are a clinical-stage company
pursuing the discovery, development, and commercialization of innovative drug therapies. We are currently focused on developing
and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment of ascites due to chronic liver
cirrhosis. Our therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver
cirrhosis (part of the same disease pathway as ascites), but not yet available in the United States. BIV201&rsquo;s active agent
is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for
BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In April 2017, we entered into
a Cooperative Research and Development Agreement (&ldquo;CRADA&rdquo;) with the McGuire Research Institute Inc. in Richmond, VA,
and began administering BIV201 to patients in September 2017. In April 2019, we announced top-line results for our Phase 2a clinical
trial of BIV201 (continuous infusion terlipressin) in six patients with refractory ascites due to advanced liver cirrhosis. The
following results were observed: </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 5pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuous
                                         infusion of terlipressin via portable infusion pump was maintained for 28 days in three
                                         patients with refractory ascites, and all patients remained hemodynamically stable during
                                         treatment.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 5pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         steady state plasma concentration data characterized terlipressin pharmacokinetics (PK)
                                         within the predicted PK model concentrations.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four
                                         of the six patients treated with BIV201 experienced an increase in the number of days
                                         between paracenteses ranging from 71% to 414% compared to prior to initiating therapy.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> On June 18, 2019, we met
with representatives of the U.S. Food &amp;Drug Administration (&ldquo;FDA&rdquo;) for a Type C Guidance Meeting to plan our next
clinical study following the recently completed Phase 2a clinical trial. We discussed our clinical development efforts with the
FDA and proposed trial endpoints. While the FDA has not provided final guidance nor do we have certainty as to what that guidance
would entail, our goal remains to proceed into a Phase 2b/3 or Phase 3 clinical trial in a manner consistent with what was reviewed
with the FDA. We may still need to address certain risks associated with unvalidated quality of life measures. The FDA is expected
to provide its final meeting minutes, which we expect will include guidance on several issues discussed at the meeting, within
30 days of the meeting. </P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">BIV201 (continuous infusion terlipressin)
has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis
due to hepatitis, NASH, and alcoholism. We have patented a method of treating a patient diagnosed with ascites due to liver cirrhosis
by administering BIV201 (terlipressin) as a continuous infusion within specified doses over a specified duration. The FDA has granted
Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant
unmet medical need. Patients with cirrhosis and ascites account for an estimated 116,000 U.S. hospital discharges annually, with
frequent early readmissions. Those requiring paracentesis (removal of ascites fluid) experience an average hospital stay lasting
8 days incurring over $86,000 in medical costs (<I>HCUP Nationwide Readmissions Database 2016</I>). This translates into a total
addressable ascites market size for BIV201 therapy exceeding $500 million based on Company estimates. The FDA has never approved
any drug specifically for treating ascites. BIV201 received Orphan Drug designation for hepatorenal syndrome (&ldquo;HRS&rdquo;)
in November 2018.</P>



</div>
<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The BIV201 development program
began at LAT Pharma LLC. On April 11, 2016, we acquired LAT Pharma LLC and the rights to its BIV201 development program and currently
own all development and marketing rights to BIV201. We and PharmaIN, Corp. (&ldquo;PharmaIN&rdquo;), LAT Pharma&rsquo;s former
partner focused on the development of new modified product candidates in the same therapeutic field but not including BIV201, had
agreed to pay royalties equal to less than 1% of future net sales of each company&rsquo;s ascites drug development programs, or if such
program is licensed to a third party, less than 5% of each company&rsquo;s net license revenues. On December 24, 2018, we returned our
partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance
due on a related debt. PharmaIN&rsquo;s rights to our program remain unchanged. We have an issued U.S. Patent covering the use
of BIV201 for the treatment of patients diagnosed with ascites due to liver cirrhosis in the outpatient setting using ambulatory
pump infusion, and have corresponding patent applications pending in Japan, Europe, China and Hong Kong.</P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Associated with our Business</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our business and ability to execute
our business strategy are subject to a number of risks of which you should be aware before you decide to buy our common stock.
In particular, you should consider the following risks, which are discussed more fully in the section entitled &ldquo;Risk Factors&rdquo;
in this prospectus:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are a development stage company with a limited operating history, making it difficult for you to evaluate our business and your investment;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mallinckrodt Pharmaceuticals Ireland Limited (&ldquo;Mallinckrodt&rdquo;), a large pharmaceutical corporation, has filed an Inter Partes Review (&ldquo;IPR&rdquo;) in the USPTO regarding our U.S. patent No. 9,655,945;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we have no products approved for commercial sale, have never generated any revenues and may never achieve revenues or profitability, which could cause us to cease operations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we will need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we have limited experience in drug development and may not be able to successfully develop any drugs, which would cause us to cease operations;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we have no manufacturing experience, and the failure to comply with all applicable manufacturing regulations and requirements could have a materially adverse effect on our business; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we fail to maintain an effective system of internal controls, we may not be able to accurately report&nbsp;&nbsp;financial results or detect fraud;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be unable to obtain or protect intellectual property rights relating to our products, and we may be liable for infringing upon the intellectual property rights of others, which could have a materially adverse effect on our business;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the biotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with enterprises equipped with more substantial resources than us, which could cause us to curtail or cease operations;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there can be no assurance that our common stock will continue to be listed on Nasdaq or, if listed, that there will be liquidity in the trading market for our common stock;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain stockholders who are also officers and directors may have significant control over our management; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are subject to the periodic reporting requirements of the Exchange Act, which require us to incur audit fees and legal fees in connection with the preparation of such reports. These additional costs will negatively affect our ability to earn a profit<B>.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Our principal executive office is
located at 2120 Colorado Avenue, #230, Santa Monica, California 90404, and our phone number (310) 444-4300. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

</div>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>The
Offering&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock offered by us</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 59%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock to be outstanding after this offering</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their over-allotment option in full).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over-allotment option</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have granted the underwriters a 45-day option to purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock at the initial public offering price to cover over-allotments, if any.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of proceeds</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We intend to use the net proceeds of this offering primarily to fund clinical trials of our lead product candidate BIV201 and for working capital and other general corporate purposes.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration of ownership</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon completion of this offering, our executive officers and directors will beneficially own, in the aggregate, approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding shares of our common stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed NASDAQ Capital Market symbol</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;BIVI&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our common stock involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page&nbsp;5 and the other information in this prospectus for a discussion of the factors you should consider carefully before you decide to invest in our common stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lock-Up</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We, each of our officers, directors, and all of our 5% or greater stockholders have agreed, subject to certain exceptions, not to sell, offer, agree to sell, contract to sell, hypothecate, pledge, grant any option to purchase, make any short sale of, or otherwise dispose of or hedge, directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of capital stock, for a period of (i) six (6) months after the date of this prospectus in the case of our directors and officers and (ii) three (3) months after the date of this prospectus in the case of the Company and any other 5% or greater holder of our outstanding securities, without the prior written consent of the representative. See &ldquo;Underwriting&rdquo; for additional information.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> All information in this prospectus assumes the underwriters do not exercise their over-allotment option. The total number of shares of our common stock outstanding as of June 27, 2019 was 4,058,441 and excludes 182,666 shares of common stock reserved for issuance pursuant to currently outstanding options and warrants. </P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
</div>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Summary
Financial Information</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> The following tables present our
summary consolidated financial and other data as of and for the periods indicated. The summary consolidated statements of operations
data for the fiscal years ended June 30, 2018 and June 30, 2017, and the summary consolidated balance sheet data as of June 30,
2018, are derived from our audited financial statements included elsewhere in this prospectus. The consolidated statement of operations
data for the nine months ended March 31, 2019 and 2018 and the summary consolidated balance sheet data as of March 31, 2019, are
derived from our unaudited consolidated financial statements included elsewhere in this prospectus and have been prepared on the
same basis as the audited consolidated financial statements. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The summarized financial information
presented below is derived from and should be read in conjunction with our audited consolidated financial statements including
the notes to those financial statements, and our unaudited consolidated financial statements including the notes to those financial
statements, both of which are included elsewhere in this prospectus along with the section entitled &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations.&rdquo; Our historical results are not necessarily indicative of
our future results.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> For the fiscal year <BR>
    ended June 30: </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> For the nine months<BR>
    ended March 31: </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2018 </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2017 </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2019 </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2018 </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"> CONSOLIDATED STATEMENTS OF OPERATIONS DATA: </TD><TD STYLE="font-size: 11pt"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt"> &nbsp; </TD><TD STYLE="font-size: 11pt"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt"> &nbsp; </TD><TD STYLE="font-size: 11pt"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt"> &nbsp; </TD><TD STYLE="font-size: 11pt"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Revenue </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> $ </TD>
    <TD STYLE="text-align: right"> &mdash;&nbsp;&nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> $ </TD>
    <TD STYLE="text-align: right"> &mdash;&nbsp;&nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> $ </TD>
    <TD STYLE="text-align: right"> &mdash;&nbsp;&nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> $ </TD>
    <TD STYLE="text-align: right"> &mdash;&nbsp;&nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; text-indent: -10pt; padding-left: 10pt"> Operating expenses </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> 2,372,166 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> 1,553,614 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> 1,840,586 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> 1,848,253 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"> Loss from operations </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (2,372,166 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (1,553,614 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (1,840,586 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (1,848,253 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"> Total other expense (income),
    net </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 40,956 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (222,942 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (52,164 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 9,827 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4.5pt; text-indent: -10pt; padding-left: 10pt"> Net loss </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> (2,413,122 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> (1,330,672 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> (1,788,422 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> (1,858,080 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 11pt; text-indent: -10pt; padding-left: 10pt"> &nbsp; </TD><TD STYLE="font-size: 11pt"> &nbsp; </TD>
    <TD STYLE="font-size: 11pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 11pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 11pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 11pt"> &nbsp; </TD>
    <TD STYLE="font-size: 11pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 11pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 11pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 11pt"> &nbsp; </TD>
    <TD STYLE="font-size: 11pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 11pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 11pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 11pt"> &nbsp; </TD>
    <TD STYLE="font-size: 11pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 11pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 11pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"> Deemed dividend </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (20,995 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &mdash;&nbsp;&nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (48,659 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &mdash;&nbsp;&nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4.5pt; text-indent: -10pt; padding-left: 10pt"> Net loss attributable to Company
    stockholders </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> (2,434,117 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> (1,330,672 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> (1,837,081 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> (1,858,080 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4.5pt; text-indent: -10pt; padding-left: 10pt"> Net loss per common share,
    basic and diluted </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> (3.18 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> (1.86 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> (0.73 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> (2.44 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4.5pt; text-indent: -10pt; padding-left: 10pt"> Weighted average shares outstanding, basic and
    diluted </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> 766,065 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> 715,130 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> 2,508,641 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right"> 760,114 </TD><TD STYLE="padding-bottom: 4.5pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>







<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of March&nbsp;31, 2019</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">CONSOLIDATED BALANCE SHEET DATA:</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma As Adjusted</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Cash</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">971,614</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right"> 971,614 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,006,614</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 1,006,614 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,964,272</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 2,964,272 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">179,054</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 179,054 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">179,054</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 179,054 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,785,218</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 2,785,758 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
</TABLE>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> The preceding table presents a summary
of our unaudited balance sheet data as of March 31, 2019: </P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 5%; text-align: justify; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="vertical-align: top; width: 86%; text-align: justify; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an actual basis;&nbsp;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 5%; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="vertical-align: top; width: 86%; text-align: justify; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    a pro-forma basis to give effect to following transactions with our controlling stockholder Acuitas Group Holdings, LLC
    (&ldquo;Acuitas&rdquo;) (i) the exchange of outstanding in-the-money warrants to purchase an aggregate of 1,606,667 shares of
    common stock for 1,526,333 shares of common stock on June 24, 2019 and (ii) the issuance of an aggregate of 1,339,958 shares
    in connection with the offering upon the closing of this offering pursuant to a committed exercise by Acuitas of its purchase
    option granted in connection with its initial investment in the Company; and</font> </td></TR></TABLE>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 5%; text-align: justify; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="vertical-align: top; width: 86%; text-align: justify; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on pro-forma as adjusted basis to give effect to the pro-forma adjustment above, as well as the receipt of the estimated net proceeds from the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares of common stock in this offering at&nbsp;the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, after
    deducting the underwriting discounts and commissions and estimated expenses payable by us.&nbsp;</FONT> </TD></TR>
</TABLE>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

</div>
<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_002"></A>Risk
Factors</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Any investment in our securities
involves a high degree of risk. You should carefully consider the risks described below, which we believe represent certain of
the material risks to our business, together with the information contained elsewhere in this prospectus, before you make a decision
to invest in our shares of common stock. Please note that the risks highlighted here are not the only ones that we may face. For
example, additional risks presently unknown to us or that we currently consider immaterial or unlikely to occur could also impair
our operations. If any of the following events occur or any additional risks presently unknown to us actually occur, our business,
financial condition and operating results may be materially adversely affected. In that event, the trading price of our securities
could decline and you could lose all or part of your investment.</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Risks Relating to Our Business and Industry</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have no products approved for commercial sale, have
never generated any revenues and may never achieve revenues or profitability, which could cause us to cease operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have no products approved for commercial sale and, to
date, we have not generated any revenues. Our ability to generate revenue depends heavily on (a) successful development program
and thereafter demonstration in human clinical trials that BIV201, our product candidate, is safe and effective; (b) our ability
to seek and obtain regulatory approvals, including, without limitation, with respect to the indications we are seeking; (c) successful
commercialization of our product candidates; and (d) market acceptance of our products. There are no assurances that we will achieve
any of the forgoing objectives. Furthermore, our product candidate is in the development stage, and we have not evaluated it in
full human clinical trials. If we do not successfully develop and commercialize our product candidate we will not achieve revenues
or profitability in the foreseeable future, if at all. If we are unable to generate revenues or achieve profitability, we may be
unable to continue our operations.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are a development stage company with a limited operating
history, making it difficult for you to evaluate our business and your investment.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioVie Inc. was incorporated on April 10, 2013. We are a
development stage biopharmaceutical company with a potential therapy that has not been fully evaluated in clinical trials, and
our operations are subject to all of the risks inherent in the establishment of a new business enterprise, including but not limited
to the absence of an operating history, the lack of commercialized products, insufficient capital, expected substantial and continual
losses for the foreseeable future, limited experience in dealing with regulatory issues, the lack of manufacturing experience and
limited marketing experience, possible reliance on third parties for the development and commercialization of our proposed products,
a competitive environment characterized by numerous, well-established and well capitalized competitors and reliance on key personnel.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Since inception, we have not established any revenues or
operations that shall provide financial stability in the long term, and there can be no assurance that we will realize our plans
on our projected timetable in order to reach sustainable or profitable operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Investors are subject to all the risks incident to the creation
and development of a new business and each Investor should be prepared to withstand a complete loss of his, her or its investment.
Furthermore, the accompanying financial statements have been prepared assuming that we will continue as a going concern. We have
not emerged from the development stage, and may be unable to raise further equity. These factors raise substantial doubt about
its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the
outcome of this uncertainty.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Because we are subject to these risks, you may have a difficult
time evaluating our business and your investment in our Company. Our ability to become profitable depends primarily on our ability
to develop drugs, to obtain approval for such drugs, and if approved, to successfully commercialize our drugs, our research and
development (&ldquo;R&amp;D&rdquo;) efforts, including the timing and cost of clinical trials; and our ability to enter into favorable
alliances with third-parties who can provide substantial capabilities in clinical development, regulatory affairs, sales, marketing
and distribution.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Even if we successfully develop and market BIV201, we may
not generate sufficient or sustainable revenue to achieve or sustain profitability, which could cause us to cease operations and
cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our U.S. patent claims covering BIV201 have been challenged
by a large pharmaceutical corporation with significantly greater resources than us. There can be no assurance regarding our ability
to maintain patent protection for any potential products until such matters have been resolved before the Patent Trials and Appeals
Board.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 30, 2018, we received notice that Mallinckrodt had
petitioned the U.S. Patent and Trademark Office (&ldquo;USPTO&rdquo;) to institute an Inter Partes Review of our U.S. Patent No.
9,655,945 titled &ldquo;Treatment of Ascites&rdquo; (the &ldquo;&rsquo;945 patent&rdquo;). Inter Partes Review is a trial proceeding
conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such
review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 15, 2018, we submitted a Preliminary Response to
the PTAB providing a rationale as to why, in our opinion, Mallinckrodt&rsquo;s request to institute the IPR should not be granted.
On November 14, 2018, the PTAB granted institution of the IPR challenge after determining that there was a reasonable likelihood
of success in proving that at least one of our 14 claims was unpatentable. On March 7, 2019, we submitted a Patent Owner&rsquo;s
Response and a Patent Owner&rsquo;s Contingent Motion to Amend our patent claims, and Declaration of Dr. Jaime Bosch, MD, PhD,
our medical expert. We are actively defending the &rsquo;945 patent and we are exploring the possibility of settlement with Mallinckrodt.
However, there can be no assurance that a favorable outcome will result, or if settlement is reached that the PTAB will accept
it. Although the PTAB encourages settlement, in view of public-interest considerations, the PTAB may continue the proceeding to
a final written decision even if the parties settle. If the IPR is not terminated due to settlement, the PTAB is statutorily required
to issue its final written decision in this case before November 14, 2019 (within one year from the date of institution).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We cannot guarantee investors that we will be successful
in defending Mallinckrodt&rsquo;s challenge against our patent. An unfavorable decision could reduce the scope of, or cancel, our
patent rights, and allow third parties to commercialize our technology or products and compete directly with us, without payment
to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it
could dissuade companies from collaborating with us to exploit our intellectual property or develop or commercialize current or
future product candidates. Our ability to establish or maintain a technological or competitive advantage over our competitors and/or
market entrants may be diminished because of these uncertainties. For these and other reasons, our intellectual property may not
provide us with any competitive advantage.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, you should note that as
of March 31, 2019, no adjustments or accruals have been reflected in our financial statements related to this matter.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If the FDA or comparable foreign regulatory authorities
approve generic versions of any of our products that receive marketing approval, or such authorities do not grant our products
appropriate periods of exclusivity before approving generic versions of our products, the sales of our products could be adversely
affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Once a new drug application (&ldquo;NDA&rdquo;) is approved,
the product covered thereby becomes a &ldquo;reference listed drug&rdquo; in the FDA&rsquo;s publication, &ldquo;Approved Drug
Products with Therapeutic Equivalence Evaluations,&rdquo; commonly known as the Orange Book. Manufacturers may seek approval of
generic versions of reference listed drugs through submission of abbreviated new drug applications (&ldquo;ANDAs&rdquo;) in the
United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials. Rather, the applicant generally
must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of
use or labeling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning
it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring
to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower
prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference
listed drug is typically lost to the generic product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA may not approve an ANDA for a generic product until any
applicable period of non-patent exclusivity for the reference listed drug has expired. The United States Federal Food, Drug, and
Cosmetic Act (&ldquo;FDCA&rdquo;) provides a period of five years of non-patent exclusivity for a new drug containing a new chemical
entity (&ldquo;NCE&rdquo;). Specifically, in cases where such exclusivity has been granted, an ANDA may not be submitted to the
FDA until the expiration of five years unless the submission is accompanied by a Paragraph&nbsp;IV certification that a patent
covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant
may submit its application four years following approval of the reference listed drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we believe that BIV201 contains active
ingredients that would be treated as NCEs by the FDA and, therefore, if approved, should be afforded five years of data exclusivity,
the FDA may disagree with that conclusion and may approve generic products after a period that is less than five years. If the
FDA were to award NCE exclusivity to someone other than us, we believe that we would still be awarded three year &ldquo;Other&rdquo;
exclusivity protection from generic competition, which is awarded when an application or supplement contains reports of new clinical
investigations (not bioavailability studies) conducted or sponsored by an applicant and essential for approval. Manufacturers
may seek to launch these generic products following the expiration of the applicable marketing exclusivity period, even if we
still have patent protection for our product. If we do not maintain patent protection and data exclusivity for our product candidates,
our business may be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Competition that our products may face
from generic versions of our products could materially and adversely impact our future revenue, profitability and cash flows and
substantially limit our ability to obtain a return on the investments we have made in those product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-align: justify"><B><I>If we fail to obtain or maintain
Orphan Drug exclusivity for BIV201, we will have to rely on our data and marketing exclusivity, if any, and on our intellectual
property rights, which may reduce the length of time that we can prevent competitors from selling generic versions of BIV201.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify">We have obtained
Orphan Drug designation for BIV201 in the U.S. for the treatment of hepatorenal syndrome (received November 21, 2018) and treatment
of ascites due to all etiologies except cancer (received September 8, 2016). Under the Orphan Drug Act, the FDA may designate a
product as an Orphan Drug if it is a drug intended to treat a rare disease or condition, defined, in part, as a patient population
of fewer than 200,000 in the U.S. In the EU, Orphan Drug designation may be granted to drugs intended to treat, diagnose or prevent
a life-threatening or chronically debilitating disease having a prevalence of no more than five in 10,000 people in the EU. The
company that first obtains FDA approval for a designated Orphan Drug for the associated rare disease receives marketing exclusivity
for use of that drug for the stated condition for a period of seven years. Orphan Drug exclusive marketing rights may be lost under
several circumstances, including a later determination by the FDA that the request for designation was materially defective or
if the manufacturer is unable to assure sufficient quantity of the drug. Similar regulations are available in the EU with a ten-year
period of market exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify">Even though
BioVie has obtained Orphan Drug designation for its lead product candidate, and intends to seek other Orphan Drug designations
for BIV201, and Orphan Drug designation for other product candidates, there is no assurance that BioVie will be the first to obtain
marketing approval for any particular rare indication. Further, even though BioVie has obtained Orphan Drug designation for its
lead product candidate, or even if BioVie obtains Orphan Drug designation for other potential product candidates, such designation
may not effectively protect BioVie from competition because different drugs can be approved for the same condition and the same
drug can be approved for different conditions and potentially used off-label in the Orphan indication. Even after an Orphan Drug
is approved, the FDA can subsequently approve the same drug for the same condition for several reasons, including, if the FDA concludes
that the later drug is safer or more effective or makes a major contribution to patient care. Orphan Drug designation neither shortens
the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval
process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-indent: 0.25in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition,
other companies have received Orphan Drug designations for terlipressin. Mallinckrodt Hospital Products IP Limited received Orphan
Drug designation in 2004 for terlipressin for the treatment of Hepatorenal Syndrome and Ferring Pharmaceuticals Inc. received Orphan
Drug designation in 1986 for terlipressin for the treatment of bleeding esophageal varices. If Mallinckrodt Hospital Products IP
Limited receives FDA approval for terlipressin for the treatment of Hepatorenal Syndrome before we do, they may obtain a competitive
advantage associated with being the first to market. Further, in connection with obtaining marketing approval for terlipressin
for the treatment of Hepatorenal Syndrome, Mallinckrodt Hospital Products IP Limited would also obtain Orphan Drug exclusivity
for terlipressin, that could prevent our approval for the same indication for seven years, although we could continue to pursue
other indications for the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify">If Ferring Pharmaceuticals
Inc. receives FDA approval for terlipressin for the treatment of bleeding esophageal varices, they would also obtain a competitive
advantage associated with being the first to market. In connection with obtaining marketing approval for terlipressin for the treatment
of bleeding esophageal varices, Ferring Pharmaceuticals Inc. would also obtain Orphan Drug exclusivity for terlipressin, but we
do not believe that Orphan Drug exclusivity for Ferring Pharmaceuticals Inc.&rsquo;s terlipressin product would have an adverse
effect on our ability to market BIV201, as the same drug would be approved for different indications under FDA rules, and we can
maintain Orphan Drug exclusivity for BIV201 for the different indication.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will need to raise substantial additional capital
in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could
have a materially adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Developing biopharmaceutical products,
including conducting pre-clinical studies and clinical trials and establishing manufacturing capabilities, requires substantial
funding. As of March 31, 2019, we had cash and cash equivalents totaling $1.0 million. Additional financing will
be required to fund the research and development of our product candidates. We have not generated any product revenues, and do
not expect to generate any revenues until, and only if, we develop, and receive approval to sell our product candidates from the
FDA and other regulatory authorities for our product candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We may not have the resources to complete the development
and commercialization of any of our proposed product candidates. We will require additional financing to further the clinical development
of our product candidates. In the event that we cannot obtain the required financing, we will be unable to complete the development
necessary to file an NDA with the FDA for BIV201. This will delay research and development programs, preclinical studies and clinical
trials, material characterization studies, regulatory processes, the establishment of our own laboratory or a search for third
party marketing partners to market our products for us, which could have a materially adverse effect on our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The amount of capital we may need will depend on many factors,
including the progress, timing and scope of our research and development programs, the progress, timing and scope of our preclinical
studies and clinical trials, the time and cost necessary to obtain regulatory approvals, the time and cost necessary to establish
our own marketing capabilities or to seek marketing partners, the time and cost necessary to respond to technological and market
developments, changes made or new developments in our existing collaborative, licensing and other commercial relationships, and
new collaborative, licensing and other commercial relationships that we may establish.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Until we can generate a sufficient amount of product revenue,
if ever, we expect to finance future cash needs, through public or private equity offerings, debt financings, or corporate collaboration
and licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable to us, or at all.
If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research
or development programs or our commercialization efforts. In addition, we could be forced to discontinue product development and
reduce or forego attractive business opportunities. To the extent that we raise additional funds by issuing equity securities,
our stockholders may experience additional significant dilution, and debt financing, if available, may involve restrictive covenants.
To the extent that we raise additional funds through collaboration and licensing arrangements, it may be necessary to relinquish
some rights to our technologies or our product candidates, or grant licenses on terms that may not be favorable to us. We may seek
to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for
additional capital at that time.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our fixed expenses, such as rent and other contractual commitments,
will likely increase in the future, as we may enter into leases for new facilities and capital equipment and/or enter into additional
licenses and collaborative agreements. Therefore, if we fail to raise substantial additional capital to fund these expenses, we
could be forced to cease operations, which could cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have limited experience in drug development and
may not be able to successfully develop any drugs, which would cause us to cease operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have never successfully developed a new drug and brought
it to market. Our management and clinical teams have experience in drug development but they may not be able to successfully develop
any drugs. Our ability to achieve revenues and profitability in our business will depend on, among other things, our ability to
develop products internally or to obtain rights to them from others on favorable terms; complete laboratory testing and human studies;
obtain and maintain necessary intellectual property rights to our products;&nbsp;successfully complete regulatory review to obtain
requisite governmental agency approvals;&nbsp;enter into arrangements with third parties to manufacture our products on our behalf;
and&nbsp;enter into arrangements with third parties to provide sales and marketing functions. If we are unable to achieve these
objectives we will be forced to cease operations and you will lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Development of pharmaceutical products is a time-consuming
process, subject to a number of factors, many of which are outside of our control. Consequently, if we are unsuccessful or fail
to timely develop new drugs, we could be forced to discontinue our operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Our lead product candidate, BIV201, has been cleared by the FDA to undergo testing in a mid-stage (Phase 2a) clinical trial. On June 18, 2019, we met with representatives of the FDA for Type C Guidance Meeting to plan our next clinical study following the recently completed Phase 2a clinical trial. We discussed our clinical development efforts with the FDA and proposed trial endpoints. While the FDA has not provided final guidance nor do we have certainty as to what that guidance would entail, our goal remains to proceed into a Phase 2b/3 or Phase 3 clinical trial in a manner consistent with what was reviewed with the FDA. We may still need to address certain risks associated with unvalidated quality of life measures and the FDA expressed concern about the inadequacy of the topline results of our Phase 2a clinical trial and their views that an additional Phase 2 clinical trial would be advisable. The FDA is expected to provide its final meeting minutes, which we expect will include guidance on several issues discussed at the meeting, within 30 days of the meeting. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Further development and extensive
testing will be required to determine its technical feasibility and commercial viability. Our success will depend on our ability
to achieve scientific and technological advances and to translate such advances into reliable, commercially competitive drugs
on a timely basis. Drugs that we may develop are not likely to be commercially available, at a minimum, for a few years, if ever.
The proposed development schedules for our product candidates may be affected by a variety of factors, including technological
difficulties, proprietary technology of others, and changes in government regulation, many of which will not be within our control.
Any delay in the development, introduction or marketing of our product candidates could result either in such drugs being marketed
at a time when their cost and performance characteristics would not be competitive in the marketplace or in the shortening of
their commercial lives. In light of the long-term nature of our projects and other risk factors described elsewhere in this document,
we may not be able to successfully complete the development or marketing of any drugs which could cause us to cease operations.&nbsp; </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We may fail to successfully develop and commercialize our
product candidate(s) if it is found to be unsafe or ineffective in clinical trials; does not receive necessary approval from the
FDA or foreign regulatory agencies; fails to conform to a changing standard of care for the disease it seeks to treat; or is less
effective or more expensive than current or alternative treatment methods.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Drug development failure can occur at any stage of clinical
trials and as a result of many factors, there can be no assurance that we or our collaborators will reach our anticipated clinical
targets. Even if we or our collaborators complete our clinical trials, we do not know what the long-term effects of exposure to
our product candidates will be. Furthermore, our product candidates may be used in combination with other treatments and there
can be no assurance that such use will not lead to unique safety issues. Failure to complete clinical trials or to prove that our
product candidates are safe and effective would have a material adverse effect on our ability to generate revenue and could require
us to reduce the scope of or discontinue our operations, which could cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have no manufacturing experience, and the failure
to comply with all applicable manufacturing regulations and requirements could have a materially adverse effect on our business.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have never manufactured products in the highly regulated
environment of pharmaceutical manufacturing, and our team has limited experience in the manufacture of drug therapies. There are
numerous regulations and requirements that must be maintained to obtain licensure and permitting required prior to the commencement
of manufacturing, as well as additional requirements to continue manufacturing pharmaceutical products. We currently do not own
or lease facilities that could be used to manufacture any products that might be developed by us, and have contracted with an experienced
Contract Manufacturing Organization (&ldquo;CMO&rdquo;) to perform the manufacturing of our new product candidate BIV201. In addition,
we do not have the resources at this time to acquire or lease suitable facilities. If we or our CMO fail to comply with regulations,
to obtain the necessary licenses and knowhow or to obtain the requisite financing in order to comply with all applicable regulations
and to own or lease the required facilities in order to manufacture our products, we could be forced to cease operations, which
would cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the FDA and other regulatory authorities require
that product candidates and drug products be manufactured according to current good manufacturing practices (&ldquo;cGMP&rdquo;).
Any failure by our third-party manufacturers to comply with cGMP could lead to a shortage of BIV201. In addition, such failure
could be the basis for action by the FDA to withdraw approval, if granted to us, and for other regulatory action, including seizure,
injunction or other civil or criminal penalties.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BIV201 and any other product candidate that we develop may
compete with other products and product candidates for access to manufacturing facilities. There are a limited number of manufacturers
that operate under cGMP regulations and that are both capable of manufacturing for us and willing to do so. If we need to find
another source of drug substance or drug product for BIV201, we may not be able to identify, or reach agreement with, commercial-scale
manufacturers on commercially reasonably terms, or at all. If we are unable to do so, we will need to develop our own commercial-scale
manufacturing capabilities, which would: impact commercialization of BIV201 in the U.S. and other countries where it may be approved;
require a capital investment by us that could be quite costly; and increase our operating expenses.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If our existing third-party manufacturers, or the third parties
that we engage in the future to manufacture a product for commercial sale or for our clinical trials, should cease to continue
to do so for any reason, we likely would experience significant delays in obtaining sufficient quantities of product for us to
meet commercial demand or to advance our clinical trials while we identify and qualify replacement suppliers. If for any reason
we are unable to obtain adequate supplies of BIV201 or any other product candidate that we develop, or the drug substances used
to manufacture it, it will be more difficult for us to compete effectively, generate revenue, and further develop our products.
In addition, if we are unable to assure a sufficient quantity of the drug for patients with rare diseases or conditions, we may
lose any Orphan Drug exclusivity to which the product otherwise would be entitled.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We do not currently have the sales and marketing personnel
necessary to sell products, and the failure to hire and retain such staff could have a materially adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an early stage development company with limited resources.
Even if we had products available for sale, which we currently do not, we have not secured sales and marketing staff at this early
stage of operations to sell products. We cannot generate sales without sales or marketing staff and must rely on officers to provide
any sales or marketing services until such personnel are secured, if ever. If we fail to hire and retain the requisite expertise
in order to market and sell our products or fail to raise sufficient capital in order to afford to pay such sales or marketing
staff, then we could be forced to cease operations and you could lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Even if we were to successfully develop approvable
drugs, we will not be able to sell these drugs if we or our third-party manufacturers fail to comply with manufacturing regulations,
which could have a materially adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If we were to successfully develop approvable drugs, before
we can begin selling these drugs, we must obtain regulatory approval of our manufacturing facility and process or the manufacturing
facility and process of the third party or parties with whom we may outsource our manufacturing activities. In addition, the manufacture
of our products must comply with the FDA&rsquo;s current Good Manufacturing Practices regulations, commonly known as GMP regulations.
The GMP regulations govern quality control and documentation policies and procedures. Our manufacturing facilities, if any in the
future, and the manufacturing facilities of our third-party manufacturers will be continually subject to inspection by the FDA
and other state, local and foreign regulatory authorities, before and after product approval. We cannot guarantee that we, or any
potential third-party manufacturer of our products, will be able to comply with the GMP regulations or other applicable manufacturing
regulations. The failure to comply with all necessary regulations would have a materially adverse effect on our business and could
force us to cease operations and you could lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We must comply with significant and complex government
regulations, compliance with which may delay or prevent the commercialization of our product candidates, which could have a materially
adverse effect on our business.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The R&amp;D, manufacture and marketing of product candidates
are subject to regulation, primarily by the FDA in the United States and by comparable authorities in other countries. These national
agencies and other federal, state, local and foreign entities regulate, among other things, R&amp;D activities (including testing
in animals and in humans) and the testing, manufacturing, handling, labeling, storage, record keeping, approval, advertising and
promotion of the product that we are developing. Noncompliance with applicable requirements can result in various adverse consequences,
including approval delays or refusals to approve drug licenses or other applications, suspension or termination of clinical investigations,
revocation of approvals previously granted, fines, criminal prosecution, recalls or seizures of products, injunctions against shipping
drugs and total or partial suspension of production and/or refusal to allow a company to enter into governmental supply contracts.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The process of obtaining FDA approval has historically been
costly and time consuming. Current FDA requirements for a new human drug or biological product to be marketed in the United States
include: (a) the successful conclusion of pre-clinical laboratory and animal tests, if appropriate, to gain preliminary information
on the product&rsquo;s safety; (b) filing with the FDA of an IND application to conduct human clinical trials for drugs or biologics;
(c) the successful completion of adequate and well-controlled human clinical investigations to establish the safety and efficacy
of the product for its recommended use; and (d) filing by a company and acceptance and approval by the FDA of a NDA for a drug
product or a biological license application (BLA) for a biological product to allow commercial distribution of the drug or biologic.
A delay in one or more of the procedural steps outlined above could be harmful to us in terms of getting our product candidates
through clinical testing and to market, which could have a materially adverse effect on our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA reviews the results of the clinical trials and may
order the temporary or permanent discontinuation of clinical trials at any time if it believes the product candidate exposes clinical
subjects to an unacceptable health risk. Investigational drugs used in clinical studies must be produced in compliance with cGMP
rules pursuant to FDA regulations.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales outside the United States of products that we develop
will also be subject to regulatory requirements governing human clinical trials and marketing for drugs and biological products
and devices. The requirements vary widely from country to country, but typically the registration and approval process takes several
years and requires significant resources.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If we experience delays or discontinuations of our clinical
trials by the FDA or comparable authorities in other countries, or if we fail to obtain registration or other approvals of our
products or devices then we could be forced to cease our operations and you will lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B>&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Even if we are successful in developing BIV201, our product
candidate, we have limited experience in conducting or supervising clinical trials that must be performed to obtain data to submit
in concert with applications for approval by the FDA. The regulatory process to obtain approval for drugs for commercial sale involves
numerous steps. Drugs are subjected to clinical trials that allow development of case studies to examine safety, efficacy, and
other issues to ensure that sale of drugs meets the requirements set forth by various governmental agencies, including the FDA.
In the event that our protocols do not meet standards set forth by the FDA, or that our data is not sufficient to allow such trials
to validate our drugs in the face of such examination, we might not be able to meet the requirements that allow our drugs to be
approved for sale which could have a materially adverse effect on our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We can provide no assurance that our product candidate
will obtain regulatory approval or that the results of clinical studies will be favorable.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The business plan we have developed
for the next twenty-four months is to complete the Phase 2 clinical development program for our lead new product candidate BIV201,
commence a pivotal Phase 3 trial required for new drug approval, and to pursue other key milestones such as additional patent
issuances and U.S. Orphan Drug designations. Due to our financial constraints, we may not have the resources necessary to complete
our application. If the results of our Phase 2a clinical trial are satisfactory to the FDA, we anticipate proceeding
to a larger Phase 2b/3 or Phase 3 clinical trials in the US. There is no guarantee the FDA will approve a Phase 2b/3 or Phase
3 trial, and even if they do our financial constraints may prevent us from undertaking clinical trials. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Confidentiality agreements with employees and others
may not adequately prevent disclosure of trade secrets and other proprietary information and disclosure of our trade secrets or
proprietary information could compromise any competitive advantage that we have, which could have a materially adverse effect on
our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success depends, in part, on our ability to protect our
proprietary rights to the technologies used in our products. We depend heavily upon confidentiality agreements with our officers,
employees, consultants and subcontractors to maintain the proprietary nature of our technology. These measures may not afford us
complete or even sufficient protection, and may not afford an adequate remedy in the event of an unauthorized disclosure of confidential
information. If we fail to protect and/or maintain our intellectual property, third parties may be able to compete more effectively
against us, we may lose our technological or competitive advantage, and/or we may incur substantial litigation costs in our attempts
to recover or restrict use of our intellectual property. In addition, others may independently develop technology similar to ours,
otherwise avoiding the confidentiality agreements, or produce patents that would materially and adversely affect our business,
prospects, financial condition and results of operations, in which event you could lose all of your investment.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be unable to obtain or protect intellectual
property rights relating to our products, and we may be liable for infringing upon the intellectual property rights of others,
which could have a materially adverse effect on our business.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ability to compete effectively will depend on our ability
to maintain the proprietary nature of our technologies. In 2017 the USPTO issued the &rsquo;945 patent directed to a method of
treating a patient diagnosed with ascites due to liver cirrhosis by administering BIV201 (continuous infusion terlipressin) as
a continuous infusion within specified doses over a specified duration. We cannot assure investors that we will continue to innovate
and file new patent applications, or that if filed any future patent applications will result in granted patents with respect to
the technology owned by us or licensed to us. Further, we cannot predict how long it will take for such patents to issue, if at
all. The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex
legal and factual considerations and, therefore, validity and enforceability cannot be predicted with certainty. Patents may be
challenged, deemed unenforceable, invalidated or circumvented. We will be able to protect our proprietary rights from unauthorized
use by third parties only to the extent that our proprietary technologies, product candidates and any future products are covered
by valid and enforceable patents or are effectively maintained as trade secrets.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Any patents we have obtained or do obtain may be challenged
by re-examination or otherwise invalidated or eventually found unenforceable. Both the patent application process and the process
of managing patent disputes can be time consuming and expensive. If we were to initiate legal proceedings against a third party
to enforce a patent related to one of our products or services, the defendant in such litigation could counterclaim that our patent
is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability
are commonplace, as are validity challenges by the defendant against the subject patent or other patents before the USPTO. Grounds
for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty,
obviousness or non-enablement, failure to meet the written description requirement, indefiniteness, and/or failure to claim patent
eligible subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution
of the patent intentionally withheld material information from the USPTO, or made a misleading statement, during prosecution. Additional
grounds for an unenforceability assertion include an allegation of misuse or anticompetitive use of patent rights, and an allegation
of incorrect inventorship with deceptive intent. Third parties may also raise similar claims before the USPTO even outside the
context of litigation. The outcome is unpredictable following legal assertions of invalidity and unenforceability. With respect
to the validity question, for example, we cannot be certain that no invalidating prior art existed of which we and the patent examiner
were unaware during prosecution. These assertions may also be based on information known to us or the Patent Office. If a defendant
or third party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps
all, of the claims of the challenged patent. Such a loss of patent protection would or could have a material adverse impact on
our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The standards that the United States Patent and Trademark
Office (and foreign countries) use to grant patents are not always applied predictably or uniformly and can change. There is also
no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology
patents. Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will
be allowed in any patents issued to us or to others.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, we rely on a combination of trade secrets, know-how,
technology and nondisclosure, and other contractual agreements and technical measures to protect our rights in the technology.
If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed
by a competitor, our business and financial condition could be materially adversely affected. The laws of some foreign countries
do not protect our proprietary rights to the same extent as the laws of the U.S., and we may encounter significant problems in
protecting our proprietary rights in these countries.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not believe that BIV201, the product candidate we are
currently developing, infringes upon the rights of any third parties nor are they infringed upon by third parties. However, there
can be no assurance that our technology will not be found in the future to infringe upon the rights of others or be infringed upon
by others. Moreover, patent applications are in some cases maintained in secrecy until patents are issued. The publication of discoveries
in the scientific or patent literature frequently occurs substantially later than the date on which the underlying discoveries
were made and patent applications were filed. Because patents can take many years to issue, there may be currently pending applications
of which we are unaware that may later result in issued patents that our products or product candidates infringe. For example,
pending applications may exist that provide support or can be amended to provide support for a claim that results in an issued
patent that our product infringes. In such a case, others may assert infringement claims against us, and should we be found to
infringe upon their patents, or otherwise impermissibly utilize their intellectual property, we might be forced to pay damages,
potentially including treble damages, if we are found to have willfully infringed on such parties&rsquo; patent rights. In addition to
any damages we might have to pay, we may be required to obtain licenses from the holders of this intellectual property. We may
fail to obtain any of these licenses or intellectual property rights on commercially reasonable terms. Even if we are able to obtain
a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event,
we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do
so, we may be unable to develop or commercialize the affected products, which could materially harm our business and the third
parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our
sales, an obligation on our part to pay royalties and/or other forms of compensation. Conversely, we may not always be able to
successfully pursue our claims against others that infringe upon our technology. Thus, the proprietary nature of our technology
or technology licensed by us may not provide adequate protection against competitors.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The pharmaceutical industry is characterized by extensive
litigation regarding patents and other intellectual property rights. Moreover, the cost to us of any litigation or other proceeding
relating to our patents and other intellectual property rights, even if resolved in our favor, could be substantial, and the litigation
would divert our management&rsquo;s efforts. We may not have sufficient resources to bring any such action to a successful conclusion.
Uncertainties resulting from the initiation and continuation of any litigation could limit our ability to continue our operations
and you could lose all of your investment.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We depend upon our management and their loss or unavailability
could put us at a competitive disadvantage which could have a material adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently depend upon the efforts and abilities of our
executive management team of Terren Peizer, our Chief Executive Officer, Jonathan Adams, our President and Chief Operating Officer,
and Wendy Kim, our Chief Financial Officer and Corporate Secretary. Mr. Adams serves the Company full-time and Ms. Kim serves the
Company part-time. The loss or unavailability of the services of either of these individuals for any significant period of time
could have a material adverse effect on our business, prospects, financial condition and results of operations which may cause
you to lose all of your investment. We have not obtained, do not own, nor are we the beneficiary of key-person life insurance.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may not be able to attract and retain highly skilled
personnel, which could have a materially adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ability to attract and retain highly skilled personnel
is critical to our operations and expansion. We face competition for these types of personnel from other pharmaceutical companies
and more established organizations, many of which have significantly larger operations and greater financial, technical, human
and other resources than us. We may not be successful in attracting and retaining qualified personnel on a timely basis, on competitive
terms, or at all. If we are not successful in attracting and retaining these personnel, our business, prospects, financial condition
and results of operations will be materially and adversely affected.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The biotechnology and biopharmaceutical industries
are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with enterprises
equipped with more substantial resources than us, which could cause us to curtail or cease operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The biotechnology and biopharmaceutical industries are characterized
by rapid technological developments and a high degree of competition based primarily on scientific and technological factors. These
factors include the availability of patent and other protection for technology and products, the ability to commercialize technological
developments and the ability to obtain government approval for testing, manufacturing and marketing.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We compete with biopharmaceutical firms in the United States,
Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations.
Many biopharmaceutical companies have focused their development efforts in the human therapeutics area. Many major pharmaceutical
companies have developed or acquired internal biotechnology capabilities or made commercial arrangements with other biopharmaceutical
companies. These companies, as well as academic institutions, government agencies and private research organizations, also compete
with us in recruiting and retaining highly qualified scientific personnel and consultants. Our ability to compete successfully
with other companies in the pharmaceutical field will also depend to a considerable degree on the continuing availability of capital
to us.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Although there are not currently any therapies approved by
the FDA specifically for the treatment of ascites due to liver cirrhosis, we still face significant competitive and market risk.
Other companies, such as Mallinckrodt Inc., are developing therapies for severe complications of advanced liver cirrhosis, which
may in the future be developed for the treatment of ascites, and these therapies could compete indirectly or directly with our
product candidate. There may be other competitive development programs of which we are unaware. Even if our product candidate is
ultimately approved by the FDA, there is no guarantee that once it is on the market doctors will adopt it in favor of current ascites
treatment procedures such as diuretics and paracentesis. These competitive and market risks could have a material adverse effect
on our business, prospects, financial condition and results of operations which may cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competition will be determined in part by the potential
indications for which drugs are developed and ultimately approved by regulatory authorities. Additionally, the timing of the market
introduction of some of our potential product candidate or of competitors&rsquo; products may be an important competitive factor. Accordingly,
the relative speed with which we can develop drugs, complete pre-clinical testing, clinical trials, approval processes and supply
commercial quantities to market are important competitive factors. We expect that competition among drugs approved for sale will
be based on various factors, including product efficacy, safety, reliability, availability, price and patent protection.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The successful development of biopharmaceuticals is highly
uncertain. A variety of factors including, pre-clinical study results or regulatory approvals, could cause us to abandon the development
of our product candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Successful development of biopharmaceuticals is highly
uncertain and is dependent on numerous factors, many of which are beyond our control. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Products that appear promising in the early phases of development
may fail to reach the market for several reasons. Pre-clinical study results may show the product to be less effective than desired
(e.g., the study failed to meet its primary objectives) or to have harmful or problematic side effects. Products may fail to receive
the necessary regulatory approvals or may be delayed in receiving such approvals. Among other things, such delays may be caused
by slow enrollment in clinical studies, length of time to achieve study endpoints, additional time requirements for data analysis
or a IND and later NDA, preparation, discussions with the FDA, an FDA request for additional pre-clinical or clinical data or unexpected
safety or manufacturing issues;&nbsp;manufacturing costs, pricing or reimbursement issues, or other factors that make the product
not economical. Proprietary rights of others and their competing products and technologies may also prevent the product from being
commercialized.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Success in pre-clinical and early clinical studies does not
ensure that large-scale clinical studies will be successful. Clinical results are frequently susceptible to varying interpretations
that may delay, limit or prevent regulatory approvals. The length of time necessary to complete clinical studies and to submit
an application for marketing approval for a final decision by a regulatory authority varies significantly from one product to the
next, and may be difficult to predict. There can be no assurance that any of our products will develop successfully, and the failure
to develop our products will have a materially adverse effect on our business and will cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>There may be conflicts of interest among our officers,
directors and stockholders. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain of our executive officers and directors and their
affiliates are engaged in other activities and have interests in other entities on their own behalf or on behalf of other persons.
Neither we nor any of our shareholders will have any rights in these ventures or their income or profits. In particular, our executive
officers or directors or their affiliates may have an economic interest in or other business relationship with partner companies
that invest in us or are engaged in competing drug development. Our executive officers or directors may have conflicting fiduciary
duties to us and third parties. The terms of transactions with third parties may not be subject to arm&rsquo;s length negotiations and
therefore may be on terms less favorable to us than those that could be procured through arm&rsquo;s length negotiations. Although we
have established an audit committee comprised solely of independent directors to oversee transactions between us and our insiders,
we do not have any formal policies in place to deal with such conflicting fiduciary duties should such a conflict arise.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<B><I>If we fail to maintain an effective system of
internal controls, we may not be able to accurately report our financial results or detect fraud. Consequently, investors could
lose confidence in our financial reporting and this may decrease the trading price of our common stock.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We must maintain effective internal controls to provide reliable
financial reports and detect fraud. We have concluded that our disclosure controls and procedures internal controls, as well as
internal controls over financial reporting, are ineffective. Failure to implement changes to our internal controls or any others
that we identify as necessary to establish an effective system of internal controls could harm our operating results and cause
investors to lose confidence in our reported financial information. Any such loss of confidence would have a negative effect on
the trading price of our common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may enter into employment agreements with our executive
officers and compensation payable thereunder may not be based on arms-length negotiations. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain of our current executive officers also serve as directors
of our Board of Directors, and we have not yet formed an independent compensation committee to determine compensation and to approve
employment agreements. Therefore, compensation which may be paid by us to our management under current arrangements may not have
been determined based on arms-length negotiations. We may grant stock options and other equity incentives to our executive officers
and directors that are consistent with the nature of the pharmaceutical industry. Although we intend to establish a compensation
committee in connection with this offering comprised of only independent directors, there can be no assurance made that the consideration
which may be payable to management will reflect the true market value of services provided to us.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>RISKS RELATING TO OUR COMMON STOCK</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>There is a risk of dilution of your percentage ownership
of common stock in the Company. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> We have the right to raise additional capital or incur borrowings from third parties to finance its business. We may also implement public or private mergers, business combinations, business acquisitions and similar transactions pursuant to which it would issue substantial additional capital stock to outside parties, causing substantial dilution in the ownership of the Company by our existing stockholders. Our Board of Directors has the authority, without the consent of any of the stockholders, to cause us to issue more shares of common stock and/or preferred stock at such price and on such terms and conditions as are determined by the Board of Directors in its sole discretion. As of June 27, 2019, there were warrants outstanding to purchase an aggregate of 124,666 shares of common stock at exercise prices ranging from $1.875 to $75.00 per share. The issuance of additional shares of capital stock by us will dilute your ownership percentage in the Company and could impair our ability to raise capital in the future through the sale of equity securities. </P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Certain stockholders who are also officers and directors
of the Company may have significant control over our management.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Our directors and executive officers currently own an aggregate 3,493,603 shares, which currently constitutes 82.3% of our issued and outstanding common stock. As a result, directors and executive officers may have a significant influence on our affairs and management, as well as on all matters requiring member approval, including electing and removing members of our Board of Directors, causing us to engage in transactions with affiliated entities, causing or restricting our sale or merger, and certain other matters. Our Chairman and Chief Executive Officer, Mr. Terren Peizer, may be deemed to beneficially own the shares held by Acuitas. Such concentration of ownership and control could have the effect of delaying, deferring or preventing a change in control of us even when such a change of control would be in the best interests of our stockholders. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>There is not now, and there may never be, an active,
liquid and orderly trading market for our common stock, which may make it difficult for you to sell your shares of our common stock</I>.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There is not now, nor has there been
since our inception, any significant volume of trading activity in our common stock or an active market for shares of our common
stock, and an active trading market for our shares may never develop or be sustained after this offering. As a result, investors
in our common stock must bear the economic risk of holding those shares for an indefinite period of time. Although our common
stock is quoted on the OTCQB Marketplace, or OTCQB, over-the-counter quotation system, trading of our common stock on such system
has only recently commenced and continues to be extremely limited and sporadic and at very low volumes. Although we have applied
to list our common stock on the NASDAQ Capital Market and expect that our common stock will be listed on the NASDAQ Capital
Market prior to the completion of this offering, an active trading market for our common stock may never develop or be sustained.
If an active market for our common stock does not develop, it may be difficult for you to sell the shares you purchase in this
offering without depressing the market price for the shares or at all. Further, an unestablished trading market for our common
stock may also impair our ability to raise capital by selling additional equity in the future, and may impair our ability to enter
into strategic partnerships or acquire companies or products by using shares of our common stock as consideration.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our common stock is subject to the &ldquo;penny stock&rdquo;
rules of the SEC and the trading market in our securities is limited, which makes transactions in our stock cumbersome and may
reduce the value of an investment in our stock.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Under U.S. federal securities legislation, our common stock
currently constitutes a &ldquo;penny stock&rdquo;. Penny stock is any equity security that has a market price of less than $5.00
per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require that a
broker or dealer approve a potential investor&rsquo;s account for transactions in penny stocks, and the broker or dealer receive
from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.
In order to approve an investor&rsquo;s account for transactions in penny stocks, the broker or dealer must obtain financial information
and investment experience objectives of the person, and make a reasonable determination that the transactions in penny stocks are
suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating
the risks of transactions in penny stocks. The broker or dealer must also deliver, prior to any transaction in a penny stock, a
disclosure schedule prepared by the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) relating to the penny stock market,
which, in highlight form sets forth the basis on which the broker or dealer made the suitability determination. Brokers may be
less willing to execute transactions in securities subject to the &ldquo;penny stock&rdquo; rules. This may make it more difficult
for investors to dispose of our common stock and cause a decline in the market value of our stock. Disclosure also has to be made
about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable
to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies
available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing
recent price information for the penny stock held in the account and information on the limited market in penny stocks.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may, in the future, issue additional common stock,
which would reduce investors&rsquo; percent of ownership and may dilute our share value.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> As of June 27, 2019, our Articles of Incorporation authorize the issuance of 800,000,000 shares of common stock. As of June 27, 2019, we had 4,058,441 shares of common stock outstanding. Accordingly, we may issue up to an additional 795,941,559 shares of common stock. The future issuance of common stock may result in substantial dilution in the percentage of our common stock held by our then existing shareholders. We may value any common stock in the future on an arbitrary basis. The issuance of Common Stock for future services or acquisitions or other corporate actions may have the effect of diluting the value of the shares held by our investors, might have an adverse effect on any trading market for our common stock and could impair our ability to raise capital in the future through the sale of equity securities. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have a large number of restricted shares outstanding,
a portion of which may be sold under Rule 144 which may reduce the market price of our shares.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Of the 4,058,441 shares of common stock issued and outstanding as of June 27, 2019, and assuming no warrants are exercised, 714,169 shares are held by non-affiliates and 3,344,272 are owned by affiliates of the Company, consisting of our officers and directors or entities controlled by them. The majority of our common stock, including all of the affiliates&rsquo; securities are deemed &ldquo;restricted securities&rdquo; within the meaning of Rule 144 as promulgated under the Securities Act. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">It is anticipated that all of the &ldquo;restricted securities&rdquo;
will be eligible for resale under Rule 144. In general, under Rule 144, subject to the satisfaction of certain other conditions,
a person, who is not an affiliate (and who has not been an affiliate for a period of at least three months immediately preceding
the sale) and who has beneficially owned restricted shares of our common stock for at least six months is permitted to sell such
shares without restriction, provided that there is sufficient public information about us as contemplated by Rule 144. An affiliate
who has beneficially owned restricted shares of our common stock for a period of at least one year may sell a number of shares
equal to one percent of our issued and outstanding common stock approximately every three months.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The respective holding periods for the shares issued to affiliates
and non-affiliates holding restricted securities commenced and were issued between May 17, 2013 and June 30, 2013. The possibility
that substantial amounts of our common stock may be sold under Rule 144 into the public market may adversely affect prevailing
market prices for the common stock and could impair our ability to raise capital in the future through the sale of equity securities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>In connection with our preparation of our annual financial
statements for the year ended June 30, 2018, we identified material weaknesses in our internal control over financial reporting.
Any failure to maintain effective internal control over financial reporting could harm us. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our management is responsible for establishing and maintaining
adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance
with U.S. generally accepted accounting principles (&ldquo;GAAP&rdquo;). During the preparation of our financial statements for
both 2017 and 2018, we identified material weaknesses in our internal control over financial reporting. Under standards established
by the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;), a deficiency in internal control over financial reporting
exists when the design or operation of a control does not allow management or personnel, in the normal course of performing their
assigned functions, to prevent or detect misstatements on a timely basis. The PCAOB defines a material weakness as a deficiency,
or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that
a material misstatement of annual or interim financial statements will not be prevented, or detected and corrected, on a timely
basis.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In our Annual Report on Form 10-K for the year ended June
30, 2018, we reported material weaknesses in our internal control over financial reporting. Our remediation efforts to date have
included hiring a Chief Financial Officer in October 2018 and the segregation of duties in certain controls, as well as the formalization
of certain controls and procedures. In addition, our Board of Directors has formed an audit committee consisting of three independent
directors, which has appointed a chairman of the audit committee with experience in the preparation of financial statements in
accordance with U.S. generally accepted accounting principles.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We and our independent registered public accounting firm
are not required to, and did not, perform an evaluation of our internal control over financial reporting as of December 31, 2018,
in accordance with the provisions of Section 404 of the Sarbanes-Oxley Act. Accordingly, we cannot assure you that we have identified
all, or that we will not in the future have additional, material weaknesses. Material weaknesses may still exist when we report
on the effectiveness of our internal control over financial reporting as required under Section 404 of the Sarbanes-Oxley Act after
the completion of this offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If we are unable to assert that our internal control over
financial reporting is effective, or when required in the future, if our independent registered public accounting firm is unable
to express an unqualified opinion as to the effectiveness of our internal control over financial reporting, investors may lose
confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be adversely affected
and we could become subject to litigation or investigations by the stock exchange on which our securities are listed, the SEC or
other regulatory authorities, which could require additional financial and management resources.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The lack of public company experience of our management
team could adversely impact our ability to comply with the reporting requirements of U.S. securities laws, which could have a materially
adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our officers have limited public company experience, which
could impair our ability to comply with legal and regulatory requirements such as those imposed by Sarbanes-Oxley Act of 2002.
Such responsibilities include complying with federal securities laws and making required disclosures on a timely basis. Any such
deficiencies, weaknesses or lack of compliance could have a materially adverse effect on our ability to comply with the reporting
requirements of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), which is necessary to maintain
our public company status. If we were to fail to fulfill those obligations, our ability to continue as a U.S. public company would
be in jeopardy in which event you could lose your entire investment in our Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are considered a smaller reporting company and is
exempt from certain disclosure requirements, which could make our stock less attractive to potential investors.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Rule 12b-2 of the Exchange Act defines a &ldquo;smaller reporting
company&rdquo; as an issuer that is not an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent
that is not a smaller reporting company and that:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Had a public float of less than $250 million as of the last business day of its most recently completed fiscal quarter, computed by multiplying the aggregate number of worldwide number of shares of its voting and non-voting common equity held by non-affiliates by the price at which the common equity was last sold, or the average of the bid and asked prices of common equity, in the principle market for the common equity; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the case of an initial registration statement under the Securities Act or the Exchange Act for shares of its common equity, had a public float of less than $250 million as of a date within 30 days of the date of the filing of the registration statement, computed by multiplying the aggregate worldwide number of such shares held by non-affiliates before the registration plus, in the case of a Securities Act registration statement, the number of such shares included in the registration statement by the estimated public offering price of the shares; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the case of an issuer who had annual revenue of less than
        $100 million during the most recently completed fiscal year for which audit financial statements are available, had a public float
        as calculated under paragraph (1) or (2) of this definition that was either zero or less than $700 million.</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As a &ldquo;smaller reporting
company&rdquo; we are not required and may not include a Compensation Discussion and Analysis (&ldquo;CD&amp;A&rdquo;)
section in our proxy statements; we provide only 3 years of business development information; provide fewer years of selected
data; and have other &ldquo;scaled&rdquo; disclosure requirements that are less comprehensive than issuers that are not
&ldquo;smaller reporting companies&rdquo; which could make our stock less attractive to potential investors, which could make
it more difficult for you to sell your shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have not held regular annual meetings of stockholders
in the past, and if we are required by the Nevada District Court to hold an annual meeting pursuant to Nevada Revised Statutes
&sect;78.345(1), it could result in the unanticipated expenditure of funds, time and other Company resources.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 1 of Article II of our bylaws provides that an annual
meeting of stockholders shall be held each year on a date and at a time designated by our Board of Directors. Section 78.345(1)
of the Nevada Revised Statutes provides that if there is a failure to hold the annual meeting for a period of 18 months after the
last election of directors, stockholders owning at least 15% of the voting power of the outstanding common stock may apply to the
Nevada district court to order the election of directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not held regular annual meetings of stockholders
in the past because a substantial majority of our stock is owned by a small number of stockholders, making it easy to obtain written
consent in lieu of a meeting when necessary. In light of our historical liquidity constraints, handling matters by written consent
has allowed us to save on financial and administrative resources required to prepare for and hold such annual meetings. Additionally,
we have applied to list our common stock on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) and expect that our common stock will
be listed on Nasdaq prior to the completion of this offering. Pursuant to Nasdaq&rsquo;s corporate governance requirements, we
will be obligated to hold regular annual meetings of stockholders in the future, and it is currently contemplated that the we will
hold such meetings beginning in 2020.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">To our knowledge, no stockholder or director has requested
our management to hold such an annual meeting and no stockholder or director has applied to the Nevada district court seeking an
order directing us to hold a meeting of stockholders. However, if one or more stockholders or directors were to apply to the Nevada
district court seeking such an order, and if the Nevada district court were to order an annual meeting before we were prepared
to hold one, the preparation for the annual meeting of stockholders and the meeting itself could result in the unanticipated expenditure
of funds, time, and other Company resources.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are subject to the periodic reporting requirements
of the Exchange Act, which require us to incur audit fees and legal fees in connection with the preparation of such reports. These
additional costs will negatively affect our ability to earn a profit.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are required to file periodic reports with the SEC pursuant
to the Exchange Act and the rules and regulations thereunder. In order to comply with such requirements, our independent registered
auditors have to review our financial statements on a quarterly basis and audit our financial statements on&nbsp;an annual basis.
Moreover, our legal counsel has to review and assist in the preparation of such reports. Factors such as the number and type of
transactions that we engage in and the complexity of our reports cannot accurately be determined at this time and may have a major
negative effect on the cost and amount of time to be spent by our auditors and attorneys. However, the incurrence of such costs
is an expense to our operations and thus has a negative effect on our ability to meet our overhead requirements and earn a profit.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Because we do not intend to pay any cash dividends
on our common stock, our stockholders will not be able to receive a return on their shares unless they sell them.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to retain any future earnings to finance the development
and expansion of our business. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. Unless
we pay dividends, our stockholders will not be able to receive a return on their shares unless they sell them. There is no assurance
that stockholders will be able to sell shares when desired.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_003"></A>Cautionary
Note Regarding Forward-Looking Statements&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This prospectus contains &ldquo;forward-looking
statements&rdquo; within the meaning of the federal securities laws, and that involve significant risks and uncertainties. We intend
the forward-looking statements to be covered by the safe harbor for forward-looking statements in these sections. Words such as
&ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;future,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo;
&ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar expressions, as well as statements in future tense, identify forward-looking
statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate
indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when
those statements are made or management&rsquo;s good faith belief as of that time with respect to future events, and are subject
to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed
in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited
to:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">- our limited operating
history and experience in developing and manufacturing drugs;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">- none of our products
are approved for commercial sale;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">- our substantial
capital needs;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">- product development
risks;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">- we do not have
sales and marketing personnel;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">- regulatory, competitive
and contractual risks;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">- risks related
to our intellectual property rights;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">- the absence of
liquidity in our common stock;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">- the risk of substantial
dilution from future issuances of our equity securities; and</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">- the other risks
set forth herein under the caption &ldquo;Risk Factors.&rdquo;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing does not represent an
exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced
with. Forward-looking statements necessarily involve risks and uncertainties, and our actual results could differ materially from
those anticipated in the forward-looking statements due to a number of factors, including those set forth above under &ldquo;Risk
Factors&rdquo; and elsewhere in this prospectus. The factors set forth above under &ldquo;Risk Factors&rdquo; and other cautionary
statements made in this prospectus should be read and understood as being applicable to all related forward-looking statements
wherever they appear in this prospectus. The forward-looking statements contained in this prospectus represent our judgment as
of the date of this prospectus. We caution readers not to place undue reliance on such statements. Except as required by law, we
undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available
or other events occur in the future. All subsequent written and oral forward-looking statements attributable to us or persons acting
on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_004"></A>Use
of Proceeds</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We estimate that the net proceeds from
the sale of the shares of common stock we are offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. If the underwriters
fully exercise the over-allotment option, the net proceeds of the shares we sell will be approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million.
&ldquo;Net proceeds&rdquo; is what we expect to receive after deducting the underwriting discount and commission and estimated
offering expenses payable by us.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to use the net proceeds of
this offering primarily to fund clinical trials of BIV201 and for working capital and other general corporate purposes. The amounts
that we actually spend for any specific purpose may vary significantly, and will depend on a number of factors including, but not
limited to, the pace of progress of our research and development, market conditions, and our ability to qualify vendors. In addition,
we may use a portion of any net proceeds to acquire complementary compounds; however, we do not have plans for any acquisitions
at this time. We will have significant discretion in the use of any net proceeds. Investors will be relying on the judgment of
our management regarding the application of the proceeds of any sale of our common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_005"></A><FONT STYLE="text-transform: uppercase"><B>Dividend
Policy</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have never declared or paid any cash
dividends on our common stock and we do not anticipate paying any cash dividends in the foreseeable future. The payment of dividends,
if any, in the future is within the discretion of our Board of Directors and will depend on our earnings, capital requirements
and financial condition and other relevant facts. We currently intend to retain all future earnings, if any, to finance the development
and growth of our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_006"></A>Capitalization</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth our
cash and capitalization as of March 31, 2019: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an actual basis; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a pro-forma basis to give effect to the following transactions with our controlling stockholder Acuitas: (i) the exchange of outstanding in-the-money warrants to purchase an aggregate of 1,606,667 shares of common stock for 1,526,333 shares of common stock on June 24, 2019 and (ii) the issuance of an aggregate of 1,339,958 in connection with the offering upon the closing of this offering; and;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    a pro forma as adjusted basis to give effect to the pro-forma adjustment above, as well as the sale of shares of our common
    stock in this offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
    share, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">You should read the information in this
table together with our financial statements and accompanying notes and &ldquo;Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations&rdquo; appearing elsewhere in this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">As of March 31, 2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma As Adjusted</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">Cash</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">971,614</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right"> 971,614 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 0.25in"> Common stock, $0.0001 par value per share, 800,000,000 shares authorized; 2,520,430, and 4,046,763 and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding actual, pro forma and pro forma as adjusted, respectively </TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">31,645</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 32,185 </TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 0.25in">Additional paid in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,359,780</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 9,359,780 </TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,606,207</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (6,606,207 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Total stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,785,218</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2,785,758 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_007"></A>Dilution</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> If you purchase shares of our common
stock in this offering, your interest will be diluted immediately to the extent of the difference between the assumed public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and the pro forma as adjusted net tangible book value per
share of our common stock immediately upon the consummation of this offering. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> The pro forma net tangible book
value of our common stock as of March 31, 2019 was $1.0 million, or $0.19 per share. Pro forma net tangible book value per
share of our common stock represents our total tangible assets (total assets less intangible assets) less total liabilities
divided by the number of shares of common stock outstanding as of that date, after giving pro-forma effect to the exchange of
outstanding in-the-money warrants to purchase an aggregate of 1,606,667 shares of common stock for 1,526,333 shares of common
stock on June 24, 2019 and the issuance of an aggregate of 1,339,958 in connection with the offering, which is expected upon
the closing of this offering. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Net tangible book value dilution
per share to new investors represents the difference between the amount per share paid by purchasers in this offering and the
pro forma as adjusted net tangible book value per share of common stock immediately after completion of this offering. After giving
effect to our sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and after deducting underwriters&rsquo; commissions
and estimated offering expenses, our pro forma as adjusted net tangible book value as of March 31, 2019 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million,
or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This represents an immediate increase in net tangible book value
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to existing stockholders and an immediate dilution in net tangible
book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to purchasers of shares in this offering, as illustrated
in the following table: </P>





<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 78%; padding-left: 10pt; text-align: justify; line-height: 107%; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed public offering price per share</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-align: justify; line-height: 107%; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    forma net tangible book value per share as of March 31, 2019</FONT> </TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.19</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-align: justify; line-height: 107%; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in net tangible book value per share attributable to new investors</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-align: justify; line-height: 107%; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Pro
    forma adjusted net tangible book value per share as of March 31, 2019, after giving effect to the offering</font></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-align: justify; line-height: 107%; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution per share to new investors in the offering</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If the underwriters exercise their option
in full to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock in this offering at the assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share of common stock, the pro forma net tangible book value per share after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the increase
in the pro forma net tangible book value per share to existing stockholders would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and the dilution to new investors
purchasing securities in this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> The pro forma number of shares of
common stock to be outstanding after this offering is based on 2,520,430 shares of common stock outstanding as of March 31, 2019
giving pro-forma effect to the exchange of outstanding in-the-money warrants to purchase an aggregate of 1,606,667 shares of common
stock for 1,526,333 shares of common stock on June 24, 2019 and the issuance of an aggregate of 1,339,958 in connection with the
offering, which is expected to occur upon the closing of this offering, which does not include: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 3%; line-height: 107%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 94%; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 58,000 shares of common stock issuable upon
    the exercise of outstanding stock options as of June 27, 2019, at a weighted average exercise price of $ 11.62 per share;
    and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 3%; line-height: 107%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 94%; line-height: 107%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">124,666
    shares of common stock issuable upon the exercise of outstanding warrants as of June 27, 2019, at a weighted average exercise
    price of $9.70 per share.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">To the extent that outstanding exercisable options or warrants
are exercised, you may experience further dilution. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, we may choose to raise additional capital due
to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating
plans. To the extent that we raise additional capital by issuing equity securities or convertible debt, your ownership will be
further diluted.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_008"></A>Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;<I>The following discussion of the Company&rsquo;s
financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto
appearing elsewhere in this prospectus.</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a clinical stage biotechnology
company engaged in the discovery, development and commercialization of therapies targeting life-threatening complications of liver
cirrhosis. Our initial disease target is ascites, a serious medical condition affecting about 100,000 Americans and many times
more worldwide. Our therapeutic product candidate BIV201 is based on a drug that is approved in about 40 countries to treat related
complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the US. The active agent
in BIV201, terlipressin, is a potent vasoconstrictor which is in use for various medical conditions around the world. The goal
is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioVie accomplished the following key
milestones during the twelve months ended April 30, 2019:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2018, we completed an equity investment with Acuitas and other investors that provided gross proceeds of $3.2 million to BioVie.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 96%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2018, the Company announced that BIV201 had been granted an Orphan Drug designation for hepatorenal syndrome.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%; width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2019, we completed patient enrollment in our mid-stage (Phase 2a) clinical trial of BIV201 for the treatment of refractory ascites.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%; width: 96%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    April 2019, we announced top-line results for the Phase 2a clinical trial of BIV201 in six patients.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> <B>Comparison of the nine months ended March 31, 2019
to the nine months ended March 31, 2018</B> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> Total operating expenses
for the nine months ended March 31, 2019 were $1,841,000 compared to $1,848,000 for the nine months ended March 31, 2018.&nbsp;&nbsp;The
net decrease of $7,000 was primarily due to a $465,000 reduction in selling, general and administrative expenses due to the issuance
of common stock in August 2017 and January 2018 as compensation for professionals, offset by the increase in research and development
expenses of $457,000 as the Company resumed its clinical trial program and hired 1 full time employee and 1 half time employee
in November 2018, who were previously consultants. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> <I>Research and Development Expenses</I> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> Research and development
expenses were $732,000 for the nine months ended March 31, 2019, an increase of $457,000, from $275,000 for the nine months ended
March 31, 2018. The increase was primarily attributed to continued analytical research and associated regulatory and clinical
trial program planning and the Phase 2a clinical trial activities which began in July 2018. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> <I>Selling, General and Administrative Expenses</I> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> Selling, general and administrative
expenses were $936,000 for the nine months ended March 31, 2019, a decline of $465,000, from $1,401,000 for the nine months ended
March 31, 2018. In August 2017 and January 2018, the Company paid for professional fees related to&nbsp;financial and strategic
advisory services with BioVie common stock. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Comparison of the Year Ended June
30, 2018 to the Year Ended June 30, 2017</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Total operating expenses for the fiscal
year ended June 30, 2018 were $2,372,166, compared to $1,553,614 for the fiscal year ended June 30, 2017.&nbsp;The net
increase of $818,552 was primarily due to the increase in professional fees of $827,773 attributed to strategic and financial advisory
services offset by fluctuations in research and development, payroll expenses and selling, general and administrative expenses
discussed below.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Research and Development</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses were
$370,853 for the fiscal year ended June 30, 2018, a decrease of $95,501, compared to $466,354 for the fiscal year ended June 30,
2017. The research and development expenses were primarily due to the expenses incurred for clinical development activities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Selling, General and Administrative</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Selling, general and administrative
expenses were $129,270 for the fiscal year ended June 30, 2018, an increase of $60,148, compared to $69,122 for the fiscal year
ended June 30, 2017. The increase in selling, general and administrative expenses was primarily due to travel and conference expenses&nbsp;associated
with financing activities.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Professional Fees</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Professional fees were $1,331,142 for
the fiscal year ended June 30, 2018, an increase of $827,773 compared to $503,369 for the fiscal year ended June 30, 2017. The
increase in professional fees related to&nbsp;a large expense for financial and strategic advisory services paid in common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Payroll Expenses</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Payroll expenses were $311,525 for the
fiscal year ended June 30, 2018, an increase of $26,133 compared to $285,392 for the fiscal year ended June 30, 2017. Payroll expenses
were related to accrued salary for the Chief Operating Officer, Jonathan Adams. The payroll expenses for fiscal year ended June
30, 2018 included a $30,547 adjustment made for fiscal year ended June 30, 2017. The adjustment was due to a correction made to
the valuation of Stock Options issued to the Chief Operating Officer.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Capital Resources and Liquidity</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Company completed a capital
raise of $3.2 million in July 2018 which enabled the Company to resume and further develop its products. As of March 31, 2019,
the Company had $1.0 million of cash to complete its Phase 2 clinical trials of the BIV201 therapy and initiate the next Phase
2b clinical trials. As further discussed below, the Company is pursuing various options to raise further financing to continue
the testing and development of its product. If the Company is not successful in raising additional funds it may reduce its monthly
spend and potentially delay the implementation of the larger scale Phase 2b clinical trial until sufficient funding is secured. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> As of March 31, 2019, the Company
had an accumulated deficit of $6.6 million and as a development stage enterprise, the Company expects substantial losses in future
periods. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/11.3pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"> In July 2018, we completed
a capital raise from Acuitas and other purchasers and received gross proceeds of $3.2 million and we have resumed clinical development
of BIV201. The Acuitas investment agreement also stipulated that if the clinical development of BIV201 continues, Acuitas may
invest an additional $3 million to fund operations in year two, unless we raise such amount in federal or FDA grant funding. On
June 24, 2019, in connection with this offering we entered into a letter agreement with Acuitas pursuant to which such option
was modified in exchange for certain waivers of rights contained in the investment agreement and obligating Acuitas to immediately
exchange its warrants for a fixed number of shares of common stock. </P>



<P STYLE="font: 10pt/11.3pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">We
cannot assure you that our product candidate will be developed, work, or receive regulatory approval; that we will ever earn revenues
sufficient to support our operations or that we will ever be profitable. Furthermore, since we have no committed source of financing,
we cannot assure you that we will be able to raise money as and when we need it to continue our operations. If we cannot raise
funds as and when we need them, we may be required to severely curtail, or even to cease, our operations.</P>

<P STYLE="font: 10pt/11.3pt Times New Roman, Times, Serif; margin: 0 0 11.8pt; text-align: justify">Management
intends to attempt to secure additional required funding primarily through additional equity or debt financings. We may also seek
to secure required funding through sales or out-licensing of intellectual property assets, seeking partnerships with other pharmaceutical
companies or third parties to co-develop and fund research and development efforts, or similar transactions. However, there can
be no assurance that we will be able to obtain required funding. If we are unsuccessful in securing funding from any of these
sources, we will defer, reduce or eliminate certain planned expenditures in our research protocols. If we do not have sufficient
funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our
stockholders losing some or all of their investment in us.</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These circumstances raise substantial
doubt on our ability to continue as a going concern. Our financial statements appearing elsewhere in this prospectus do not include
any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities
that might result from this uncertainty.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has no off-balance sheet
arrangements that have or are reasonably likely to have a current or future effect or change on the Company&rsquo;s financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.
The term &ldquo;off-balance sheet arrangement&rdquo; generally means any transaction, agreement or other contractual arrangement
to which an entity unconsolidated with the Company is a party, under which the Company has (i) any obligation arising under a guarantee
contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity
or similar arrangement that serves as credit, liquidity or market risk support for such assets.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Critical Accounting Policies and
Estimates</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Basis of Presentation</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements
in conformity with accounting principles generally accepted in the United States of America requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results
could differ from those estimates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Use of Estimates</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements
in conformity with accounting principles generally accepted in the United States of America requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results
could differ from those estimates.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Cash</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash is maintained at financial institutions
and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances.
All of the Company&rsquo;s cash balances were fully insured at March 31, 2019.&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Financial Instruments</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&rsquo;s financial instruments
include cash, accounts payable, related party loans and a demand promissory note. The carrying amounts of cash and accounts payable
approximate their fair value, due to the short-term nature of these items.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Long-Term Notes Payable</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&rsquo;s long-term notes
payable at June 30, 2018 include accrued payroll to officers and accrued payments to third party consultants.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Research and Development</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are charged
to operations when incurred and are included in operating expenses.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Income Taxes</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred income tax assets and liabilities
arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities,
as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and
liabilities are classified as current or non-current, depending on the classification of the assets or liabilities to which they
relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending
on the periods in which the temporary differences are expected to reverse.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of
FASB ASC 740-10 &ldquo;<I>Uncertainty in Income Taxes</I>&rdquo; (ASC 740-10), January 1, 2007. The Company has not recognized
a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized
tax benefits has not been provided since there are no unrecognized benefits at March 31, 2019 and since the date of adoption.
The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an
unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense
and penalties in operating expenses.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Earnings (Loss) per Share</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic earnings per share are computed
by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings
per common share are computed by dividing net income by the weighted average number of shares of common stock outstanding and
dilutive options outstanding during the year. For the years ended June 30, 2017 and 2018 and for the nine months ended March
31, 2019, all outstanding options have been excluded from the calculation of the diluted net loss per share since their effect
was anti-dilutive.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Stock-based Compensation</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has accounted for stock-based
compensation under the provisions of FASB ASC 718 &ndash; &ldquo;Stock Compensation&rdquo; which requires the use of the fair-value
based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity
instruments (stock options and common stock purchase warrants). For employee awards, the fair value of each stock option award
is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected
dividends, expected term, and the risk-free interest rate. For non-employees, the fair value of each stock option award is estimated
on the measurement date using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends,
expected term, and the risk-free interest rate. For non-employees, the Company utilizes the graded vesting attribution method under
which the entity treats each separately vesting portion (tranche) as a separate award and recognizes compensation cost for each
tranche over its separate vesting schedule. Expected volatilities are based on historical volatility of peer companies and other
factors estimated over the expected term of the stock options. For employee awards, the expected term of options granted is derived
using the &ldquo;simplified method&rdquo; which computes expected term as the average of the sum of the vesting term plus the contract
term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected
term.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Goodwill</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill is recorded when the purchase
price paid for an acquisition exceeds the fair value of net identified tangible and intangible assets acquired. The Company performs
an annual impairment test of goodwill and further periodic tests to the extent indicators of impairment develop between annual
impairment tests. The Company&rsquo;s impairment review process compares the fair value of the reporting unit to its carrying value,
including the goodwill related to the reporting unit. To determine the fair value of the reporting unit, the Company may use various
approaches including an asset or cost approach, market approach or income approach or any combination thereof. These approaches
may require the Company to make certain estimates and assumptions including future cash flows, revenue and expenses. These estimates
and assumptions are reviewed each time the Company tests goodwill for impairment and are typically developed as part of the Company&rsquo;s
routine business planning and forecasting process. While the Company believes its estimates and assumptions are reasonable, variations
from those estimates could produce materially different results.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Impairment of Long-Lived Assets</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets, including intangible
assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may
not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset
to estimated undiscounted future cash flows expected to be generated by the asset.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If the carrying amount of an asset exceeds
its undiscounted estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount
by which the carrying amount of the asset exceeds the fair value of the asset. Generally, fair value is determined using valuation
techniques such as expected discounted cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented
in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated
or amortized. The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate
asset and liability sections of the balance sheet.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>New Accounting Pronouncements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For a description of recent accounting
standards, including the expected dates of adoption and estimated effects, if any, on our financial statements, see &ldquo;Note
3: Significant Accounting Polices: Recent Accounting Standards&rdquo; in the financial statements appearing elsewhere in this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><BR STYLE="clear: both">
</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_009"></A>BUSINESS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">We are a clinical-stage company
pursuing the discovery, development, and commercialization of innovative drug therapies. We are currently focused on developing
and commercializing BIV201, a novel approach to the treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201 is
based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same disease
pathway as ascites), but not yet available in the United States and has never been approved in the United States. BIV201&rsquo;s
active agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The
goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites
patients.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> In April 2017, we entered into a CRADA with the McGuire Research Institute Inc. in Richmond, VA, and began administering BIV201 to patients in September 2017. In April 2019, we announced top-line results for our Phase 2a clinical trial of BIV201 (continuous infusion terlipressin) in six patients with refractory ascites due to advanced liver cirrhosis. On June 18, 2019, we met with representatives of the FDA for Type C Guidance Meeting to plan our next clinical study following the recently completed Phase 2a clinical trial. We discussed our clinical development efforts with the FDA and proposed trial endpoints. While the FDA has not provided final guidance nor do we have certainty as to what that guidance would entail, our goal remains to proceed into a Phase 2b/3 or Phase 3 clinical trial in a manner consistent with what was reviewed with the FDA. We may still need to address certain risks associated with unvalidated quality of life measures. The FDA is expected to provide its final meeting minutes, which we expect will include guidance on several issues discussed at the meeting, within 30 days of the meeting. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">BIV201 has the potential to improve
the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and
alcoholism. It is covered by an issued U.S. patent, has FDA Fast-Track status and we have obtained Orphan Drug designation for
it in the U.S. for the treatment of hepatorenal syndrome (received November 21, 2018) and treatment of ascites due to all etiologies
except cancer (received September 8, 2016). Orphan Drug designation for the most common of these complications, ascites, which
represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites. BIV201 also
has an Orphan Drug designation for HRS.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The BIV201 development program
began at LAT Pharma LLC. On April 11, 2016, we acquired LAT Pharma LLC and the rights to its BIV201 development program and currently
own all development and marketing rights to the product candidate. We and PharmaIN, LAT Pharma&rsquo;s former partner focused on
the development of new modified product candidates in the same therapeutic field but not including BIV201, have agreed to pay royalties
equal to less than 1% of future net sales of each company&rsquo;s ascites drug development programs, or if such program is licensed to
a third party, less than 5% of each company&rsquo;s net license revenues. On December 24, 2018, we returned our partial ownership rights
to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt.
PharmaIN&rsquo;s rights to our program remain unchanged. We have an issued U.S. patent covering the use of BIV201 for the treatment
of patients diagnosed with ascites due to liver cirrhosis in the outpatient setting using ambulatory pump infusion, and have corresponding
patent applications pending in the U.S., Japan, Europe, China and Hong Kong.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>About Ascites and Liver Cirrhosis</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">About 600,000 Americans and millions
worldwide suffer from liver cirrhosis. Cirrhosis is the 8th leading cause of death due to disease in the US, killing more than
30,000 people each year. The condition results primarily from hepatitis, alcoholism, and fatty liver disease linked to obesity.
Ascites is a common complication of advanced liver cirrhosis, involving kidney dysfunction and the accumulation of large amounts
of fluid in the abdominal cavity.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>The Need for an Ascites Therapy</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">With no medications approved by
the FDA specifically for treating ascites, an estimated 40% of patients die within two years of diagnosis. Certain drugs approved
for other uses such as diuretics may provide initial relief, but patients may fail to respond to treatment as ascites worsens.
This represents a critical unmet medical need. U.S. treatment costs for liver cirrhosis, including ascites and other complications,
are estimated at more than $4 billion annually.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>The Ascites Development Pathway</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 510px; width: 624px"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Most
experts agree that ascites develops through a sequence of events illustrated by the above diagram. High blood pressure in the vein
that supplies blood to the liver, called &ldquo;portal hypertension,&rdquo; occurs as increasing liver damage (fibrosis) impedes
blood flow through the liver.&nbsp;This causes vasodilation and blood pooling in the central or &ldquo;splanchnic&rdquo; region
of the body and low blood volume in the arteries. The decrease in effective blood volume activates a signaling pathway (&ldquo;neurohormonal
systems&rdquo;) which tells the kidneys to retain large amounts of salt and water in an effort to increase blood volume. Ultimately
the retention of excess sodium and water leads to the formation of ascites as these substances &ldquo;weep&rdquo; from the liver
and lymph system and collect in the patient&rsquo;s abdomen.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>The BIV201 Mechanism of Action</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">BIV201 is being developed by BioVie
with the goal of alleviating the portal hypertension and correcting splanchnic vasodilation, thereby increasing effective blood
volume and&nbsp;reducing the&nbsp;signals to the kidneys to retain excess salt and water. If successful, BIV201 could halt the
cycle of accelerating fluid generation in ascites patients and reduce the need for the frequent and painful paracentesis procedures
many of these patients currently require.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>Future Possible BIV201 Indications</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Based on investigative studies
around the world of the active agent in BIV201, terlipressin, our new product candidate may have potential future applications
in&nbsp;other life-threatening conditions due to liver cirrhosis, such as those listed below. Securing marketing approvals for
any of these new uses will require well-controlled clinical trials to satisfy the FDA and/or other countries&rsquo; regulatory
requirements, none of which have commenced at this time. We may be unable to, or chose not to, pursue the development BIV201 for
these indications.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; padding-bottom: 6pt; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&middot;</B></FONT></TD>
    <TD STYLE="padding-bottom: 6pt; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bleeding Esophageal Varices (BEV): The bursting of blood vessels lining the esophagus due to high blood pressure (&ldquo;portal hypertension&rdquo;) in the vein which supplies blood to the liver resulting as a result of advanced liver cirrhosis. This situation requires emergency treatment to avoid blood loss and death.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 6pt; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&middot;</B></FONT></TD>
    <TD STYLE="padding-bottom: 6pt; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hepatorenal syndrome (HRS): As their disease progresses, liver cirrhosis patients&rsquo; kidneys may begin to fail, and this deadly condition may set in. It often occurs once a patient no longer responds to (off-label) drugs used to control ascites. The second stage is called &ldquo;type 1 HRS&rdquo; and requires hospitalization as multiple organ failure and death may occur. We obtained Orphan Drug designation for BIV201 in the U.S. for the treatment of hepatorenal syndrome on November 21, 2018.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>Efflux Pump Antibiotics Program</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Prior to the Merger of Lat Pharma
LLC and NanoAntibiotics Inc. in April 2016, we were exclusively developing novel nanotechnology anti-infective drugs to combat
multi-drug resistant bacteria. We are at an early stage of discovery and development of broad spectrum antibiotics for gram-negative
and gram-positive bacterial infections. Developing this technology in-house is resource-intensive with respect to time, personnel
and capital necessary for scientific discovery. For further development of our nanoantibiotic technology we will need to find and
license additional nanotechnology to complete our planned products. Presently this program is inactive as we are focusing our efforts
on BIV201.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">BioVie relies on a combination
of patent, trade secret, other intellectual property laws (such as FDA data exclusivity), nondisclosure agreements, and other measures
to protect our proposed products. We require our employees, consultants, and advisors to execute confidentiality agreements and
to agree to disclose and assign to us all inventions conceived during the workday, using our property, or which relate to our business.
Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products
or to obtain and use information that we regard as proprietary. In May 2017 we announced the issuance of a U.S. patent 9,655,945
directed to a method of treating a patient diagnosed with ascites due to liver cirrhosis by administering BIV201 as a continuous
infusion within specified doses over a specified duration. As discussed above, this patent has been challenged by Mallinckrodt
in an IPR proceeding before the PTAB. In July 2017 we announced filing an application for similar patent coverage in Japan, and
subsequently filed for patent protection in Europe, China and Hong Kong. BioVie has secured Orphan Drug designations in the U.S.
for the treatment of hepatorenal syndrome (received November 21, 2018) and treatment of ascites due to all etiologies except cancer
(received September 8, 2016). We have applied for an additional Orphan Drug designation which could be granted in 2019.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>Government Regulation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Government authorities in the
United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research,
development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising,
distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are developing.
Any pharmaceutical candidate that we develop must be approved by the FDA before it may be legally marketed in the United States
and by the appropriate foreign regulatory agency before it may be legally marketed in foreign countries.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B><I>United States Drug Development
Process</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">In the United States, the FDA
regulates drugs under the Federal Food, Drug and Cosmetic Act, or FDCA, and implementing regulations. Drugs are also subject to
other federal, state and local statutes and regulations. Biologics are subject to regulation by the FDA under the FDCA, the Public
Health Service Act, or the PHSA, and related regulations, and other federal, state and local statutes and regulations. Biological
products include, among other things, viruses, therapeutic serums, vaccines and most protein products. The process of obtaining
regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations
require the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements
at any time during the product development process, approval process or after approval, may subject an applicant to administrative
or judicial sanctions. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, a clinical
hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions,
fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement
action could have a material adverse effect on us.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">The process required by the FDA
before a drug or biological product may be marketed in the United States generally involves the following:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Completion of preclinical laboratory tests, animal studies and formulation
studies according to Good Laboratory Practices or other applicable regulations;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Submission to the FDA of an Investigational New Drug Application,
or an IND, which must become effective before human clinical trials may begin;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Performance of adequate and well-controlled human clinical trials
according to the FDA&rsquo;s current good clinical practices, or GCPs, to establish the safety and efficacy of the proposed drug or biologic
for its intended use;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Submission to the FDA of a New Drug Application, or an NDA, for a
new drug product, or a Biologics License Application, or a BLA, for a new biological product;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Satisfactory completion of an FDA inspection of the manufacturing
facility or facilities where the drug or biologic is to be produced to assess compliance with the FDA&rsquo;s current good manufacturing
practice standards, or cGMP, to assure that the facilities, methods and controls are adequate to preserve the drug&rsquo;s or biologic&rsquo;s
identity, strength, quality and purity;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Potential FDA audit of the nonclinical and clinical trial sites that
generated the data in support of the NDA or BLA; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">FDA review and approval of the NDA or BLA.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">The lengthy process of seeking
required approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial
resources. There can be no certainty that approvals will be granted.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Clinical trials involve the administration
of the drug or biological candidate to healthy volunteers or patients having the disease being studied under the supervision of
qualified investigators, generally physicians not employed by or under the trial sponsor&rsquo;s control. Clinical trials are conducted
under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion
criteria, and the parameters to be used to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND.
Clinical trials must be conducted in accordance with the FDA&rsquo;s good clinical practices requirements. Further, each clinical trial
must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the
clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers
such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation
to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or
his or her legal representative and must monitor the clinical trial until it is completed.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Human clinical trials prior to
approval are typically conducted in three sequential Phases that may overlap or be combined:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt"><I>&bull;</I></TD><TD STYLE="text-align: justify"><I>Phase&nbsp;1.</I>&nbsp;&nbsp;The drug or biologic is initially introduced into healthy human
subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products
for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy
volunteers, the initial human testing is often conducted in patients having the specific disease.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt"><I>&bull;</I></TD><TD STYLE="text-align: justify"><I>Phase&nbsp;2.</I>&nbsp;&nbsp;The drug or biologic is evaluated in a limited patient population
to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted
diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt"><I>&bull;</I></TD><TD STYLE="text-align: justify"><I>Phase&nbsp;3.</I>&nbsp;&nbsp;Clinical trials are undertaken to further evaluate dosage, clinical
efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials,
which usually involve more subjects than earlier trials, are intended to establish the overall risk/benefit ratio of the product
and provide an adequate basis for product labeling. Generally, at least two adequate and well-controlled Phase&nbsp;3 clinical trials are required by the FDA
for approval of an NDA or BLA.</TD></TR></TABLE>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Post-approval studies, or Phase&nbsp;4
clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional experience from the
treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Progress reports detailing the
results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted
to the FDA by the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that
suggests a significant risk for human subjects. Phase&nbsp;1, Phase&nbsp;2 and Phase&nbsp;3 clinical trials may not be completed
successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical
trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable
health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is
not being conducted in accordance with the IRB&rsquo;s requirements or if the drug or biologic has been associated with unexpected serious
harm to patients.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Concurrent with clinical trials,
companies usually complete additional animal studies and develop additional information about the chemistry and physical characteristics
of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with
cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug or biological
candidate and, among other things, must include methods for testing the identity, strength, quality and purity of the final drug
or biologic. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate
that the drug or biological candidate does not undergo unacceptable deterioration over its shelf life.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B><I>U.S. Review and Approval
Processes</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">The results of product development,
preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the
chemistry of the drug or biologic, proposed labeling and other relevant information are submitted to the FDA as part of an NDA
or BLA requesting approval to market the product. The submission of an NDA or BLA is subject to the payment of substantial user
fees; a waiver of such fees may be obtained under certain limited circumstances.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">The FDA reviews all NDAs and BLAs
submitted before it accepts them for filing and may request additional information rather than accepting an NDA or BLA for filing.
Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA or BLA.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">After the NDA or BLA submission
is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective
for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&rsquo;s
identity, strength, quality and purity. The FDA reviews a BLA to determine, among other things, whether the product is safe, pure
and potent and the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&rsquo;s
continued safety, purity and potency. In addition to its own review, the FDA may refer applications for novel drug or biological
products or drug or biological products which present difficult questions of safety or efficacy to an advisory committee, typically
a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should
be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such
recommendations carefully when making decisions. During the approval process, the FDA also will determine whether a risk evaluation
and mitigation strategy, or REMS, is necessary to assure the safe use of the drug or biologic. If the FDA concludes that a REMS
is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if
required.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Before approving an NDA or BLA,
the FDA will inspect the facilities at which the product is to be manufactured. The FDA will not approve the product unless it
determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent
production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA will typically
inspect one or more clinical sites to assure compliance with cGMP. If the FDA determines the application, manufacturing process
or manufacturing facilities are not acceptable it will outline the deficiencies in the submission and often will request additional
testing or information.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">The NDA or BLA review and approval
process is lengthy and difficult and the FDA may refuse to approve an NDA or BLA if the applicable regulatory criteria are not
satisfied or may require additional clinical data or other data and information. Even if such data and information is submitted,
the FDA may ultimately decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials
are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.
The FDA will issue a &ldquo;complete response&rdquo; letter if the agency decides not to approve the NDA or BLA. The complete response
letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The deficiencies identified
may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally,
the complete response letter may include recommended actions that the applicant might take to place the application in a condition
for approval. If a complete response letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the
deficiencies identified in the letter, or withdraw the application.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">If a product receives regulatory
approval, the approval may be limited to specific diseases and dosages or the indications for use may otherwise be limited, which
could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions
be included in the product labeling. In addition, the FDA may require Phase&nbsp;4 testing which involves clinical trials designed
to further assess a product&rsquo;s safety and effectiveness and may require testing and surveillance programs to monitor the safety
of approved products that have been commercialized.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B><I>Orphan Drug Designation</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Under the Orphan Drug Act, the
FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally
a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the
United States and for which there is no reasonable expectation that the cost of developing and making a drug or biological product
available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan product
designation must be requested before submitting an NDA or BLA. After the FDA grants orphan product designation, the identity of
the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey
any advantage in or shorten the duration of the regulatory review and approval process.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">If a product that has Orphan designation
subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled
to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological
product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to
the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which
the Orphan product has exclusivity or obtain approval for the same product but for a different indication for which the Orphan
product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor
obtains approval of the same drug or biological product as defined by the FDA or if our drug or biological candidate is determined
to be contained within the competitor&rsquo;s product for the same indication or disease. If a drug or biological product designated
as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan
product exclusivity. Orphan Drug status in the European Union has similar but not identical benefits in the European Union.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B><I>Expedited Development and
Review Programs</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">The FDA has a Fast Track program
that is intended to expedite or facilitate the process for reviewing new drug and biological products that meet certain criteria.
Specifically, new drug and biological products are eligible for Fast Track designation if they are intended to treat a serious
or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation
applies to the combination of the product and the specific indication for which it is being studied. Unique to a Fast Track product,
the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if
(i) the sponsor provides a schedule for the submission of the sections of the NDA or BLA, (ii) the FDA agrees to accept sections
of the NDA or BLA and determines that the schedule is acceptable, and (iii) the sponsor pays any required user fees upon submission
of the first section of the NDA or BLA.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Any product submitted to the
FDA for marketing approval, including those submitted to a Fast Track program, may also be eligible for other types of FDA
programs intended to expedite development and review, such as priority review and accelerated approval. Any product is
eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative
therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared with marketed
products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or
biological product designated for priority review in an effort to facilitate the review. Additionally, a product may be
eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious
or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive
accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical studies
establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit,
or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of
approval, the FDA generally requires that a sponsor of a drug or biological product receiving accelerated approval perform
adequate and well-controlled post-marketing clinical studies to establish safety and efficacy for the approved
indication. Failure to conduct such studies or conducting such studies that do not establish the required safety and efficacy
may result in revocation of the original approval. In addition, the FDA currently requires as a condition for accelerated
approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch or
subsequent marketing of the product. Fast Track designation, priority review and accelerated approval do not change the
standards for approval but may expedite the development or approval process.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B><I>Post-Approval Requirements</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Any drug or biological products
for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping
requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information
on an annual basis or as required more frequently for specific events, product sampling and distribution requirements, complying
with certain electronic records and signature requirements and complying with FDA promotion and advertising requirements, which
include, among others, standards for direct-to-consumer advertising, prohibitions against promoting drugs and biologics for uses
or in patient populations that are not described in the drug&rsquo;s or biologic&rsquo;s approved labeling (known as &ldquo;off-label use&rdquo;),
rules for conducting industry-sponsored scientific and educational activities, and promotional activities involving the internet.
Failure to comply with FDA requirements can have negative consequences, including the immediate discontinuation of noncomplying
materials, adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors,
and civil or criminal penalties. Although physicians may prescribe legally available drugs and biologics for off-label uses, manufacturers
may not market or promote such off-label uses.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">We will need to rely on third
parties for the production of our product candidates. Manufacturers of our product candidates are required to comply with applicable
FDA manufacturing requirements contained in the FDA&rsquo;s cGMP regulations. cGMP regulations require among other things, quality control
and quality assurance as well as the corresponding maintenance of comprehensive records and documentation. Drug and biologic manufacturers
and other entities involved in the manufacture and distribution of approved drugs and biologics are also required to register their
establishments and list any products made there with the FDA and comply with related requirements in certain states, and are subject
to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly,
manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.
Discovery of problems with a product after approval may result in serious and extensive restrictions on a product, manufacturer,
or holder of an approved NDA or BLA, including suspension of a product until the FDA is assured that quality standards can be met,
continuing oversight of manufacturing by the FDA under a &ldquo;consent decree,&rdquo; which frequently includes the imposition of
costs and continuing inspections over a period of many years, and possible withdrawal of the product from the market. In addition,
changes to the manufacturing process generally require prior FDA approval before being implemented and other types of changes to
the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and
approval.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">The FDA also may require post-marketing
testing, known as Phase&nbsp;4 testing, risk minimization action plans and surveillance to monitor the effects of an approved product
or place conditions on an approval that could otherwise restrict the distribution or use of the product.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Our business is managed by
our officers. Our Chairman and Chief Executive Officer, Terren Peizer began devoting part-time efforts to the Company&rsquo;s
activities in July 2018. Our President and Chief Operating Officer, Jonathan Adams, began devoting full-time efforts to the
Company on July 1, 2017. Our Chief Financial Officer and Corporate Secretary, Wendy Kim, devotes part-time efforts to the
Company&rsquo;s activities. Our Chief Scientific Officer began devoting full-time efforts and our Chief Medical Officer began
devoting part-time efforts to the Company in November 2018 and previously were each consultants to the Company. We also rely
on a team of highly experienced scientific, medical, and regulatory consultants to conduct its product development
activities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_010"></A>Management</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Directors and Officers</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth certain
information regarding our Board of Directors, our executive officers, and some of our key employees, as of the date of this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 6.5in; border-collapse: collapse">
<TR>
    <TD STYLE="text-align: left; border-bottom: black 1pt solid; line-height: 107%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%"><B>Name</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left; border-bottom: black 1pt solid; line-height: 107%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%"><B>Age</B></FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; line-height: 107%; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%"><B>Director
    Since</B></FONT> </TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: black 1pt solid; line-height: 107%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%"><B>Position</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 26%; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Terren Peizer</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 7%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">59</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 9%; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;2018</FONT> </TD>
    <TD STYLE="vertical-align: top; width: 4%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 46%; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Chairman &amp; Chief Executive Officer</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Jonathan Adams</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">56</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;2016</FONT> </TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">President &amp; Chief Operating Officer</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Joanne Wendy Kim</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">64</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;--</FONT> </TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Chief Financial Officer and Corporate Secretary</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Patrick Yeramian, MD</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">60</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;--</FONT> </TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Chief Medical Officer</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Penelope Markham, PhD</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">53</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;--</FONT> </TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Chief Scientific Officer</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Jim Lang</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">54</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;2016</FONT> </TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Independent Director</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Cuong Do</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">52</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;2016</FONT> </TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Independent Director</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Hari Kumar</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">63</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;2017</FONT> </TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Independent Director</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Michael Sherman</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">59</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;2017</FONT> </TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Independent Director</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Richard
    J. Berman</FONT> </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">76</FONT> </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;2019</FONT> </TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Independent Director</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">According to our Bylaws, the directors
shall be elected at the annual meeting of the stockholders and each director shall be elected to serve until his successor shall
be elected and shall qualify. A director need not be a stockholder. Directors shall not receive any stated salary for their services
as directors or as members of committees, but by resolution of the Board of Directors a fixed fee and expenses of attendance may
be allowed for attendance at each meeting. The Bylaws shall not be construed to preclude any director from serving the Company
in any other capacity as an officer, agent or otherwise, and receiving compensation therefor.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no familial relationships
among any of our directors or officers. Mr. Terren Peizer, Chairman of the Board of Directors and Chief Executive Officer, is also
the founder of Catasys, Inc. a U.S. reporting company listed on Nasdaq on whose board Mr. Sherman also serves. Additionally, Jim
Lang currently serves as a director at OptimizeRX, a U.S. reporting company that is listed on the Nasdaq stock exchange. None of
our other directors or officers is or has been a Director or has held any form of directorship in any other U.S. reporting companies.
None of our directors or officers has been affiliated with any Company that has filed for bankruptcy within the last five years.
We are not aware of any proceedings to which any of our officers or directors, or any associate of any such officer or director,
is a party that are adverse to the Company. We are also not aware of any material interest of any of our officers or directors
that is adverse to our own interests.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Information</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Mr. Terren Peizer, Chairman of the
Board of Directors and Chief Executive Officer, is an entrepreneur, investor, and financier with a particular interest in healthcare,
having founded and successfully commercialized several healthcare companies. Mr. Peizer is the founder of Catasys, Inc., a leader
in behavioral and mental health management services, having served as the Chairman of the Board of Directors and CEO of Catasys
since inception in 2004. Mr. Peizer also is the Founder, Chairman and CEO and majority shareholder of NeurMedix, Inc., a biotechnology
Company with a focus on inflammatory, neurological and neuro-degenerative diseases. Mr. Peizer is Chairman of Acuitas Group Holdings,
LLC, his personal holding company that owns his portfolio Company interests. Through Acuitas, he owns Crede Capital Group, LLC,
an industry leader in investing in micro and small capitalization public equities, having invested over $1.2 billion directly
into portfolio companies. Previously he was Chairman of Cray, Inc., the leading supercomputing Company, and held senior executive
positions at various publicly-traded growth companies and with the investment banking firms Goldman Sachs, First Boston, and Drexel
Burnham Lambert. He received his B.S.E. in finance from The Wharton School of Finance and Commerce. </P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Jonathan Adams has served as the
Company&rsquo;s Chief Executive Officer and Chief Financial Officer from the time acquired LAT Pharma LLC on April 11, 2016 until
July 2018. In July 2018, he began serving as the Company&rsquo;s President and Chief Operating Officer. He founded LAT Pharma LLC
and served as its Chief Executive Officer prior to its acquisition. Mr. Adams is a co-inventor of the Company&rsquo;s patent covering
the use of terlipressin to treat ascites patients. He has over 29 years of biopharmaceutical industry experience, including corporate
finance, company acquisitions and licensing deals, marketing and sales support. At Searle Pharmaceuticals he was a member of the
global launch team for Celebrex, and he has worked on launching numerous new drugs and medical devices. Mr. Adams earned a BS at
Cornell University and an MBA at the Tuck School at Dartmouth.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Joanne Wendy Kim has served as the Company&rsquo;s
Chief Financial Officer since October 2018. Ms. Kim previously served as CFO for several companies throughout her career, most
recently with Landmark Education Enterprises, and she has provided interim CFO services to various organizations through Group
JWK from 2016 to 2018. In her various roles, Ms. Kim oversaw corporate finance and operational groups, closed eight acquisitions,
secured bank financings, developed and implemented new business strategies, managed risk and implemented new financial policies
and procedures. As a CPA, Ms. Kim provided accounting, SEC filing review and other business consultative services to clients serving
as a Director at BDO USA, LLP&rsquo;s National Office SEC Department in 2008-2016 and as a Senior Manager at KPMG in earlier part
of her career. She brings more than 30 years of accounting experience to this position. Ms. Kim earned her BBA in accounting and
finance at California State University, Long Beach.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Yeramian has served as the Company&rsquo;s
Chief Medical Officer since November 2018. Dr. Yeramian has over 25 years of experience in the pharmaceutical industry. He has
supervised the clinical development of new drugs, biopharmaceuticals, cellular therapy agents, and vaccines as well as having held
a prominent role in the approval of several new drug (metronidazole &ndash; Flagyl MR &reg;), biological (interferon alpha &ndash;
Multiferon&reg;, nafarelin &ndash; Synarel&reg;) and device (Inerpan&reg;) applications in the U.S. in the EC and the granting
of over 20 successful INDs and IMPDs. Dr Yeramian was the Medical Director of the Vaccine and Gene Therapy Institute, Florida from
October 2011 to February 2015 and a consulting Medical Director for Tapimmune Inc. from February 2015 to January 2017 and Kantum
Diagnostics from March 2017 to March 2019. Dr. Yeramian currently serves as the Medical Director of Amylyx Inc. (since March 2019)
and as the General Manager of DLx Therpeutics LLC (since January 2018). Previously he served as Chief Medical Officer at Viragen,
Inc. where he was responsible for development of global clinical and regulatory strategies and for implementation of clinical programs
worldwide. Earlier Dr. Yeramian also served as Director of clinical research at GD Searle where he supervised the clinical programs
for antibiotics, antivirals, sepsis/thrombosis, and cancer vaccines. Dr. Yeramian holds a Medical Degree from the University of
Paris together with a Master of Clinical Science in experimental oncology and a Graduate Degree in molecular virology. He also
earned a Master of Business Administration from Rutgers University. He completed his medical residency in oncology at the Saint-Louis
Hospital in Paris.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Markham has served as the Company&rsquo;s
Chief Scientific Officer since November 2018. She was previously our Chief Scientist. Dr. Markham served as a Technical Consultant
at LAT Pharma for 7 years prior to our acquisition of LAT Pharma. She has spent 15 years in immunology, infectious disease, bacteriology
and drug discovery research. Dr. Markham was a co-founder and Research Director for Influx, Inc. involved in antibiotic drug discovery.
She has been a member of NIH grant review panels and consulted for several pharmaceutical companies in a variety of therapeutic
areas including Orphan Drug development. Dr. Markham has more than 20 publications in peer-reviewed journals and three patents.
She holds a BS in Biochemistry from the University College Cork, Ireland, a Masters from Strathclyde University, Scotland, and
a PhD from Rush University, Chicago.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Cuong Do has been President, Global
Strategy Group, at Samsung since February 2015. Mr. Do helps to set the strategic direction for Samsung Group&rsquo;s diverse business
portfolio. He was previously the Chief Strategy Officer for Merck from October 2011 to March 2014, Tyco Electronics, and Lenovo.
Mr. Do is a former senior partner at McKinsey &amp; Company, where he spent 17 years and helped build the healthcare, high tech
and corporate finance practices. He holds a BA from Dartmouth College, and an MBA from the Tuck School of Business at Dartmouth.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Jim Lang is currently CEO of Water
Street Capital&rsquo;s and JLL Partner&rsquo;s Global Life Sciences Services Platform. He formerly served as the CEO of Decision
Resources Group (DRG), which he transformed into a leading healthcare data and analytics firm. Prior to that, Jim was CEO of IHS
Cambridge Energy Research Associates (IHS CERA), a recognized leader in energy industry subscription information products, and
formerly the President of Strategic Decisions Group (SDG), a leading global strategy consultancy. Mr. Lang holds a BS summa cum
laude in electrical and computer engineering from the University of New Hampshire and an MBA with Distinction from the Tuck School
of Business. Jim Lang currently also serves as a Director at OptimizeRX, a Nasdaq listed Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Hari Kumar, PhD held positions of increasing
responsibility at Roche Pharma culminating in serving as Global Business Development Director, and in 2007 assumed the role of
Chief Business Officer for Amira Pharmaceuticals. He led the sale of Amira to Bristol-Myers Squibb in 2011 for $475 million. He
then served as Chief Executive Officer (CEO) for Panmira Pharmaceuticals LLC, which is developing anti-inflammatory compounds,
and in 2013 became CEO for Adheron Therapeutics, which Roche Pharma acquired in 2015 for $580 million. Dr. Kumar earned a PhD in
immunology in 1984.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Richard J. Berman was Chairman
of National Investment Managers, a company with $12 billion pension administration assets from 2006-2011. Mr. Berman is a
director of four other public healthcare companies: Catasys, Inc., Advaxis, Inc., Cryoport Inc. and Immuron Ltd. and a public
fintech company, Cuentas, Inc. From 1998-2000, he was employed by Internet Commerce Corporation (now Easylink Services) as
Chairman and CEO, and was a director from 1998-2012. Previously, Mr. Berman was Senior Vice President of Bankers Trust
Company, where he started the M&amp;A and Leveraged Buyout Departments; created the largest battery company in the world in
the 1980&rsquo;s by merging Prestolite, General Battery and Exide and advised on over $4 billion of M&amp;transactions
(completed over 300 deals). He is a past Director of the Stern School of Business of NYU where he obtained his BS and MBA. He
also has US and foreign law degrees from Boston College and The Hague Academy of International Law, respectively. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Michael Sherman JD retired from his
position as a Managing Director at Barclays Plc in 2018, where he had worked since 2008. Previously he was a Managing Director
at Lehman Brothers, Inc. He has worked in investment banking for 30 years. Mr. Sherman has significant experience in healthcare
finance, most recently assisting on a $450 million convertible transaction for Neurocrine Biosciences. He has worked on successful
financial transactions for Teva Pharmaceutical Industries, Amgen Inc., Cubist Pharmaceuticals, Merck &amp; Co., and Cardinal Health,
among other companies. After graduating from the University of Pennsylvania, Michael Sherman received his JD, cum laude, from the
Harvard Law School.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Terren Peizer&rsquo;s qualifications
to serve on our Board of Directors are primarily based on his experience as an entrepreneur, investor, and financier with a particular
interest in healthcare, having founded and successfully commercialized several healthcare companies. Mr. Peizer is the founder
of Catasys, Inc., a leader in behavioral and mental health management services, having served as the Chairman of the Board of
Directors and CEO of Catasys since inception in 2004. Mr. Peizer also is the Founder, Chairman and CEO and majority shareholder
of NeurMedix, Inc., a biotechnology Company with a focus on inflammatory, neurological and neuro-degenerative diseases. Mr. Peizer
is Chairman of Acuitas Group Holdings, LLC, his personal holding Company that owns his portfolio Company interests. Through Acuitas,
he owns Crede Capital Group, LLC, an industry leader in investing in micro and small capitalization public equities, having invested
over $1.2 billion directly into portfolio companies. </P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Jonathan Adams&rsquo;s qualifications
to serve on our Board of Directors are primarily based on his founding of LAT Pharma LLC and his over 26 years of biopharmaceutical
industry experience. As Chief Executive of LAT Pharma LLC, Mr. Adams was a key contributor to inventing the BIV201 product candidate.
He also helped to secure an Orphan Drug designation for a terlipressin analogue (a prior product candidate which is no longer in
development). Mr. Adams&rsquo;s biopharmaceutical experience includes work in corporate finance, company acquisitions and licensing deals,
marketing and sales support.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Wendy Kim&rsquo;s qualifications to
serve as our Chief Financial Officer are primarily based on her 35 years of accounting experience and having served as CFO for
several companies and the provision of interim CFO services, accounting and business consultative services to various organizations
through Group JWK, BDO USA, LLP and KPMG.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Yeramian&rsquo;s
qualifications to serve as our Chief Medical Officer are primarily based on his extensive experience in the pharmaceutical
industry, including the supervision of the clinical development of new drugs, biopharmaceuticals, cellular therapy agents,
and vaccines as well as having held a prominent role in the approval of several new drugs and having been Chief Medical
Officer responsible for development of global clinical and regulatory strategies and for implementation of clinical programs
worldwide at Viragen.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Markham&rsquo;s qualifications to
serve as our Scientific Officer are primarily based on her years of experience with LAT Pharma, as well as having been a member
of NIH grant review panels and consulted for several pharmaceutical companies in a variety of therapeutic areas including Orphan
Drug development.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Cuong Do&rsquo;s qualifications to serve
on our Board of Directors are primarily based on his decades of experience as an executive in the pharma, biotech, and other high
technology industries. He was previously the Chief Strategy Officer for Merck, a leading U.S. pharmaceuticals Company, Tyco Electronics,
and Lenovo. Mr. Do is a former senior partner at McKinsey &amp; Company, where he spent 17 years and helped build the healthcare,
high tech and corporate finance practices.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Jim Lang&rsquo;s qualifications to serve
on our Board of Directors are primarily based on his decades of experience as a strategy consultant, broad industry expertise,
and senior-level management experience running several healthcare and information technology companies. This includes his experience
as CEO of Decision Resources Group, CEO of IHS Cambridge Energy Research Associates (IHS CERA), and President of Strategic Decisions
Group (SDG), a leading global strategy consultancy.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Hari Kumar&rsquo;s qualifications to
serve on our Board of Directors are primarily based on his decades of biopharma industry experience including serving as the chief
executive officer at multiple companies, extensive technical and business knowledge, and outstanding track record for delivering
value to investors. He led the sale of Amira to Bristol-Myers Squibb in 2011 for $475 million, and as CEO for Adheron Therapeutics,
he led the sale of this Company to Roche Pharma for $580 million in 2015.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Richard J. Berman&rsquo;s qualifications
to serve on our board of directors include his experience in the healthcare industry, and his current and past experience in numerous
private and publicly traded companies. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Michael Sherman&rsquo;s qualifications to serve on our Board
of Directors are primarily based on his decades of finance industry experience including as a Managing Director at Barclays Plc
and as a Managing Director at Lehman Brothers, Inc. He has worked in investment banking for 30 years. Mr. Sherman has significant
experience in healthcare finance including having worked on successful financial transactions for several pharmaceutical and healthcare
focused companies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>Committees of
the Board of Directors</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Upon the effective date of the registration
statement of which this prospectus forms a part, our Board of Directors will have three standing committees: an audit committee,
a compensation committee and a nominating and corporate governance committee. Both our audit committee and our compensation committee
will be composed solely of independent directors. Subject to phase-in rules, the rules of Nasdaq and Rule 10A-3 of the Exchange
Act require that the audit committee of a listed company be comprised solely of independent directors, and the rules of Nasdaq
require that the compensation committee and the nominating and corporate governance committee of a listed company be comprised
solely of independent directors. Each committee operates under a charter approved by our Board of Directors and will have the
composition and responsibilities described below. The charter of each committee will be available on our website following the
closing of this offering. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>AUDIT COMMITTEE</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> We have established an audit committee
of the Board of Directors. The members of our audit committee are Michael Sherman, Jim Lang and Richard J. Berman, each of which
is an independent director within the meaning of the Nasdaq rules. Mr. Sherman serves as chairman of the audit committee. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have adopted an audit committee
charter, detailing the principal functions of the audit committee, including:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting
board oversight of&thinsp;(1) the integrity of our financial statements, (2) our compliance with legal and regulatory requirements,
(3) our independent auditor&rsquo;s qualifications and independence, and (4) the performance of our internal audit function and
independent auditors; the appointment, compensation, retention, replacement, and oversight of the work of the independent auditors
and any other independent registered public accounting firm engaged by us;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving all audit and non-audit services
to be provided by the independent auditors or any other registered public accounting firm engaged by us, and establishing pre-approval
policies and procedures; reviewing and discussing with the independent auditors all relationships the auditors have with us in
order to evaluate their continued independence;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">setting clear policies for audit partner rotation
in compliance with applicable laws and regulations;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
and reviewing a report, at least annually, from the independent auditors describing (1) the independent auditor&rsquo;s internal
quality-control procedures and (2) any material issues raised by the most recent internal quality-control review, or peer review,
of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years
respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting
to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent
auditor, including reviewing our specific disclosures under &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations&rdquo;; reviewing and approving any related party transaction required to be disclosed pursuant to Item
404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
with management, the independent auditors, and our legal advisors, as appropriate, any legal, regulatory or compliance matters,
including any correspondence with regulators or government agencies and any employee complaints or published reports that raise
material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or
rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities.<B>&nbsp;</B></FONT></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>COMPENSATION COMMITTEE</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> We have established a compensation committee of the Board of Directors. The members of our Compensation Committee are Mr. Berman, Mr. Kumar and Mr. Sherman. Mr. Berman serves as chairman of the compensation committee. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"> We have adopted a compensation
committee charter, which details the principal functions of the compensation committee, including: </P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer&rsquo;s compensation,
evaluating our Chief Executive Officer&rsquo;s performance in light of such goals and objectives and determining and approving
the remuneration (if any) of our Chief Executive Officer based on such evaluation;</FONT></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
and making recommendations to our Board of Directors with respect to the compensation, and any incentive-compensation and equity-based
plans that are subject to board approval of all of our other officers;</FONT></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
our executive compensation policies and plans;</FONT></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing
and administering our incentive compensation equity-based remuneration plans; assisting management in complying with our proxy
statement and annual report disclosure requirements;</FONT></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees;</FONT></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">producing
a report on executive compensation to be included in our annual proxy statement; and reviewing, evaluating and recommending changes,
if appropriate, to the remuneration for directors.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The charter  also provides that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, independent legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B><I>Nominating
and Corporate Governance Committee</I></B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B><I>&nbsp;</I></B></FONT></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> We have established a nominating and corporate governance committee of the Board of Directors. The members of our nominating and corporate governance committee are Mr. Do, Mr. Lang and Mr. Kumar. Mr. Do serves as chair of the nominating and corporate governance committee. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> We have adopted a nominating and
corporate governance committee charter, which details the purpose and responsibilities of the nominating and corporate governance
committee, including: </P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
screening and reviewing individuals qualified to serve as directors, consistent with criteria approved by the Board of Directors,
and recommending to the Board of Directors candidates for nomination for election at the annual meeting of stockholders or to fill
vacancies on the Board of Directors;</FONT></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
and recommending to the Board of Directors and overseeing implementation of our corporate governance guidelines;</FONT></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">coordinating
and overseeing the annual self-evaluation of the Board of Directors, its committees, individual directors and management in the
governance of the company; and</FONT></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing on a regular basis our overall corporate
governance and recommending improvements as and when necessary.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The charter also provides that the nominating and corporate governance committee may, in its sole discretion, retain or obtain the advice of, and terminate, any search firm to be used to identify director candidates, and will be directly responsible for approving the search firm&rsquo;s fees and other retention terms.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not formally established any specific, minimum qualifications
that must be met or skills that are necessary for directors to possess. In general, in identifying and evaluating nominees for
director, the Board of Directors considers educational background, diversity of professional experience, knowledge of our business,
integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our stockholders.
Prior to our initial business combination, holders of our public shares will not have the right to recommend director candidates
for nomination to our Board of Directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Compensation Committee Interlocks and Insider Participation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">None of our officers currently serves, or in the past year
has served, as a member of the compensation committee of any entity that has one or more officers serving on our Board of Directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>CODE OF ETHICS</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have adopted a code of conduct and
ethics meeting the requirements of Section 406 of the Sarbanes-Oxley Act of 2002. We believe our code of conduct and ethics is
reasonably designed to deter wrongdoing and promote honest and ethical conduct; provide full, fair, accurate, timely and understandable
disclosure in public reports; comply with applicable laws; ensure prompt internal reporting of violations; and provide accountability
for adherence to the provisions of the code of ethic. Our code of conduct and ethics is available on our website<B>.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_011"></A>EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> We did not pay any compensation
to any of our executive officers prior to the start of our fiscal year ending June 30, 2019; however, we did accrue salary for
Mr. Adams in accordance with his related employment agreements for all periods subsequent to their effective dates. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="27" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Annual Compensation</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Name&nbsp;and&nbsp;Principal Position</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Year</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Salary</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Bonus</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Stock Awards</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Option Awards(1)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">All Other Compensation</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"> Terren Peizer </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2019 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash;&nbsp;&nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash;&nbsp;&nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 7,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash;&nbsp;&nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash;&nbsp;&nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 7,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"> Chief Executive Officer and
    Chairman(2) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 37%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Jonathan Adams</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">2019</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">250,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">7,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">11,789</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">268,789</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"> President and Chief Operating
    Officer(2) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,978</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">280,978</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The aggregate
grant date fair value of such awards were computed in accordance with Financial Accounting Standards Board ASC Topic 718, Stock
Compensation (ASC Topic 718), and do not take into account estimated forfeitures related to service-based vesting conditions, if
any. The valuation assumptions used in calculating these values are discussed in Note 8 of the Notes to Consolidated Financial
Statements appearing elsewhere herein. These amounts do not represent actual amounts paid or to be realized. Amounts shown are
not necessarily indicative of values to be achieved, which may be more or less than the amounts shown as awards may subject to
time-based vesting.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mr.
Peizer became our Chief Executive Officer and Chairman in July 2018 at which time Mr. Adams became President and Chief Operating
Officer, having previously served as our Chief Executive Officer and Chief Financial Officer, Treasurer and Corporate Secretary.
The stock awards received by Mr. Peizer and Mr. Adams represented 1,600 shares of common stock and vested in full upon grant. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Employment Agreement</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 11, 2016, we entered into an employment agreement
with Mr. Adams, pursuant to which Mr. Adams is entitled to receive $250,000 as annual salary. The agreement was effective beginning
April 11, 2016 and as amended to date, currently expires on July 2, 2019. In the event Mr. Adams&rsquo;s employment is terminated
without &ldquo;Good Cause&rdquo; (as defined therein), Mr. Adams will be entitled to receive his base salary for the remainder
of the term of the agreement, subject to the provision of a mutual release of all claims against the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 9, 2018, Mr. Adams, our
President and Chief Operating Officer, entered into an Accord and Debt Satisfaction Agreement with us, pursuant to which he
agreed to release us from all liabilities (including the original contract dated March 23, 2017 to defer payment of his
accrued salary, the promissory note issued by us to defer payment of accrued salary and subsequent unpaid salary), for an
aggregate amount of $534,722, and received a cash payment of $25,694 in satisfaction. The gain of $509,028 on the settlement
of debt was reflected as additional paid in capital.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Option/SAR Grants</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with his employment agreement, on April 11, 2016 Mr. Adams received options to acquire 24,000 shares exercisable at $7.50 per share, the closing price on that date. These options vested and became exercisable as follows: (i) 8,000 shares on April 11, 2017, (ii) 8,000 shares on April 11, 2018, and (iii) 8,000 shares on April 11, 2019.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Between November 16, 2016 and May 19, 2017, we issued options to acquire 8,000 exercisable at an average price of $30.00 per share to consultants and members of our Board of Directors for services provided to us.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Long-Term Incentive Plans and Awards</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Other than the options granted as
described above and our recently adopted 2019 Omnibus Equity Incentive Plan (the &ldquo;2019 Plan&rdquo;), we do not currently have any long-term
incentive plans that provide compensation intended to serve as incentive for performance. Since prior to such grants, no individual
grants or agreements regarding future payouts under non-stock price-based plans had been made to any executive officer or any
director or any employee or consultant since our inception, no future payouts under non-stock price-based plans or agreements
had been granted or entered into or exercised by our officer or director or employees or consultants. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>2019 Omnibus Equity Incentive Plan</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> On April 30, 2019, our Board of Directors and our stockholders approved and adopted the 2019 Plan, subject to complying with the notification requirements of Regulation 14C of the Exchange Act which were complied with effective May 29, 2019. The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and directors. The 2019 Plan allows for the issuance of up to 253,163 shares of common stock pursuant to new awards granted under the 2019 Plan. This description is qualified in its entirety by reference to the actual terms of the 2019 Plan, a copy of which is attached as Appendix D to our Definitive Information Statement on Schedule 14C, filed with the SEC on May 8, 2019. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Compensation of Directors</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> There are no arrangements pursuant
to which our directors are or will be compensated in the future for any services provided to the Company, except that each director
shall receive stock options and common share grants as remuneration for their service in lieu of cash compensation. For the fiscal
year ended June 30, 2019, each director received 800 stock options on the one-year anniversary of his or her service to the Company
with an exercise price equal to the closing stock price on the day of the option grant. The total value of the options granted
to directors for the fiscal year ended June 30, 2019 was $8,804 based on the Black-Scholes option value method. Each director
also receives a stock grant of 1,600 common shares for every year of service. On January 2, 2019, our directors received a combined
grant of 11,200 shares of common stock with a face value of $210,000 based on the closing stock price of $18.75 on the grant date. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_012"></A><FONT STYLE="text-transform: uppercase"><B>Principal
Stockholders</B></FONT></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Based solely upon information made
available to us, the following table sets forth information as of June 27, 2019 regarding the beneficial ownership of our common
stock by: </P>

<P STYLE="font: 7pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our named executive officers and directors; and&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all our executive officers and directors as a group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 7pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> The percentage ownership information shown in the table is based upon 4,058,441 shares of common stock outstanding as of June 27, 2019. </P>

<P STYLE="font: 7pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Beneficial ownership is determined in
accordance with the rules of the SEC and includes voting or investment power with respect to the securities. Except as otherwise
indicated, each person or entity named in the table has sole voting and investment power with respect to all shares of our capital
shown as beneficially owned, subject to applicable community property laws.</P>

<P STYLE="font: 7pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In computing the number and percentage
of shares beneficially owned by a person as of a particular date, shares that may be acquired by such person (for example, upon
the exercise of options or warrants) within 60&nbsp;days of such date are counted as outstanding, while these shares are not counted
as outstanding for computing the percentage ownership of any other person.</P>

<P STYLE="font: 7pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The address of each holder listed below,
except as otherwise indicated, is c/o BioVie Inc., 2120 Colorado Avenue, #230, Santa Monica , California 90404. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Name and Address of Beneficial Owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Number of Common Shares of
    Beneficial Ownership (1) </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Percentage of Beneficial
    Ownership </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: justify; padding-left: 5.4pt">Terren Peizer(2)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 12%; text-align: right"> 3,127,933 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 12%; text-align: right"> 73.5 </TD><TD STYLE="width: 1%; text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 5.4pt">Jonathan Adams(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 94,635 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2.2 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 5.4pt">Joanne Wendy Kim(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 800 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 106%">*</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 5.4pt">Patrick Yeramian, MD(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,400 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 106%">*</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 5.4pt">Penolope Markham, PhD(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 13,091 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 106%">*</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 5.4pt">Cuong Do(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 168,303 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3.9 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 5.4pt">James Lang(7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 44,630 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 5.4pt">Hari Kumar(8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,527 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 106%">*</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 5.4pt">Michael Sherman(9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 34,284 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 106%">*</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 5.4pt"> Richard J. Berman </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &mdash;&nbsp;&nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &mdash;&nbsp;&nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-left: 5.4pt">All directors and executive officers as a group (ten persons):</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: right"> 3,493,603 </TD><TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: right"> 82.3 </TD><TD STYLE="font-weight: bold; text-align: left"> % </TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 7pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">_________________________________</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">*Less than 1%</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Beneficial ownership is determined in accordance with the rules of
the SEC and generally includes voting or investment power with respect to securities. In accordance with SEC rules, shares of common
stock issuable upon the exercise of options or warrants which are currently exercisable or which become exercisable within 60 days
following the date of the information in this table are deemed to be beneficially owned by, and outstanding with respect to, the
holder of such option or warrant, however none of the persons listed hereinabove has the right to acquire beneficial ownership
in any other shares of the Company. Subject to community property laws where applicable, to our knowledge, each person listed is
believed to have sole voting and investment power with respect to all shares of common stock owned by such person.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0  0 ">&nbsp;</P>
<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">All shares and warrants are held of record by Acuitas Group Holdings, LLC, a limited liability company 100% owned by Terren S. Peizer, and as to which, Mr. Peizer may be deemed to beneficially own or control. Mr. Peizer disclaims beneficial ownership of any such securities. Does not include 1,339,958 shares expected to be issued to Acuitas upon completion of this offering.  Giving effect to such issuance and the completion of this offering, Acuitas will beneficially own 4,467,891 shares in total, or &nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding shares of common stock.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Includes
                                         warrants to purchase 8,563 shares of common stock and options to purchase 24,000 shares
                                         of common stock, all of which are exercisable within the next 60 days. Common stock beneficially
                                         owned by Mr. Adams includes 1,120 and 1,200 shares of common stock held of record by
                                         Mr. Adams, as custodian for Elliott P. Adams and Jeremy P. Adams, respectively; and 2,924
                                         shares of common stock held of record by Elliott P. Adams. Each of Elliott P. Adams and
                                         Jeremy P. Adams are family members of Mr. Adams and, as a result, Mr. Adams may be deemed
                                         to beneficially own shares held by (or for the benefit of) such family members.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents options to purchase shares of common stock exercisable
in the next 60 days.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes
                                         options to purchase 2,400 shares of common stock exercisable in the next 60 days.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes
                                         warrants to purchase 70,666 shares of common stock and options to purchase 2,400
                                         shares of common stock, all of which are exercisable within the next 60 days. All
                                         shares of common stock, warrants and options are held of record by Do &amp; Rickles Investments,
                                         LLC, a limited liability company 100% owned by Cuong Do and his wife, and as such, Mr.
                                         Do may be deemed to beneficially own or control. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(7)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes
                                         warrants to purchase 18,788 shares of common stock and options to purchase 2,400
                                         shares of common stock, all of which are exercisable in the next 60 days.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(8)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes
                                         warrants to purchase 909 shares of common stock and options to purchase 800
                                         shares of common stock, which are exercisable within the next 60 days.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(9)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes
                                         warrants to purchase 13,606 shares of common stock and options to purchase 1,600
                                         shares of common stock, all of which are exercisable within the next 60 days. Common
                                         stock held by Michael Sherman includes 13,333 shares of the common stock held
                                         of record by Sherman Children&rsquo;s Trust Brian Krisber, Trustee. All shares of common
                                         stock, warrants and options are deemed to be beneficially owned or controlled by Michael
                                         Sherman.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_013"></A><FONT STYLE="text-transform: uppercase"><B>Certain
Relationships and Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period commencing July 1,
2015 and through the date of this prospectus, we have not engaged in any transactions with any officer, director or holder of more
than 5% of our common stock, except as follows:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Purchase of Preferred Stock</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 3, 2018, we entered into a
Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with Acuitas Group Holdings, LLC (&ldquo;Acuitas&rdquo;) and certain other purchasers
identified in the Purchase Agreement (together with Acuitas, the &ldquo;Purchasers&rdquo;) pursuant to which (i) the Purchasers agreed to
purchase an aggregate of 2,133,332 shares of the our Series A Convertible Preferred Stock (the &ldquo;Preferred Stock&rdquo;) at a price per
share of $1.50 per share of Preferred Stock (the &ldquo;Initial Sale&rdquo;) and (ii) we agreed to issue warrants (the &ldquo;Warrants&rdquo;) to purchase
1,706,666 shares of common stock, each subject to the terms and conditions set forth in the Purchase Agreement, for an
aggregate consideration of $3.2 million. We received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas
also received an additional 6,667 Warrants in connection with the payoff of a note issued by us in favor of Acuitas. The
Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas had the option to purchase up to an additional
1,600,000 shares of common stock at a price per share of $1.875, and warrants on the same terms as the Warrants,
within two weeks following the one year anniversary of the closing of the Initial Sale (the &ldquo;Subsequent Sale&rdquo;) in the event that
we did not obtain $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of
the Initial Sale, less any federal or FDA grant funding received by the Company. Acuitas is controlled by our Chairman and Chief
Executive Officer, Terren Peizer and the Purchasers included Jonathan Adams, James Lang, Cuang Do and Michael Sherman, who are
members of our Board of Directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Purchase Agreement contained
customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties,
we also disclosed customary information, including the following: (i) the existence of the Mallinckrodt petition before the U.S.
Patent Trial and Appeal Board, (ii) our capitalization, (iii) our obligation to pay a low single digit royalty on the net sales
of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge,
Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation
to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000
per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy),
and (v) certain recent issuances of common stock by us. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Each share of Preferred Stock automatically converted into
100 shares of common stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to
our Articles of Incorporation (the &ldquo;Amendment&rdquo;) on August 13, 2018 that increased the number of authorized shares of
common stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of our issued
and outstanding common stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days
following the distribution of our Definitive Information Statement on Schedule 14 that was filed with the SEC on July 13, 2018.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to a letter agreement dated
June 24, 2019, Acuitas has agreed to modify its existing rights under the Purchase Agreement so that:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">- Acuitas agreed to immediately exchange
its existing Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless
exercise thereof at an assumed current market price of $45.00 per share and, as a result received an aggregate of 95% of
the shares covered thereby, or 1,526,333 shares of common stock;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> - Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a &ldquo;cashless purchase&rdquo; at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of our common stock on NASDAQ or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the &ldquo;Subsequent Sale Shares&rdquo;) to Acuitas, which is expected to occur concurrently with the closing of this offering; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">- Acuitas shall in exchange for the
foregoing agreements and waivers have the option to purchase additional shares of common stock and warrants to purchase
one share of common stock for each share of common stock purchased during the period from September 1, 2019 to November 30,
2019 at the then-effective purchase price of the Preferred Stock in the Initial Sale (the &ldquo;Funding Option&rdquo;), provided
that any shares issued pursuant to any exercise of the Funding Option will reduce share-for-share the amount of shares issued
pursuant to the deemed exercise of its rights to purchase securities in a Subsequent Sale mentioned above. Assuming the closing
of this offering occurs on or prior to September 1, 2019, we anticipate that such option will lapse unexercised in the event of
such closing. In the event such closing occurs subsequent to September 1, 2019 and prior to November 30, 2019, we anticipate that
Acuitas may elect to continue to fund our on-going clinical trials and operations by means of exercising such Funding Option,
with any shares so purchased being deducted from the amount of Subsequent Sale Shares deliverable at closing as described above.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Issuance of Shares in Settlement of Debt</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> During the nine months ended March
31, 2019, we settled $1,475,765 of debt including $1,313,765 owed to related parties, by issuing 975,361 shares of common
stock with a fair value of $1,150,135. See Notes 5 and 6 to the financial statements appearing elsewhere in this prospectus.</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_014"></A>Description
of Capital Stock</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following description of our capital stock and provisions
of our Articles of Incorporation, bylaws and the Nevada corporations law are summaries and are qualified in their entirety by reference
to our Articles of Incorporation and our bylaws. We have filed copies of these documents with the SEC as exhibits to the Registration
Statement of which this prospectus forms a part. Pursuant to our Articles of Incorporation, as amended, our authorized capital
stock consists of 800,000,000 shares of Class A common stock, par value of $0.0001 per share (which we refer to as our common stock),
and 10,000,000 shares of preferred stock, par value $0.001 per share, to be designated from time to time by our Board of Directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are authorized to issue up to 300,000,000 shares of Class
A common stock, par value $0.0001 per share. Each outstanding share of common stock entitles the holder thereof to one vote per
share on all matters. Our bylaws provide that elections for directors shall be by a plurality of votes. Stockholders do not have
preemptive rights to purchase shares in any future issuance of our common stock. Upon our liquidation, dissolution or winding up,
and after payment of creditors and preferred stockholders, if any, our assets will be divided pro-rata on a share-for-share basis
among the holders of the shares of common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The holders of shares of our common stock are entitled to
dividends out of funds legally available when and as declared by our Board of Directors. Our Board of Directors has never declared
a dividend and does not anticipate declaring a dividend in the foreseeable future.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the issued and outstanding shares of our common stock
are duly authorized, validly issued, fully paid and non-assessable. To the extent that additional shares of our common stock are
issued, the relative interests of existing stockholders will be diluted.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> As of June 27, 2019, there were 4,058,441 shares of our common stock outstanding. </P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are authorized to issue up to 10,000,000 shares of preferred
stock, par value $0.001 per share, in one or more classes or series within a class as may be determined by our Board of Directors,
who may establish, from time to time, the number of shares to be included in each class or series, may fix the designation, powers,
preferences and rights of the shares of each such class or series and any qualifications, limitations or restrictions thereof.
Any preferred stock so issued by the Board of Directors may rank senior to the common stock with respect to the payment of dividends
or amounts upon liquidation, dissolution or winding up of us, or both. Moreover, under certain circumstances, the issuance of preferred
stock or the existence of the unissued preferred stock might tend to discourage or render more difficult a merger or other change
of control.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> As of June 27, 2019, there were no shares of our preferred stock outstanding. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Anti-Takeover Effects of Our Articles of Incorporation
and Bylaws</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Articles of Incorporation and bylaws contain certain
provisions that may have anti-takeover effects, making it more difficult for or preventing a third party from acquiring control
of us or changing our Board of Directors and management. According to our Articles of Incorporation and bylaws, neither the holders
of our common stock nor the holders of any preferred stock we may issue in the future have cumulative voting rights in the election
of our directors. The combination of the present ownership by a few stockholders of a significant portion of our issued and outstanding
common stock and lack of cumulative voting makes it more difficult for other stockholders to replace our Board of Directors or
for a third party to obtain control of us by replacing our Board of Directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Anti-Takeover Effects of Nevada Law</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Business Combinations</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The &ldquo;business combination&rdquo; provisions of Sections
78.411 to 78.444, inclusive, of the Nevada Revised Statutes, or NRS, generally prohibit a Nevada corporation with at least 200
stockholders from engaging in various &ldquo;combination&rdquo; transactions with any interested stockholder for a period of two
years after the date of the transaction in which the person became an interested stockholder, unless the transaction is approved
by the board of directors prior to the date the interested stockholder obtained such status or the combination is approved by the
board of directors and thereafter is approved at a meeting of the stockholders by the affirmative vote of stockholders representing
at least 60% of the outstanding voting power held by disinterested stockholders, and extends beyond the expiration of the two-year
period, unless:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<UL STYLE="margin-top: 0in; list-style-type: disc">

<LI STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">the combination was approved by the board of directors prior
to the person becoming an interested stockholder or the transaction by which the person first became an interested stockholder
was approved by the board of directors before the person became an interested stockholder or the combination is later approved
by a majority of the voting power held by disinterested stockholders; or</LI>

</UL>

<UL STYLE="margin-top: 0in; list-style-type: disc">

<LI STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">if the consideration to be paid by the interested stockholder
is at least equal to the highest of: (a) the highest price per share paid by the interested stockholder within the two years immediately
preceding the date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever
is higher, (b) the market value per share of common stock on the date of announcement of the combination and the date the interested
stockholder acquired the shares, whichever is higher, or (c) for holders of preferred stock, the highest liquidation value of the
preferred stock, if it is higher.</LI>

</UL>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A &ldquo;combination&rdquo; is generally defined to include
mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other disposition, in one transaction or
a series of transactions, with an &ldquo;interested stockholder&rdquo; having: (a) an aggregate market value equal to 5% or more
of the aggregate market value of the assets of the corporation, (b) an aggregate market value equal to 5% or more of the aggregate
market value of all outstanding shares of the corporation, (c) 10% or more of the earning power or net income of the corporation,
and (d) certain other transactions with an interested stockholder or an affiliate or associate of an interested stockholder.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, an &ldquo;interested stockholder&rdquo; is a
person who, together with affiliates and associates, owns (or within two years, did own) 10% or more of a corporation&rsquo;s voting
stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage
attempts to acquire our Company even though such a transaction may offer our stockholders the opportunity to sell their stock at
a price above the prevailing market price.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Control Share Acquisitions</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The &ldquo;control share&rdquo; provisions of Sections 78.378
to 78.3793, inclusive, of the NRS apply to &ldquo;issuing corporations&rdquo; that are Nevada corporations with at least 200 stockholders,
including at least 100 stockholders of record who are Nevada residents, and that conduct business directly or indirectly in Nevada.
The control share statute prohibits an acquirer, under certain circumstances, from voting its shares of a target corporation&rsquo;s
stock after crossing certain ownership threshold percentages, unless the acquirer obtains approval of the target corporation&rsquo;s
disinterested stockholders. The statute specifies three thresholds: one-fifth or more but less than one-third, one-third but less
than a majority, and a majority or more, of the outstanding voting power. Generally, once an acquirer crosses one of the above
thresholds, those shares in an offer or acquisition and acquired within 90 days thereof become &ldquo;control shares&rdquo; and
such control shares are deprived of the right to vote until disinterested stockholders restore the right. These provisions also
provide that if control shares are accorded full voting rights and the acquiring person has acquired a majority or more of all
voting power, all other stockholders who do not vote in favor of authorizing voting rights to the control shares are entitled to
demand payment for the fair value of their shares in accordance with statutory procedures established for dissenters&rsquo; rights.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A corporation may elect to not be governed by, or &ldquo;opt
out&rdquo; of, the control share provisions by making an election in its articles of incorporation or bylaws, provided that the
opt-out election must be in place on the 10th day following the date an acquiring person has acquired a controlling interest, that
is, crossing any of the three thresholds described above. We have not opted out of the control share statutes, and will be subject
to these statutes if we are an &ldquo;issuing corporation&rdquo; as defined in such statutes.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The effect of the Nevada control share statutes is that the
acquiring person, and those acting in association with the acquiring person, will obtain only such voting rights in the control
shares as are conferred by a resolution of the stockholders at an annual or special meeting. The Nevada control share law, if applicable,
could have the effect of discouraging takeovers of our Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Trading Market</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Prior to this offering, there has
been a limited public market for our common stock on the OTCQB Marketplace under the ticker &ldquo;BIVI.&rdquo; We have applied to list our
common stock on The NASDAQ Capital Market under the symbol &ldquo;BIVI&rdquo;. No assurance can be given that our application will be approved.
This offering will occur only if NASDAQ approves the listing of our common stock on NASDAQ. If NASDAQ does not approve the listing
of our common stock, we will not proceed with this offering. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our independent stock transfer agent is West Coast Stock
Transfer, Inc., located at 721 N. Vulcan Ave., Suite 205, Encinitas, California 92024. Their phone number is (619) 664-4780.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Disclosure of Commission Position
on Indemnification for Securities Act Liabilities</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing
provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in
the Securities Act and is, therefore, unenforceable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="a_015"></A><B>Underwriting&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">ThinkEquity, a division of Fordham Financial
Management, Inc., is acting as the representative of the underwriters of the offering. We have entered into an underwriting agreement
dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 with the representative. Subject to the terms and conditions of the underwriting agreement, we have agreed to
sell to each underwriter named below, and each underwriter named below has severally agreed to purchase, at the public offering
price less the underwriting discounts set forth on the cover page of this prospectus, the number of shares of common stock at the
initial public offering price, less the underwriting discounts and commissions, as set forth on the cover page of this prospectus,
the number of shares of common stock listed next to its name in the following table:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Shares</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 89%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThinkEquity, a division of Fordham Financial Management, Inc.</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The underwriters are committed to purchase
all the shares of common stock offered by the Company, other than those covered by the over-allotment option to purchase additional
shares of common stock described below. The obligations of the underwriters may be terminated upon the occurrence of certain events
specified in the underwriting agreement. Furthermore, the underwriting agreement provides that the obligations of the underwriters
to pay for and accept delivery of the shares offered by us in this prospectus are subject to various representations and warranties
and other customary conditions specified in the underwriting agreement, such as receipt by the underwriters of officers&rsquo;
certificates and legal opinions.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have agreed to indemnify the underwriters
against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters may
be required to make in respect thereof.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The underwriters are offering the shares
of common stock subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by
their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel
or modify offers to the public and to reject orders in whole or in part.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have granted the underwriters an
over-allotment option. This option, which is exercisable for up to 45 days after the date of this prospectus, permits the underwriters
to purchase up to an aggregate of additional shares of common stock (equal to 15% of the total number of shares of common stock
sold in this offering) at the public offering price per share, less underwriting discounts and commissions, solely to cover over-allotments,
if any. If the underwriters exercise this option in whole or in part, then the underwriters will be severally committed, subject
to the conditions described in the underwriting agreement, to purchase the additional shares of common stock in proportion to their
respective commitments set forth in the prior table.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Discounts, Commissions and Reimbursement</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The representative has advised us that
the underwriters propose to offer the shares of common stock to the public at the initial public offering price per share set forth
on the cover page of this prospectus. The underwriters may offer shares to securities dealers at that price less a concession of
not more than $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of which up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share may be reallowed to other dealers. After the initial offering to the public, the public offering price and other selling
terms may be changed by the representative.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the underwriting
discounts and commissions and proceeds, before expenses, to us assuming both no exercise and full exercise by the underwriters
of their over-allotment option:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per Share</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Without Option</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>With Option</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 67%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering price</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discounts and commissions (7%)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accountable expense allowance (1%) (1)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds, before expenses, to us</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 1pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The non-accountable expense allowance of 1% is not payable with respect to shares sold upon exercise of the underwriters&rsquo; over-allotment option.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have paid an expense deposit of $35,000
to (or on behalf of) the representative, which will be applied against the actual out-of-pocket accountable expenses that will
be paid by us to the underwriters in connection with this offering, and will be reimbursed to us to the extent not incurred.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> In addition, we have also agreed
to pay the following expenses of the underwriters relating to the offering: (a) all fees, expenses and disbursements relating
to background checks of our officers and directors in an amount not to exceed $15,000 in the aggregate; (b) all filing fees and
communication expenses associated with the review of this offering by FINRA; (c) all fees, expenses and disbursements relating
to the registration, qualification or exemption of securities offered under the securities laws of foreign jurisdictions designated
by the underwriter, including without limitation, all filing and registration fees, and if the offering is commenced on either
The Nasdaq Global Market, The Nasdaq Global Select Market or the New York Stock Exchange, we will pay $5,000 for the reasonable
fees and expenses of the underwriter&rsquo;s blue sky counsel at the closing of this offering, or if the offering is commenced
on The Nasdaq Capital Market, the NYSE American or OTCQB, we will pay $5,000 to such counsel upon the commencement of blue-sky
work by such counsel and an additional $10,000 at the closing of this offering; (d) $29,500 for the underwriters&rsquo; use of
Ipreo&rsquo;s book-building, prospectus tracking and compliance software for this offering; (e) the costs associated with bound
volumes of the public offering materials as well as commemorative mementos and lucite tombstones, (f) the fees and expenses of
the representatives&rsquo; legal counsel incurred in connection with this offering in an amount up to $75,000; and (g) up to $20,000
of the representative&rsquo;s actual accountable road show expenses for the offering. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> We estimate the expenses of this
offering payable by us, not including underwriting discounts and commissions, will be approximately $625,000. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Representative Warrants</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon the closing of this offering, we
have agreed to issue to the representative warrants, or the Representative&rsquo;s Warrants, to purchase a number of shares of
common stock equal to 5% of the total number of shares sold in this public offering. The Representative&rsquo;s Warrants will be
exercisable at a per share exercise price equal to 125% of the public offering price per share of common stock sold in this offering.
The Representative&rsquo;s Warrants are exercisable at any time and from time to time, in whole or in part, during the four year
period commencing one year from the effective date of the registration statement related to this offering. The Representative&rsquo;s
Warrants also provide for one demand registration right of the shares underlying the Representative&rsquo;s Warrants, and unlimited
&ldquo;piggyback&rdquo; registration rights with respect to the registration of the shares of common stock underlying the Representative&rsquo;s
Warrants and customary antidilution provisions. The demand registration right provided will not be greater than five years from
the effective date of the registration statement related to this offering in compliance with FINRA Rule 5110(f)(2)(G). The piggyback
registration right provided will not be greater than seven years from the effective date of the registration statement related
to this offering in compliance with FINRA Rule 5110(f)(2)(G).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Representative&rsquo;s
Warrants and the shares of common stock underlying the Representative&rsquo;s Warrants have been deemed compensation by the
Financial Industry Regulatory Authority, or FINRA, and are therefore subject to a 180-day lock-up pursuant to
Rule&nbsp;5110(g)(1) of FINRA. The representative, or permitted assignees under such rule, may not sell, transfer, assign,
pledge, or hypothecate the Representative&rsquo;s Warrants or the securities underlying the Representative&rsquo;s Warrants,
nor will the representative engage in any hedging, short sale, derivative, put, or call transaction that would result in the
effective economic disposition of the Representative&rsquo;s Warrants or the underlying shares for a period of 180&nbsp;days
from the effective date of the registration statement. Additionally, the Representative&rsquo;s Warrants may not be sold
transferred, assigned, pledged or hypothecated for a 180-day period following the effective date of the registration
statement except to any underwriter and selected dealer participating in the offering and their bona fide officers or
partners. The Representative&rsquo;s Warrants will provide for adjustment in the number and price of the
Representative&rsquo;s Warrants and the shares of common stock underlying such Representative&rsquo;s Warrants in the
event of recapitalization, merger, stock split or other structural transaction, or a future financing undertaken by us.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Right of First Refusal</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Until &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, twelve (12) months
from the effective date of the registration statement of which this prospectus is a part, the representative shall have an irrevocable
right of first refusal to act as sole investment banker, sole book-runner and/or sole placement agent, at the representative sole
discretion, for each and every future public and private equity and debt offerings for the Company, or any successor to or any
subsidiary of the Company, including all equity linked financings, on terms customary to the representative. The representative
shall have the sole right to determine whether or not any other broker-dealer shall have the right to participate in any such offering
and the economic terms of any such participation. The representative will not have more than one opportunity to waive or terminate
the right of first refusal in consideration of any payment or fee.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Discretionary Accounts</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The underwriters do not intend to confirm
sales of the securities offered hereby to any accounts over which they have discretionary authority.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, each of its directors and
officers and 5% or greater holders of the Company&rsquo;s outstanding shares of common stock as of the date of this prospectus,
have agreed for a period of (i) six months after the date of this prospectus in the case of directors and officers and (ii) three
months after the date of this prospectus in the case of the Company and the 5% or greater holders of the Company&rsquo;s outstanding
common stock, without the prior written consent of the representative, not to directly or indirectly:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue (in the case of us), offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of any shares of common stock or other capital stock or any securities convertible into or exercisable or exchangeable for our common stock or other capital stock; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the case of the Company, file or cause the filing of any registration statement under the Securities Act with respect to any shares of common stock or other capital stock or any securities convertible into or exercisable or exchangeable for our common stock or other capital stock; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete any offering of debt securities of the Company, other than entering into a line of credit, term loan arrangement or other debt instrument with a traditional bank; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter into any swap or other agreement, arrangement, hedge or transaction that transfers to another, in whole or in part, directly or indirectly, any of the economic consequences of ownership of our common stock or other capital stock or any securities convertible into or exercisable or exchangeable for our common stock or other capital stock, whether any transaction described in any of the foregoing bullet points is to be settled by delivery of our common stock or other capital stock, other securities, in cash or otherwise, or publicly announce an intention to do any of the foregoing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Electronic Offer, Sale and Distribution
of Securities</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A prospectus in electronic format may
be made available on the websites maintained by one or more of the underwriters or selling group members. The representative may
agree to allocate a number of securities to underwriters and selling group members for sale to its online brokerage account holders.
Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on
the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part
of, nor incorporated by reference into, this prospectus or the registration statement of which this prospectus forms a part, has
not been approved or endorsed by us, and should not be relied upon by investors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stabilization</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with this offering, the
underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering transactions, penalty bids
and purchases to cover positions created by short sales.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Stabilizing transactions permit bids
to purchase shares so long as the stabilizing bids do not exceed a specified maximum, and are engaged in for the purpose of preventing
or retarding a decline in the market price of the shares while the offering is in progress.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Over-allotment transactions involve
sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase. This creates
a syndicate short position which may be either a covered short position or a naked short position. In a covered short position,
the number of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the over-allotment
option. In a naked short position, the number of shares involved is greater than the number of shares in the over-allotment option.
The underwriters may close out any short position by exercising their over-allotment option and/or purchasing shares in the open
market.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Syndicate covering transactions involve
purchases of shares in the open market after the distribution has been completed in order to cover syndicate short positions. In
determining the source of shares to close out the short position, the underwriters will consider, among other things, the price
of shares available for purchase in the open market as compared with the price at which they may purchase shares through exercise
of the over-allotment option. If the underwriters sell more shares than could be covered by exercise of the over-allotment option
and, therefore, have a naked short position, the position can be closed out only by buying shares in the open market. A naked short
position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on
the price of the shares in the open market that could adversely affect investors who purchase in the offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Penalty bids permit the representative
to reclaim a selling concession from a syndicate member when the shares originally sold by that syndicate member are purchased
in stabilizing or syndicate covering transactions to cover syndicate short positions.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These stabilizing transactions, syndicate
covering transactions and penalty bids may have the effect of raising or maintaining the market price of our shares of common stock
or preventing or retarding a decline in the market price of our shares of common stock. As a result, the price of our common stock
in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriters
make any representation or prediction as to the effect that the transactions described above may have on the price of our common
stock. These transactions may be effected in the&nbsp;over-the-counter&nbsp;market or otherwise and, if commenced, may be discontinued
at any time.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Other Relationships</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain of the underwriters and their
affiliates may in the future provide various investment banking, commercial banking and other financial services for us and our
affiliates for which they may in the future receive customary fees.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Offer restrictions outside the United
States</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than in the United States, no
action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus
in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or
sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer
and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in
compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes
are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus
in any jurisdiction in which such an offer or a solicitation is unlawful.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Australia</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This prospectus is not a disclosure
document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian Securities and Investments
Commission and does not purport to include the information required of a disclosure document under Chapter 6D of the Australian
Corporations Act. Accordingly, (i)&nbsp;the offer of the securities under this prospectus is only made to persons to whom it is
lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or more exemptions
set out in section 708 of the Australian Corporations Act, (ii)&nbsp;this prospectus is made available in Australia only to those
persons as set forth in clause (i)&nbsp;above, and (iii)&nbsp;the offeree must be sent a notice stating in substance that by accepting
this offer, the offeree represents that the offeree is such a person as set forth in clause (i)&nbsp;above, and, unless permitted
under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the
offeree within 12 months after its transfer to the offeree under this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>China</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The information in this document does
not constitute a public offer of the securities, whether by way of sale or subscription, in the People&rsquo;s Republic of China
(excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan).
The securities may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than directly to
&ldquo;qualified domestic institutional investors.&rdquo;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>European Economic Area&mdash;Belgium,
Germany, Luxembourg and Netherlands</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The information in this document has
been prepared on the basis that all offers of securities will be made pursuant to an exemption under the Directive 2003/71/EC (&ldquo;Prospectus
Directive&rdquo;), as implemented in Member States of the European Economic Area (each, a &ldquo;Relevant Member State&rdquo;),
from the requirement to produce a prospectus for offers of securities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">An offer to the public of securities
has not been made, and may not be made, in a Relevant Member State except pursuant to one of the following exemptions under the
Prospectus Directive as implemented in that Relevant Member State:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to any legal entity that has two or more of (i)&nbsp;an average of at least 250 employees during its last fiscal year; (ii)&nbsp;a total balance sheet of more than &euro;43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii)&nbsp;an annual net turnover of more than &euro;50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive) subject to obtaining the prior consent of the Company or any underwriter for any such offer; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall result in a requirement for the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>France</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This document is not being distributed
in the context of a public offering of financial securities (<I>offre au public de titres financiers</I>) in France within the
meaning of Article&nbsp;L.411-1&nbsp;of the French Monetary and Financial Code (<I>Code Mon&eacute;taire et Financier</I>) and
Articles&nbsp;211-1 et seq. of the General Regulation of the French <I>Autorit&eacute; des march&eacute;s financiers</I> (&ldquo;AMF&rdquo;).
The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This document and any other offering
material relating to the securities have not been, and will not be, submitted to the AMF for approval in France and, accordingly,
may not be distributed or caused to distributed, directly or indirectly, to the public in France.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Such offers, sales and distributions
have been and shall only be made in France to (i) qualified investors (<I>investisseurs qualifi&eacute;s</I>) acting for their
own account, as defined in and in accordance with Articles L.411-2-II-2&deg; and D.411-1 to D.411-3, D.744-1, D.754-1 ;and D.764-1
of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified investors
(<I>cercle restreint d&rsquo;investisseurs</I>) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&deg;
and D.411-4, D.744-1, D.754-1; and D.764-1 of the French Monetary and Financial Code and any implementing regulation.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to Article 211-3 of
the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly)
to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3 of
the French Monetary and Financial Code.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ireland</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The information in this document does
not constitute a prospectus under any Irish laws or regulations and this document has not been filed with or approved by any Irish
regulatory authority as the information has not been prepared in the context of a public offering of securities in Ireland within
the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the &ldquo;Prospectus Regulations&rdquo;). The securities
have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public
offering, except to (i)&nbsp;qualified investors as defined in Regulation 2(l) of the Prospectus Regulations and (ii)&nbsp;fewer
than 100 natural or legal persons who are not qualified investors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Israel</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The securities offered by this prospectus
have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor have such securities been registered
for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication
of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering or publishing the prospectus;
nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to
the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities offered
by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities
laws and regulations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Italy</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The offering of the securities in the
Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Societ&agrave;
e la Borsa, &ldquo;CONSOB&rdquo; pursuant to the Italian securities legislation and, accordingly, no offering material relating
to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer within
the meaning of Article 1.1(t) of Legislative Decree No.&nbsp;58 of 24&nbsp;February 1998 (&ldquo;Decree No.&nbsp;58"), other
than:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to Italian qualified investors, as defined in Article 100 of Decree no.58 by reference to Article&nbsp;34-ter&nbsp;of CONSOB Regulation no. 11971 of 14&nbsp;May 1999 (&ldquo;Regulation no. 1197l&rdquo;) as amended (&ldquo;Qualified Investors&rdquo;); and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree No.&nbsp;58 and Article&nbsp;34-ter&nbsp;of Regulation No.&nbsp;11971 as amended.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Any offer, sale or delivery of the securities
or distribution of any offer document relating to the securities in Italy (excluding placements where a Qualified Investor solicits
an offer from the issuer) under the paragraphs above must be:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">made by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative Decree No.&nbsp;385 of 1&nbsp;September 1993 (as amended), Decree No.&nbsp;58, CONSOB Regulation No.&nbsp;16190 of 29&nbsp;October 2007 and any other applicable laws; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Any subsequent distribution of the securities
in Italy must be made in compliance with the public offer and prospectus requirement rules provided under Decree No.&nbsp;58 and
the Regulation No.&nbsp;11971 as amended, unless an exception from those rules applies. Failure to comply with such rules may result
in the sale of such securities being declared null and void and in the liability of the entity transferring the securities for
any damages suffered by the investors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Japan</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The securities have not been and will
not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948),
as amended (the &ldquo;FIEL&rdquo;) pursuant to an exemption from the registration requirements applicable to a private placement
of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of the FIEL and
the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan
or to, or for the benefit of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional Investor
who acquires securities may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition
by any such person of securities is conditional upon the execution of an agreement to that effect.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Portugal</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This document is not being distributed
in the context of a public offer of financial securities (<I>oferta p&uacute;blica de valores mobili&aacute;rios</I>) in Portugal,
within the meaning of Article 109 of the Portuguese Securities Code (<I>C&oacute;digo dos Valores Mobili&aacute;rios</I>). The
securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This
document and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese
Securities Market Commission (<I>Comiss&#259;o do Mercado de Valores Mobili&aacute;rios</I>) for approval in Portugal and, accordingly,
may not be distributed or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances
that are deemed not to qualify as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of
securities in Portugal are limited to persons who are &ldquo;qualified investors&rdquo; (as defined in the Portuguese Securities
Code). Only such investors may receive this document and they may not distribute it or the information contained in it to any other
person.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Sweden</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This document has not been, and will
not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this document
may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances that are deemed
not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (<I>Sw. lag</I> (1991:980) <I>om handel
med finansiella instrument</I>). Any offering of securities in Sweden is limited to persons who are &ldquo;qualified investors&rdquo;
(as defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute
it or the information contained in it to any other person.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Switzerland</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The securities may not be publicly offered
in Switzerland and will not be listed on the SIX Swiss Exchange (&ldquo;SIX&rdquo;) or on any other stock exchange or regulated
trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses
under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27
ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither
this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly
available in Switzerland.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Neither this document nor any other
offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory authority. In
particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market
Supervisory Authority (FINMA).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This document is personal to the recipient
only and not for general circulation in Switzerland.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>United Arab Emirates</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Neither this document nor the securities
have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental
authority in the United Arab Emirates, nor has the Company received authorization or licensing from the Central Bank of the United
Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within the United
Arab Emirates. This document does not constitute and may not be used for the purpose of an offer or invitation. No services relating
to the securities, including the receipt of applications and/or the allotment or redemption of such shares, may be rendered within
the United Arab Emirates by the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">No offer or invitation to subscribe
for securities is valid or permitted in the Dubai International Financial Centre.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>United Kingdom</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Neither the information in this document
nor any other document relating to the offer has been delivered for approval to the Financial Services Authority in the United
Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended (&ldquo;FSMA&rdquo;)
has been published or is intended to be published in respect of the securities. This document is issued on a confidential basis
to &ldquo;qualified investors&rdquo; (within the meaning of section 86(7) of FSMA) in the United Kingdom, and the securities may
not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document, except in
circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not be
distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person
in the United Kingdom.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Any invitation or inducement to engage
in investment activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities
has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United
Kingdom in circumstances in which section 21(1) of FSMA does not apply to the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United Kingdom, this document
is being distributed only to, and is directed at, persons (i)&nbsp;who have professional experience in matters relating to investments
falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order
2005 (&ldquo;FPO&rdquo;), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth
companies, unincorporated associations, etc.) of the FPO or (iii)&nbsp;to whom it may otherwise be lawfully communicated (together
&ldquo;relevant persons&rdquo;). The investments to which this document relates are available only to, and any invitation, offer
or agreement to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act
or rely on this document or any of its contents.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Canada</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The securities may be sold in Canada
only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument&nbsp;45-106&nbsp;Prospectus
Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103&nbsp;Registration
Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption
from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. Securities legislation in
certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including
any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the
purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars
of these rights or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument 33-105 Underwriting
Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI33-105 regarding
underwriter conflicts of interest in connection with this offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_016"></A><FONT STYLE="text-transform: uppercase"><B>Experts</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The audited financial statements of
BioVie Inc. included in this prospectus and elsewhere in the registration statement have been so included in reliance upon the
reports of D. Brooks and Associates CPA&rsquo;s, P.A., independent registered public accountants, upon the authority of said firm
as experts in accounting and auditing.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_017"></A><FONT STYLE="text-transform: uppercase"><B>Legal
Matters</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Loeb &amp; Loeb LLP, Los Angeles, California, will pass upon the validity of the securities offered hereby. Certain matters are being passed on for the underwriters by Greenberg Traurig, LLP, New York, New York.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_018"></A>Where
You Can Find More Information&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have filed with the SEC a registration
statement on Form&nbsp;S-1 under the Securities Act with respect to the shares of our common stock offered by this prospectus.
This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the
registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations
of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including
the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of
any contract or any other document is not necessarily complete. If a contract or document has been filed as an exhibit to the registration
statement, please see the copy of the contract or document that has been filed. Each statement is this prospectus relating to a
contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains an Internet website
that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The
address of that website is <U>www.sec.gov</U>.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are subject to the information and
reporting requirements of the Securities Exchange Act of 1934, as amended, and, in accordance with this law, file periodic reports,
proxy statements and other information with the SEC. These periodic reports, proxy statements and other information are available
on the website of the SEC referred to above.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><A NAME="a_019"></A>Index to Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Contents</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 92%; padding-bottom: 8pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-bottom: 8pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-bottom: 8pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Report of Independent Registered Public Accounting Firm</FONT></TD>
    <TD COLSPAN="4" STYLE="text-align: right; padding-bottom: 8pt; line-height: 107%; vertical-align: top"><FONT STYLE="font: 10pt/107% Times New Roman, Times, Serif">F-2</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Financial Statements for the years ended June 30, 2018 and 2017 </FONT></TD>
    <TD COLSPAN="4" STYLE="text-align: right; padding-bottom: 8pt; line-height: 107%; vertical-align: top">F-3</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 8pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Unaudited
    financial statements for the nine months ended March 31, 2019 and 2018 </FONT></TD>
    <TD COLSPAN="4" STYLE="padding-bottom: 8pt; line-height: 107%; text-align: right; vertical-align: top">F-23</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><IMG SRC="image_004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">To the Board of Directors and<BR>
Stockholders of BioVie, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">We have audited the accompanying balance sheets of BioVie,
Inc. (the Company) as of June 30, 2018 and 2017, and the related statements of operations, stockholders&rsquo; equity, and cash
flows for each of the years then ended, and the related notes (collectively referred to as the financial statements). In our opinion,
the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2018 and
2017, and the results of its operations and its cash flows for each of the two years ended June 30, 2018 and 2017, in conformity
with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">These financial statements are the responsibility of
the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on
our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">We conducted our audits in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Our audits included performing procedures to assess the
risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as
well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis
for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">D. Brooks and Associates CPA&rsquo;s, P.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">We have served as the Company&rsquo;s auditor since 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Palm Beach Gardens, Florida</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">October 4, 2018<BR STYLE="clear: both">
</P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">June 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">June 30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">2018</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">2017</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 20pt">Cash</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">45,800</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,140</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 30pt">Total Current Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">45,800</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,140</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">OTHER&nbsp;&nbsp;ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Intangible Assets (Net of Amortization)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,783,980</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,013,357</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 20pt">Goodwill</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">345,711</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">345,711</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 30pt">Total Other Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,129,691</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,359,068</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">TOTAL ASSETS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,175,491</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,364,209</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Accounts Payable and accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">884,207</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">470,973</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Related Party Loan</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">35,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Accrued Payroll</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">354,167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">125,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 30pt">Total Current Liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,238,374</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">630,973</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">LONG-TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Demand Promissory Note</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Notes Payable, Related Parties</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">575,918</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">575,918</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 30pt">&nbsp;Total Long-Term Liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">825,918</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">575,918</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">TOTAL LIABILITIES</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,064,292</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,206,891</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Common stock, $0.0001 par value; 300,000,000 shares authorized; 98,503,199 and 91,925,000 shares issued and outstanding, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,850</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,192</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Additional paid in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,870,475</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,483,134</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,769,126</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,335,009</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total Stockholders&rsquo; Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">111,199</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,157,317</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,175,491</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,364,209</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><I>The accompanying notes are an integral part of the
financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0">&nbsp;</P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Twelve Months</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Twelve Months</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ended</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2017</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">REVENUE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">OPERATING EXPENSES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Amortization</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">229,377</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">229,377</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Research and development expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">370,853</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">466,354</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Payroll expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">311,525</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">285,392</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Professional fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,331,142</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">503,369</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Selling, general and administrative expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">129,270</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">69,122</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">TOTAL OPERATING EXPENSES</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,372,166</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,553,614</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">LOSS FROM OPERATIONS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,372,166</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,553,614</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">OTHER EXPENSE (INCOME):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Other Income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(222,928</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,960</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">TOTAL OTHER EXPENSE (INCOME), NET</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40,956</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(222,942</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">NET LOSS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,413,122</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,330,672</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Deemed dividend</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,995</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">NET LOSS ATTRIBUTABLE TO COMPANY STOCKHOLDERS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,434,117</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">NET LOSS PER COMMON SHARE, BASIC AND DILUTED</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.03</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.01</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">WEIGHTED AVERAGE NUMBER OF</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">COMMON&nbsp;&nbsp;SHARES OUTSTANDING, BASIC AND DILUTED</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">95,758,079</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">89,391,302</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>The accompanying notes are an
integral part of the financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Statement of Changes in Stockholders&rsquo;
Equity</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018
and 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Additional</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Paid in</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Accumulated</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Stockholders&rsquo;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Deficit</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font: 10pt Times New Roman, Times, Serif">Balance, June 30, 2016</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">87,160,001</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">8,716</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,911,560</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,004,337</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,915,939</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of shares and warrants for cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,764,999</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">477</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">479,523</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">479,999</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Options vested</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">92,051</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">92,051</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,330,672</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,330,672</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Balance, June 30, 2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">91,925,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,193</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,483,134</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,335,009</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,157,317</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of shares and warrants for cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,729,699</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">172</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">444,827</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">444,999</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Issuance of shares for services</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,748,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">475</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">642,375</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">642,850</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Options vested</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">238,165</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">238,165</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Exercise of options for cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,990</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of warrants for services</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,469</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,469</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of warrants with debt</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">26,519</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">26,519</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Deemed dividends for ratchet adjustment to warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20,995</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(20,995</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,413,122</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,413,122</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, June 30, 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">98,503,199</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,850</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,870,474</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,769,126</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">111,197</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0pt"><I>The accompanying notes are an integral part of the
financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Twelve Months</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Twelve Months</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ended</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ended June 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ended June 30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2017</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Net loss</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,413,122</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,330,672</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash to cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Amortization of intangible assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">229,377</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">229,377</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Amortization of debt discount</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">26,519</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Share based compensation expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">893,484</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">92,052</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Changes in operating assets and liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Decrease in prepaid expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,982</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Increase in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 30pt">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">413,234</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">350,674</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 30pt">Accrued payroll</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">229,167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">27,972</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net cash used in operating activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(621,341</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(623,615</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Repayment of loan</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(35,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Proceeds from related party</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Proceeds from demand promissory note</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Proceeds from issuance of common stock and warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">344,999</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">479,999</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Proceeds from exercise of options</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Proceeds from issuance of warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net cash provided by financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">661,999</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">504,999</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Increase (decrease) in cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,658</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(118,616</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Cash, beginning of period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,140</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">123,757</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Cash, end of period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">45,800</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,140</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">SUPPLEMENTAL CASH FLOW INFORMATION:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Non-cash Investing and Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Issuance of warrants with debt</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26,519</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0pt"><I>The accompanying notes are an integral part of the
financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018 and
2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>1.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Background Information</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt">BioVie Inc. (the &ldquo;Company&rdquo;) is a clinical-stage
company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused
on developing and commercializing BIV201, a novel approach to the treatment of ascites due to chronic liver cirrhosis. In March
2017, the Company received notification from the US Food and Drug Administration (FDA) that it could initiate a Phase 2a US clinical
trial. In April the Company signed a Cooperative Research and Development Agreement (CRADA) with the McGuire Research Institute/VA
in Richmond, VA, and began dosing patients with BIV201 in September 2017.&nbsp;As of June 2018, three&nbsp;patients had been treated
with BIV201 therapy in this ongoing Phase 2a clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">BIV201 has the potential to improve the health of thousands
of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH),
and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which
represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The BIV201 development program began at LAT Pharma LLC.
On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently
owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (&ldquo;PharmaIN&rdquo;), LAT
Pharma&rsquo;s former partner focused on the development of new modified drug candidates in the same therapeutic field but not
including BIV201, agreed to pay royalties equal to less than 1% of future net sales of each company&rsquo;s ascites drug development
programs, or if such program is licensed to a third party, less than 5% of each company&rsquo;s net license revenues. The Company&rsquo;s
relationship with PharmaIN could advance into a collaboration or be terminated. The Company has an issued US Patent covering the
use of BIV201 for the treatment of ascites patients in the outpatient setting using ambulatory pump infusion, and has filed patent
applications for its drug candidate in Japan, and Europe, and China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company&rsquo;s activities are subject to significant
risks and uncertainties including failure to secure additional funding to properly execute the Company&rsquo;s business plan.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>2.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Liquidity</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">We believe that our existing cash and cash equivalents,
including the amounts received after the end of the fiscal year, will be sufficient to meet our operating and capital requirements
for at least 12 months from the date of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On July 3, 2018, the Company, entered into a Securities
Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with Acuitas Group Holdings, LLC (&ldquo;Acuitas&rdquo;) and certain
other purchasers identified in the Purchase Agreement (together with Acuitas, the &ldquo;Purchasers&rdquo;) pursuant to which (i)
the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the Company&rsquo;s newly created Series A Convertible Preferred
Stock (the &ldquo;Preferred Stock&rdquo;) at a price per share of $1.50 per share of Preferred Stock (the &ldquo;Initial Sale&rdquo;)
and (ii) the Company will issue associated warrants (the &ldquo;Warrants&rdquo;) to purchase 213,333,200 shares of the Company&rsquo;s
Class A Common Stock (the &ldquo;Common Stock&rdquo;), each subject to the terms and conditions set forth in the Purchase Agreement,
for an aggregate consideration of $3.2 million.</P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018 and
2017</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>3.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Significant Accounting Policies</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Basis of Presentation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions
that affect the reported amounts and disclosure of contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Use of Estimates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ
from those estimates.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Cash</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Cash is maintained at financial institutions and, at
times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. All
of the Company&rsquo;s cash balances were fully insured at June 30, 2018.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Financial Instruments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company&rsquo;s financial instruments include cash,
accounts payable, related party loans and a demand promissory note. The carrying amounts of cash and accounts payable approximate
their fair value, due to the short-term nature of these items.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Long-Term Notes Payable</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company&rsquo;s long-term notes payable include accrued
payroll to officers and accrued payments to third party consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Research and Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Research and development costs are charged to operations
when incurred and are included in operating expenses. The Company expensed $370,853 and $466,354 for research and development for
the years ended June 30, 2018 and 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Income Taxes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Deferred income tax assets and liabilities arise from
temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as
measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities
are classified as current or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred
tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods
in which the temporary differences are expected to reverse.&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018 and
2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>3.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company follows the provisions of FASB ASC 740-10
"<I>Uncertainty in Income Taxes</I>&rdquo; (ASC 740-10), January 1, 2007. The Company has not recognized a liability as a
result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has
not been provided since there are no unrecognized benefits at June 30, 2018 and since the date of adoption. The Company has not
recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit,
the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating
expenses.&nbsp; The Company&rsquo;s tax returns for the years ended June 30, 2015, 2016, 2017 and 2018 remain open to examination
by taxing authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Earnings (Loss) per Share</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Basic earnings per share are computed by dividing net
income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share
are computed by dividing net income by the weighted average number of shares of common stock outstanding and dilutive options outstanding
during the year. For the years ended June 30, 2017 and 2018 all outstanding options have been excluded from the calculation of
the diluted net loss per share since their effect was anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The following potentially dilutive securities were excluded
from the computation of diluted loss per share for the years ended June 30, 2017 and 2018:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">Number of Shares (Thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">Number of Shares (Thousands)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Stock Options</TD><TD STYLE="width: 8%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">4,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">5,150</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 5.4pt">Warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,174</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,774</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">10,174</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,924</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Stock-based Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company has accounted for stock-based compensation
under the provisions of FASB ASC 718 &ndash; &ldquo;Stock Compensation&rdquo; which requires the use of the fair-value based method
to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (stock
options and common stock purchase warrants). For employee awards, the fair value of each stock option award is estimated on the
date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected
term, and the risk-free interest rate. For non-employees, the fair value of each stock option award is estimated on the measurement
date using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term,
and the risk-free interest rate. For non-employees, the Company utilizes the graded vesting attribution method under which the
entity treats each separately vesting portion (tranche) as a separate award and recognizes compensation cost for each tranche over
its separate vesting schedule. Expected volatilities are based on historical volatility of peer companies and other factors estimated
over the expected term of the stock options. For employee awards, the expected term of options granted is derived using the &ldquo;simplified
method&rdquo; which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free
rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term.</P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018 and
2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>3.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Goodwill</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Goodwill is recorded when the purchase price paid for
an acquisition exceeds the fair value of net identified tangible and intangible assets acquired. The Company performs an annual
impairment test of goodwill and further periodic tests to the extent indicators of impairment develop between annual impairment
tests. The Company&rsquo;s impairment review process compares the fair value of the reporting unit to its carrying value, including
the goodwill related to the reporting unit. To determine the fair value of the reporting unit, the Company may use various approaches
including an asset or cost approach, market approach or income approach or any combination thereof. These approaches may require
the Company to make certain estimates and assumptions including future cash flows, revenue and expenses. These estimates and assumptions
are reviewed each time the Company tests goodwill for impairment and are typically developed as part of the Company&rsquo;s routine
business planning and forecasting process. While the Company believes its estimates and assumptions are reasonable, variations
from those estimates could produce materially different results. The Company did not recognize any goodwill impairments for the
years ended June 30th, 2017 and June 30th, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;<I>Impairment of Long-Lived Assets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Long-lived assets, including intangible assets, are reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted
future cash flows expected to be generated by the asset.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">If the carrying amount of an asset exceeds its undiscounted
estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying
amount of the asset exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as
expected discounted cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance
sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized.
The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset
and liability sections of the balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Recent accounting pronouncements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company has reviewed recent accounting pronouncements
issued by the FASB (including its EITF), the AICPA, and the SEC and did not or are not believed by management to have a material
impact on the Company&rsquo;s financial statements.</P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018 and
2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>4.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Intangible Assets</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The company&rsquo;s intangible assets consist of intellectual
property acquired from LAT Pharma, Inc., and are amortized over their estimated useful lives as indicated below. The following
is a summary of the intangible assets as of June 30, 2018 and 2017.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">June 30, 2018</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">June 30, 2017</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Intangible Assets subject to Amortization</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,293,770</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,293,770</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accumulated Amortization</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">509,790</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">280,413</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Intangible Assets (Net of Amortization)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,783,980</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,013,357</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;Future expected Amortization of intangible assets
is as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: left">Year Ending June 30,</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 73%; text-align: left">2019</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">229,377</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,377</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">2021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,377</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">2022</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,377</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">2023</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,377</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Thereafter</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">637,095</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,783,980</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>5.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Demand Note</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On May 21, 2018, the Company received $250,000 in exchange
for a promissory note from Acuitas Group Holding LLC. The promissory note carries 10% interest per year and has a maturity date
of 10 business days of demand by Payee. The promissory note also has a provision that in the event of a superseding equity financing
transaction, the Payor will receive 50% warrant coverage on same terms as if the superseding transactions occurs. On July 3, 2018,
the Company entered into an equity financing transaction which resulted in Acuitas Group Holding LLC., receiving 833,333 warrants
that expire on July 3<SUP>rd</SUP> 2024 with an exercise price of 1.8 cents per share. The Company valued the warrants at $29,666
using the Black Scholes Model and the following assumptions were used: volatility &ndash; 169%; Term &ndash; 6 years; Risk Free
Rate &ndash; 2.96%; dividend rate &ndash; 0.00%. Based on their relative fair value, the Company allocated $26,519 of the proceeds
to the warrants, which was recorded as additional interest expense for the year ended June 30, 2018. As the promissory note was
converted into common stock subsequent to June 30, 2018, the balance as of June 30, 2018 is classified as long term on the accompanying
balance sheet.</P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018 and
2017</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>6.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Related Party Transactions</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Notes Payable</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">LAT Pharma was given a zero-interest bearing loan by
the Company&rsquo;s CEO, Jonathan Adams in the amount of $5,000 in August 2015 and $5,000 in November 2015.&nbsp; The total of
$10,000 was outstanding when the Company merged with LAT Pharma. On June 16<SUP>th</SUP>, 2017, the Company was given an additional
$25,000 zero-interest bearing loan by Jonathan Adams.&nbsp; During the quarter ended December 31, 2017, the Company repaid the
$35,000 outstanding balance of the loan. During the quarter ended March 31, 2018, the Company was given an additional $25,000 zero-interest
bearing loan by Jonathan Adams. During the quarter ended June 30, 2018, the Company repaid the $25,000 outstanding balance of the
loan. The outstanding balance of the loan was $35,000 as of June 30, 2017 and zero as of June 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On March 23, 2017, Barrett Ehrlich agreed to defer the
payment of his consulting fee debt of $173,333 until&nbsp;December 31, 2019, through the issuance of a Promissory note.&nbsp; The
promissory note does not carry any interest charge as long as the amount is paid in full before&nbsp;December 31, 2019.&nbsp; The
consulting fee debt has thereby been reclassified from a current liability to a long-term liability on the balance sheet.&nbsp;Any
portion of the balance due under the note that remains unpaid after&nbsp;December 31, 2019&nbsp;will accrue interest at a rate
of 5% per annum until paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On March 23, 2017, Elliot Ehrlich agreed to forgive 50%
of his salary debt of $444,056.&nbsp; The adjusted salary debt is $222,028.13.&nbsp; Elliot Ehrlich also agreed to defer the payment
of his salary debt of $222,028 until&nbsp;December 31, 2019, through the issuance of a Promissory note.&nbsp; The promissory note
does not carry any interest charge as long as the amount is paid in full before&nbsp;December 31, 2019.&nbsp; The salary debt has
thereby been reclassified from a current liability to a long-term liability on the balance sheet and the salary debt forgiven has
been reflected on the income statement as other income.&nbsp;Any portion of the balance due under the note that remains unpaid
after&nbsp;December 31, 2019&nbsp;will accrue interest at a rate of 5% per annum until paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On March 23, 2017, Jonathan Adams agreed to defer the
payment of his salary debt of $180,555 until&nbsp;December 31, 2019, through the issuance of a Promissory note.&nbsp; The promissory
note does not carry any interest charge as long as the amount is paid in full before&nbsp;December 31, 2019.&nbsp; The salary debt
has thereby been reclassified from a current liability to a long-term liability on the balance sheet.&nbsp;Any portion of the balance
due under the note that remains unpaid after&nbsp;December 31, 2019&nbsp;will accrue interest at a rate of 5% per annum until paid
in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The outstanding balance of the long-term note payable
was $575,917 as of June 30, 2017 and $575,917 as of June 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Sale of Common Stock and Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In January 2018, the Company sold an aggregate of 333,333
shares of common stock and warrants to purchase 333,333 shares of common stock to a member of its board of directors for aggregate
gross proceeds of $50,000. The purchase price for the common stock and warrants was $0.15 per share. The warrants are exercisable
at an exercise price of $0.15 at any time from date of issuance until 7 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Common Stock issued for Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In January 2018, the Company issued 1,400,000 shares
of common stock as compensation for the Board of Directors. The shares were valued at $0.15 per share which was the trading price
on date of issuance, and the value of the compensation was $210,000.</P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018 and
2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>7.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Commitments and Contingencies</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Office Lease</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On January 1, 2014, the Company executed a lease agreement
with Cummings Properties for the Company&rsquo;s office of 270 square feet at 100 Cummings Center, Suite 247-C, Beverly, MA 01915.
The lease is for a term of five years from January 1, 2014 to December 30, 2018 and requires monthly payments of $379. The Company
notified the lessor that it will terminate the lease on December 30, 2018.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Employment Agreements</I><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On April 11, 2016, the Company entered into employment
agreement with CEO Jonathan Adams. The Company&rsquo;s agreement provides for a three-year term with minimum annual base salary
of $250,000 per year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Challenge to US Patent</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On April 30, 2018, the Company received notice that Mallinckrodt
Pharmaceuticals Ireland Limited had petitioned the US Patent and Trademark Office (USPTO) to institute an Inter Partes Review of
BioVie&rsquo;s US Patent No. 9,655,945 titled &ldquo;Treatment of Ascites&rdquo; (the &rsquo;945 patent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Inter Partes Review is a trial proceeding conducted with
the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited
to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications. Although a petition
for Inter Partes Review has been filed, grant of the petition by the PTAB is required for the proceeding to be instituted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On August 15, 2018, BioVie submitted a Preliminary Response
to the PTAB providing a rationale as to why, in the Company&rsquo;s opinion, Mallinckrodt&rsquo;s request to institute the IPR
should not be granted. If he IPR is allowed to proceed, BioVie will seek to defend the &rsquo;945 patent and/or pursue a favorable
settlement. As of June 30, 2018, no adjustments or accruals are reflected as the Company is unable to determine a likely outcome
at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Royalty Agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Pursuant to the Agreement and Plan of Merger entered
into on April 11, 2016 between LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty
on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation; and The
Barrett Edge, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Pursuant to the Technology Transfer Agreement entered
into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty
on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at significantly
less than $500,000 per year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company and PharmaIN, Corporation, LAT Pharma&rsquo;s
former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201,
agreed to pay royalties equal to less than 1% of future net sales of each company&rsquo;s ascites drug development programs, or if such
program is licensed to a third party, less than 5% of each company&rsquo;s net license revenues. The Company&rsquo;s relationship with
PharmaIN could advance into a collaboration or be terminated. The Company has an issued US Patent covering the use of BIV201 for
the treatment of ascites patients in the outpatient setting using ambulatory pump infusion, and has filed patent applications for
its drug candidate in Japan, and Europe, and China.</P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018
and 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>8.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Stockholders&rsquo; Equity</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">During the year ended June 30, 2017 and 2018, the Company
issued stock options to consultants and board of directors for services provided to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The following is a summary of stock option activity for
the years ended June 30, 2017 and 2018.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares (Thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-Average Exercise Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Remaining Average Contractual Term</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Options</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; padding-left: 5.4pt">Outstanding at July 1, 2016</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">3,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">0.06</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">6.5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 5.4pt">Granted</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.24</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">Outstanding at June 30, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.9</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Options Exercised</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(100</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.02</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 5.4pt">Outstanding at June 30, 2018</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,150</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.12</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5.8</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 5.4pt">Exercisable at June 30, 2018</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,150</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.13</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4.8</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 10pt">The following is a summary of stock options outstanding
and exercisable by exercise price as of June 30, 2018.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-weight: bold; border-bottom: Black 1pt solid">Exercise Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Outstanding</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average Contract Life</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><B>Exercisable</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">0.06</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; text-align: right">3,100,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; text-align: right">6.5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; text-align: right">2,100,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">550,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">550,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,150,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,150,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018
and 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>8.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Stockholders&rsquo;
    Equity (continued)</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The fair value of options granted during the year ended
June 30, 2018 was estimated using the Black Scholes Method and the following assumptions: volatility - 124.7% to 143.46%; Term
&ndash; 5 years; Risk Free Rate &ndash; 2.45% to 2.61%; dividend rate &ndash; 0.00%. The fair value of options granted during the
year ended June 30, 2017 was estimated using the Black Scholes Method and the following assumptions: volatility &ndash; 136.8%
to 143.1%; Term &ndash; 4 years; Risk Free Rate &ndash; 0.53% to 1.4%; dividend rate &ndash; 0.00%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The compensation expense for the year ended June 30,
2018 includes $30,978 related to the stock options described above and an adjustment for year ended June 30, 2017 of $30,547. The
adjustment was due to a correction made to the valuation of Stock Options issued to the Chief Operating Officer. The legal and
professional expenses for the year ended June 30, 2018 includes $176,641 related to the stock options described above. The Company
expects to recognize $11,486 of future expenses related to the vesting of stock options through April 11, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The compensation expense for the year ended June 30,
2017 includes $35,392 related to the stock options described above. The legal and professional expenses for the year ended June
30, 2017 includes $56,660 related to the stock options described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Extension of Maturity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In November 2017, the Company extended the maturity date
of stock options to acquire 800,000 shares at exercise prices ranging from $0.21 to $0.25 issued to the board of directors between
November 2016 and December 2016 by 3 years. The Company recorded an incremental expense of $79,491 based on the increase in fair
value of the options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><U>Offerings of Common Stock and Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Issuance of Shares for Cash</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In September 2016, the Company sold and issued an aggregate
of 49,999 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately $5,000. The purchase
price for the common stock was $0.10 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In October 2016, the Company sold and issued an aggregate
of 225,000 shares of common stock and warrants to purchase 112,500 shares of common stock in a private placement transaction for
aggregate gross proceeds of approximately $45,000. The purchase price for the common stock and warrants was $0.20 per share. The
warrants are exercisable at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In November 2016, the Company sold and issued an aggregate
of 250,000 shares of common stock and warrants to purchase 125,000 shares of common stock in a private placement transaction for
aggregate gross proceeds of approximately $50,000. The purchase price for the common stock and warrants was $0.20 per share. The
warrants are exercisable at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In December 2016, the Company sold and issued an aggregate
of 100,000 shares of common stock and warrants to purchase 50,000 shares of common stock in a private placement transaction for
aggregate gross proceeds of approximately $20,000. The purchase price for the common stock and warrants was $0.20 per share. The
warrants are exercisable at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.</P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018
and 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>8.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Stockholders&rsquo;
    Equity (continued)</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In January 2017,&nbsp;the Company, entered into a common
stock purchase agreement (the &ldquo;Purchase Agreement&rdquo;) with Aspire Capital Fund, LLC, an Illinois limited liability company
(&ldquo;Aspire Capital&rdquo;) which provides that, on the terms and subject to the conditions and limitations set forth therein,
Aspire Capital is committed to purchase up to an aggregate of $12.0 million of shares of the Company&rsquo;s common stock over
the 30-month term of the Purchase Agreement (&ldquo;Aspire Equity Line&rdquo;). On execution of the Purchase Agreement, the Company
agreed to sell to Aspire Capital 1,000,000 shares of common stock and warrants to purchase 500,000 shares of common stock for proceeds
of $200,000. The Warrant Shares will each have a five-year term and will be exercisable at $0.50 per share. Concurrently with entering
into the Purchase Agreement, the Company also entered into a registration rights agreement with Aspire Capital (the &ldquo;Registration
Rights Agreement&rdquo;), in which the Company agreed to file one or more registration statements, as permissible and necessary
to register under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), registering the sale of the shares
of the Company&rsquo;s common stock that have been and may be issued to Aspire Capital under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Under the Purchase agreement, after the Securities and
Exchange Commission (the &ldquo;SEC&rdquo;) has declared effective the registration statement referred to above, on any trading
day selected by the Company, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice
(each, a &ldquo;Purchase Notice&rdquo;), directing Aspire Capital (as principal) to purchase up to 100,000 shares of the Company&rsquo;s
common stock per business day, up to $12.0 million of the Company&rsquo;s common stock in the aggregate at a per share price (the
&ldquo;Purchase Price&rdquo;) equal to the lesser of:</P>

<UL STYLE="margin-top: 0in; list-style-type: disc">

<LI STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">the lowest sale price of the Company&rsquo;s common stock
on the purchase date; or</LI>

<LI STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">the arithmetic average of the three (3) lowest closing sale
prices for the Company&rsquo;s common stock during the twelve (12) consecutive trading days ending on the trading day immediately
preceding the purchase date.</LI>

</UL>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In addition, on any date on which the Company submits
a Purchase Notice to Aspire Capital in an amount equal to 100,000 shares and the closing sale price of our stock is equal to or
greater than $0.30 per share, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted
average price purchase notice (each, a &ldquo;VWAP Purchase Notice&rdquo;) directing Aspire Capital to purchase an amount of stock
equal to up to 30% of the aggregate shares of the Company&rsquo;s common stock traded on its principal market on the next trading
day (the &ldquo;VWAP Purchase Date&rdquo;), subject to a maximum number of shares the Company may determine. The purchase price
per share pursuant to such VWAP Purchase Notice is generally 95% of the volume-weighted average price for the Company&rsquo;s common
stock traded on its principal market on the VWAP Purchase Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Purchase Price will be adjusted for any reorganization,
recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the
Purchase Price. The Company may deliver multiple Purchase Notices and VWAP Purchase Notices to Aspire Capital from time to time
during the term of the Purchase Agreement, so long as the most recent purchase has been completed.</P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018 and
2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>8.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Stockholders&rsquo;
    Equity (continued)</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Purchase Agreement provides that the Company and
Aspire Capital shall not affect any sales under the Purchase Agreement on any purchase date where the closing sale price of the
Company&rsquo;s common stock is less than $0.10. There are no trading volume requirements or restrictions under the Purchase Agreement,
and the Company will control the timing and amount of sales of the Company&rsquo;s common stock to Aspire Capital. Aspire Capital
has no right to require any sales by the Company but is obligated to make purchases from the Company as directed by the Company
in accordance with the Purchase Agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions
on future funding, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement. In
consideration for entering into the Purchase Agreement, concurrently with the execution of the Purchase Agreement, the Company
issued to Aspire Capital 2,400,000 shares of the Company&rsquo;s common stock (the &ldquo;Commitment Shares&rdquo;). The Purchase
Agreement may be terminated by the Company at any time, at its discretion, without any cost to the Company. Aspire Capital has
agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling
or hedging of the Company&rsquo;s common stock during any time prior to the termination of the Purchase Agreement. Any proceeds
that the Company receives under the Purchase Agreement are expected to be used for working capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In March 2017, the Company sold and issued an aggregate
of 500,000 shares of common stock and warrants to purchase 250,000 shares of common stock in a private placement transaction for
aggregate gross proceeds of approximately $100,000. The purchase price for the common stock and warrants was $0.20 per share. The
warrants are exercisable at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In May 2017, the Company sold and issued an aggregate
of 240,000 shares of common stock and warrants to purchase 120,000 shares of common stock in a private placement transaction for
aggregate gross proceeds of approximately $60,000. The purchase price for the common stock and warrants was $0.25 per share. The
warrants are exercisable at an exercise price of $0.60 at any time from date of issuance until 5 years from the date of issuance.
In August 2017, the Company issued an aggregate of 32,727 shares of common stock and 16,364 warrants to compensate these investors
who purchased common stock at a $0.25 share price in a Series C offering prior to a reduction in the offering price to $0.22 per
share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In July 2017 and August 2017, the Company sold and issued
an aggregate of 886,364 shares of common stock and warrants to purchase 443,182 shares of common stock in a private placement transaction
for aggregate gross proceeds of approximately $195,000. The purchase price for the common stock and warrants was $0.22 per share.
The warrants are exercisable at an exercise price of $0.60 at any time from date of issuance until 5 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Between July 2017 and September 2017, the Company sold
an aggregate of 250,000 shares of common stock in transactions under the Aspire Equity Line for aggregate gross proceeds of $50,000.
The average purchase price for the common stock was $0.20 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In October 2017, the Company sold and issued an aggregate
of 159,091 shares of common stock and warrants to purchase 79,545 shares of common stock in a private placement transaction for
aggregate gross proceeds of approximately $35,000. The purchase price for the common stock and warrants was $0.22 per share. The
warrants are exercisable at an exercise price of $0.60 at any time from date of issuance until 5 years from the date of issuance.</P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018 and
2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>8.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Stockholders&rsquo;
    Equity (continued)</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In November 2017, the Company also sold and issued an
aggregate of 68,182 shares of common stock and warrants to purchase 34,091 shares of common stock in a private placement transaction
for aggregate gross proceeds of approximately $15,000. The purchase price for the common stock and warrants was $0.22 per share.
The warrants are exercisable at an exercise price of $0.60 at any time from date of issuance until 5 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In January 2018, the Company sold an aggregate of 333,333
shares of common stock and warrants to purchase 333,333 shares of common stock to a member of its board of directors for aggregate
gross proceeds of $50,000. The purchase price for the common stock and warrants was $0.15 per share. The warrants are exercisable
at an exercise price of $0.15 at any time from date of issuance until 7 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In June 2018, 100,000 shares of stock options were exercised
for $2,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Issuance of Shares for Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In August 2017, the Company issued 1,500,000 shares of
common stock to Aspire Capital in exchange for services. The shares were valued at $0.22 per share which was the trading price
on date of issuance, and the value of the services were $330,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In November 2017, the Company issued 150,000 shares of
common in exchange for services. The shares were valued at $0.23 per share which was the trading price on date of issuance, and
the value of the services were $34,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In January 2018, The Company issued 30,000 shares of
common stock in exchange for services. The shares were valued at $0.13 per share which was the trading price on date of issuance,
and the value of the services were $3,900.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In January 2018, the Company issued 1,400,000 shares
of common stock as compensation for the Board of Directors. The shares were valued at $0.15 per share which was the trading price
on date of issuance, and the value of the compensation was $210,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In February 2018, the Company issued 600,000 shares of
common stock in exchange for services. The shares were valued at $0.0475 per share which was the trading price on date of issuance,
and the value of the services were $28,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In April 2018, the Company issued 300,000 shares of common
in exchange for services. The shares were valued at $0.045 per share, and the value of the services were $13,500. In April 2018,
the Company issued 150,000 shares of common in exchange for services. The shares were valued at $0.024 per share which was the
trading price on date of issuance, and the value of the services were $3,600.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In May 2018, the Company issued 250,000 shares of common
in exchange for services. The shares were valued at $0.018 per share which was the trading price on date of issuance, and the value
of the services were $4,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In May 2018, the Company issued 68,500 shares of common
in exchange for services. The shares were valued at $0.10 per share which was the trading price on date of issuance, and the value
of the services were $6,850.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In June 2018, the Company issued 300,000 shares of common
in exchange for services. The shares were valued at $0.025 per share which was the trading price on date of issuance, and the value
of the services were $7,500.</P>



<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018 and
2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>8.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Stockholders&rsquo;
    Equity (continued)</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Issuance of Warrants for Cash</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In December 2017, the Company issued warrants to purchase
2,500,000 shares of common stock in a private placement transaction for aggregate gross proceeds of $100,000. The purchase price
for the warrants were $0.04 per warrant. The warrants are exercisable at an exercise price of $0.20 at any time from date of issuance
until 7 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Issuance of Warrants for Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In January 2018, the Company issued warrants to purchase
105,000 shares of common stock in exchange for services. The warrants are exercisable at an exercise price of $0.15 any time from
the date of issuance until 7 years from the date of issuance. The warrants were valued at $9,444. The fair value of the warrants
granted was estimated using the Black Scholes Method and the following assumptions: volatility &ndash; 166.7%; Term &ndash; 7 years;
Risk Free Rate &ndash; 2.48%; dividend rate &ndash; 0.00%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In February 2018, the Company issued warrants to purchase
105,000 shares of common stock in a termination agreement. The warrants are exercisable at an exercise price of $0.15 any time
from the date of issuance until 7 years from the date of issuance. The warrants were valued at $3,025. The fair value of the warrants
granted was estimated using the Black Scholes Method and the following assumptions: volatility &ndash; 166.7%; Term &ndash; 7 years;
Risk Free Rate &ndash; 2.81%; dividend rate &ndash; 0.00%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Warrant Price Adjustment</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In December 2017, the Company issued warrants to purchase
2,500,000 shares of common stock in a private placement transaction for aggregate gross proceeds of $100,000. The warrants were
exercisable at an exercise price of $0.20 at any time from date of issuance until 7 years from the date of issuance. The warrants
have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In January 2018, the Company
sold shares at $0.15, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair
value of the warrants between the stated exercise price and the reduced exercise price and recorded $20,995 as a deemed dividend.
The fair value of the warrants granted was estimated using the Black Scholes Method and the following assumptions: volatility &ndash;
164.7%; Term &ndash; 7 years; Risk Free Rate &ndash; 2.47%; dividend rate &ndash; 0.00%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The following table summarizes the warrants that have
been issued:</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Exercise Price</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Remaining Life (Years)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Outstanding at June 30, 2016</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,000,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 19%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.50</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Granted</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,173,864</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.51</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3.5</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Outstanding at June 30, 2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,173,864</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,600,151</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Expired</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.50</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Outstanding at June 30, 2018</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,774,015</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.29</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5.5</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018 and
2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>8.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>Stockholders&rsquo;
    Equity (continued)</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The following table summarizes the warrants by price:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Exercise Price</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Remaining Life (Years)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 26%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.15</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 26%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,043,333</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 26%; font: 10pt Times New Roman, Times, Serif; text-align: right">6.4</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,037,501</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.60</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">693,181</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4.1</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,774,015</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5.5</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>9.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>&nbsp;Income Taxes</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Deferred income taxes reflect the net tax effects of
temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used
for income tax purposes. At June 30, 2018, the Company has a Net Operating Loss (&ldquo;NOL&rdquo;) carryforward of approximately
$1,800,000. The NOL expires during the years 2032 to 2037. Realization of any portion of the $832,186 of net deferred tax assets
at June 30, 2018 is not considered more likely than not by management; accordingly, a valuation allowance has been established
for the full amount. The valuation allowance as of June 30, 2018 was $832,186. The change in the valuation allowance during the
year ended June 30, 2018 amounted to $357,231. The Company does not have any uncertain tax positions or events leading to uncertainty
in a tax position. The Company&rsquo;s 2015, 2016 and 2017 Corporate Income Tax Returns are subject to Internal Revenue Service
examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On December 22, 2017, the Tax Cuts and Jobs Act (the
&ldquo;Act&rdquo;) was signed into law. The Act decreases the U.S. corporate federal income tax rate from a maximum of 35% to a
flat 21% effective January 1, 2018. The Act also includes a number of other provisions including, among others, the elimination
of net operating loss carrybacks and limitations on the use of future losses, the repeal of the Alternative Minimum Tax regime
and the repeal of the domestic production activities deduction. These provisions are not expected to have a material effect on
the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Given the significant complexity of the Act and anticipated
additional implementation guidance from the Internal Revenue Service, further implications of the Act may be identified in future
periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Significant components of the Company&rsquo;s deferred
tax assets are as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">June 30, 2018</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">June 30, 2017</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Tax loss carryforward</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">555,064</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">446,071</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Intangible assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19,277</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,735</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Stock based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">257,845</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,149</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Valuation Allowance</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(832,186</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(474,955</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Net deferred tax assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018 and
2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>9.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>&nbsp;Income Taxes (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Since management of the Company believes that it is more
likely than not that the net deferred tax assets will not provide future benefit, the Company has established a 100 percent valuation
allowance on the net deferred tax assets as of June 30, 2018.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Reconciliation of the differences between income tax
benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for the years ended June
30, 2018 and 2017 is as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-left: 5.4pt">Income tax expense (benefit) at federal statutory rate</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">34</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">34</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">State taxes, net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(39</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(39</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 11pt; padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>10.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>&nbsp;Subsequent Events</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On July 3, 2018, BioVie Inc., the Company, entered into
a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with Acuitas Group Holdings, LLC (&ldquo;Acuitas&rdquo;)
and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the &ldquo;Purchasers&rdquo;) pursuant
to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the Company&rsquo;s newly created Series A Convertible
Preferred Stock (the &ldquo;Preferred Stock&rdquo;) at a price per share of $1.50 per share of Preferred Stock (the &ldquo;Initial
Sale&rdquo;) and (ii) the Company will issue associated warrants (the &ldquo;Warrants&rdquo;) to purchase 213,333,200 shares of
the Company&rsquo;s Class A Common Stock (the &ldquo;Common Stock&rdquo;), each subject to the terms and conditions set forth in
the Purchase Agreement, for an aggregate consideration of $3.2 million. Acuitas also received an additional 833,333 Warrants in
connection with the payoff of a note issued by the Company in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred
on July 3, 2018. In addition, Acuitas has the option to purchase up to an additional 200,000,000 shares of Common Stock at a price
per share of $0.015, and associated warrants on the same terms as the Warrants, within two weeks following the one year anniversary
of the closing of the Initial Sale (the &ldquo;Subsequent Sale&rdquo;) in the event that the Company has not obtained $3,000,000
of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Each share of Preferred Stock automatically converted
into 100 shares of Common Stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment
to the Company&rsquo;s Articles of Incorporation (the &ldquo;Amendment&rdquo;) on August 13, 2018 that increased the number of
authorized shares of Common Stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than
a majority of the Company&rsquo;s issued and outstanding Common Stock on July 3, 2018, and was filed with the Secretary of State
of the State of Nevada 20 calendar days following the distribution of the Company&rsquo;s Definitive Information to be filed with
the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">See the heading &ldquo;Series A Convertible Preferred
Stock&rdquo; below for additional information related to the Preferred Stock. The purchase price of the Preferred Stock in
the Initial Sale, the exercise price of the Warrants, and the Common Stock in the Subsequent Sale is subject to adjustment.
First, in the event that the volume weighted average price of the Common Stock during the five-trading day period following
July 3, 2018 is less than $0.015 per share, the price per share of Common Stock, the associated conversion ratio of the
Preferred Stock, and the exercise price of the Warrants shall be retroactively adjusted to reflect such lower price. Second,
in the event that Mallinckrodt Pharmaceuticals Ireland Limited prevails in any proceeding which results in the useful life of
the Company&rsquo;s current intellectual property rights being reduced by more than 75 percent, then the price per share of
Common Stock, the associated conversion ratio of the Preferred Stock, and the exercise price of the Warrants shall be
retroactively adjusted to 50 percent of the then-effective price per share of Common Stock under the Purchase Agreement (for
example, if the then-effective price per share of Common Stock is $0.015, then following such event, the price per share will
be $0.0075). In each case, the Company may be required to issue additional shares of Common Stock, but in no event will the
Company be required to pay cash, to reflect such lower price per share.</P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended June 30, 2018 and
2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>10.</B></FONT></TD>
    <TD STYLE="width: 95%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>&nbsp;Subsequent
    Events (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Purchase Agreement contained customary representations
and warranties. In connection with the disclosure schedule associated with the representations and warranties, the Company also
disclosed customary information, including the following: (i) the existence of the Mallinckrodt Pharmaceuticals Ireland Limited
petition before the US Patent Trial and Appeal Board, (ii) the current capitalization of the Company, (iii) the Company&rsquo;s
obligation to pay a royalty on the net sales of BIV201 (continuous infusion terlipressin) in the amount of five percent to be allocated
four percent to LAT Pharma LLC members, 0.4 percent to PharmaIn Corporation and 0.6 percent to The Barrett Edge, Inc. pursuant
to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and the Company, (iv) the Company&rsquo;s
obligation to pay a royalty of five percent on net sales of all terlipressin products covered by specified patents up to a maximum
of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between the Company and the University
of Padova (Italy), and (v) certain recent issuances of Common Stock by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Pursuant to the Purchase Agreement, Terren Peizer, the
Chairman of Acuitas, was appointed as a member of the Company&rsquo;s Board of Directors (the &ldquo;Board&rdquo;) and as the Chief
Executive Officer of the Company, effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and the underlying
common stock under the Purchase Agreement is exempt from registration under the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On July 9, 2018, Elliot Ehrlich entered into an Accord
and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the original
contract to defer payment of his accrued salary dated March 23, 2017 totaling the amount of $222,028.13 and received the settled
sum of $22,203 and 222,028 common shares in satisfaction. This settlement reduced the Company&rsquo;s debt by $222,028.13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On July 9, 2018, Jonathan Adams entered into an Accord
and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the original
contract to defer payment of his accrued salary dated March 23, 2017 and subsequent unpaid salary, totaling the amount of $513,889,
and received the settled sum of $25,694 in satisfaction. This settlement reduced the Company&rsquo;s debt by $513,889.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On July 19, 2018, Geis-Hides Consulting LLC entered into
an Accord and Debt Satisfaction Agreement with the Company in which the consulting firm agreed to release the Company from all
liabilities arising from the Original Contract and Debt Repayment Plan dated December 15, 2013 totaling $130,000 and received the
settled sum of $65,000 and 260,000 common shares in satisfaction. This settlement reduced the Company&rsquo;s debt by $130,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">As a result of the conversion of the Series A Preferred
Stock in July 2018, the exercise of warrants to purchase 2,500,000 shares of common stock was reduced from $0.15 per share to $0.015
per share. On August 4, 2018, the Company issued 2,241,913 shares of common stock pursuant to a cash less exercise of warrants
to purchase 2,500,000 shares at an exercise price of $0.015 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On August 8, 2018, Barrett Ehrlich on behalf of The Barrett
Edge Inc. (&ldquo;Barrett&rdquo;) entered into an Accord and Debt Satisfaction Agreement with the Company in which Barrett agreed
to release the Company from all liabilities including the original contract to defer payment of Barrett&rsquo;s accrued salary
dated March 23, 2017, loan to the Company for $14,000, and subsequent unpaid consulting fees, totaling $493,333, and received the
settled sum of $131,333 and 493,333 common shares in satisfaction. This settlement reduced the Company&rsquo;s debt by $507,333.</P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Condensed Balance Sheets</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">June 30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018*</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; padding-left: 20pt">Cash</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">971,614</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">45,800</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Other Assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 30pt">Total Current Assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,006,614</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">45,800</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">OTHER&nbsp;&nbsp;ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Intangible Assets, Net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,611,947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,783,980</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 20pt">Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">345,711</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">345,711</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 30pt">Total Other Assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,957,658</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,129,691</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,964,272</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,175,491</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Accounts Payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">179,054</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">884,207</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Accrued Payroll</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">354,167</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 30pt">Total Current Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">179,054</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,238,374</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">LONG-TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Demand Promissory Note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Notes Payable, Related Parties</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">575,918</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 30pt">&nbsp;Total Long-Term Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">825,918</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL LIABILITIES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">179,054</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,064,292</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Commitments and contingencies (Note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Common stock, $0.0001 par value; 800,000,000 and 300,000,000 shares authorized at March 31, 2019 and June 30, 2018, respectively; 316,453,673 and 98,503,199 shares issued and outstanding at March 31, 2019 and June 30, 2018, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,645</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,850</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,359,780</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,870,475</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,606,207</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,769,126</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total Stockholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,785,218</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">111,199</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,964,272</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,175,491</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">*Derived from audited balance sheet as of June 30, 2018</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to unaudited condensed
financial statements</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Condensed Statements of Operations</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Nine Months</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Nine Months</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Ended</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">March 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">REVENUE</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING EXPENSES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; padding-left: 10pt">Amortization</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">172,033</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">172,033</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">732,373</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275,116</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Selling, general and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">936,180</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,401,104</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">TOTAL OPERATING EXPENSES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,840,586</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,848,253</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">LOSS FROM OPERATIONS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,840,586</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,848,253</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OTHER EXPENSE (INCOME):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(51,400</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">272</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,828</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Interest income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,036</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">TOTAL OTHER EXPENSE (INCOME), NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(52,164</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,827</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,788,422</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,858,080</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Deemed dividend related to ratchet adjustment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">48,659</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,837,081</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,858,080</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS PER SHARE BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.01</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">WEIGHTED AVERAGE NUMBER OF</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">COMMON&nbsp;&nbsp;SHARES OUTSTANDING BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">313,580,066</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">95,014,206</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to unaudited condensed
financial statements</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Condensed Statements of Cash Flows</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Nine Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Nine Months Ended</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-left: 10pt">Net loss</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(1,788,422</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(1,858,080</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash to cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Common shares issued for service</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Amortization of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">172,033</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">172,033</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,306</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">811,203</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Gain on settlement of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Changes in operating assets and liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(382,203</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275,283</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accrued payroll</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">187,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,869,886</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(412,061</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Repayment of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(244,300</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Proceeds from issuance of preferred shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,040,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Proceeds from issuance of common stock and warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">445,001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,795,700</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">435,001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net increase in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">925,814</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,940</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Cash, beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">45,800</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,140</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Cash, end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">971,614</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">28,080</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">SUPPLEMENTAL CASH FLOW INFORMATION:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">&nbsp;&nbsp;Cash paid for interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">&nbsp;&nbsp;Cash paid for taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Conversion of preferred shares to common stock</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,200,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Settlement of debt by issuance of common stock and forgiveness of debt</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,150,135</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Cashless exercise of warrants</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">224</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Deemed dividends for ratchet adjustments to warrants</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">48,659</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to unaudited condensed
financial statements</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Condensed Statements of Stockholders&rsquo;
Equity </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8.5pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">Preferred</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">Preferred</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">Common</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">Common</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">Additional</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">Total</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center"> Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center"> Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Paid in</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Stockholders&rsquo;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Equity</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%">Balance, June 30, 2017</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">91,925,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">9,193</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">3,483,134</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(2,335,009</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">1,157,318</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of shares in a private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,169,091</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">244,883</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">245,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Issuance of shares for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">329,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">330,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock option compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,752</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,752</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(662,841</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(662,841</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance, September 30, 2017 (Unaudited)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94,594,091</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,460</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,070,619</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,997,850</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,082,229</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of shares in a private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">227,273</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,977</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Issuance of shares for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,485</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of warrants in a private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock option compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,021</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(502,682</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(502,682</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Balance, December 31, 2017 (Unaudited)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">94,971,364</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,498</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,282,102</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,500,532</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">791,068</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of shares in a private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">333,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,967</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock option compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">152,062</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">152,062</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Issuance of shares for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,030,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">203</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">242,197</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">242,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of warrants for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,469</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,469</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(692,557</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(692,557</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Balance, March 31, 2018 (Unaudited)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">97,334,697</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,734</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,738,797</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,193,089</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">555,442</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance, June 30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,503,199</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,870,475</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(4,769,126</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">111,199</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of preferred stock in a private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,133,332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Conversion of preferred stock to common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,133,332</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,200,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,333,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21,333</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of shares in exchange for debt settlement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">975,361</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,150,037</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,150,135</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock option compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,412</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,412</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Cashless exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,241,913</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(224</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deemed dividends for ratchet adjustment to warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,659</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(48,659</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(439,871</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(439,871</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance, September 30, 2018 (Unaudited)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">315,053,673</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,505</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,251,026</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,257,656</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,024,875</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock option compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,285</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,285</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(500,510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(500,510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance, December 31, 2018 (Unaudited)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">315,053,673</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,505</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,267,310</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,758,166</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,540,650</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock option compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,609</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,609</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Issuance of shares for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,860</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(848,041</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(848,041</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Balance, March 31, 2019 (Unaudited)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">316,453,673</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">31,645</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,359,780</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,606,207</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,785,218</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to unaudited condensed
financial statements</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Nine Months Ended March 31,
2019 and 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="width: 97%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Background Information</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioVie Inc. (the &ldquo;Company&rdquo;)
is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company
is currently focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment
of ascites due to chronic liver cirrhosis. The Company began dosing patients with BIV201 in September 2017 at the McGuire Research
Institute Inc. in Richmond, VA. All six of the planned patients have been treated with BIV201 therapy in this Phase 2a clinical
trial. In May 2019, the Company announced that the primary study objectives to assess the safety, tolerability, and pharmacokinetics
(PK) of a continuous infusion of terlipressin over 28 days had been achieved. Detailed results will be presented to the Food &amp;
Drug Administration (&ldquo;FDA&rdquo;) in the first half of 2019.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BIV201 has the potential to improve
the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic
steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications,
ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites.
The Company has secured a US Patent covering the use of BIV201 for the treatment of ascites patients in the outpatient setting
using ambulatory pump infusion, and has filed patent applications for its product candidate in Japan, and Europe, Hong Kong, and
China. BIV201 also received Orphan Drug designation for hepatorenal syndrome (&ldquo;HRS&rdquo;) in November 2018.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The BIV201 development program began
at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The
Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (&ldquo;PharmaIN&rdquo;),
LAT Pharma&rsquo;s former partner focused on the development of new modified drug candidates in the same therapeutic field but
not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company&rsquo;s ascites drug development
programs, or if such program is licensed to a third party, less than 5% of each company&rsquo;s net license revenues. On December 24,
2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously
paid the remaining balance due on a related debt. PharmaIN, Corp.&rsquo;s rights to our program remain unchanged.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company&rsquo;s activities
are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the Company&rsquo;s
business plan.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="width: 97%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity and Going Concern</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company&rsquo;s operations
are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are
not limited to: the results of clinical testing and trial activities of the Company&rsquo;s products, the Company&rsquo;s ability
to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other
companies, the price of, and demand for, Company products, the Company&rsquo;s ability to negotiate favorable licensing or other
manufacturing and marketing agreements for its products, and the Company&rsquo;s ability to raise capital. The Company&rsquo;s
financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization
of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced losses since inception
and has an accumulated deficit of approximately $6.6 million at March 31, 2019. In addition, the Company has not generated any
revenues and no revenues are anticipated in the foreseeable future. The Company&rsquo;s future operations are dependent on the
success of the Company&rsquo;s ongoing development and commercialization efforts, as well as continuing to secure additional financing.</P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Nine Months Ended March 31,
2019 and 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="width: 97%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity and Going Concern (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2018, the Company completed a
capital raise from Acuitas Group Holdings, LLC (&ldquo;Acuitas&rdquo;) and other purchasers and received net proceeds of $3.2 million
and has resumed further clinical development of BIV201. The Acuitas investment agreement also stipulated that if the clinical development
of BIV201 continues, Acuitas may at its option invest up to an additional $3 million to fund operations in year two, less any federal
or FDA grant funding received by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The future viability of the Company
is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources
of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue
these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to
the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company&rsquo;s ability
to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this
uncertainty.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="width: 97%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant Accounting Policies</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Basis of Presentation &ndash; Interim Financial Information</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The accompanying unaudited interim
financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United
State of America (&ldquo;U.S. GAAP&rdquo;) for interim financial information and with the instructions to Form 10-Q and Article
10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect
all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair
presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for
the full year. The Condensed Balance Sheet at June 30, 2018 was derived from audited annual financial statements but does not contain
all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included
under the heading: &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; should
be read in conjunction with our Company&rsquo;s audited financial statements and related notes included in our Company&rsquo;s
Form 10-K for the year ended June 30, 2018 filed with the SEC on October 5, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">For a summary of significant accounting
policies, see the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October
5, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Net Loss per Common Share</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Basic net loss per common share
is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding
during the period. Diluted net loss per common share is computed by dividing net loss by the weighted
average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect
the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock
and convertible debentures. Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect
was considered anti-dilutive.</P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Nine Months Ended March 31,
2019 and 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="width: 97%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The table below shows the number
of outstanding stock options and warrants as of March 31, 2019 and June 30, 2018:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">March 31, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">June 30, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Stock Options</TD><TD STYLE="width: 8%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">7,250,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5,150,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 5.4pt">Warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">216,440,548</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,774,015</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">223,690,548</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,924,015</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Recent accounting pronouncements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company considers the applicability
and impact of all Accounting Standard Updates (&ldquo;ASU&rsquo;s&rdquo;). ASU&rsquo;s not discussed below were assessed and determined
to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In June 2018, the FASB issued ASU
2018-07, &ldquo;Compensation &ndash; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting&rdquo;.
This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment
transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings
as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair
value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim
periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on the
financial statements.</P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Nine Months Ended March 31,
2019 and 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify; background-color: white"><B>4.
Intellectual Property</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify; background-color: white">Intellectual
property, stated at cost, less accumulated amortization consists of the following:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-left: 5.4pt">Intellectual Property</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,293,770</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,293,770</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accumulated Amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">681,823</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">509,790</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Intellectual Property, Net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,611,947</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,783,980</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> Amortization
expense for the nine-month periods ended March 31, 2019 and 2018 was $172,033. Estimated future amortization expense is as follows: </P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; width: 68%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ending June 2019 (remaining three months)</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;57,344 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;229,377 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;229,377 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;229,377 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;229,377 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;637,095 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,611,947 </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B>5. Renegotiated Debt</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 19, 2018, Geis-Hides Consulting
LLC entered into an Accord and Debt Satisfaction Agreement with the Company in which the consulting firm agreed to release the
Company from all liabilities arising from the Original Contract and Debt Repayment Plan dated December 15, 2013 totaling $132,000
and received cash of $65,000 and 260,000 common shares in satisfaction. The common shares were valued at the market price on the
date of settlement at $0.06 per common share. The gain of $51,400 on the settlement of debt was reflected on the Statements of
Operations as &ldquo;other income&rdquo; for the nine-month period ended March 31, 2019.</P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Nine Months Ended March 31,
2019 and 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>6. Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 9, 2018, Jonathan Adams
(COO) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all
liabilities including the original contract to defer payment of his accrued salary dated March 23, 2017, the promissory note issued
by the Company to defer payment of accrued salary; and subsequent unpaid salary, totaling the amount of $534,722, and received
cash of $25,694 in satisfaction. The gain of $509,028 on the settlement of debt was reflected in the additional paid in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 9, 2018, Elliot Ehrlich
(former CEO and shareholder) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release
the Company from all liabilities including the original contract to defer payment of accrued salary dated March 23, 2017, totaling
the amount of $222,028 the promissory note issued by the Company to defer payment of accrued salary; and received cash of $22,273
and 222,028 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06
per common share. The gain of $186,503 on the settlement of debt was reflected in the additional paid in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On August 8, 2018, Barrett Ehrlich
(Independent contractor, related party to Elliot Ehrlich and shareholder) on behalf of The Barrett Edge Inc. (&ldquo;Barrett&rdquo;)
entered into an Accord and Debt Satisfaction Agreement with the Company in which Barrett agreed to release the Company from all
liabilities including the original contract to defer payment of accrued consulting fees dated March 23, 2017, the promissory note
issued by the Company to defer payment of accrued consulting fees; loan to the Company for $14,000, and subsequent unpaid consulting
fees, totaling $543,014, and received cash of $131,333 and 493,333 common shares in satisfaction. The common shares were valued
at the market price on the date of settlement at $0.13 per common share. The gain of $361,548 on the settlement of debt was reflected
in the additional paid in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">See note 8 for other related party
transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>7. Commitments and Contingencies</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Office Lease&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 1, 2018, the Company
executed a lease agreement with Acuitas Group Holdings, LLC (related party) for the Company&rsquo;s office at 11601 Wilshire Blvd
Ste 1100, Los Angeles, CA 90025. The lease is a month-to-month lease that may be cancelled upon 30 days&rsquo; written notice and
requires monthly payments of $1,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Challenge to US Patent</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On April 30, 2018, the Company
received notice that Mallinckrodt Pharmaceuticals Ireland Limited had petitioned the US Patent and Trademark Office (USPTO) to
institute an Inter Partes Review of BioVie&rsquo;s US Patent No. 9,655,945 titled &ldquo;Treatment of Ascites&rdquo; (the &rsquo;945
patent). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the
patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior
art consisting of patents and printed publications.</P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Nine Months Ended March 31,
2019 and 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>7. Commitments and Contingencies (continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On August 15, 2018, BioVie submitted
a Preliminary Response to the PTAB providing a rationale as to why, in the Company&rsquo;s opinion, Mallinckrodt&rsquo;s request
to institute the IPR should not be granted. On November 14, 2018, the PTAB granted institution of the IPR challenge after determining
that there was a reasonable likelihood of success in proving that at least one of the Company&rsquo;s 14 claims was unpatentable.
On March 7, 2019, we submitted a Patent Owner&rsquo;s Response and a Patent Owner&rsquo;s Contingent-Motion to Amend our patent
claims, and Declaration of Dr. Jaime Bosch, MD, PhD, our medical expert. We are actively defending the &rsquo;945 patent and may
explore the possibility of settlement with Mallinckrodt. However, there can be no assurance in that a favorable outcome will result,
or if settlement is reached that the PTAB will accept it. Although the PTAB encourages settlement, in view of public-interest considerations,
the board may continue the proceeding to a final written decision even if the parties settle. If the IPR is not terminated due
to settlement, the PTAB is statutorily required to issue its final written decision in this case before November 14, 2019. As of
March 31, 2019, no adjustments or accruals are reflected as the Company is unable to determine a likely outcome at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Royalty Agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to the Agreement and Plan
of Merger entered into on April 11, 2016 between LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single
digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation;
and The Barrett Edge, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company and PharmaIN Corporation,
LAT Pharma&rsquo;s former partner focused on the development of new modified drug candidates in the same therapeutic field but
not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company&rsquo;s ascites drug development
programs, or if such program is licensed to a third party, less than 5% of each company&rsquo;s net license revenues. On December 24,
2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously
paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to the Technology Transfer
Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single
digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped
at a maximum of $200,000 per year.</P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Nine Months Ended March 31,
2019 and 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B>8. Equity Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The following table summarizes
the activity relating to the Company&rsquo;s stock options for the nine months ended March 31, 2019:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-Average Exercise Price</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Remaining Average Contractual Term</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate Intrinsic Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-size: 10pt; padding-left: 5.4pt">Outstanding at June 30, 2018</TD><TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,150,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.12</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5.8</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 5.4pt">Granted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,100,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.04</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4.6</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">88,370</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 5.4pt">Options Exercised or Forfeited</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt">Outstanding at March 31, 2019</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,250,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.10</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5.3</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">166,175</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt">Exercisable at March 31, 2019</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,250,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.10</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5.3</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The fair value of each option grant
on the date of grant is estimated using the Black-Scholes Option &ndash; Pricing model reflecting the following weighted-average
assumptions:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-left: 5.4pt">Expected life of options (In years)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69.77</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69.66</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.60</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.59</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Dividend Yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Expected volatility is based on
the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected
life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as
they are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company recorded stock-based
compensation expense of $43,609 and $63,306 for the three-and nine-month periods ended March 31, 2019, respectively, and $152,062
and $191,835 for the three-and nine-month periods ended March 31, 2018, respectively.</P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Nine Months Ended March 31,
2019 and 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B>8. Equity Transactions (continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The fair value of options vested
during the nine-month period ended March 31, 2019 and 2018, was $10,235 and $25,281 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">As of March 31, 2019, there was
approximately $1,555 of unrecognized compensation cost related to non-vested options granted which is expected to be recognized
over a weighted-average period of 1 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The following is a summary of stock
options outstanding and exercisable by exercise price as of March 31, 2019:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 11pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 11pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Weighted Average </TD><TD STYLE="font-size: 11pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Outstanding</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Contract Life</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><B>Exercisable</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">0.03</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; text-align: right">700,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; text-align: right">4.8</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; text-align: right">700,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,300,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,100,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">550,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">550,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.25</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">500,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.6</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">500,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,250,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,250,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><U>Offerings of Common Stock and
Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Issuance of Shares for Cash</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 3, 2018, BioVie Inc.,
the Company, entered into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with Acuitas Group Holdings, LLC
(&ldquo;Acuitas&rdquo;) and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the &ldquo;Purchasers&rdquo;)
pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the Company&rsquo;s newly created Series
A Convertible Preferred Stock (the &ldquo;Preferred Stock&rdquo;) at a price per share of $1.50 per share of Preferred Stock (the
&ldquo;Initial Sale&rdquo;) and (ii) the Company will issue associated warrants (the &ldquo;Warrants&rdquo;) to purchase 213,333,200
shares of the Company&rsquo;s Class A Common Stock (the &ldquo;Common Stock&rdquo;), each subject to the terms and conditions set
forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. The Company received $160,000 of the $3.2 million
in April and May 2018 as prepaid equity. Acuitas also received an additional 833,333 Warrants in connection with the payoff of
a note issued by the Company in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition,
Acuitas has the option to purchase up to an additional 200,000,000 shares of Common Stock at a price per share of $0.015, and associated
warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale
(the &ldquo;Subsequent Sale&rdquo;) in the event that the Company has not obtained $3,000,000 of funding through various non-dilutive
grants prior to the one year anniversary of the closing of the Initial Sale.</P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Nine Months Ended March 31,
2019 and 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B>8. Equity Transactions (continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Each share of Preferred Stock automatically
converted into 100 shares of Common Stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of
Amendment to the Company&rsquo;s Articles of Incorporation (the &ldquo;Amendment&rdquo;) on August 13, 2018 that increased the
number of authorized shares of Common Stock to 800,000,000. The Amendment was approved by the written consent of the holders of
more than a majority of the Company&rsquo;s issued and outstanding Common Stock on July 3, 2018 and was filed with the Secretary
of State of the State of Nevada 20 calendar days following the distribution of the Company&rsquo;s Definitive Information that
was filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The purchase price of the Preferred
Stock in the Initial Sale, the exercise price of the Warrants, and the Common Stock in the Subsequent Sale is subject to adjustment.
In the event that Mallinckrodt Pharmaceuticals Ireland Limited prevails in any proceeding which results in the useful life of the
Company&rsquo;s current intellectual property rights being reduced by more than 75 percent, then the price per share of Common
Stock, the associated conversion ratio of the Preferred Stock, and the exercise price of the Warrants shall be retroactively adjusted
to 50 percent of the then-effective price per share of Common Stock under the Purchase Agreement (for example, if the then-effective
price per share of Common Stock is $0.015, then following such event, the price per share will be $0.0075). In this case, the Company
may be required to issue additional shares of Common Stock, but in no event will the Company be required to pay cash, to reflect
such lower price per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Purchase Agreement contained
customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties,
the Company also disclosed customary information, including the following: (i) the existence of the Mallinckrodt Pharmaceuticals
Ireland Limited petition before the US Patent Trial and Appeal Board, (ii) the current capitalization of the Company, (iii) the
Company&rsquo;s obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be
shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger,
dated April 11, 2016, by and between LAT Pharma LLC and the Company, (iv) the Company&rsquo;s obligation to pay a low single digit
royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to
the Technology Transfer Agreement, dated July 25, 2016, by and between the Company and the University of Padova (Italy), and (v)
certain recent issuances of Common Stock by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to the Purchase Agreement,
Terren Peizer, the Chairman of Acuitas, was appointed as a member of the Company&rsquo;s Board of Directors (the &ldquo;Board&rdquo;)
and as the Chief Executive Officer of the Company, effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and
the underlying common stock under the Purchase Agreement is exempt from registration under the Securities Act of 1933, as amended
(the &ldquo;Securities Act&rdquo;), pursuant to the exemption for transactions by an issuer not involving any public offering under
Section 4(a)(2) of the Securities Act.</P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Nine Months Ended March 31,
2019 and 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B>8. Equity Transactions (continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Issuance of Shares for Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On January 2, 2019, the Company
issued 1,400,000 shares of common stock as part of the annual board of director compensation. The share price on date of issuance
was $0.035 per share.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Issuance of Shares in Settlement
of Debt</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">During the nine months ended March
31, 2019, the Company settled $1,475,765 of debt including $1,313,765 owed to related parties, by issuing 975,361 shares of common
stock with a fair value of $1,150,135. See notes 5 and 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Issuance of Stock Options </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 1, 2018, the Company
issued stock options to purchase 100,000 shares of common stock to the Chief Financial Officer as part of her compensation. The
stock options were issued and are exercisable at an exercise price of $0.07 at any time from date of issuance and expire in 5 years
from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 13, 2018, the Company
issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock
options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 27, 2018, the Company
issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock
options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On November 10, 2018, the Company
issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock
options are exercisable at an exercise price of $0.05 at any time from date of issuance and expire in 5 years from the date of
issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On January 19, 2019, the Company
issued stock options to purchase 100,000 shares of common stock to each of five key employees or consultants and two company directors
as part of his or her annual compensation, for an aggregate total of 700,000 stock options. The stock options are exercisable at
an exercise price of $0.025 at any time from date of issuance until 5 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On March 11, 2019, the Company
issued stock options to purchase 1,000,000 shares of common stock to an investor relations (IR) consultant. The stock options were
issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><I>Cashless exercise of warrant</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On August 4, 2018, the Company
issued 2,241,913 shares of common stock pursuant to a cash less exercise of warrants to purchase 2,500,000 shares at an exercise
price of $0.015 per share. As a result of the conversion of the Series A Preferred Stock in July 2018, the exercise of warrants
to purchase 2,500,000 shares of common stock was reduced from $0.15 per share to $0.015 per share.<BR STYLE="clear: both">
</P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Nine Months Ended March 31,
2019 and 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B>8. Equity Transactions (continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><I>Warrant Price Adjustment</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In December 2017, the Company issued
warrants to purchase 2,500,000 shares of common stock in a private placement transaction for aggregate gross proceeds of $100,000.
The warrants were exercisable at an exercise price of $0.20 at any time from date of issuance until 7 years from the date of issuance.
The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In January
2018, the Company sold shares at $0.15, which therefore triggered the reduction in the strike price. The Company calculated the
difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $20,995
as a deemed dividend. In July 2018, the Company sold shares at $0.015, which therefore triggered the reduction in the strike price.
The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise
price and recorded $44,889 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In January 2018, the Company issued
warrants to purchase 210,000 shares of common stock in exchange for banking services which was recognized at fair value. The warrants
were exercisable at an exercise price of $0.15 at any time from date of issuance until 7 years from the date of issuance. The warrants
have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In July 2018, the Company
sold shares at $0.015, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair
value of the warrants between the stated exercise price and the reduced exercise price and recorded $3,770 as a deemed dividend.
The fair value of the warrants granted was estimated using the Black Scholes Method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The following table summarizes
the warrants that have been issued:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Weighted </TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Weighted Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Aggregate</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Average Exercise Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Remaining Life (Years)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Intrinsic Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; padding-left: 5.4pt">Outstanding at June 30, 2018</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4,774,015</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.29</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5.5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">214,166,533</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14,284,908</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 5.4pt">Exercised</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,500,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.02</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Outstanding and exercisable at March 31, 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">216,440,548</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.03</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,284,908</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Of the above warrants, 1,173,864 expire
in fiscal year ending June 30, 2022, 556,818 expire in fiscal year ending June 30, 2023, and 214,709,866 expire in fiscal year
ending June 30, 2025.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B>9. Subsequent Events</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In April 2019, to facilitate
the Company&rsquo;s planned uplisting to the NASDAQ Stock Market and related potential future issuances and sales of equity securities
for ordinary corporate finance and general corporate purposes and as recommended by the Board of Directors (&ldquo;Board&rdquo;),
the Company&rsquo;s stockholders approved an amendment to the Company&rsquo;s Articles of Incorporation to effect a reverse split
of its outstanding Class A common stock in the range of 50:1 to 200:1, as determined by the Board. Following that approval, the
Company filed a Registration Statement on Form S-1 (Registration No. 333-231136) (the &ldquo;S-1 Registration Statement&rdquo;)
pursuant to which it anticipates completing an offering of equity securities with proceeds sufficient to enable the launch and
completion of the BIV201 Phase 2b study and fund internal operations for at least the next twelve months.</P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 14pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Shares of Common Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_003.jpg" ALT="CzAwX4YXEAAAOf2 (1)" STYLE="height: 62px; width: 179px"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 2in; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%; border-top: Black 1pt solid; font: 11pt/107% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 11pt/107% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 11pt/107% Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 48pt 0 0; text-align: center"><B>ThinkEquity</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>a division of Fordham Financial Management,
Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 1in 0 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center">&nbsp;&nbsp; , 2019</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 47pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Through
and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 (the 25</FONT><FONT STYLE="font-size: 6pt"><SUP>th</SUP></FONT>
<FONT STYLE="font-size: 10pt">day after the date of this offering), all dealers effecting transactions in these securities, whether
or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s obligation
to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 106 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-bottom: Black 1.5pt solid"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART II &ndash; INFORMATION NOT REQUIRED
IN PROSPECTUS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Item 13. Other Expenses of Issuance and Distribution</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the expenses
in connection with this registration statement. All of such expenses are estimates, other than the filing fees payable to the Securities
and Exchange Commission and to FINRA.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: 1.5pt solid">Amount<BR> to be paid</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">SEC registration fee</TD><TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 08%; text-align: right">2,787.60</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINRA filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,950.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">The NASDAQ Capital Market initial listing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transfer agent and registrar fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Blue sky qualification fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Printing expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Miscellaneous expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: 1.5pt solid; text-align: right">73,262.40</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: black 4.5pt double; text-align: right">625,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 14. Indemnification of Directors and Officers</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a Nevada corporation and generally governed by the
Nevada Private Corporations Code, Title 78 of the Nevada Revised Statutes, or NRS.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 78.138 of the NRS provides that, unless the corporation&rsquo;s
articles of incorporation provide otherwise, a director or officer will not be individually liable unless it is proven that (i)
the director&rsquo;s or officer&rsquo;s acts or omissions constituted a breach of his or her fiduciary duties, and (ii) such breach
involved intentional misconduct, fraud or a knowing violation of the law.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 78.7502 of the NRS permits a Nevada corporation to
indemnify its directors and officers against expenses, judgments, fines, and amounts paid in settlement actually and reasonably
incurred in connection with a threatened, pending, or completed action, suit, or proceeding, except an action by or on behalf of
the corporation, if the officer or director (i) is not liable pursuant to NRS 78.138, or (ii) acted in good faith and in a manner
the officer or director reasonably believed to be in or not opposed to the best interests of the corporation and, if a criminal
action or proceeding, had no reasonable cause to believe the conduct of the officer or director was unlawful. Section 78.7502 of
the NRS also requires a corporation to indemnify its officers and directors if they have been successful on the merits or otherwise
in defense of any claim, issue, or matter resulting from their service as a director or officer.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 78.751 of the NRS permits a Nevada corporation to
indemnify its officers and directors against expenses incurred by them in defending a civil or criminal action, suit, or proceeding
as they are incurred and in advance of final disposition thereof, upon determination by the stockholders, the disinterested board
members, or by independent legal counsel. Section 78.751 of NRS requires a corporation to advance expenses as incurred upon receipt
of an undertaking by or on behalf of the officer or director to repay the amount if it is ultimately determined by a court of competent
jurisdiction that such officer or director is not entitled to be indemnified by the corporation if so provided in the corporation&rsquo;s
articles of incorporation, bylaws, or other agreement. Section 78.751 of the NRS further permits the corporation to grant its directors
and officers additional rights of indemnification under its articles of incorporation, bylaws or other agreement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 107; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 78.752 of the NRS provides that a Nevada corporation
may purchase and maintain insurance or make other financial arrangements on behalf of any person who is or was a director, officer,
employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or
agent of another company, partnership, joint venture, trust or other enterprise, for any liability asserted against him and liability
and expenses incurred by him in his capacity as a director, officer, employee or agent, or arising out of his status as such, whether
or not the corporation has the authority to indemnify him against such liability and expenses.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Articles of Incorporation and bylaws implement the indemnification
and insurance provisions permitted by Chapter 78 of the NRS by providing that:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36px; padding-left: 13pt; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We shall indemnify our directors and officers to the fullest extent permitted by the NRS against expense, liability and loss reasonably incurred or suffered by them in connection with their service as an officer or director; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 18px; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may purchase and maintain insurance, or make other financial arrangements, on behalf of any person who holds or who has held a position as a director, officer, or representative against liability, cost, payment, or expense incurred by such person.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At the present time, there is no pending litigation or proceeding
involving a director, officer, employee or other agent of ours in which indemnification would be required or permitted. We are
not aware of any threatened litigation or proceeding which may result in a claim for such indemnification.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 15. Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has not sold any within the past three years
which were not registered under the Securities Act except as follows:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Acuitas Group Transaction</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> On July 3, 2018, the registrant,
entered into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with Acuitas Group Holdings, LLC (&ldquo;Acuitas&rdquo;)
and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the &ldquo;Purchasers&rdquo;) pursuant
to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the Company&rsquo;s newly created Series A
Convertible Preferred Stock (the &ldquo;Preferred Stock&rdquo;) at a price per share of $1.50 per share of Preferred Stock (the
&ldquo;Initial Sale&rdquo;) and (ii) the registrant agreed to issue associated warrants (the &ldquo;Warrants&rdquo;) to purchase
1,706,666 shares of the registrant&rsquo;s Class A Common Stock (the &ldquo;Common Stock&rdquo;), each subject to the terms and
conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. The registrant received $160,000
of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 6,667 Warrants in connection
with the payoff of a note issued by the registrant in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred
on July 3, 2018. In addition, Acuitas had the option to purchase up to an additional 1,600,000 shares of Common Stock at a price
per share of $1.875, and associated warrants on the same terms as the Warrants, within two weeks following the one year anniversary
of the closing of the Initial Sale (the &ldquo;Subsequent Sale&rdquo;) in the event that the registrant had not obtained $3,000,000
of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale, less any
federal or FDA grant funding received by the Company. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Each share of Preferred Stock automatically
converted into 0.8 shares of Common Stock upon the filing with the Secretary of State of the State of Nevada of a Certificate
of Amendment to the registrant&rsquo;s Articles of Incorporation (the &ldquo;Amendment&rdquo;) on August 13, 2018 that increased
the number of authorized shares of Common Stock to 800,000,000. The Amendment was approved by the written consent of the holders
of more than a majority of the registrant&rsquo;s issued and outstanding Common Stock on July 3, 2018 and was filed with the Secretary
of State of the State of Nevada 20 calendar days following the distribution of the registrant&rsquo;s Definitive Information that
was filed with the Securities and Exchange Commission. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Pursuant to a letter agreement dated
June 24, 2019, Acuitas has agreed to modify its existing rights under the Purchase Agreement so that: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> - Acuitas agreed to immediately
exchange its existing Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to
a cashless exercise thereof at an assumed current market price of $45.00 per share and, as a result received an aggregate of 95%
of the shares covered thereby, or 1,526,333 shares of common stock, on June 24, 2019; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> - Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a &ldquo;cashless purchase&rdquo; as an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of our common stock on NASDAQ or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the &ldquo;Subsequent Sale Shares&rdquo;) to Acuitas, which is expected concurrently with the closing of this offering; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> - Acuitas shall in exchange for the foregoing agreements and waivers have the option to purchase additional shares of common stock and warrants to purchase one share of common stock for each share of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the then-effective purchase price of the Preferred Stock in the Initial Sale (the &ldquo;Funding Option&rdquo;), provided that any shares issued pursuant to any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant to the deemed exercise of its rights to purchase securities in a Subsequent Sale mentioned above. Assuming the closing of this offering occurs on or prior to September 1, 2019, we anticipate that such option will lapse unexercised in the event of such closing. In the event such closing occurs subsequent to September 1, 2019 and prior to November 30, 2019, we anticipate that Acuitas may elect to continue to fund our on-going clinical trials and operations by means of exercising such Funding Option, with any shares so purchased being deducted from the amount of Subsequent Sale Shares deliverable at closing as described above. </P>





<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The issuance of the Preferred Stock, the Warrants and the
underlying common stock under the Purchase Agreement is exempt from registration under the Securities Act of 1933, as amended (the
&ldquo;Securities Act&rdquo;), pursuant to the exemption for transactions by an issuer not involving any public offering under
Section 4(a)(2) of the Securities Act.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Aspire Capital Transaction</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 4, 2017, the registrant entered into a Common
Stock Purchase Agreement, or the Purchase Agreement, with Aspire Capital Fund, LLC, an Illinois limited liability company, or Aspire
Capital, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is
committed to purchase up to an aggregate of $12.0 million of shares of the registrant&rsquo;s common stock (the &ldquo;Purchase
Shares&rdquo;) over the 30-month term of the Purchase Agreement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Upon execution of the Purchase Agreement,
the registrant issued 19,200 shares of its common stock to Aspire Capital in consideration for entering into the Purchase Agreement,
and sold an additional 8,000 shares and warrants relating to 4,000 shares for aggregate proceeds of $200,000. The Purchase Shares
may be sold by the registrant to Aspire Capital on any business day the registrant selects in two ways: (1)&nbsp;through a regular
purchase of up to 800 shares at a known price based on the market price of our common stock prior to the time of each sale, and
(2)&nbsp;through a VWAP purchase on the terms and conditions set forth in the Purchase Agreement. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> The issuance of the 19,200 Commitment
Shares, 8,000 Initial Purchase Shares and all other shares of common stock that may be issued from time to time to Aspire Capital
under the Purchase Agreement is exempt from registration under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
pursuant to the exemption for transactions by an issuer not involving any public offering under Section&nbsp;4(a)(2) of the Securities
Act. </P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Aspire Capital Transaction</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> In the second quarter of the registrant&rsquo;s
fiscal year ending June 30, 2017, the registrant sold 4,600 shares to a number of accredited investors for $25.00 per share, for
aggregate gross proceeds of $115,000. The registrant also issued warrants to purchase 2,300 shares to such investors, which warrants
expire five years following issuance and are exercisable for $62.50 per share. Mr. James Lang, who joined the registrant&rsquo;s Board
of Directors on December 7, 2016, purchased 2,000 shares and received warrants to purchase 1,000 shares on November 11, 2016. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The issuance of the shares and warrants to the accredited
investors was exempt from registration under the Securities Act pursuant to Rule 506(b) of Regulation D under the Securities Act.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Item 16. Exhibits</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The following is a list of exhibits filed as a part of this
registration statement:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 7%; border-bottom: black 1.5pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 92%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description of Document</B></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriting Agreement.**</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013816000847/nnab-20160415_8kex2z1.htm">Agreement and Plan of Merger, dated April 11, 2016, among the Company, LAT Acquisition Corp and LAT Pharma, LLC (incorporated by reference to Exhibit 2.1 the Company&rsquo;s Current Report on Form 8-K filed on April 15, 2016).</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000154823313000011/nano0813ex-3.1.htm">Articles of Incorporation of the Company as filed with the Secretary of State of Nevada (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s registration statement on Form S-1 filed on August 15, 2013, File No. 333-190635).</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013816001063/nnab-20160722_8kex3z1.htm">Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed on July 22, 2016).</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013818000151/bivi-20180713_def14c.htm">Certificate of Amendment to Articles of Incorporation (incorporated by reference to Appendix A to the Company&rsquo;s Information Statement on Schedule 14C filed on July 13, 2018).</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013818000134/biovie-20180703_8kex3z1.htm">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed on July 3, 2018).</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000154823313000011/nano0813ex-3.2.htm">Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company&rsquo;s registration statement on Form S-1 filed on August 15, 2013, File No. 333-190635).</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000127/bivi-20190426_s1ex4z1.htm">Specimen Certificate representing shares of Class A Common Stock.</A>*</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013818000134/biovie-20180703_8kex4z1.htm">Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K filed on July 3, 2018).</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013817000006/bivi-20170105_8kex4z1.htm">Registration Rights Agreement, dated January 4, 2017, between the Company and Aspire Capital Fund, LLC (incorporated by reference to Exhibit 4.1 the Company&rsquo;s Current Report on Form 8-K filed on January 5, 2017).</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="bivi-20190628_s1ex5z1.htm">Opinion of Loeb &amp; Loeb LLP.</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013817000006/bivi-20170105_8kex10z1.htm">Common Stock Purchase Agreement, dated January 4, 2017, between the Company and Aspire Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed on January 5, 2017).</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013818000134/biovie-20180703_8kex10z1.htm">Securities
    Purchase Agreement, dated as of July 3, 2018, by and among BioVie Inc., Acuitas Group Holdings, LLC and the Purchasers
    identified therein (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed
on July 3, 2018).</A></FONT></TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000127/bivi-20190426_s1ex10z3.htm">Employment Agreement between Jonathan Adams and the Company dated, April 11, 2016.</A>*</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000127/bivi-20190426_s1ex10z4.htm">Amendment No. 1 to Employment Agreement between Jonathan Adams and the Company dated July 3, 2018.</A>*</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%">10.5</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><A HREF="bivi-20190628_s1ex10z5.htm">Letter Agreement between Acuitas Group Holdings, LLC and the Company dated June 24, 2019.</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%">10.6</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000134/bivi_14cdef.htm">BioVie Inc.2019 Omnibus Equity Incentive Plan (incorporated by reference to Appendix D to the Definitive Information Statement on Schedule 14C, filed on May 8, 2019)</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="bivi-20190628_s1ex14z1.htm">Code of Conduct and Ethics of BioVie Inc</A>.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="bivi-20190628_s1ex23z1.htm">Consent of D. Brooks and Associates CPA&rsquo;s, P.A., Independent Registered Public Accounting Firm.</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="bivi-20190628_s1ex5z1.htm">Consent of Loeb &amp; Loeb LLP.</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%">24.1</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000127/bivi-20190426_s1.htm#a_020">Powers of Attorney (included on signature page to this registration statement)</A>*</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">*</TD>
    <TD STYLE="text-align: justify; line-height: 107%">Previously filed.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be filed by amendment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Undertakings</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">1. For purposes of determining any liability
under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) the information omitted from the form of prospectus
filed as part of this registration statement in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the
registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration
statement as of the time it was declared effective.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">2. For the purpose of determining any
liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">3. To provide to the underwriters at
the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required
by the underwriters to permit prompt delivery to each purchaser.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to
the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid
by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will,
unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed
by the final adjudication of such issue.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Signatures</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the
Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Los Angeles, State of California, on June 28, 2019. </P>





<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIOVIE INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; line-height: 107%">/s/ Terren Peizer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 62%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 3%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 5%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 30%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terren Peizer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> KNOW ALL MEN BY THESE PRESENTS,
that we, the undersigned officers and directors of BioVie Inc., do hereby constitute and appoint Terren Peizer as his or her true
and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him and in his name, place, and
stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other
documents in connection therewith) to this registration statement and any subsequent registration statement filed by the registrant
pursuant to Rule 462(b) of the Securities Act of 1933, as amended, which relates to this registration statement, and to file the
same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting
unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary
to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and
confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by
virtue hereof.&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the
Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the
dates indicated.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 29%; border-bottom: black 1.5pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Person</B></FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 49%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capacity</B></FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 20%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%; text-align: left; vertical-align: bottom">/s/ Terren Peizer</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief
    Executive Officer </FONT> </TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">June<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 28, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terren Peizer</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">(Principal Executive Officer)</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%; text-align: left; vertical-align: bottom">/s/ J. Wendy Kim</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Corporate Secretary </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J. Wendy Kim</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">(Principal Financial Officer)</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">/s/ Jonathan Adams</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief
    Operating Officer and Director</FONT> </TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan Adams</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%"> * </TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cuong Do</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%"> * </TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jim Lang</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%"> * </TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hari Kumar</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%"> * </TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Sherman</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">/s/ Richard J. Berman</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard J. Berman</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%"> *By: /s/ Terren Peizer </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attorney-in-fact</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    28, 2019</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terren Peizer</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 113; Options: Last -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>bivi-20190628_s1ex5z1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>

<DIV STYLE="width: 6.25in; margin:0 auto">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; font: 11pt Arial, Helvetica, Sans-Serif"><IMG SRC="image_008.jpg" ALT="" STYLE="height: 120px; width: 120px"></TD>
    <TD STYLE="width: 26%">
        <P STYLE="font: small-caps bold 9pt/10pt Arial, Helvetica, Sans-Serif; margin: 0.35in 0 0">Loeb&amp;Loeb LLP</P>
        <P STYLE="font: 1pt/normal Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 8pt/9pt Arial, Helvetica, Sans-Serif; margin: 9pt 0 0">345 Park Avenue<BR>
        New York, NY 10154</P></TD>
    <TD STYLE="width: 26%; padding-top: 53pt; font: 8pt/9pt Arial, Helvetica, Sans-Serif"><B>Main</B>&#9;212.407.4000<BR>
<B>Fax</B>&#9;212.407.4990<BR>
<BR>
</TD></TR>
</TABLE>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">June 28, 2019</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">BioVie Inc.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">2120 Colorado Ave., #230</P>

<P STYLE="margin: 0">Santa Monica, CA 90404</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Ladies and Gentlemen:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have acted as special
counsel to BioVie Inc., a Nevada corporation (the &ldquo;Company&rdquo;), in connection with the Registration Statement on Form
S-1 (File No. 333-231136) (the &ldquo;Registration Statement&rdquo;) filed by the Company with the Securities and Exchange Commission
under the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;), relating to the offer and sale by the Company of shares of
Class A common stock, par value $0.0001 per share, at an aggregate initial offering price of up to $17,250,000 (the &ldquo;Shares&rdquo;).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have examined originals
or copies, certified or otherwise identified to our satisfaction, of such corporate records of the Company and other certificates
and documents of officials of the Company, public officials and others as we have deemed appropriate for purposes of this letter.
We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the conformity
to authentic original documents of all copies submitted to us as conformed and certified or reproduced copies.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based on the foregoing,
and subject to the qualifications, assumptions and limitations stated herein, we advise you that, in our opinion, when the Pricing
Committee of the Board of Directors of the Company (the &ldquo;Pricing Committee&rdquo;) has taken all necessary corporate action
to authorize and approve the issuance of the Shares, and when the Shares have been issued and delivered against payment therefor
in accordance with the terms of the applicable definitive underwriting agreement approved by the Board of Directors of the Company
or the Pricing Committee, the Shares will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our opinion is limited
to the applicable statutory provisions of the Nevada Private Corporations Chapter of the Nevada Revised Statutes, Nev. Rev. Stat.&nbsp;78,
including interpretations thereof in published decisions of the Nevada courts, and applicable provisions of the Nevada Constitution.
We express no opinion with respect to any other laws.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We hereby consent to the
filing of this opinion as an exhibit to the Registration Statement and to the reference made to us under the caption &ldquo;Legal
Matters&rdquo; in the prospectus constituting part of the Registration Statement. In giving this consent, we do not thereby admit
that we are within the category of persons whose consent is required under Section 7 of the Act, the rules and regulations of the
Securities and Exchange Commission promulgated thereunder or Item 509 of Regulation S-K promulgated under the Act.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in">Very truly yours,</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in">/s/ Loeb &amp; Loeb LLP</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in">Loeb &amp; Loeb LLP</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
        <P STYLE="font: 8pt Arial, Helvetica, Sans-Serif; margin: 0">Los Angeles &nbsp;&nbsp;&nbsp;New York &nbsp;&nbsp;&nbsp;Chicago &nbsp;&nbsp;&nbsp;Nashville &nbsp;&nbsp;&nbsp;Washington, DC &nbsp;&nbsp;&nbsp;San Francisco
        &nbsp;&nbsp;&nbsp;Beijing &nbsp;&nbsp;&nbsp;Hong Kong &nbsp;&nbsp;&nbsp;www.loeb.com</P>
        <P STYLE="font: 6pt Arial, Helvetica, Sans-Serif; margin: 9pt 0 0">A limited liability partnership including professional corporations</P></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>bivi-20190628_s1ex10z5.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>

<DIV STYLE="width: 6.5in; margin:0 auto">
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><IMG SRC="image_009.jpg" ALT="" STYLE="height: 61.5pt; width: 196.5pt"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">June 24, 2019</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Acuitas Group Holdings, LLC</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">2120 Colorado Ave.<BR>
Suite 230</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Santa Monica, CA 90404</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">Attention: Terren Peizer</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">Dear Mr. Peizer:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">Reference is hereby made to the following
documents: (i) that certain Securities Purchase Agreement, dated July 3, 2018, by and among BioVie Inc., a Nevada corporation (&ldquo;<U>BioVie</U>&rdquo;),
Acuitas Group Holdings, LLC (&ldquo;<U>Acuitas</U>&rdquo;), and the other purchasers identified on the signature pages thereto
(the &ldquo;<U>Securities Purchase Agreement</U>&rdquo;), and (ii) that certain Common Stock Purchase Warrant, No. B-1 and B-2,
issued by BioVie to Acuitas on July 3, 2018 (collectively, the &ldquo;<U>Warrant</U>&rdquo;). All capitalized terms used herein
without definition shall have the same meanings herein as such terms have in the Securities Purchase Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">The purpose of this letter agreement
(this &ldquo;<U>Letter Agreement</U>&rdquo;) is to confirm certain waivers under the Securities Purchase Agreement, grant future
purchase rights to Acuitas in exchange for the waivers under the Securities Purchase Agreement, and provide for the terms of the
exchange of the Warrant for shares of Common Stock pursuant to Section 3(a)(9) of the Securities Act. The Board of Directors, based
upon the findings and recommendations of the Capital Structure Committee of the Board of Directors, has determined that such waivers,
grant and exchange are in the best interest of BioVie and its stockholders and will facilitate the ability of BioVie to raise capital.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">In consideration of the foregoing, the
covenants and agreements herein contained, other valuable consideration (the receipt of which is hereby acknowledged) and intending
to be legally bound hereby, BioVie and Acuitas hereby agree as follows:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waivers
under Securities Purchase Agreement</U>. Acuitas hereby irrevocably and unconditionally waives any and all rights under Section
4.11 (Future Purchase Rights) of the Securities Purchase Agreement, solely with respect to Acuitas. Acuitas specifically waives
and disclaims any and all rights to purchase additional shares of Common Stock together with Warrants pursuant to Section 4.11
of the Securities Purchase Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant
of Future Purchase Right</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BioVie
shall issue to Acuitas 167,494,750 shares of Common Stock, subject to adjustment as set forth in Section 2(c) (the &ldquo;<U>Transaction
Shares</U>&rdquo;), in the event that either of the following occurs on or before November 30, 2019:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>BioVie shall have successfully commenced the listing its Common Stock on the Nasdaq Capital Market; or</TD></TR></TABLE>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 3pt; margin-bottom: 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD>BioVie shall have sold securities with an aggregate purchase price of at least $2,000,000 (excluding any securities purchased
by Acuitas) beginning on the date hereof and ending on or before November 30, 2019.</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In the case of an issuance under Section
2(a)(i), BioVie shall issue the Transaction Shares to Acuitas substantially concurrently with the closing of the transaction occurring
at the time of the listing, or absent the occurrence of such a transaction, on the first Business Day the Common Stock is listed
on the Nasdaq Capital Market. In the case of an issuance under Section 2(a)(ii), BioVie shall issue the Transaction Shares to Acuitas
substantially concurrently with the closing of the transaction resulting in BioVie having sold $2,000,000 or more of its securities
on or before November 30, 2019. Upon the issuance of Transaction Shares under Section 2(a)(i), Acuitas hereby irrevocably and unconditionally
waives any and all rights under Section 2.4(b) (Purchase Price Adjustments), solely with respect to Acuitas and specifically waives
and disclaims any and all rights to additional Shares and Warrants under the Securities Purchase Agreement following a proceeding
in which the useful life of BioVie&rsquo;s intellectual property rights is reduced by more than 75%.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
consideration for the waivers provided by Acuitas under Section 1 of this Letter Agreement and subject to earlier curtailment or
termination as set forth in Section 2(c) of this Letter Agreement, Acuitas shall have the right commencing September 1, 2019 and
expiring November 30, 2019 to purchase up to 200,000,000 shares of Common Stock, in one or more closings, at the then effective
Per Share Purchase Price, together with a common stock purchase warrant relating to one share of Common Stock for each share of
Common Stock so purchased, with the common stock purchase warrants exercisable from November 30, 2019 until November 30, 2025,
subject to early expiration in the event of any issuance of Transaction Shares, but otherwise in the form attached as Exhibit A
to the Securities Purchase Agreement and having an exercise price per share equal to the then effective Exercise Price (as defined
in the form of common stock purchase warrant), in each case subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization (the right, the &ldquo;<U>Option</U>&rdquo;).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Option shall lapse and any warrants purchased shall terminate immediately upon the issuance of the Transaction Shares by BioVie
pursuant to Section 2(a) of this Letter Agreement, and for the avoidance of doubt, Acuitas shall not the right to exercise the
Option, and BioVie shall not have any obligation to issue shares of Common Stock upon any purported exercise of the Option, if
BioVie shall have issued the Transaction Shares pursuant to Section 2(a) hereof. In addition, the number of Transaction Share shall
be reduced proportionally upon the exercise of the Option pursuant to the following formula:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.75in">X = Y ((B &ndash; A) &divide; B)</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.75in">where:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.75in"><I>X</I> is the number of Transaction Shares as adjusted
following an exercise of the Option;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.75in"><I>Y</I> is 167,494,750 shares of Common Stock, subject
to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.75in"><I>B</I> is 200,000,000 shares of Common Stock, subject
to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization; and</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.75in"><I>A</I> is the cumulative number of shares of Common
Stock purchased by Acuitas upon one or more exercises of the Option.</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 3pt; margin-bottom: 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange
of Warrant</U>. No later than the close of business on the second Business Day after the date hereof, BioVie will issue and deliver
(or cause to be issued and delivered) 190,791,666 shares of Common Stock (the &ldquo;<U>Exchange Shares</U>&rdquo;) to Acuitas,
or in the name of a custodian or nominee of Acuitas, and Acuitas will surrender the Warrant to BioVie (the &ldquo;<U>Exchange</U>&rdquo;).
The Exchange shall be consummated pursuant to Section 3(a)(9) of the Securities Act.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of BioVie</U>. BioVie hereby represents and warrants as follows:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BioVie
has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Letter Agreement
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Letter Agreement by BioVie
and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part
of BioVie and no further action is required by BioVie, the Board of Directors or BioVie&rsquo;s shareholders in connection herewith
other than in connection with the Required Approvals. This Letter Agreement has been (or upon delivery will have been) duly executed
by BioVie and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of BioVie enforceable
against BioVie in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii)
as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
execution, delivery and performance by BioVie of this Letter Agreement, the issuance of the Exchange Shares and the consummation
by it of the transactions contemplated hereby do not and will not (i) conflict with or violate any provision of BioVie&rsquo;s
or any Subsidiary&rsquo;s certificate or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict
with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the
creation of any Lien upon any of the properties or assets of BioVie or any Subsidiary, or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt
or other instrument (evidencing a BioVie or Subsidiary debt or otherwise) or other understanding to which BioVie or any Subsidiary
is a party or by which any property or asset of BioVie or any Subsidiary is bound or affected, or (iii) subject to the Required
Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction
of any court or governmental authority to which BioVie or a Subsidiary is subject (including federal and state securities laws
and regulations), or by which any property or asset of BioVie or a Subsidiary is bound or affected; except in the case of each
of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BioVie
is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration
with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution,
delivery and performance by BioVie of this Letter Agreement, other than: (i) the filing of a Current Report on Form 8-K following
the execution of this Letter Agreement, (ii) application(s) to each applicable Trading Market for the listing of the Exchange Shares
for trading thereon in the time and manner required thereby, and (iii) such filings as are required to be made under applicable
state securities laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Exchange Shares are duly authorized and, when issued in accordance herewith, will be duly and validly issued, fully paid and nonassessable,
free and clear of all Liens imposed by BioVie.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
BioVie nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the forgoing, has paid or given,
or agreed to pay or give, directly or indirectly, any</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 3pt; margin-bottom: 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">commission or other remuneration (within the meaning of Section
3(a)(9) of the Securities Act and the rules and regulations promulgated thereunder) for soliciting the Exchange. Assuming the representations
and warranties of Acuitas contained herein are true and complete, the Exchange will qualify for the registration exemption contained
in Section 3(a)(9) of the Securities Act.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of Acuitas</U>. Acuitas hereby represents and warrants as follows:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acuitas
is an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation
or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and
to consummate the transactions contemplated by this Letter Agreement and otherwise to carry out its obligations hereunder. The
execution and delivery of this Letter Agreement and performance by Acuitas of the transactions contemplated hreby have been duly
authorized by all necessary limited liability company or similar action on the part of Acuitas. This Letter Agreement has been
duly executed by Acuitas, and when delivered by Acuitas, will constitute the valid and legally binding obligation of Acuitas, enforceable
against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii)
as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
Acuitas nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the forgoing, has paid or given,
or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section 3(a)(9) of
the Securities Act and the rules and regulations promulgated thereunder) for soliciting the Exchange, and Acuitas will receive
no additional consideration for the Warrant other than the Exchange Shares.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Other Amendments or Waivers</U>. Except as expressly set forth herein, this Letter Agreement shall not be deemed to be a waiver,
amendment or modification of any provisions of the Securities Purchase Agreement, or of any right, power or remedy of Acuitas or
the other Purchasers, or constitute a waiver, amendment or modification of any provision of the Securities Purchase Agreement (except
to the extent herein set forth). Except as set forth herein, Acuitas reserves all rights, remedies, powers, or privileges.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conflicts</U>.
Except as expressly set forth in this Letter Agreement, the terms and provisions of the Securities Purchase Agreement shall continue
unmodified and in full force and effect. In the event of any conflict between this Letter Agreement and the Securities Purchase
Agreement, this Letter Agreement shall control.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>; <U>Waiver of Jury Trial</U>. All questions concerning the construction, validity, enforcement and interpretation of this
Letter Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York,
without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Letter Agreement (whether brought against a party hereto or its
respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement
of this Letter Agreement), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 3pt; margin-bottom: 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">jurisdiction of any such court, that such Action or Proceeding
is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Letter Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence
an Action or Proceeding to enforce any provisions of this Letter Agreement, then the prevailing party in such Action or Proceeding
shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred
with the investigation, preparation and prosecution of such Action or Proceeding. <B>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY
JURISDICTION BROUGHT BY EITHER PARTY AGAINST THE OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT
PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>;
<U>Miscellaneous</U>. Section 5.4 (Notices) of the Securities Purchase Agreement shall govern any and all notices or other communications
or deliveries required or permitted to be provided hereunder. Sections 5.6 (Headings), 5.12 (Severability), 5.15 (Remedies), and
5.19 (Construction) of the Securities Purchase Agreement are incorporated herein, with each reference to the &ldquo;Agreement&rdquo;
or the &ldquo;Transaction Documents&rdquo; therein being replaced by a reference to this Letter Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution</U>.
This Letter Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and
the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile
transmission or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation
of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo;
signature page were an original thereof.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 3pt; margin-bottom: 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">Kindly acknowledge your acceptance of
this Letter Agreement by executing in the space provided below.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0.25in 3.25in">Sincerely,</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0.25in 3.25in"><B>BIOVIE INC.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.25in">By<U>:/s/ Jonathan M. Adams</U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.25in">Name: Jonathan M. Adams</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 3.25in">Title: Chief Operating Officer</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.25in 0; text-indent: 0.25in">Acknowledged and agreed:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-indent: 0.25in"><B>ACUITAS GROUP HOLDINGS, LLC</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">By<U>:/s/ Terren S. Peizer</U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">Name:&#9;Terren S. Peizer</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in">Title:&#9;Managing Member</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>
<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</FONT></P></DIV>
    <!-- Field: /Page -->
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-14.1
<SEQUENCE>4
<FILENAME>bivi-20190628_s1ex14z1.htm
<DESCRIPTION>EXHIBIT 14.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<DIV STYLE="width: 6.50in; margin:0 auto">

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">CODE OF CONDUCT AND ETHICS</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">OF<BR>
BIOVIE INC.</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Adopted: June 10, 2019</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board of Directors
of BioVie Inc. (the &ldquo;Company&rdquo;) has adopted this Code of Ethics (this &ldquo;Code&rdquo;) to provide value for our shareholders;
and</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To encourage honest and ethical conduct, including fair dealing and the ethical handling of conflicts of interest;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; padding-left: 0.5in; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To prompt full, fair, accurate, timely and understandable disclosure;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To comply with applicable laws and governmental rules and regulations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To prompt internal reporting of violations of this Code;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To protect the Company's legitimate business interests, including corporate opportunities, assets and confidential information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To deter wrongdoing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All directors, officers,
employees and independent contractors of the Company are expected to be familiar with this Code and to adhere to the principles
and procedures set forth in this Code. For purposes of this Code, all directors, officers, employees and independent contractors
are referred to collectively as &ldquo;employees&rdquo; or &ldquo;you&rdquo; throughout this Code.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>I. Honest and Ethical Conduct</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All directors, officers,
employees and independent contractors owe duties to the Company to act with integrity. Integrity requires, among other things,
being honest and ethical. This includes the ethical handling of actual or apparent conflicts of interest between personal and professional
relationships. Deceit and subordination of principle are inconsistent with integrity.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All directors, officers,
employees and independent contractors have the following duties:</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To conduct business with professional courtesy and integrity, and act honestly and fairly without prejudice in all commercial dealings;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To work in a safe, healthy and efficient manner, using skills, time and experience to the maximum of abilities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To comply with applicable awards, Company policies and job requirements, and adhere to a high standard of business ethics;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To observe both the form and spirit of laws, governmental rules, regulations and accounting standards;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Not to knowingly make any misleading statements to any person or to be a party to any improper practice in relation to dealings with or by the Company;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To ensure that Company resources and properties are used properly;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To maintain the confidentiality of information where required or consistent with Company policies; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Not to disclose information or documents relating to the Company or its business, other than as required by law, not to make any unauthorized public comment on Company affairs and not to misuse any information about the Company or its associates, and not to accept improper or undisclosed material personal benefits from third parties as a result of any transaction or transactions of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>II. Conflicts of Interest</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A &ldquo;conflict
of interest&rdquo; arises when an individual's personal interest interferes or appears to interfere with the interests of the Company.
A conflict of interest can arise when a director, officer or employee takes actions or has personal interests that may make it
difficult to perform his or her Company work objectively and effectively.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There are a variety
of situations in which a conflict of interest may arise. While it would be impractical to attempt to list all possible situations,
some common types of conflicts may be:</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To serve as a director, employee or contractor for a company that has a business relationship with, or is a competitor of the Company;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To have a financial interest in a competitor, supplier or customer of the Company;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To receive improper personal benefits from a competitor, supplier or customer, as a result of any transaction or transactions of the Company;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To accept financial interest beyond entertainment or nominal gifts in the ordinary course of business, such as a meal or a coffee mug;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To present at a conference where the conference sponsor has a real or potential business relationship with the Company (e.g. vendor, customer, or investor), and, the conference sponsor offers travel or accommodation arrangements or other benefits materially in excess of the Company&rsquo;s standard; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">To use for personal gain, rather than for the benefit of the Company, an opportunity that you discovered through your role with the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Fidelity or service
to the Company should never be subordinated to or dependent on personal gain or advantage. Conflicts of interest should be avoided.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In most cases, anything
that would constitute a conflict for a director, officer or employee also would present a conflict if it is related to a member
of his or her family.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Interests in other
companies, including potential competitors and suppliers, that are purely for management of the other entity, or where an otherwise
questionable relationship is disclosed to the Board and any necessary action is taken to ensure there will be no effect on the
Company, are not considered conflicts unless otherwise determined by the Board.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Evaluating whether
a conflict of interest exists can be difficult and may involve a number of considerations. Please refer to other policies, such
as the employee handbook, for further information. We also encourage you to seek guidance from your manager, Chief Executive Officer
or Chief Financial Officer, or their equivalents, when you have any questions or doubts.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>III. Disclosure</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each director, officer
or employee, to the extent involved in the Company&rsquo;s disclosure process, including the Chief Executive Officer, Chief Operating
Officer or Chief Financial Officer, or their equivalents, the (the &ldquo;Senior Financial Officers&rdquo;), is required to be
familiar with the Company&rsquo;s disclosure controls and procedures applicable to him or her so that the Company's public reports
and documents comply in all material respects with the applicable securities laws and rules. In addition, each such person having
direct or supervisory authority regarding these securities filings or the Company's other public communications concerning its
general business, results, financial condition and prospects should, to the extent appropriate within his or her area of responsibility,
consult with other Company officers and employees and take other appropriate steps regarding these disclosures with the goal of
making full, fair, accurate, timely and understandable disclosure.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each director, officer
or employee, to the extent involved in the Company&rsquo;s disclosure process, including the Senior Financial Officers, must:</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Familiarize himself or herself with the disclosure requirements applicable to the Company as well as the business and financial operations of the Company.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Not knowingly misrepresent, or cause others to misrepresent, facts about the Company to others, whether within or outside the Company, including to the Company's independent auditors, governmental regulators and self-regulatory organizations.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>IV. Compliance</B></P>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>




<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">It is the Company's
policy to comply with all applicable laws, rules and regulations. It is the personal responsibility of each employee, officer and
director to adhere to the standards and restrictions imposed by those laws, rules and regulations in the performance of their duties
for the Company, including those relating to accounting and auditing matters and insider trading.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board endeavors
to ensure that the directors, officers and employees of the Company act with integrity and observe the highest standards of behavior
and business ethics in relation to their corporate activities.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Specifically, directors,
officers and employees must:</P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Comply with the law;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Act in the best interests of the Company;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Be responsible and accountable for their actions; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Observe the ethical principles of fairness, honesty and truthfulness, including disclosure of potential conflicts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Generally, it is
against Company policies for any individual to profit from undisclosed information relating to the Company or any other company
in violation of insider trading or other laws. Anyone who is aware of material nonpublic information relating to the Company, our
customers, or other companies may not use the information to purchase or sell securities in violation of securities laws.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If you are uncertain
about the legal rules involving your purchase or sale of any Company securities or any securities in companies that you are familiar
with by virtue of your work for the Company, you should consult with the Chief Executive Officer or Chief Financial Officer, or
their equivalents, before making any such purchase or sale. Other policies issued by the Company also provide guidance as to certain
of the laws, rules and regulations that apply to the Company's activities.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>V. Reporting and Accountability</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board of Directors
has the authority to interpret this Code in any particular situation. Any director, officer or employee who becomes aware of any
violation of this Code is required to notify the Chief Executive Officer or Chief Financial Officer, or their equivalents, promptly.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any questions relating
to how these policies should be interpreted or applied should be addressed to your manager, Chief Executive Officer or Chief Financial
Officer, or their equivalents. Any material transaction or relationship that could reasonably be expected to give rise to a conflict
of interest, as discussed in Section II of this Code, should be discussed with your manager, Chief Executive Officer or Chief Financial
Officer, or their equivalents. A director, officer or employee who is unsure of whether a situation violates this Code should discuss
the situation with the Chief Executive Officer or Chief Financial Officer, or their equivalents, to prevent possible misunderstandings and embarrassment at a later date.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each director, officer
or employee must:</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Notify the Chief Executive Officer or Chief Financial Officer, or their equivalents, promptly of any existing or potential violation of this Code.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Not retaliate against any other director, officer or employee for reports of potential violations.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company will
follow the following procedures in investigating and enforcing this Code and in reporting on the Code:</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">The Chief Executive Officer or Chief Financial Officer, or their equivalents, as the case may be, will take all appropriate action to investigate any violations reported. In addition, the Chief Executive Officer or Chief Financial Officer, or their equivalents, as appropriate, shall report each violation and alleged violation involving a director or an executive officer to the Chairman of the Board of Directors. To the extent he or she deems appropriate, the Chairman of the Board of Directors shall participate in any investigation of a director or executive officer. After the conclusion of an investigation of a director or executive officer, the conclusions shall be reported to the Board of Directors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">The Board of Directors will conduct such additional investigation as it deems necessary. The Board will determine that a director or executive officer has violated this Code. Upon being notified that a violation has occurred, the Chief Executive Officer or Chief Financial Officer, or their equivalents, as the case may be, will take such disciplinary or preventive action as deemed appropriate, up to and including dismissal or, in the event of criminal or other serious violations of law, notification of appropriate law enforcement authorities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>VI. Corporate Opportunities</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Employees, officers
and directors are prohibited from taking (or directing to a third party) a business opportunity that is discovered through the
use of corporate property, information or position, unless the Company has already been offered the opportunity and turned it down.
More generally, employees, officers and directors are prohibited from using corporate property, information or position for personal
gain and from competing with the Company.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sometimes, the line
between personal and Company benefits is difficult to draw, and sometimes there are both personal and Company benefits in certain
activities. Employees, officers and directors who intend to make use of Company property or services in a manner not solely for
the benefit of the Company should consult beforehand with your manager, the Chief Executive Officer or Chief Financial Officer,
or their equivalents.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>VII. Confidentiality</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In carrying out
the Company's business, employees, officers and directors often learn confidential or proprietary information about the Company,
its customers, suppliers, or joint venture parties. Employees, officers and directors must maintain the confidentiality of all
information so entrusted to them, except when disclosure is authorized or legally mandated. Confidential or proprietary information
of our Company, and of other companies, includes any non-public information that would be harmful to the relevant company or useful
or helpful to competitors if disclosed.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>VIII. Fair Dealing</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our core value of
operating is based on responsiveness, openness, honesty and trust with our members, business partners, employees and shareholders.
We do not seek competitive advantages through illegal or unethical business practices. Each employee, officer and director should
endeavor to deal fairly with the Company's customers, service providers, suppliers, competitors and employees. No employee, officer
or director should take unfair advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation
of material facts, or any unfair dealing practice.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>IX. Protection and Proper Use of
Company Assets</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All employees, officers
and directors should protect the Company's assets and ensure their efficient use. All Company assets should be used only for legitimate
business purposes. Theft, carelessness and waste have a direct impact on our profit.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>XI. Waivers and Amendments</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time,
the Company may waive provisions of this Code. Any employee or director who believes that a waiver may be called for should discuss
the matter with your manager, the Chief Executive Officer or Chief Financial Officer, or their equivalents.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any waiver of the
Code for executive officers (including Senior Financial Officers) or directors of the Company may be made only by the Board of
Directors and must be promptly disclosed to shareholders along with the reasons for such waiver in a manner as required by applicable
law or the rules of the applicable stock exchange. Any amendment or waiver of any provision of this Code must be approved in writing
by the Board or, if appropriate, its delegate(s) and promptly disclosed pursuant to applicable laws and regulations.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any waiver or modification
of the Code for a Senior Financial Officer will be promptly disclosed to shareholders if and as required by applicable law or the
rules of the applicable stock exchange.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is committed
to continuously reviewing and updating its policies, and therefore reserves the right to amend this Policy at any time, for any
reason, subject to applicable law.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>bivi-20190628_s1ex23z1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 6.5in; margin:0 auto">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 23.1</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;<IMG SRC="image_004.jpg" ALT=""></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">FORM OF CONSENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></DIV>

<DIV STYLE="width: 6.5in; margin: 0 auto"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify">We consent to the inclusion in this Registration
Statement of BioVie, Inc. on Form S-1/A to be filed on or about June 28, 2019, of our audit report dated October 4, 2018, with
respect to the financial statements of Biovie, Inc. for the years ended June 30, 2018 and 2017. We also consent to the reference
to our firm under the caption &ldquo;Experts&rdquo; in this Registration Statement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><IMG SRC="image_010.jpg" ALT="" STYLE="height: 70px; width: 368px"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">D. Brooks and Associates CPA&rsquo;s, P.A.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Palm Beach Gardens, FL</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">June 28, 2019</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>


</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1"  R )$# 2(  A$! Q$!_\0
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M%)+8W&K2C$FI3M-T_AZ*/R%=)FA;%SCRR<1:*3-(6 ZT$#J*8LBMT.?QIV:
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MR^^R,!B/K0 KM]MUZ-(SF.R4L[?[;< ?E6H>E06EG#8P"&!<+U)/)8^I-3T
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+Z=110-!1110,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '^ G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XWQ!X@U&T\5Q:
M5;:CIVGP&S-P9KU,@MNQM'S#M5;3O%VJ7S^'#+'#"E[=7$,Q1<K,B*2KIGD
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBJ\-_:7%J]U#<Q20)NW2*P*C;U
MY]J +%%06=Y;7]I%=VDR36\J[DD0Y5AZ@U/0 4456.H6BZBNGFYC%XT9E6'=
M\Q0'&['IF@"S115&VUC3[R[:UM[E))UW[D7/&TA6_(G'USZ4 7J*KW=_:V"Q
M-=3I$)9%B0L?O.>@'N:L4 %%%% !115>YOK6S>!+F=(FN)!%$&/WW/0#WXH
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MK.)1L'XT 7J*P]#\0IK>IZK# 89+6T>(131/N$@9-Q_(\5N4 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%&1ZTC,%4LQ 4#))[4 <]XQU_\
ML/1R(6_TRXS'"/3U;\/YXKR2-<#)))/))[UI^(M7;7M=FN@2;=/W< ]%'?\
M'K6?0 M%%% !24M)0 M)VHJ6PL+K5[^.RLDW2OU)Z*.Y/M0 VUM;G4KQ+2RB
M:69^@'8>I/85Z?X;\%VFC!;FYVW-_P!=Y'RQ_P"Z/ZUH^'_#UIX?L_*@&^9A
MF69A\SG^@]JUZ "BBB@ HHHH **** "BBB@ HHR 0,]>E% !1110 53U/2K+
M5[0VU[ LL9Z'NI]0>QJY10!X]XB\*W?AV0S*6GL"?EE Y3V;_&L56#"O>9(T
MFB:*5%>-AAE89!%>5>+?"3Z)(U]8JS:>Q^9>IA/_ ,3[T <Y2TU6##-+0 4M
M)2T )01GBEI* .C\#ZZ=)U;[#.^+2[8 9/"2=C^/3\J]7KP*5-R\=:]=\':W
M_;6AHTK9NH/W4WJ2.C?B/ZT =!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !111TH *PM>\7:1X>0B\N T^,B"/E_Q]!]:X;X@?%2+2TDL=(ER^2K7"<DG
MN$_^*_*O"[R_OM8F:2ZD?8QW%,DY]R>Y^M 'J^N_'"X9VCTR*.%>Q4>8WYG@
M?D:S;K5O%%]%&;F]NUFD0.\;2D! >0,# SC^=<UX+TJUDU<75XBFWLT\\1-_
MRV8$!5^F2"?:NV:Y\V=YYVW.[%F/J30!SSQ:P,L9G)]2S?XT^VOM=,%Q;V]Q
M<-<>6Q2%9F"R@#)3&>N,X]:VKS5(?+V[%XKGI;]XKI+BW8QRQL'1AV(.0: *
M&F^,X$<"ZMV"]P^<?F.17=:5?>'M65,/) [=,RY5C[-_C7G_ (GL(9KZ/4K&
M-?)OU\UH$&3%)G#J!Z9R1[&L>"VOK63S+:*XC;N/*;!^HQ0![G_PCMG_ 'YO
M^^A_A2'P[:]I9A^(_P *XGPOXVN+5TLM2CD5<<(X(8#U7/4>U>E0S1W$*30N
M'C<95AW% &2?#=OVN)A^ II\-1=KJ0?\ %;=!.!0!A?\(N)76..Z<LQP!L'6
MNY\.Z%%X>LC''LDGDYEF(Y8^GT%&BV7EQ_:I!\[CY >P]?QK6H D\Y_[J_G3
M)KU+="\SQQJ.I9L5S&O:S*MR;*TE**O^L=>I/H#7.L"[%G=G/JQS0!V,OC"S
M20JD,LBC^(< _G6%>>,O$7VN1K'3=--IT03SN)#[G"X_"LP<>E+0!%J/BGQ[
M=P/%:1Z+9EACS$9W=?IN&/TKS"?4_$4-W(+GQ9>B?<<E+ER/KQ7J;+N4KG&0
M1FO*=8T.[M-0D$J@*S9#,< _CWH ?-XK\51R)')XCU$F,[D/F_D??\<U$WBW
MQ,Y0GQ#J64.5_P!(/!]?_P!=9UVZ[T1/F$:!-W]ZJI9_\CM0!OMXU\5,A0^(
M]1*XP1YN"?Q S5B+XA^,84(7Q!<'_KHB,?U6N6)DS]/:@N\K_,X7B@#1N-:U
MNZNDN;C6K^2=&+K(TS90GNO/'X59A\7>*[-0(/$-^JC^ S$X_P"^LUS^Z1CM
M#'GM2B/=(4D8I@<Y.>: .W\-_$+Q)/XCL;34-9N)K.>81.CD?Q<#D 'K7OPL
M;".Q%PTCQC;DOO(.:^5]!3S=?T]=A9C=Q8?LOS"OH?QGJ)T[P1/, "4MW(!/
M'/RC^= 'G6N_%K6;#Q'*-(OX;JPB 6.-X@RR<<DMP<Y]#42?&KQ6Z-&MKIQ9
MCD2>2_R>V-W-><P.1("[995 &1C K6M-H?) /M0!V<WQ8\:W<.($L;=N!F.W
M+$^_S$U47XB>.DD,<MW!<PL,.D]HI4CN#C'%4[>^2!.,9J*YU17!!YS0!57Q
M!J<;,7L8-I8X"L0![#K4%UK^J2R!5DCMESR(UR?S-0SW:/@ \^AJE)(N&.Y0
M,XP30!HVWB34;:;$I%W%GH5 ;'L176V5Y#?VJW$#91N"#P5/<'WKSPW 0[D(
M/E]Q6SX5NI(K\Q$ATN@6('\!'?\ I0!V-%+10 E;7@W5?[(\1QJ[8M[O]S)Z
M _PG\_YUBU'*,KD'##D'TH ]^HK*\-ZI_:^@6MV3F0IMD_WQP?\ '\:U: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *\\\?>)YFG_ .$=TM\32#_2I5/W%/\
M#G^?M77>(]930="N;]L%T7$:G^)SPH_.O#-+U"2YO[V.>&=;I_GEFF&"P)Y(
M^OK0 :?H=O#J,E^-SR'Y8RQZ#IQZ UNS/=QQ@L65>U5_.$1R ..E5[K4Y'&"
MQQ0!)I5C8ZAKK)=$QW5RACBN-Y&),?*&]1QCVK+O&FMIY()04EC8HZGL1UJI
M<73;MP8A@<@CL:UY9&\9:E!':P2QZHT(-PY7,+X&-Y(^Z3COUH YZ:;)/-4P
M);F>."!"\LC!$4=6). *[5_A?XA=-PEL<>\I_P *- \/77A?QGIHU*T:=YWV
M13H#Y,;$'OW; ]@,T -UR[T7P UC;1V<>I>(H8%W-(Q,<!)+;L>N2<8YQ6#+
M\1?&LQ,BZDL*'^&*!0H_,&N;UF[DO/$FI7=P2TLES(23_O$ ?D*A:]8KM'2@
M#J8_'1U*Y@7Q3807JQ."EU%&$FB]^.&'M76VES_PCUY%MF\_1[P!XY0<A<]"
M/\_RKR,DL<FO0M'GO)? 6GVD6G27YDNIXE"'!C4 -G/08)/6@#TC@C(.0>XJ
MQ8VQO+Q(_P" ?,_TKEO"^H2/;R:;<G]_:G R<Y7_ .M7H.B6_E6AF(^:4Y_#
MM0!I    # ' %8/B#5_(!L8&99F WN/X1Z#WK1U744TVS,I!9V.U%'<UPIDD
MD9GD<N['+,>I- " 8SZ^M*!1G-._"@  ]Z>%Z4#K6/KOB6WT=#$F)+QA\L?9
M?=O\* +.KZM;:/;>9,=TC?ZN)3RQ_H/>O,]6O;K5KG[1=R9_NQC[J#T I;J_
MFO;AI[B0O*_5F_I[54>7@G(YH @** <C)[5$YPFW I[N*B),F<L!@=Z (WW*
MO7AJA<  $-G/;TJ4[,*S-G)Y J([#+C)"$]Z &MM$@V$X]:3:KH[L_S#L>]*
M&,4C-'R!WQ38]ADW3 [#G[M &YX)C\WQAI2/S$;@%E]2 2./KBO5OC#?&U\+
M06BG!G:-,D]A\Q^O2O._AE%YOCBT*+NVQR]!]WC )_/%=!\:+]Y==LM-4 +$
MADR3]XGY?PQM_6@#S!6&X]<=<D<U;AG"KSR3T.:K-R5"J$_A)SP:3<T<A^<9
M7H1T- &E]K+'"':0/6J[7)."6&/3-4RQ;DYR3U[4_P"80NV$VD[<]Z '%G<A
M0,L_(/>H\$$Y!R.">O-. 03*K$*!U93G-,.T2-@@@'C/>@!Z?*X; 9DZJ1Q@
M5W?ANPCL]*CE"CS;@>8[8['H/I7"*%!&8RX'RE0W)/M7HVG*\6F6L<@PZQ*&
M'H<4 7<TTM49<4TR4 2EJ:6J$R4PR>] 'H7PRU'$M]IC-P<3QC]&_I7HU>)^
M$[DZ=XHL)V.!(_E-]&X_GBO;* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \B^
M-6N&V@M[&-O]7&9B/]IOE7^IKE/ASK":K92^&-1F)NI/WEA<2<D,!G83UQZ?
M4U6^+]XUUXLN8^PF6/\ !%']37':>]S;W]M-9,RW22*82O4-GB@#O[J1XG>.
M0%70E64]B.HK+GN.O-=;J.B7^I:[?7.J-;Z79(0OVN5@HD;:.BYYYSSQTJJ?
M!VB3Q;U\9Z><^FW_ .*H Y73[*XUO5[?3K;_ %L[[=W9%[L?H*Z7X@>(1X?\
MCPOX>E,#11J+J>+A\8^5=W7/4GZUK^$_#UYH'BH/%$EUI\\3*M^C*V2,'M]T
M$\=\UY!J-S/)K=_-=9^TO<2&3=USN- %\7NM",,=6OL>GVE_\:Z[X>^,KRTU
MR+3-5O))K.Y;9&TS;C%)VY/.#TKSXW+MQFD#,/F!((Y!]* .D^(7A^70O%UV
M=A^RW;F>!\<'/)7Z@YKF *]NU*74=3L-&>XL[&?3);5)+]K]PL:DXZ-U5L9(
MQ5)/#'PWD!D;4+=#U"+?X'\Z /*;"PN=2O8K.SA::XE;:B+W/]![UN>+=5:Q
MAMO"FFW3?8M/7;=/$V!<7!.7/'50>!]*[E]^CK)'X5TRV%C):SM_:$+>:[N$
M.U=P/RG/8]:\:&3R223R2>IH ZKP%J#6NKQPER%\P#D_PN<']<&OI>-0D:JO
M10 *^3=(<Q:I&0<;E(_'J/Y5]4:3<?:M-MIO^>D2M^8% &!XLGWW=O;AON*6
M8>A/_P"JL*GWDKSW\\DF=S2'.>W.,4SMTZT *.M.'TIA("Y) '<GM7!>)_&I
M<O8:5(=G*R7*]3[+_C0!K>)/%Z:>6LM/97NL8>3JL?\ B?Y5P#SM)(TDC%W/
M+,QR2:IQL2P P2>>309.">.3Z]* +1<C&<\]*C:7WP*@=@%7#9/<>E-SG@#.
M> <XH E=F8X Y YQ43,&7))+YIK2#<-@(XP>:9N[8/\ ]>@"0@(6!&XXX(/2
MHF)^4'!XXQ2J[H3LQD\'V]J%"B,R>9B0'@4 -^^_! SR>PI.,,0F#GKZ5(%&
MR,2)M4MGS.Y%.VNRS>4^Z(8R3W% '>_!Z!V\; /C:+5F'_?2UD?$F^%]XYU!
MB^?(98 GL!D_J36_\$HP?&-T^X-ML_RRW_UJX_Q2SOXKUK[G[N]D.X]3S0!D
M(\)N-SQXC_NBE2;"R111@A^F>H%1[FE=V9E!(R<TN3,R*B!6QCCO0 F 0-N[
M;QN)Z9IS?,&D$0"'@>@-)@),5E!"YY532;28F8,-H/W2: 'E0CN'57^7C:>]
M1DD($R,9S3O,Q*)(U$94<5U'@+PC+XM\3BRF,D5I'&9KIUZ[.@ ]"3_6@!_A
M[0;F*RBUR: ?9I7:&V?&-Q'5A_+/L:W2Y'7BO6/&VE01^"_*M8ECCL2C1JHX
M51\N/R->8 *Z#< ?K0!3,GO3#)5F2S5ON,5/H>1526WFCR2N1ZKS0 A>K5K"
M3B1Q_N@_SJ&TMS*V]Q\@['O6C0 R1FC*R+PR$,/J#FO=[.<75E!<#I+&K_F,
MUX3(,H:]?\&W!N/"6GL3DK'L/_ 21_2@#=HHHH **** "BBB@ HHHH ****
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M6=C@ 5J>-Y[31YA?W,JI'*F#GJ6'&!ZFO%/$7B.[UN?RV_=6B-\D(/ZL>YH
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M)B.GF-_,U[M<R"*UFD)P$1F)^@KP6 Y7=W/- $U%%% !124M "'H:]"^&?\
MR"K[_KX_]E%>>GH:]&^&J8T.Z?'WKD_H!0!V9 ;J <<\T$!A@@$>]8OBZ_N=
M,\)ZC>V<GEW$,6Z-R,X.1V-<SJ&OZYX=EU,37BZCMTL7L6Z$)Y;E]A''51G/
M/IUH ] "*'+A1N/!..32"-!T1>N>G?UKSB^UCQ1IF@:C=-/*T0LUFCN)UA#)
M)O4':$)RA!/4<5<U[Q%J5GJ&IQVUV D&A?:T 53B7?C=^7:@#O,#.<#/K5>6
MZM+:Z@MY)(XY[EF\I#P9"!DX_"N,-UKYU/2M'EUP1R:C#)=R7*6Z@H%"XB0'
MCJ<Y.369'?ZGKFHZ!&]ZD=Y;ZA>V@O8X@1($C^^%Z9(X],T >FB-!G"+R<GC
MOZTNQ2X?:-P& <<UYY#K^MSI8Z.VH+'<3:I<63ZAY2[MD0R,+]W>W3\*CD\0
MZ\,:9#J,;7,.M)I_VTP@B2-HRWS+TW#V]* /1]BD$;1SUXZTI (P1D>E><ZG
MJ?B&PEUQ(]:+C1K."X^:W3]^Q4E@WH#CM3;GQ1K>B#43-=I?$Z5'J$6^(*(7
M9PI''51G///% 'HP1 @0(H4=!CBG5Y[>:QK6ASSV;ZL-0,VDS7J2F)5:"1!P
M>."ISQGTJ6VUK5=.O[4ZEK$<EM>Z4]X[R0!5MF4*<@#DCYNAZT =O=W=O86D
MMU=2K#!$NYY'. H]34D<B2Q))&P9' 96'<'H:\JU36=1GTGQ!IUU=W-U;OI!
MNXY+FV6%L[MOR@?PGJ,\UZ7I/_(&L?\ KWC_ /010!<HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *\]\>>&KF*X_X231T NXE/GJ
M%SD8QO ]1W]J]"HH ^-Y'GCOI3>DM<LQ=G;G>2<[OQJ5[N1QC/%>W>/OA;%J
M2O?:/$!)RS6Z\$'U3_XG\J\2N["ZTV5H[F-@%."VTC!]".QH L:-JMQHNKV^
MHVQ_>PMDC.-RG@J?J*]5U'6O#_BRS;1[QKBV\V)+B*X9<K&2,C)['J.>M>>>
M$O"USXJU(PPLL=K#A[F=CPB_U)YKK];N(KB[;[.BI;QJ(X0!CY5& 30!5C\!
M>&A:;I?%T8G] J@?EUK4\)MHOAW7+;3-.G^WW=Z6$M[PJQJ%)"@=\XKD+CO4
M6FZI-HNJP7\')B;YE_OKW'Y4 =I>W[7.H27EP<LQR!Z =!534/%%PT/DJYV#
M@*.E3ZW;1PF&XMG\RRNXQ-;O_LGJI]P>*Y.ZD!<H@WOZ#M]: *5]=R2RB0DA
M@<J5ZY[8]Z[S0]'G\:ZU%JVH6ZQB.%([F5?^6S+V^I[U4\*> KG59DO+X-%;
M=0<8+#_9']?RKV;3=-@LK:."WB6.)!A5 X% %BSMEAC554*JC  ' %7:11@4
M.ZQHSNP55&23T H ^=/B_P"(I=3\<&P0X@TQ?+4>KL 6/\A^%>?3B0D2.#AN
MA]:U/$FK1ZSXFU;48T&RXN6>-N^WH/T K'+,^%))QT% "L4*H%3!'4YZTX1E
M@[",A<[1ST-&]S&N"H"-QZTLZNK9=PQ?YC@T #*$\Q6;8PP-HY!IK-)*^6)+
M'BD=#&1D@Y&>#3W=[AAA1D#'RB@!PCEN2[?*#&,'MTJ-BI92JE%(P>^:6.-G
M5R'"[1R,]:;&H=L,X4 =30 NYFBV!<JO.0*7 0*PD^\.0O44WD]?E4\$@<48
MW#<J\*!GF@!S(JQ*ZR98]0.U+\OF*5C/RCY@W>E.&D+", M@J%/2M_PSX1US
MQ=>A=-A;R"VV>[<8CB]<GN<=A0!FZ3I=]KFI)8Z=9/<SS9VHG 7_ &B>P'J:
M^D? /@>W\%Z4\?F">_N-K7,P& 2!PJ^PR?K5WPCX.TSP=IGV2P0O*^#/<./G
ME;W]!Z#M70T %%%% !1110 4444 %%%% &1XINOL?A?49L\^25'U;C^M>,Q#
M;&!7H_Q)O?*T>VLE/S7$VXC_ &5Y_F17G2\ 4 .HHHH 2EHHH :Y^4UZG\/H
M3%X3A8_\M)'?]<?TKRJ8[8R:]H\-6OV/PWI\!&"L"D_4\G^= %Z\L[?4+.6T
MNXEFMY1AXVZ,*C?3+*2Y:X>VC:5H/LY9AG,><[3[57\0:G-HVA76H06CW4D*
MY6),\\XSQS@=3]*P+?QA<BVTV\F.FW%E<W?V::>SE8B(L/D)# $?-P0?:@#:
ML_"NA6$=Q';:9 B7">7*N"0R?W>>@]A38/"6@6L,L4.EP(DL1@DZDNA.2I.<
MD5SUUXZO4BBN([6T@L[FZFB@O+IG$01. 7*@X+'..V!4AUG6CXYCB#V?V%-,
M6YD19692I8;F7 Y;@@=L4 =/J.AZ9JUK%;7UG'-%%_JP<@IQC@CD4L.B:9;"
MS$%E#&++=]G"C'E[A@X^HKE-'\>7.IW=H391?9;W?Y8C\PR0X!*F3*[<''8\
M9%-L?&6O7\>DM'IE@IU>-_LI,[81DY8OQTQG '- '4S^'=(N;26UFT^%X)9C
M<.I'60]6SU!]Q1%H&D6MK;016,,<-K+]HB & DG/SY]>3R:Y1_']V=+TV<6E
MI:O<230SSW+O]GB>-MNW<H)^8]":U?&-S+)X."!U1[Z2"W=XGW*!(ZAL'N,$
M\T ;4VC:;=&\>6TBD-]&([@G_EJ@& #[8-+_ &-IWG&8V<1<V_V4DC.8O[GT
MKS7Q'/I]EXJUQ+Y-1,%O96ZVHM)'586((!)! 7)V\GBM/7;Z[MO">@:%J^IK
M;7^H%$N[KS0I2-1N<[O7H,]R: .ML_"NAV$%S#:Z;#&ERGES 9.Y/[N3SCVJ
MQ+HFF3^7YME$XC@:V0,,@1D %?IP*Y31O%R6WPZN[Z:X2>XTL/;,X?<)77A#
MGON!7GZU3\":BUO>WFAC5X[^6>U6\BF$WF;)2,2)WZ-@@>E '6Q^%=!@@FC7
M3H1'+"89"Q)+1YSM))SCBM>)(XX4CB $:J @'0 =*\W\-V\-GJT&G^(;/4[?
M6+A98VGDN&DM[W(.[OCIT&!BNH\#322>%;>*1RYMI)+8,QY*HY4?H!0!T=%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A:]
MX1TCQ"A-W;A9\8$\?#_CZ_C6[10!Y'/\.M;T".[70YH98+@8D"CRW8?R_(]Z
MY:]TW7K7(N=-G7'<QG'YC(KZ%IC1*W:@#YEEMK]R<6C?]\G_  J./P_K%XV(
MK20_[L3'^E?3)M4/:C[*M 'B^D^"O$EQI,>FW)6*T20R(9C\R9Z@ <XKLM"^
M'VFZ85DE3[5.#G=(OR@^R_XYKN!;J.U2! .U %:&V"@<5:50!2T4 %>??&#Q
M!)HW@PVUM<"*ZU"00#!^;R\9<C\.,^]>@]*^5O'_ (ED\5>+KJ\W-]CA8V]J
M#T"*<9^I.3^5 '//$+?,8VR%EX([5"CF,JR$AAWITRA& #!ACJ*"H^58VW%A
MR,=Z  (/,(E;:<9]:(Q&S@2,5&.33 <;@5R3QSVIXRJ/&=GJ3W_"@!$(!=0F
M_(P/:B-G3+HP! _.@2$2;H_D)XXI9(C%(%<CGG(H :4;R_,R,$XQGF@%/+(V
MG?G@YXQ0P42$(<C/&171>'/!NN>+I;EM-M8W6W(65WD$:@GH!ZGO0!@%4!($
MN5 R >YK1TSP]K&MW#1:7ID]VP(W&(91,]BW0?B:]BT+X&:=;&.36]0DO2!D
MP0KY:;O][.XC\J].TS2K#1K%++3;2*UMDZ1QK@?4^I]S0!X_X:^!SR@7/B2\
M:(GD6EHW(_WG_P /SKV#2]+LM%TV'3]/MU@M85VHB_S]S[U<HH **** "BBB
M@ HHHH **** "BBLSQ!JJ:+HEQ>,1O5=L8_O.> * /,_&^IC4?%,J(V8K0>2
MO^]U;]>/PK#!JJK/O9I"2[$LQ/<GO4JO0!-13 U.!H =2444 .@MVO;^VM%&
M3-*J?F:]V1%C144850 ![5Y/X%LOMOBI)2,I:H9#]3P/Y_I7K5 %>^M3>V<E
MNMS/;,_26!@KKSV)!KF-3\(%/"^J:?9;KN\U*0--/<N%.[(&_@ #:!D #J*Z
M^B@#"NO#$<VE6NG6]_>6=O!#Y!2 KB1",'<"#S[^YIB^$;&'4+&[M9[FW^R6
MRVAC1@5EB!R%?(.1],5T%% '/:;X3BTN55M]3U'[$@8161E'E(&SQTR0,\ G
MBI++PI86*:,L4DY&DB00;F!W;Q@[N.?TK=HH YD^"[=-,.GV^IZA;V[O*TJH
MZD2"1LL#E3^!ZBK.K^'8[KPDVC6)$'DQH+4DY"-&04S^*C-;M% &(GANTFNK
M^\O5,DVI6T<%U%G,>%!'R\9[FHM-\(6&GW4-P\UQ>/!:_9(1=,'"1YSQQUZ#
M/H*Z"B@#F[KP3I=UJ<EX6G1)9HIY;9"!$[Q_=)7'Y^M7;[PW87M[9W@#VT]J
M7V-;X0L&7:RG Z5KT4 <U;^$5LKA+S^T;Z_N+6-Q9)?3;DA8C&>!DGMDY.*T
M?#NE-HN@VMC)())D4M*XZ,[$LQ_,FM2B@ HHHH **** "BBB@ HHHH ****
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M80Z7IT%E ,1PH%'OZG\30!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH K3ZA:VUU!;33JDTYQ&AZM]*AO]:T_3)DBO+CRY'4NJA&8E1U/ /
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M>2KC(HMK:"TA$-O$D48Z*@P*EHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "HXH(H%811J@9B[;1C+'J?K4E% !1110 4444 %%%% !1110 54M],L
M;2=YK>TABE?.61 #SUJW10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  ^ +,# 2(  A$! Q$!_\0
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3Q6Y1132L9SDI.Z5@HHHIDG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !A E@# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WUW5%+,0
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M)ZX Q4YK)>[#JAY'0J0<YR5DR>BBBO(/H@HHHH **** "BBB@ HHHH ****
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M -%&K'PX53\&M*! P;"3(_%J):<WD):V\SI/#WB;3_$GAJWUZT<I:31ESYN
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M-9\GC^[OKS4X?#7AV;6(],D,-U-]J2!3(!DK&#DN1]!65\+O^1M^()_ZB_\
M\56QX9U*#Q#-J4OAN"#3]*6]9)[M(AYEW,,;V4= .VXY)]!1T^0=7ZFEX;\7
MVWBSPM_;>D6D\ARR?99"J.)%X*DDX'KG-<;\-/%7B;7M0UBXNM%BD@EU1XIK
MA;U0+4(BJ$5,98# YR,EB:L? Q2G@J_4DDC59QD]3]VF_!/G2?$G_8<G_DM-
M=?3_ "%T^?\ F=1?>*KQ[V[L_#VB2ZS-9OY=R_VA8(8WQG8';.YP",@# SR0
M>*;X=\>Z7KFFZE<RI-I\^E%EU"VN0-]OM!))QG(X."/2N)^$\-AK5CKEG>75
M\NJ6NJ3M<117\T7#-D-M1P.N1G':NQ7P9X5L9=8@BA>&YU6U87TTEU)(SQG(
MW$NQP<D\^U3T^0[:V\RH?'VI1::FKS>$;]='FV&&X6XC:7:Y 5GBSE%Y!ZDC
M/(KN17BTMUXW^%-DL6J)#XD\(P@1^8J[9[>+H 1Z?7(]Q7L=G<Q7MC;W4!S#
M/&LD9(QE6&1^AI]+H1Y5\==6N?[/T3PS:RF,ZU=B.9AW1648^A+ _A7J6G:?
M;Z5IMM86D:QV]O$L4:J,  #%>3?'>QGMQX;\31Q-)!I5YF?'\*LR$'Z97'XB
MO6[*\@U"R@O+6026\\:RQNO1E89!H7POU&]T0ZCI5MJ4EG),O[RSN%N(7'56
M (_(@D&O-/C)_P C!X!_[#"_^A1UZI-/%;JK2N%#,$7/<G@"O)_C7#'<ZQX%
M@F0/%)JP1U/1E+("*%\4?5!T?H7_ (\7%A'\-+B"[9/M,TT8M$)^8N&&2![+
MNS]:ZWP-#>V_@31(M1W_ &M+.,2!_O XX!]P,56M?AQX2L]3348](5[J,YC>
M>:281G.?E5V(7GT%;NJZE!HVDWFHW)Q!:PM,_P!%&?SI+1,'JT<'XTT'_A8-
M_JNC9)M])LB(N2 ;Z1=R'CKM3''_ $UJU\'O$3:]X!M(KAS]MTXFSN%;J"GW
M<_\  <?B#46@^'?&]MIQGC\0:9:RWTC7D\4FF&1UDD^8J6\P9VC"]!PHKF?"
MZ7W@+XSW6C:I=0RP>(H?M$<D$/E1F?)/"Y..CCKW%-?R_P!7![7_ *L>QW<=
MQ+:R):SK!.RX25DW[#ZX[U5TW3K3P_I"VT3$0Q;Y))9&RSL26=V/J2236BIR
M*AO(H9K.:*X($+QLLA)Q\I'/-+T!'%-\0=0.DOKL/A._FT+R_,BN4GC\Z1,\
M/Y).0IZYSG'.*[B)_,B1_P"\ :\9DC\;_"C3VV>3XD\'P@@QD;9[>(_S'/\
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MV\^:-I$4(Q!5<9^;&!U'!.31TL'6YQLW@/6;_3?[$U3Q;/=Z&0JR1&T1;B5
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M.<)'=*O"B08.<#C(P<<9J:Y\*VTVISW]M=W5C+=1+#=+;,H6=%!"[@0<, 2
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MH;[P)((8'N"#49\(QG6-*U)=5U 2Z;&\:*S(XEWXWER5)); Z$8QQBFFNO\
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3.]*:**.@!VH'2BB@!:***8'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9(
M   !_]L 0P ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8%Q(4%!04$A<7
M&QP>'!L7)"0G)R0D-3,S,S4[.SL[.SL[.SL[_]L 0P$-"PL-#@T0#@X0% X/
M#A04$!$1$!0=%!05%!0=)1H7%Q<7&B4@(QX>'B,@*"@E)2@H,C(P,C([.SL[
M.SL[.SL[_\  $0@ ,@$% P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" !X '@# 2(  A$! Q$!_\0
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MX9//7VJ*B;CH:4VE+4YT=*['YE^$'^C]&U;%UCTV_+GVSMJ'S/AY_P ^VO\
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MVC'Y99<9RWL/\:Y41R8_U;_]\FNSTNVDU_X<7.DV:E[_ $V\^U^0/O21D8)
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&***!'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I 5 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;\82R16=L8Y'0F
M0Y*L1V]JZ2N9\:?\>5M_UT/\J$!NZ<2VFVQ8DDQKDD^U6:JZ;_R#+7_KDO\
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M3_T)J]EB_P!2G^Z*YZ4FZDTSVLQHTX8/#3C%)M._GZCZ***Z#Q1&940N[!5
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M (2;0O\ H+V7_?Y?\:\F\$>&M/U_6-2M-463= -R*K;2#N(/]*[G_A5GAO\
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M/^^2W\ZTZ* &HB1J%10JCH ,4ZBB@ HHHH **** (;BTM[M ES!',H.0)%#
M'\:?##%;Q"*&-(XUZ*@P!3Z*+#YG:U] HHHH$%%%% %"\T72]0G$UYI]K<2@
M;0\L08X],FKX  P.E%%*R*<Y223>B"BBBF2%-DC25"DB*Z'JK#(-.HH Y^[\
M$>'+W)DTJ%2>IBRG\L56B^'7A>*0.NFY([-*Y'Y$UU-%1[.'8ZECL5%<JJ2M
MZLJV&G66F0>18VT5O$3DK&N 3ZU:HHJTK;'-*3D[R=V%%%% @HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& 7 # 2(  A$! Q$!_\0
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M-&GZN\MS]@U"$6NH 9\O.4E _BC/<>W446NKH+]S5HHSSBBI&%%%% !1110
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %A G,# 2(  A$! Q$!_\0
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M6X8+#-ORKDC/!'48'7I0!J4453U75;+1--FU'4)O)M8<>9)M+8R0!P 3U(H
MN45#:74-]9P7=N^^">-9(VP1N4C(.#ST-4Y=?TR'7H-#DN<:E/$98X=C'<HS
MSNQ@?=/?M0!I45GZ9KFF:P]RFG7L5RUJ_ES",YV-SP?R/Y5H4 %%9MOK^F76
MN76BPW._4+1 \T.QAM!Q@[B,'[PZ'O6E0 4444 %%%% !1110 4444 %%%%
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M86UNZ33;E 0D28&,Y_B'04 -\)>*M;O/$FJ>'?$%M:I?V40F$EMG8R\>I/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%&:,T %%&:* "BBB@ HHHH **** "BBB@ HHHH **** "BC-
M&: "BC-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !111F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI,UA^)/%VD^%[;??SDS
M,,QV\8S(_P"'8>YP*3:2NS2E2G5FH4U=OHC<S65JWB;1=$'_ !,=2@@;^X6R
MY_X",G]*\5\0_$W7=;+Q6TG]G6AX$<#?.1_M/U_+%<6S%F+,2S$Y))R37)/%
MI?"CZ;"<,3DN;$RMY+5_?M^9[A>_&'0(&*VMM>W1_O! BG_OHY_2LF7XU@']
MUH!(_P!NZQ_[)7D\44D\@CAC>1ST5%+'\A6I'X5\0RKN30M2(/?[*X_I6/UB
MJ]OR/5_L/+:2M47WRM^J/18OC6I/[[06 ]4NL_S05K67QA\/SL%NH+VU/]YH
MPZC_ +Y)/Z5Y)+X7\00J6DT/4E [_97Q_*LN2-X7*2HT;CJK@@_D:/K%5;_D
M#R/+:J_=K[I7_5GT]I7B/1];7.FZC!<'&2BMAQ]5/(_*M/-?)JLR.'1BKJ<A
ME."/H:[;P[\4-<T8I#>M_:-H."LQ_>*/9^_XYK:&+3TDCRL7PQ4BN;#2YO)Z
M/[]OR/?<T5B>'?%6D^)K8RZ=<9D49D@?Y9(_J/3W&16W76FFKH^8J4ITI.%1
M6:Z,****9 4449H *,U4U'4K+2;)[R_N8[>W3[SN<#Z#U/L*\D\2_%Z[N'>W
M\/Q?9X>GVJ909&]U7HOXY/TK.I5C#<[L%EV(QCM2CIW>W]>AZY?:E9:9 9[Z
MZAMHA_'*X4?K7(:A\6/#%F2L$MS>L/\ GA%@?FV*\*N[VZU"X-Q>7,UQ,>KR
MN6/ZU .2 .2>PKDEBY/X4?48?ABA%7K3<GY:+]6>OS?&N 9^SZ'*_IYEP%_D
MIJ%?C8VX;_#_ ,O?%YS_ .@5YS;^'M;NU#6^CZA*IZ,ELY'YXJ9O"7B-1DZ#
MJ6/:V<_TJ/;5OZ1U?V1E,=&E_P"!?_;'J-K\9M(D8"ZTV]@]T*R ?J#^E=3I
M7CKPWK#*EKJD2RGI%-F-C] V,_A7SG<V=U9/MN[6>W;TFC*']14'!'M36*FM
MS.KPY@JBO2;CZ.Z_'_,^M,TN:^;- \;Z[X=95M+QI;<=;:<EX_P[K^!%>P>%
M/B+I7B0I;2G[%J)X\B1N)#_L-W^G!^M=5/$0GILSYS'9'B<(G->]'NOU7_#H
M[.BDS2UN>,%%%% !1136=50LQ 4#)). * '9IDDL<4;22.J(HRS,< #W->;^
M*/BS9V#/:Z$B7MP,@W#?ZE?ICE_T'N:\HUCQ#JVO3&34KZ6?G(C)PB_11P*Y
MJF)C'1:GOX+A[$XA*=3W(^>_W?Y_<>ZZE\2O"VFLR'4/M,B]5M4,G_CWW?UK
MF[CXTZ>K'[-H]U(.QDD5/Y9KQO('M5RTTG4K\9L].N[@>L,#./T%<[Q-26Q[
MT.'L!2C>I=^KM^5OS/3/^%V/G_D7UQ_U^?\ V%6X/C58L1]IT:YC'<QRJ_\
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MA*QO%.A1>(O#]UIT@7>Z[H7/\$@^Z?S_ $)K&M2]I'S/4RG,)8*NFW[CT?\
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M]"D3CFOI7P5I T;PAIUIC$AB$LOKO;YC^6<?A7SKIEL+W5K*T/2>XCB/_ F
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M9)/-2/S&,2/_ '@F< _I0!GQQRZK\1=7E7YCI6E):(0?^6LN7)'O@ 5P4,T
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M,O!G^*(GD#_=)_(BM<+.TG%]3SN)<(ZM".(A]G?T?_!_,],HH%%=Y\.%%%%
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M'E!1110 4444 %%%% !112&@#GO'&KC1?"&H70;$K1F*+UWO\H_+.?PKYL'
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MMWK]X4444R2&YMH;RUFMIT#PS(8W4]U(P17S3XH\/S^&M>N-.EW,BG?#(?\
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MT%>#Z?R_\#\NIV5%%%=1\Z%%%% !1110 4'I0:X/QK\1K3P^DMCI[)<ZIC!
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M]*+O5J-^2T_S9W7B3XHZSK2/;V0_LZT;@B-LRL/=^WX8^IKA?<UO:)X-UWQ
MZ_8K%UA;_EXF&R,#UR>OX9KUKPM\+]+T1DNM0*ZA>CD;U_=1GV7N?<_D*A0J
M5G=G=5QN7Y73]G3M?LM7\W_F_D<5X'^&UQK#Q:CK,;P:;PR0G*O/Z>ZK[]3V
M]:]N@ABMX4AAC6.*-0J(@P% Z "I**[J=*--61\9C\QK8ZIS5-ELNB_X/F%%
M%%:' 5=1TZTU6PELKV!9K>48=&[_ .!]Z\%\9^ +[PO,]S;A[G2B?EF RT6>
M@?'3TW=#[$XKZ$ILB)(C(ZJR,"&5AD$>AK*K1C46NYZ679I6P,[QUB]U_6S_
M *9\GQR/%(LD;LDB'<K*<%3Z@]J]#\._%S4M/5+?6(?M\ X\Y2%F ]^S?H?>
MND\3_"6ROW>ZT.1+&<\FW<$Q,?;NOZCV%>5ZQX:UC0)"NI6$T*@X$H&Z,_1A
MQ7"XU:+NC[&&(R_-H*,K-]GI)>G_  +^A[QI/Q \-:NH\K4XH)2.8KH^4P]N
M>#^!-=(CK(@=&#*>0RG(-?)O!J2&>:W;=!-)$?6-RO\ *M8XM]4>?6X6IMWI
M5&O57_'0^L*BGN8+6(RW$T<,8ZM(X4#\37R^=:U9EVMJE\5]#</C^=4I':5M
MTCL[>K')_6F\9V1C#A65_?J_<O\ -GT#K'Q-\-:4"L=X;^8?P6@WC_OK[OZF
MO,?$GQ,UK7E>WMS_ &?9-P8X6)=AZ,_]!C\:XK('6NBT+P1K_B!U-K8O%;G_
M )>+@%$QZCN?P!K*5:I4T7X'J4<IP& 7M:CNUUDU^"V_,YW@#T%>E^!OAG-J
M#QZGKT+168^:*U;AYO=A_"OMU/L.O9>%OAKI7A]DNKK%_?KR))%^2,_[*^ON
M<GZ5VXK:EAK:S/*S/B+G3I831=9?Y?Y_<)&B1QJB(JHH 55&  .PIU%%=A\F
M%%%% !1110 4444 %%%!( ))P!0 51U#2=/U6+RM0LK>Y3L)8PV/IGI3M,U6
MQUFR6\TZYCN;=F*B1#QD'!%1IK5@^E7.IK*3:6WF^:^PY7RR0_&,G!4T-7'&
M4HN\79G+WOPH\+W;$Q07-H3_ ,\)C_)LUDR?!?2R3Y6JWJCT94;^@KTN*5)X
M4EC.4D4,IQU!Y%/K)T:;Z'H0S?'05E5?Y_FF>8Q_!?2P?WNJWK#T547^AK7L
MOA3X6M&#26]Q=D?\]YCC\EP*[>JJZA;/JDNG*Y-U%"L[IM/",6 .>G530J--
M= J9MCIJSJO\OR2&Z?I=AI<7E6%E!;)W$,87/UQUJY56RU&UU'[1]ED+_9YV
MMY/E(PZ]1SUZ]:=<WMM:26\<\JH]S)Y4(/\ &^"<#\ ?RK5*VQY\I.3O)W98
MHK)N?$VCV<<CSWR*$G:W8!69O,4;F4 #)P.3CI6I'(DL:R1L&1@&5AT(/0T"
M'4444 %%%% !1145S<16EK+<SN(X84,DCGHJ@9)_*@ G@AN8FBGB26-N&1U#
M _@:Y:_^&OA6_)8Z:+=S_%;.8_T'R_I6])K>F0A#+>1('MFNU+' \I<9?/H-
MP_.I-.U.SU:V-Q92^;$&*$E"I!X."" >A!_&IE&,MT;4<16HN]*;CZ,X"?X,
MZ,QS!J-_'[,4;_V45$OP6TX'YM7NR,]!&HKU"JEUJ5I9B;SIAN@B\Z2- 7<)
MDC=M7)(R#T':L_84^QW+.L>E;VK_  _R.*M?A#X;@(,SWMSZB28*/_'0#^M=
M3I?AG1-%P=.TRV@<?\M F7_[Z.3^M:P.1FHY[B&UB\VXE2*/<J[G8 9)  R?
M4D#\:N-.$=D<U;'XJNK5*C:]?TT):***LY HHHH **** "BBB@ I"..E9D'B
M+2+E-\%_#(OVK['E2?\ 7?W/K6I0!SNI>!_#>K,SW6DVXD;K)$#$V?4E<9_&
MN<N?@YH$A)@N]0ASV$BL!^:Y_6O1"0 2>@JOI]_;:II\%]:.7MYT#QL5(R#[
M'FLW2@]T=M+,<725H5&EZW_.YYO_ ,*7T_/_ "&+K'_7-:MV_P &]"C(,][J
M$V.V]%!_)<_K7HU%+V%/L;2SG'R5G5?X?Y'-:;X"\,:6RO!I,+R#^.?,ISZ_
M-G'X5TBJ% 4  #@ 52@U>SN;N]MHG<O9$+.QC8(K8#;=V,$@$$@'C(K/3QIX
M>DLQ=IJ*F NL:N(W^9F!( &,GA2>/2M%%1V1PU:U6J[U)-OS;9O45E2^)-&@
MTB/59-2MQ82,$2<-E2Q.,<=\_E@UJTS(**** "BBLS4_$.DZ//%!J%]%!+*-
MRHV2=N<;CCHN>YXH TZ*** $*A@00"#P0>]<WJ7@+PSJC,\^DPI(?XX,Q'Z_
M+@'\:W+^^M],T^XOKMREO;QM)(P!.% R3@<FIPZE ^?E(SD^E)Q4MT:TJU6D
M[TY-/R=CSNX^#>A2$F"]U"'V+HP'YKG]:J?\*6T_/_(7NL?]<UKTV">&ZMX[
MBWD26&50\<B-E64C(((ZBH;G4+:TN;2WF<K+=R&*$;2=S!6<C/;A3UK-T*?8
M[HYSCXJWM7^'^1PEM\'- B(,]UJ$Y'8R*H/Y+G]:Z33/!'AO2&5[72;?S%Z2
M2@R,/H6SC\*NR^(](AU<:5+?1)>EE3RFR/F895<XQDCH,Y-6M/U"VU2R2[M'
M+P.S*K%2.58J>#[@TU2@MD8U<QQ=96G4;7K_ )6+6!1116AQ!168GB'29-:.
MCK?1'4!G]SSDX&2 >A(!R1UK3H **** "BD=U1"S'"J,D^@K/77M+>.RD%[%
MLO8FFMV)P)$5=Q;)Z  YYH T::Z*ZE64,I&"",@U0L-<TW4[26ZL[I9((N7?
M:5P,9SR!QCG/0TFE:_I6N!SIM['<&,*S*,@@-RIP0#@]CT- &5J/P_\ #&IL
MSRZ5%%(?X[<F(_DN!^E<]<?!K0W),%]J$6>Q9& _\=KT/[3!]J^S>:GVC9YG
ME;ANVYQNQZ9XS4M9NE![H[J69XRDK0JO[[_G<\N'P6T_/.KW6/3RUJ];?![P
M]$09[B_G]FD50?R7/ZUWWVF#[5]E\Z/[1L\SRMPW;<XW8ZXSQFI:2H4UT-99
MSCY*SJO\/\C!TOP;X=T=@]GI-NL@Z2./,8?0MDBMZBH!=1&]:T&_SEC$A&QM
MNTD@?-C&<@\9S6B26B."I5J57S5)-OS=R>BFNZQHSNP5%&68G  ]:KP:A:W,
MZQ02>87A6X1T4E&1C@$/C:?IG/>F9EJBBLZXUS3K75H-+FN MY.I:.(@Y8?Y
M_D?2@#1HK.TW7-.U>:YBL;E97MG"2@ _*?\ /\C6C0 4444 %%%% !65XC@O
M[OP_>VNF@?:[B/R48M@(&.UF_ $G\*U:* /.9?".MVD5U9)';WNG/=6UT8(/
M]'695&R2+:6/98VY.#@U2N?!>LOHL5HVFI.H@OHTM_MN!;RRREHY-W\?RG'K
M^9KT'5M>TS0UC;4KI8/-#&,%68OM&3@ $G YJO!XMT.ZAN);;4$G2WV%_*1G
M)W'"[0!ELGCY<\B@#F;GPCJ<MMKTT2B.^N([>.U?S_\ EFL<0E0=EW;"N<<\
M9XJ)O"^II9:=]FLI6E@O))D@NWA,$*L4SE%/R@88J4.5.?6NH?Q?HNRW$5ZD
MDMS&SV\85LR8)![<8((.>AZU'I_C'3+K2+>\GE$4LD4+201JTK*\B;P@VC+-
MC)P!G') % '-'PWK"1ZE"FE03VUQ>)*?M31O/(-TA<Y#!7 W+MW\@$@@[16?
M)X,\026]JKV:R7:Z?!:QW1O,&UE2:1O,XY;"E>G/8=3CN[7Q7I5[K<>E6TKR
MRRVJW4<BH3&Z-G&&^@SZ=NO%)?\ BBQM8[L02)--:ND<@?>D8)=5(\S:1D;Q
MP,GD XH Y+4_"6LW#S_N&DMI+^\F,,4D>[$FSRY!O.W(PW/5<Y%=-K>F:A)9
M:+-:(;JYTVYCF>*64*TP",C?-TW?-GG .*LGQ7HHEN8OMA\VVD6.2(0OOW$D
M *NW+$[6^Z#T)JG>^+XX=1TB"RLY;VVU'!2YA!**#GKQVQG'H#G&* ,*Z\.:
MO)ILUPNGR+JD]]/>026MZL;V3.H506/#@@?,.?H:[RR6Y2QMTO)$DNEB43.@
MPK/@;B!Z9S26E[;7T;R6LRRI'(T3%3T=3AA^!%6* "BBB@ HHHH *IZM9G4=
M&OK%7"-<V\D(8] 64C/ZU<K,UW7;/P[IPOK[S/*,J1#RT+'+''3T'7\.YP*
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MOC#[9<:8K6EG')'I["X4*K.F&D<#YB3PH Z D\FF^!]&U/29]0>^M([2*>.
MI#&R[1( PD(52<9^7DG)XSS6WX>UO^WM,-VUI+:2I,\,D$I!:-E."#BM:@ H
MHHH 9,GFPO'G&]2N?3(K@=/\/:RT6CVM_ID'DZ-83VQ!N05O69 @ P,JI R2
M>F>AKT&LZ?7=.MM3BTZ:XV7,K!4!C;:6()"[\;0Q .!G)H PO#VDZO::+JME
M<"9+5U*:?:W-PLTD*[,%2XZKGH,G '6LM?!M[:>&[+,7]HZBT%K;7,5R498H
M8P24C VJ<,?XLYZ\X%=#HOBZQU2SLFE(@NKF 3M" SK$OS8+.!A<[6QG&<&K
M^E:_I>M&0:?=K,8PK,-K*=K?=8 @94X.".#CK0!P</@W7(X87$"+J!T>6R%W
M]H&ZWERVPYZD%"%!'(_"KEEX0NI(;*"XM)H[3^T/.N+:2:-56/R&0[1&<8+$
M9'?DD<FNAT[Q%>7?B.31KO1WM9$MS<&3[0D@V[MJY Z$\X^AJY_PD>D<9OHU
MR\T?S9&&BR9,Y'&W!R3QT]10!RWA[POJ&GZWHE]?623/!I[VLDWG M"P<E#U
M^8;#MXSBENO#>IR>*[V_N+::\@=W>+RY8U5XC"4\A]WS!2V>!QDANM=)_P )
M5H_V)KL7+F-9/+91;R%U;;NY3;N'R_-G&,<]*;)XNT&*3RVU.'=Y N> 2/**
M[@V0,8(Z>O0<T <"/#VK:;'I5CJEF=4FDOOFQ<[1<QBT("$YX"%2.>&QD\L:
MT5\(:Z^GV]K<DR_Z)8PR$7)!'EW3/(H;(/$9 SWQQ7<2:U80Z5_:<TYAM.FZ
M6-D;.[;C:0&SGC&,DUD7/C2S-]H]KIVRY.HSM'O;>@C"<-D;2=P/&TX]R!S0
M!A3>$M1F\1/Y>GVT&G[9K??&X D@:#9&&Y+'# <8 &!C/)J"#PIK<>CPV\5B
M(!'IUM;S6PN0!,R3EY5W \;USS_M8/>NLU7Q)+9W\UCI^F2ZA<6\ N+@+*L:
MQ(<[06/5CM.![<XIL/C;09;>.5KX1%K1;QHW0[HXBN[+8! X]_I0!SB>#KZY
M6"*ZLQ'8>;>2+9?:>($=%$:<'!^92V!D GVKI=(\/0"QT>ZU2TCDUBTLXXGF
M;YF#A5SSW.0>?<^IJM?>.M(MX;6>WN$GAEO#;2O\P\O"%R<8RW & !SN&*NO
MXNT));6(ZC$7NDC>$*K'<)/N=!P6[ \GGTH K:GH^EZ5I\QLM&\V2\NH T5N
MS1,[>8N#N7[JK@L>W!]3725E:?XET?5;Y[*QOHY[A%9V10>BMM/.,'!X/U'K
M6K0 4444 %%%% !17#ZOK^MP^,)M/TYO-$/V4I:BS9Q(LC,)"THXCVJ,@GTZ
M&KD?C.>=?W.C2,\U\]C:!KA0)W0R;V)_A4",GD$DG&.Y -;5-$74]2L+PSM&
M;-9@%"YW>8FS\,=:Q_\ A"62SBA@U66-XK"UL@XCP&$+$_, P)5LX*@CZU4D
M\>1QNE\\-RL)L68VGR8\X7 AQNZ_>.,YQCG&:OV_C&:\-I!:Z/+)>S/,&B,H
M1 D14,ZLP&X'>N.!GG.,4 &D>#(])='%\TA6TGM<>4!_K9C+NZ]LXQ6?#\-X
M;73[>T@U$A+>2.>))(-R"41F.1B P)#C!QD8(R#S3H_'5W!'<_;M-B$O]I2V
M5JJ385@@9B7."1@+U .21P.346M>-[R72BVE6%Q ZQ6DT\TNQ6M_.D "E&^\
M2 P..F1^ !N:?X9_LW5;.]M[I(TALA9RV\=N%20!BP*\_)RQXYJG>^"?MU[J
M,[:AY27I0F*&':I*RI(&<;L._P FT-@'!.<U6\:^(-7TG488=++X%C/=%$M?
M/W,C( &Y!5/F.2.:AN?%FHI<7=W%-;OIUI+822[$R#!,I#D$\\%E8'T!H M7
M'@:2Z>YDGU42R2WOVU&DM@<-@J%;Y@60(=H (QC/K72Z5IZ:7IEO9((L0KC]
MU'Y:Y)R2%R<<GU-<EJ6NZR^@:AJMGJ$-L!>RPV$(M?.>YV_NT1>1RTBN<X/&
M.F#3;GQ)KD.K,9&MXXK2YL;2XM%BW>8TX7>P;.1M+C&/[ISG- '7:4E^EHW]
MI2H]P\LC@(!A$+$JN0!G"X&:O5S_ (?U#4KG6==L]0E@?['/&L7DQE JM&&Q
MR22>>OZ#I67'XCU%M-LIC)'YDNOO8/\ (/\ 5"5UQ]<*.: .THKD_"^L:G=:
MM?6&M2M#?Q@R"S-L%58]Y >.0$[U(P#GG/ITKK* "BBB@ K-U[2CK6D2V2W!
MMW9XY$E"[MK(X=3CN,J.*S_&.IWNEZ9:R6#LDT][% 2D(E;:Q.=JGJ:P+;Q-
MKNH6MA;V\L*ZA-!J".I@VD30E1&&4D[3R-PR1SQ0!?N_ LE]J$]W<ZQ)(TB3
MJ T62GFQ&,@$MC:,Y  '?)/6J>L^&=7.MZ?-I\$5Q%:VEO C2L!&623<3(NX
M' &",;N1T'6K=GXDN]=CFN+.^M["SATR&>:>6(.(IG^9@<D?=13WZL"<XQ69
M%XC\2SZ38HUQ#;7,EK>7WGR6N#-%$P$64)^3<&#'N!C&* -B'P):Q7.H$SQM
M!=K< 9@_?1&;.[$F>G)Q\N?4FHX_ H%Y:74]]!<RQ10PS>=:9$@B8E"HW?*V
M#@_>' .!4VG:WJ=YXBTA96@2QU#2VNQ"D9W*X\KJQ//,A& !^/:CXG\4:S8S
M>(+:UMXXHK"UMYH;E&5GW.Y!!5N#G! ],9[C !HZ9X/;3M7M;O\ M.26WLWN
M6M[<P@;!.VY@6SDX/3V_.G2^$G%TU[::D8+P7\E[%(T(=5WQB-D*Y&1@=<BJ
MLWCO[/$T<VEO'J O'M/L[3 KE8Q*6WJ#QM9>W4XZ<U*/&K2/*8M*=((;.*[F
MENIT@$7F E58-T.5P?\ ]0(!;T+PK#H-U'-#<R2A+);7#J,DB1Y"Y(]2YXQQ
M70UQ:>/9)XHEM=&>>Z9[E&C6X4*IAVEB&(&00XQP#GC'>K-MXX@N[NUMHK&7
MS;M[8VZLX!>*6,R&3Z*$<$>J]>: .KHHHH **** "N:UKPH^L:S!?-J4J0Q-
M"XMRFY0T<F_*\@#=T/!/ YKI:;(^R-GVLVT$[5')]A0!YVG@G57\.W0N9]]T
MEO?16=F H"-.[')?/.1C&>F3^&S:^#)!<17M[J3SW@NH+AV\E5!6)&54P#_M
MDEOT%16_CJ:[M[/[-H_FW=U++&ML+H*T11 Y$FX#8V"01CC'&0<T0_$&VNKF
MPCMM/N)%N([>23'WH_..%PH!W8QEN1@<C/2@"Y'X05-6%PU\[V*WLFH+:&(9
M$SJ5.7[K\S'&._4UGQ?#JVBTDV?V]Y9ENX[B&:6(,$6--D<3*"-RA21U!YS4
M\GBJYN[2"[@M)K>SEU&*V@G$B,9QYIC;*D':#@^^/0UCZ=XQU"T1]0UE[@Q,
MM_,+9/*9-L,J(JJ0H88)*\DY.23@C !IWG@'[19M;V^I+:+-9&SN%@M5".N]
MG!4$_*<LV>3D'UYK6U[PZ^L74%S!J#V<T<$ULY$0DWQ2;=PP>ARH(/Z&J.K>
M,9]#M(9M0TN.*4@O+ +Q&=4# 90 ?-USSM';-8O_  ENK6FISO(SW<%O/JA:
MW544ND!BV ''4!F^O?- &VG@B$:5JE@][(RW]G!:EQ& 4\J/8&'/.>N*R=:\
M'ZJP66.Y?49IKLW-RR*D+ ^1Y0"C<!M]?F!QZUU.G:\NKVVHW%A!YL5LYC@?
MS %N&"!C@]AEMN?8UA:/XVO;NSTHW>D@2W5A]OGDBF 2.(8!< Y/.<A>3[T
M7=+\-74>J6&K74]O;W$5JL4UO90E%<[-NUFS\R \J",@]\<47?A*6>]NKF'4
MVB,E['?P*8 PBF5-ASR-RE>,<8]:K67CQ;W3I[I=.\G:L+Q&>?9&ZRDA07*\
M.,<J W48SFG:/XOO-:UW3X(-.1+&YLI)Y&:7YXV238?J,C'3)R#Q@B@#>T32
M5T;3S;^>T\CRR3S2LH7?([%F.!P!D\#TK1HHH ***BN9TM;6:XE.(XD+L?0
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M@S .^0<YSGJ!P..*9-X0T.XM8[::R:6.-F9=\\C,-P 8;BV=I &5S@^E;E%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&%%NBD@XV(F8&,C]/E)((V]0>N>!FM:+7XY+];4P%=\JQH2X^<%6;>!W3Y<
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M3SYHQZ<D8Z$6Y+_4(+^[/GPS6MO-#$R^3M.Z1AE0<_PJZ'ISG%2:YJ]QI]S
MEN$\I%\Z[=DW"*+<!N)R,#&_D9/ XQDT 9J7'B.1KAII)+?$"E46V+C)5.5P
MI^;<7!Y;']TX&7ZY;ZE>Z/:E4O!(]G/'+ "K;G:$[0^!Z\9&.3VK3N-7FCM=
M)N!:O_I<@$D*C<X!B=\#ISE1^M9)\1:B]Y;!42.-YBC+)#T'VAH@&;=\AVCC
MKEORH LRKKZ7%S'!/-*L2S-"SQQ@2MLB**Q '&YI!QC@=>,U6BF\1E[)?/D\
MIW)+O;'/WE^5QL'&-_.%^O SK:9?7TEY/;7JKYZODQ*FT1QG=M<-D[P=H'8@
MYR!T%1O$I36[RU$?G0Q1N(DB0F226,!F4'H<AB !SF-NO8 FNXEG\36Q-M-'
MY2Y^TK$Q\S*L-F\<*HSDY/)V^F:+*#4K+1WBM(D+I)=%%G=BQS(YCY/4'CJ>
MAIK>)T0*SVWR-$'#K)D.V[:54XY*]^A'I2W'B812.L=C+*(W97*NHQMD$?&3
MSR?R!_$ QIY-;@MM0GL8]1DN)MIBEEA16++$<*5"]"W'0?[V,9W].FO;C4;^
M":8^5:NT0=0OSLYWCM_ C(ON2<U!'XF$EW%:C3[EIBVV81J7$7[QHP<@8(RC
M')QQS[4'5)/^$7O+^PMX+:>%9)6AD&=C %V#J,$,<Y(..3GGN 9MN/$$&D1A
M)KPM#;6\;"6-2^XN1,WW26( &.O'.&)%)>OXBN(OLJ&ZW/:.CR(@0,QB8JPR
MORMNVKUZY^4<&M:/5+MM<\DF(VS7+6HC"'>I$7F;RV>G48QW4Y]8KCQ!(FH1
M[8@EF#.A=W'[QH^,8ZCYN!Z_ED K2#779VM[N]6+)$8:&,-M$"LI.5ZF3(/U
M(P.,()O$<MU/N>2$&2)0B0@A4,L8+*2N,[#)D$GZ#'-R#Q0DR+BQN/.<D+$,
M;G*M(K@9Q]WRR><?>7H3BK*:WYFGVL\=N'GN93"D(DQAP&)#$CC 4Y&,Y&,4
M 5M(CU%=8F>^FNW0PF--ZJ$;9-( QP.&*>6>V<GCCBE"_B03:<))I,/'')*7
MA!!?/SHVU?E 7&#D<D\G&*N6FLW=[>7<D<.VVALED2)G&6D+."&(!Z&,@$''
M4\Y&*EMXIFBCEN-0M2(,*Q:$@^6?LPF*XZMT;GW ]2 "K%>ZU.[(C7,T\,*2
MNLL$8,<K17&=N!TWB, \_4@\W)1XB@6=H)Y[AUD=(DECC"L#;[PQP!_RU^4=
MNWO4MEK,%LGE1Z0;%-LLTNY1"BA-N6Y )SO SCJ#Z<N'BH&$R'3Y0(TD>?+@
M>6L;[6P#@D]P,#\#Q0!7B;Q 4C<7$[J@W@&!5,G[Q1M?<H/W=W0+QCTR;=O<
MZFFDW[2I=33I*1$^T(64XY52F0!D\$-G'!;-7]/U5=0EEC6%D,(Q(20=K[F4
MI]1MS]"/6M"@#E;*3Q"YCDG:X C,(V&) ) 9Y%<MQG(C$;<8['':DBN-?M8(
M'G^U7&Z%'DQ"A82-$^5  ' <)]-W)QTZNB@#CY&UN\N4AF@N# %A,BLJ[=ZR
M0G<"%&,CS"1D].W IVG37]HMMI\KS0QQ01S.8T4LF[]VL6"#U?+9]B.E==3$
MACCD>1(U5Y""[!0"Q P,GOP,4 8US I\1"6]LY+F$K$+1Q'O2%PQW$C^$_=.
M[T&,\5AZ?I&IVD,"+ L4LGV63>L)V+M+;_,4-R_S<MD;ACCY37<44 8VBQ7<
M$]TMVTA=II'RL>V-@2,$9)(/MFMFBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO=WMM81
M++=3QPHSK&K.V 68X JQ44]M#<JJSQ)(JL& <9 (Z'ZT 5SJE@]E=W N(Y(+
M8/YY0[MNT9;('M5/4)=%B*VEW;I(T2*B0I;-(0K9(554'C]T3@=-G-7+G3+>
M?3;VR15A6[1UD9% .7&"WN:R[G1+Z\6:6XELWNI?+0,J.HC";\,I#;@^7)R#
MTX]Z -)M-TME<R6=L!.5+!XP-Q!^7.>X./QI&32K!%)6U@6)T5>%78Q&Q![<
M' ]JS-:T2XU*:SA_<2@64\$MQ<0[\%O*&X#(PW#'TX/2HIO"\\UY/<R7%O*6
M*E!)#G=ME5UW\X. I7/7G/M0!L'3M)'F,;6T&(Q"YVJ,* ,*?8 #\ *#;Z5=
M VAAM9!9$9B*@B(X!'';C%8]IX0CAN$><PSJL_F,9%9C*H64#<"2,YESD#L?
M7B]I&AG3(9HO,B;S8(HS(B%7W)&$/.>1\H(],F@!EYJ/AZ[C6>Z$-T(R5!\@
MRE?E#,> 2%P5)/3I2WECI#W(M!$L<D[+//Y$&1(JL6'F,%(52P)Y(S@X[U7E
M\)PC25L()#RQ#32.^X(5V8&&'\(48/!QR*>^@SS:G'>F2&,J%4@!B55&?: <
MXPRL V1V/M@ L6VH:5NCNK>VF62^/#"SD#N!CYF^7(7YAR>.:? =&M;]=/M[
M>**99-P"0$*)-F<;L;=^PDXSG;[507PU,+6.(-:1$3>8IBC8?9AA1B'GY<[2
M3VRW3L9+CP_)J-VMQ<RBV9DW/]E=@QD*%">25X5B-VW)XY &* +$=YHMW<1R
M0PK/)=[U\Q+9F#!3Y;%FQ@#MD\$=,BKOV#3XIC)]FMTDE*Y;8 6*X*_4C:#^
M ]*R8O#<T/V11<QN8+AYOM#1!954R;_+4K@!2/E/'<\=,7-4TAM0OK2=7CC\
MD,K,5W-M.,J >.<=>H[4 1ZAIVC,Z1S0P1M=3*[.L:_O"I\S#''0[>_\ZLP6
M-I!?K,F(_(3[-#%L"*@;#-MXYSA?7[OUK&'AB[VPM++8321,F$DMR8V"Q-'R
M,]?FS^GO5>V\+/.8VEW>5#($"S[E:11'"GF?*<ALPG&>Q[4 =&%TZSOMV^);
MBXD**"1G<5!*CTR$!([D9ZU%'9Z&99_+M['?$!;RX1?E!4#8?^ [1CTP*IP^
M'WB>U8_8V-M=^>LAA^>0$."7.?O_ #YSW(]^&W/AQY+ZYN8Q9.)93)Y5Q!N4
M[HU0[AGDC;D'T9AWS0!>N/[)TF,>;#%$JQF0!82QVQ_-Q@=BQ(]SQ6<]SX:%
MM';-;".(L[;!:.GDGA6+?+^[X8#)QP?2K-[H#7.G6]FMTV(;1[;S),EFW*%W
M$@]>,U'>^&(9Y(Y+:0Q-"C&/>6?=(75PSY/SCY "#GCH1@4 7]1BTR MJ5[#
M"9;>,R"0IEPJ9;CN<<G'O4D-KIT%NL4,%M'"\@<(JJ%+@@@X]05'Y>U4-4T.
M2_N+N17@'VFS:V+21EGB)5P"AST._D>U5+OPK)+)(MM-;PV[W G$8AQL(6(
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MSN-!6: VT4,4]S*Y0>04?>H;=N!&5(&[KCJ?6I;271]6LW\F.*2"-V8K)"4
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M' /1@,JPP<]#4G]@::+J*?[)#B%2(X_+7:I+!BPXZY'6JV@Z-<Z,C1M/"\3
M;E56&2JA0V23@G'(Z<#'<G<H I6>F06;O+CS+B1W=YF4!B6VYZ#@81!_P$5=
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
IHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $B E$# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCU%&1ZBEHH 3(]11D>HI:* $R/449'J*6B@!,CU%&1ZBEHH 3(]11D>HI:*
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M\TPU2)&&F&GFF&F(8:C-2&HS5$C37F&IVWV/4[F#& CG;]#R*]/-<%XO\O\
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MCUJE45[$.FTKG%9QR.HKL8G\R&-_[R@UQU=98_\ 'A;_ .X*LS+UJVV[B/\
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MIL3$C)!7.W:?3%<[H>H"UM]'F>)YIUM=1E5VF8 ;),X*]#GU/2NGLO",%A+
M(M3U,VENP>*T:X_=KCH.F2!Z$TL7A#3X8K=%EGQ!#<0KEAR)CEL\=?2D49T'
MB6^NEM([^Q@C@U.PDGA\F8EEVH&*L<=P>".E1:)KE[<V.G:=HUC 6CTZ*YE-
MU.Q"A_NH#@DG@\FMS_A&[,+IH\R;_0+9[:+YARK*%)/O@567PC:P):?8[V]M
M)+>V6T,L+@-+&O0-D=1SR.>:!%?5O$\^E:G%#*EB83+%$T2W!,_SD#<%Q@ $
M]#U%2>%6D9-<&[<RZM<*N\G'; ^E.E\(6<D]PYN[P13SI<O"'&TRKC#$XR?N
MCC.*T]/TV'3/M7DLY^TW+W+[CG#-U ]N*8'(:?XCUFV\.&_N8(+MY=2-M$@D
M(.6E*XR1@ <8]JNI>W5OKU^]S;6Z:A'ID4DA^U,(/]8P YX &,YQFKJ^$[..
M)H!=71M_MBWB0EAMC<.7XXS@D\U)JGANSU6XNIYWF5[F&.%MC ;0C[U(]\GO
M0(YJ^U^35K06[F#S;75;-3+:2$QR*[9&"<'U!IZZU-IME-J(CC+ZAJ<R23SE
MO*@1"57=M!(&%P/<UM/X6M2TLLMU=332SP3O([#):(_+T& .>E-CT&=/ML*W
M\UO;R73SP^01G#CYU8$$$;LD?6F(KV<S#Q6CAHRNHZ<)Y!$^]-Z,%#*>X(;'
MX5O-63IF@IINHF5"!;0VJ6EHF<E4!+.6/J6_E6LU4B61FHVJ0U&U40R-JB-2
MM41IHED;5&:D:HS5(EC#3#3S3#31(PTPT\TPU2$,-,-/-,-42R,TPT\TPTQ#
M#3#3S3#5(D8:8:>:8:8AAJ,U(:C-42-/6O,M8N/MFK74V<J7('T' KT:\D:*
MSG=/OA&V_7'%>6<]^O>J$:6H:[>ZE)I\DK+')80)! \0VD*IR#]?>M5?'NLC
M7VUEUM9;M[46KAXLHR>XSU-<Q14\L>P^>7<Z&_\ &>IW]JMF(;*UL@ZR/;6D
M C24@Y&_')''2J>H>(M3U+73K$TY2ZWJZ^62JKMQ@ >G%0:.NFOJUN-7EECL
M 29C"N7( X ^IXS79#PYHWB/3='O-.L9-(>]U(V@B:8R>;$ 29!GN,?3-2^6
M/0M<T^IQFKZI-K6JSZC<I$D\Y#.(EVJ3C&<>^*DT?6KO1)+J2T$9:YMWMI-Z
MY^1NN/>NHOM*\/ZIINOC2+&6RN-$8%96F,GVB,,58L#T/!/%2VNF^$]7T[5X
M-/L[F--.L?M U:60@R2?W2AX )X HYU:U@Y)7O<P-.\8:IID6DQVX@VZ69#;
M[DSG>"&W<\]:=9>,M5L!I8A%O_Q+'E>#<F>9,[MW//7BM*QT/0)OA_JNH1SR
M76KV\,<KG!5+<LV @_O'@Y-<932C*^@FY1MJ='H7BI]-:SM;N+S-.BU$7\BQ
MC$F\#L?3VK4\4^*-*U71YK:+_3;R6<2K<O8I;F%>XRO+$^]<111R*]Q*I*U@
M/2NPMT\NVB3^Z@'Z5RUE#]HO(H^Q;)^@KK:L@EMEW740_P!H5O5CZ<FZ[#=E
M&:V#P* /0?!B;=!W?WY6/]/Z5T-9OA^W-MH-G&1AO+#'\>?ZUI5YE1WFV>M3
M5H)!1114%A1110 4444 %%%% !333J,4 1FHVZ5/M%)Y:GM3N*Q4:H'ZUH&%
M#V_6FFVB/\/ZTTR7%F2_2JTG>MTV4!ZJ?SIITZV/5#^9JE)$N#.;DZU U=0=
M*M#UC/\ WT::='LCUC/_ 'T:I5$0Z4CDGJ%Z[$Z)8'_ED?\ OHTTZ#IY_P"6
M)_[Z-4JL270D<2U0/7>'P[II_P"6)_[[--/AK2S_ ,L&_P"^S5JO$EX>1Y^]
M:GA6W\_7XV(R(D9_Z#^==4?#&E'_ )8-_P!]FK-AH]EILCR6L11G&TDL3Q1*
MO%Q:00P\E)-EJ,'SYCLVY(^;^]Q4M0Q;?M,^"2<KD'H..U35RLZT)12T8I#&
M&D-/P*-HH$1&D-2[!Z4;%]*=PL0&F&K/EKZ4>4GI1<5BE)]TTC5:FA01DX[C
MO[T[[/'_ '?UIW%RLSS3&K2^S1?W?UI#:0G^$_G3YD+E9E&HVK8^Q0?W3^=(
M;"W/\!_.GS(7(S$:HC6^=.MC_ ?S-)_9EJ?X#_WT:.=$^S9SK5&:Z0Z5:'_E
MF?\ OHTG]D6?_/,_]]&J]HA>RD<R:8:ZC^Q[+_GF?^^C1_8UC_SR/_?1I^T0
MO8R.4-,-=;_8EC_SR/\ WT:3^P[#_GD?^^C3]K$7L9'(&F&NQ_L'3_\ GD?^
M^C49T+3_ #57R3@@G[Q]J?M8B="1QQIAKMO^$?T[_GB?^^S2?\([II_Y8G_O
MLT_;1%]7D<.:8:[K_A'-,_YXM_WV:/\ A&M+_P">#?\ ?9I^WB+ZO,X(TPUW
M_P#PC.E_\\&_[[-)_P (QI7_ #P;_OLT_;Q%]6F>?&HS5_7;%M+U66 9\H_/
M$3_=/^%94ID,3>6V'QP<5T1U5T<\E9V95U63;;!!U9OY5P6K6OV>[+*/W<GS
M#Z]Q753W$LY'FG)7C&,8JG=VJ7=NT3\=U/H:H@Y*BI)H7MYFBD&&7]:CH OZ
M*-+.K0'6GF73U.Z40KEFQT7\?6NOUCQ/HBZUI^M:3>7TLUA*@@L)(!'!'"."
MJX[X[]ZX&BI<$W=EJ;2LCM;[7O#UKI^M)HS7K3ZVX$WGQA1;1EMS 8/S'DU9
MU'4_!LOAR/2+#4-4MH(E+LBVP_TF7'#2'.3].@K@:*7LUW'[1]CL?#^H^'+/
MPIJ>GWU_>I<ZG&BRB.U#+$48D8.?FS7''&3CIGBBBJ4;-LERNDNP445<T^Q:
M]FYR(E^^W]*9)HZ':E(VN6'+\)]/6M>D50JA5 "@8 ':I8(3/,L8[]3Z"@#2
MTV+9 9".7/Z5JV-JU[?P6R]9'"GZ=_TJLJA5"@8 &!76^"=.WSRZ@X^5!Y<?
MU[G^E14ERQ;+IPYY)':JH10JC  P!2T45YAZP4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!%'N\^;)4C(P!U''>I:A
MC'^D3G9C)'S?WN*FIL2"BBBD,**** "BBB@ HHHH CF_U1^H_G4E1S?ZH_4?
MSJ2@ HHHH **** "BBB@ HHHH **** "BBB@ J-O]>G^Z?Z5)4;?Z]/]T_TH
M DHHHH **** "BBB@##\4:0=2T[S(ES<099/]H=Q7G->Q5POBO03:S-J%LG[
MASF51_ WK]#75AZEO<9QXFE?WT<+J%KR9T'^^/ZUG5T=9=Y8E"9(AE.Z^E=A
MQ&->V,5['AOE<?=<=17.7-I-:2;95P.S#H:ZVFNB2(4=0RGJ"* .-HK>N-#B
M<EH',9_NMR*SY-(O(^D8<>JG- %&BIC9W*G!MY/^^:<MC=.?EMY/RQ0!7HK1
MBT6[D/S[8Q[G)K3MM'MH"&<&5QW;I^5 &38Z9+=D.V8X?[QZGZ5T<,,<$2QQ
MJ%4=!3Z55+,%4$D] * $ )( &2>@K:L[;[/%\W^L;[WM[4RSLA!^\DYD]/[M
M7 "2  23P .] $UI:RWUW';0C,DAP/;WKU2QLXM/LHK6(?)&N,^I[FL?PQH7
M]FV_VFX7_2I1T_N+Z?7UKH*X*]3F=ELCT</2Y%=[L****P.@**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ABQ]IGPQ
M)RN0>W%34U5(=V)!#8P,=*=0Q(****!A1110 4444 %%%% $<W^J/U'\ZDJ.
M;_5'ZC^=24 %%%% !1110 4444 %%%% !1110 4444 %1M_KT_W3_2I*C;_7
MI_NG^E $E%%% !1110 4444 %-=%D1D=0RL,$$<$4ZB@#S_Q!X:DTYFNK12]
MH3DJ.3'_ /6KG:]B(!&",@URFM>$$G+7&G;8Y#R83PK?3TKLI8CI,XJV&^U
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M8R/&K%2Q8'@G!(&*ZNN;M?#%WITS0Z?K4MOIC3&;[+Y*L5R=S*KGHI.>,=Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-:6-&57=5+'"@G&
M?I3JJ7>FVM[<6\\\>Z2W;=&<]#0!,;B %P9HP4(#C</E)Z ^F<U+7+ZAH5[+
MJ-S>6P0--<P^8I;B2)=AS]5*G'L3ZU%#IFO+ [&YE^U;U5@T@V,#N#..3T#
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M7K%KA$P[%LDGZ]Z +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $A J<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH ***R_$&O6?AK1Y=3OMYAC(7;&,LQ)P !0!J45E^']
M>LO$NCQ:G8%_)D)7;(,,I!P016I0 445@VWBB,Q:Q<:A87>FVNF2%6GN8R%E
M49^=,=1_B* -ZBH;.[@O[.&[MI!)!.@DC< C<I&0>:FH ***R_$.OV?AK1Y=
M3OQ*8(RJD1+N8DG XR* -2BN4TGXA:-JVJQ:88KZRNYAF%+VW,?F_P"Z>0:Z
MN@ HJA<ZUI]GJMGIEQ<A+R\#&"+:27VC)YQC\Z@CUF63Q/-HYTN\6*. 2B^*
M?N6)Q\H/KS^AH UJ*** "BJ>J:I9:+ILVH:A.(+6$ R2$$[<D <#GJ15F&:.
MX@CFB;='(H=6]01D&@!]%%8]MXDLKKQ3>>'HTF%Y:0K-(Q4;"IQT.>O([4 ;
M%%%% !1110 444T2(9#&'7>!DKGD#UQ0 ZBJ>JZI9Z+IL^H7\PAMH5R[D9]@
M .Y)KEO"OCA]<UR[L[FTNK>*9C)IS26K()(0HR2QXSG)^E ':T5P\GQ3T9+J
M>"/3M9G,,K0L\-IO7<IP<$&NW4[E!P1D9YH 6BN%/Q7T("60V>K"VBE,4ER+
M3,2L#CD@UOW?B(0W.D)::?=7]OJ3<7-NN8X5P"&8]@<_H: -NBN+F^(*16/B
MBY_LUS_8,PB*^:/WV3C(X^7]:U8/$LD]_H]NFD7C1:C:BX-RBYB@RN=K-Z_X
MB@#?HHHH ***BN;B*SM9KF=ML4*&1V]% R: ):*YWPIXTTOQA'<MIRSHUN5#
MI.@5L'H1@GC@UT5 !1110 4444 %%9/B;6QX<\.7NKF W MD#>4&V[LD#KVZ
MU*FKH?#J:PT$Q1K47)AB7>^"N[:!W- &C17!?\+8T;[1]G_LK7//"[O*^Q?/
MCUV[LXKMK*Z6]L8+I(Y8UFC60)*NUU!&<$=C0!/1110 454U/4K/1].FU"_F
M$-K -TDA!.T9QT'/>I[>>*ZMHKB!]\4J!T8=U(R#^5 $E%%% !1110 450U7
M6M/T2*"74;D0)/,L$9*D[G;H.!5^@ HKC]5^(^D:;JLVFP6U_J-S!_KQ8P>8
M(O4$YZUT>DZI:ZUI5OJ-FS&WG7<F]2IZX((/0Y!H NT44R::.W@DFE;;'&I=
MF] !DF@!]%4]+U2RUK38=0T^<3VLP)CD (W8)!X//4&KE !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>8_$?6;<^*O#^D
MSQ7$]K;2_;[N*WB,C,%X0;1VSG\Z].K*MO#UA:^(KS74$C7UU&L3L[Y 48X4
M=N@H \Z^'VID:IXGT'3S-:BXWWFG"YC,;1EACE3Z$K^5)X/D_L/74LM;M=6M
M_$?V>9Q)+=M+!>X!).,X[<?2N_U'PEI6J:VFKW"2_:EMWMB4D*AXV!!! Z_>
M-5M'\#:1HVI)J,;WEU=1H8X7O+AI?*4]0N>E ')> ='_ .$DTZ#Q7J.LZA_:
M37C,=ER5C4!L>64Z8(XQ[BLB[C?4_#_Q$^TW-TPL]1:6%1,V 1N 7']WGITX
M%=Y#\-_#MOJZZC##<QE9A.+=9V$/F Y#;/8_A6C;>$M)M4UA!$\B:O(TEVLC
MDABV<X]!R: /,;V.70/ 7AVWTVYO_P#B>S0_:=MS\V-@S'&3P@.<5N^'M)\1
MV&M7\5A8W^G:7<6+JBWUVL_E7./E=?F)Q70P?#GP_#H<^D-'<SVLLBRCSIV9
MHV P-A_AQST]:FTWP-I6F_:?W^H71N(&MG-U=O)B-NH7TZ=>M ''^!=FD^)K
M?3=<M]6M/$+Q29DFNVE@O!U+ 9(R,<?2MSXN_P#)/+S/3S8O_0Q6KHW@?2-%
MU)=1C>\NKN-#'%)>7#2F)3U"YZ5I:_H-EXDTF33-0$AMY"K'RWVG(.1S0!P]
MGH7B/Q+KWA_4]8L[73K#25$D0CF\R28X&,^@X'ZURGB*ZMY-,U#7M#/B*66"
MZXU:6[VQ!M_*JF?N\X''I7N<,2001PH/D10JY] ,5QTWPN\-S"YC*WJVT[%_
MLRW3")'/\2KT!_.@#E?%.BV^K?$/PQ]HN+M#JEL3,8IRI0JG&S^[GOCK6C)?
M7.D_$C75AGGDBLO#XDBBDD+ LH&"1Z\<FNLU[P7I'B*WLXKQ9T:S&()8)2CJ
M, 8R/H*GM?"VF6FMOJT:2&Y>T6S;>Y93&N,<'OP.: /)M)L_$FH:-I^N:59Z
MO-K$DHF>_>_7R9EW$,OEEN%QQC%=#<:7+XD^*NO:5<:G?V]BMI!*\-M.4W':
MH ]@"2>.M=#%\,] @N-\#ZA%;^9YOV2.\=8=V<_=ST]JW+?P_86WB.\UV,2?
M;;N)8927RNU<8P.W04 >/S";4_@SJ4E[=W,TFDWSQP,TI^9=RC#_ -X#<<9Z
M<5TFI^%]2MO ^DQZ$]_>6S2I=7UK]L*RS(4&41NP]A78VO@O1K30;[1EAD>R
MO9'EF220DEFQG![=!BJ2?#O1XM*AL(KG4XUAE:6.9+QA(I( (!_NX XH 7X?
M7NEW?A^5=+%]&L5PR2V]](7D@?C*9.>/3\:YY&*_%?Q<RDAAHX((."/E6NZT
M+P_I_ARP-GIT3*C.9'=V+/(YZLQ/4U"/"^FC7+_5]LOVJ^MQ;3?O#MV8 X'8
M\"@#QP65Y%\+++Q:-;U,ZC!*JP@W!V(@DV[<=_7)^E==JOF^+/B-;:!?7MS;
M:=%IRW7E6TIC,TAQU(ZXS^AKJCX'T9O"*^&2L_\ 9RG<!YIWYW;OO?6EUSP1
MHWB![:6Z2>*XMD\N.XMYC'(%],CJ* .6UF!]%\7>!=-@U&[F@26="\LY8R#C
M 8_Q8SCGTH6\F?X@^-D6ZD:.+2@442$JC!!T&< UTE[X T"_T2RTF2&9(;)B
MUO)',1(A)R3N[Y/)I^E^!-"T>2[>RAF0W=M]FFS*6WKSD\_Q'/)H YWX6:*\
MVB6'B2[U.^N;J6!H5CDF)C2,-@#!ZGY<Y]ZM^/H/#D%Q!J5[J]SI>LJFRVEL
MG)F<9X7RQ]X9S_C76:)HUIX?T>WTNQ#BV@!";VW-R2>3]34K:58/J8U)[2%K
MU4$:SL@+JN2< ]NIH X6PL=:\:>"KW3?%0-F)9%%E<O&(Y9,'(9X\\'@<<9R
M:9HFN>)/#GBO3O"GB![:^ANHS]ENX1AP%!QN'X8_J:[;7-#L?$.F/8:A"982
MP< .5*L.A!'(-8/@SP+:>';>&\O$6XUK85DN3(TF 2>%W=!C H YG5+3Q/\
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M34;-V"BX16/9_E/ZU:!!&0<BFO&D@PZ*P]&&:JG38D.ZV=[=O^F9^7_OD\4
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MJ"K*<.C=5/H:FJI=6[AQ=6P_?H,%>TB^A_I4\$Z7,*RQGY6]>H/H: )****
M"BBB@ HHHH **** "H;FY2V0$@L['"(O5C3IYTMX6ED.%4?B?:H+2!RYNK@?
MOW'"]HU]!_6@!(;1GD%Q>$/*.50?=C^GO[U<IDLBPPO*YPJ*6/T%>1^'IO%/
MB>S%W%XVALGGE<1VKJC.%!XP.M 'K]%<KKVA>);Z:U;2O$AL8XX DJF$-YC@
M_?\ ;/I7+^'[CQ.WQ%_L>;Q$^H6UDADO6$2J@..$Z=<D?KZ4 >I45S'CSQ++
MX7\.-=6JJUY-((8 PR QSSCO@ _I7)W]]XM\#C3=6U36/[2L[F18[NW:,#RB
M1GY2/09_+I0!ZG17G6I:OKGB?QM<>'M#U+^S;2QB$EQ<H@9W8XX&>W('X&H]
M&\:ZCI$?B'3?$#K=7FCQF6.91M\Y>  ?Q*\^_M0!Z35.6T>*1I[/"R'EHS]V
M3Z^A]Z\P^V>.%\*_\)G_ &XA&/._L_R1Y?E9Q_\ 7]<=\UZ7H>JQZWH=EJ<:
M[5N8@^W^Z>X_ YH M6URES&64%64X=&ZJ?0U-5.Z@=9!=VX_?*,,O_/1?0^_
MI5B&9+B%98SE6&10!)1110 4444 %%%% !1110 5!<W*VR#(+R,<(B]6-.N)
MTMH&E?H.PZD]@*AM+=]QN;C!G<=.R+_=% "0VC/(+B[(DFZJH^[']/?WJVS!
M5+,0 !DD]J6FR,5B=E0NP4D*/XO:@#F+#QYIM_J%K;K:7T5O>2-':7DL.V*=
MAGA3G/8XR.:2+Q[ILVH1P+:WPM);G[)'?F+$#RYQM!SGJ",XQ7-G5!KOC#0;
MFQMM0%U#,5NM.NH"(K-0I#.#@ /Z$$YS2:KJW]MZ[HXL[348]3M;]5ETJXA/
MD(H8YF) QG!R&S^% '76/C#3[V_>W\N>"+$K17,RA8IA$<2%3GC:?4"M'1M6
MCUK3EOH()H[>1CY1E7:9%[.!Z'J,]JX#Q!H\%S>ZL=%TR1X+*-Y+O)<K<2GY
MO(C7/"DX9]O7@>M=3X/U2]U.TO!/)'<002*EM=I;F%91L!("'IM)*_A0!TNX
M;MN1GKBLBP\0PZGK=[IUK:W#)9-Y<UT0!$).#L'.2<'TQ7F-O!)MM42"]'C4
M:KNFD*R9\O><DM]WR]GX5UO@72+2TUOQ)<)9B*2/4)(8GVD8CPIP/;- '<U2
MDM7MY#/9X!/+PGA7_P #5VB@"*WN$N8MZ9!!PRGJI]#4M4KJ)X9/MENN7 _>
M(/\ EHO^([5:BE2:)9(SE&&0: 'T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%([!$9V.%49)H I77^EW2V
M8_U:@/-[CLOX_P!*O 8&!5/3D/V<SN,23MYC9[ ]!^ Q5LD*,L0!ZF@#'\2Z
MSIVD:1-_:%Y%;>?&\<7F-C>VT\"N3^$6JV#^%H=+6[B-_&TDKP!OF5=W4CTY
M%=[=6UG=*%NX8)@GS 2J&V^_/2FV]CI]HWFVUK;0LPQOCC520>V10!YAXH\2
MZ+-\2/#MW'J=LUO9&1;F0/Q$<D8-3>-'TRY\:^'M2UAA+X;EMFVR\F+><D9Q
MV/RG\*]%.D:4[L3IUDS9RW[A2<GUXJQ):6TML+:2WB>   1,@*X'3CI0!Y7X
M<FTJW^(NH:AX<_=^'[>Q9KQX5/E%@,_*._3]#4OBK6+2^O/"WC6R\V72[:X:
M.=MA!C&1R1^?Z>M>EBTM[>U:UM%BM/,5@@C10 <=0O0U!I>C6>D:+%ID2![>
M-2&\P [R>6+=N22: //M0OK3QQ\1]&31YOM-I80O)<7" [5W=!G\OS]JI^%/
M%%AX0\*ZMH>KR&WU*TEE"0,IS+N'&WUY_3FO5;.WL;:,K8PV\2'!(@55!]#Q
M1-I]E<SK//9V\LJ_=D>)68?0D4 >*6^E7?AK0O"'B"\@D$-O=O+<KM.8T<C:
M2.W /YBNDO=2M?&?Q+T#^Q9?M5KIJF>XG0':O.0,_@!^->FN(IE>)PDBXPZ'
M!'/8BH[:RM;)"EK;0P*3DK%&%!/X4 3U1(^QWX8<07!P?]E^Q_'^=7JANX!<
MVLD6<$CY3Z'L: )J*@LYS<6D<IX8C##T8<']:GH **** "BBB@ HHJ*ZF^SV
MLDV,[5) ]3V% %;_ (_-0YYAMC_WU)_]8?J:O5!90?9[1$/+XW.?5CR3^=3T
M 5=1FLX--N9=0=$LUB;SF<X 3'.?PKR3QCIO@.V\(?;-":U6^+H;5K>8F0G(
MR",Y'&>O3BO8Y(XYHVCE17C8896&01Z$5A6W@OPSI][]O@T>TBG4[A)MX4^H
M!X% %:^U^;P[\/XM4U+F]2T0%7ZM,5  /X]?QJI\-]%DTOPVVHWQ)O\ 4F-U
M.[]<'E0?P.?QK?OM.T;Q':6[7<5O?6P?S(26W(6]1@X/>K\$T%U;)+;R1RP.
MOR,A!4CVQVH \S^)5_9^(/"-OJFD7*7EO87R^<8\G;QCG\2/SIOQ)UVPU_PW
MI>G:7<1W5U?W,;1QQ,&8#!'('3D@<^]=IX;\,6^B:5<VLJ02->3/-<*D>(CN
M_A53_"!@8J73?"/A_2+PWEAI-M!<'_EHJY(^F>GX4 </H$T'AGXJ:U:ZE.D"
MWD"/!+*VU7QCN?Q_*L6[MW\4ZWXXU'309K9;011NG(D92AP/7B,_I7JNLZ-H
M.MRP6NKVMK<3$,T*2'#D#&=O?'(S4^G6VE:3'_9NGI;6PB <P1D @,<!B.O)
M'4]<4 ><MXITK_A2P@^V0_:OLGV3R-PW[_N].N,<YKM? ME-IW@C2;:X4I*(
M=S*>HW$MC]:D'@OPV-2_M :-:?:MV_?LXW>N.F?PK=H *HJ/L=_L'$-P<C_9
M?O\ F/Y5>JO?0F>T=5XD7YD/HPY% %BBHK>87%M',. Z@X]*EH **** "BBB
M@ HHJ&[G^SVLDH&2H^4>I[#\Z *X_P!,ORQYAMC@?[4G<_A5ZH+2#[-:QQ=6
M RQ]2>I_.IZ "L+7O%$.@WEC:-8WEY<7N_RH[9 Q.T GJ1V-;M<)XTMKVY\9
M^%EL)S;3;KC%QY/F+'\HZCISTYH Z30_$=CKT%P]N)H9+:3RKB"X39)$WHPJ
MW>ZI::?):1W,NUKN800@ G<Y!./R!YKSW7=%MO#UM%'J$9U:XU6],US>W0=(
M495P-R1<D8. OK6"EG&-#\/W.KVDS6MKJT\$Q>*0^7!R57'WMN>G>@#URSU0
MW>J7UE]BN8EM=F)Y%Q'-N&?D/?'>KX92 000>X->0:AI]S:IXNMM$MYXK036
M3&.)7Y@*Y?:.IZY('/6H+JUB/A^_;3;MI;66]LQY%I9S01QMOPQ3<2<D=<=*
M /7;_4+73-.N+^ZE"6]NA>1P,X Z\"IXYHY(DD5AM< J3WS7DNNZ(EN/&NFV
M%E+]EBMK:YMX5#,HEP=S+ZG&<U%KR:2MII5YIB1W,*6C+'I4]M.$F8M\QC8?
M=DSZT >Q45%:DM:0EHC$QC4F,G)3CIGVJ6@ JC$/L=\8>D,^6C_V7[C\>OYU
M>JM?Q-+:,8_];'^\0^XYH LT5'#*L\$<J_==0P_&I* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>IDFS,0ZS,L
M?X$\_IFKE4[SYKNR3MYI8_@I_P : +8 4 #@#@5B>,+*XU#PEJ-M:1&6=XP4
MC!Y;!!P/?BMRB@#S?5HCKMWJ.HFUU*WLC#:PJSV+.6=)&<AHCRT8R U7+BVU
M&X\%Z&D6G+9W*:C"PBCA;9&HD.'*9RHQAB">,XKO** /.F77=/US5I)7N4@G
MNX1<7EG:$ML$!V[$.[C=@$C-17>N^*;.SEN;HSQR+IAE*K %2"0*3N?*X.3C
M@-P>,5Z55/4[NTL[%I+Y0;9F6-P4W#YF"C(],D4 <%*^N:DV56[GC'VD6EU)
M:A)1FV[?*-HWY4' STYIT&H:V/[*M+=-4DMQ!%'<"XM\*P9&W'[F<J0!DD?0
MYS70WGC'3TLW:PFCDF61HP)$8(-DBHV<#(&7&/6JC^.T%U"/[/N5M_M-S;RD
MQ,S_ +I2=R@#GISZ4 <Y8G5],T=8H8KZQGD6SB6:&SW;0(!O,@VDL%Y '7.!
M5K6+WQ%??VQ:VRZF+8VTH4-" P9&3;M(4?>4L<9)/L>*]%MKB*\M8KF!P\,R
M"1&'\2D9!J6@#SPR:K:7MW)%)J"V,]Q$9;Y+(&X*>1E?EV<_/A2=N1TXI]OJ
M'BYIH)KD7$;*]HDD"VP*$.I\TGC/'!X/!XKT"B@#G?!]WJ=UI]Q_:AN'F27:
M)I8]BR# Y12JD#/&".#W-=%110!3L_W=U=P=@XD7Z,/\0:N53 VZP?\ ;@Y_
M!O\ Z]7* "BBB@ HHHH *IW_ .\>U@QD22@M]%Y_F!5RJ<ISJULO]V)V_D*
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ME#,F89 X0@C=EN2.5SQS3)?'5K#IK:A)IUXMJ)7CWL8UW;"0S*"V6 (/3DT
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M=E1@D8'&#4%CX/T6TMK))<SS6J1J)3(5WF,Y0LH."1DXSZUX!D_WF_,T9/\
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MG5J*G&[.[+\!+'572@TG:^I[+17SE_PE?B'_ *#E_P#]_C1_PE?B'_H.7_\
MW^-<_P!<CV/:_P!5J_\ S\7W,^C:*^<O^$K\0_\ 0<O_ /O\:/\ A*_$/_0<
MO_\ O\:/KD>P?ZK5_P#GXON9]&T5\Y?\)7XA_P"@Y?\ _?\ -'_"5^(?^@Y?
M_P#?\T?7(]@_U6K_ //Q?<SZ-HKYR_X2OQ"?^8Y?_P#?\T?\)7XA_P"@Y?\
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M[\G/I5M/%.DI=:5>7EV;BZB<!S;+((T3RBH<QOP'4D?=]ZXS^P=9_P"@1?\
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M $_QJ.3P!XEB9%?3U#.<*HF0D_AFE*-66Z_ NA7P%!-0J1U_O(R=##'7].V
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MM/\ 1KF2S/W,>9#_ +O<?@?YU>JEJ(\N)+I?O0-O/^[T;]*N@@C(Z4 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1[:;5[6.UOV7,L,;[E4Y]?IBM"L_1+6_LM'MK;4[[[;>(N)+@)MWG/I]*T*
M"J>G?)'/#G_53,H^A^8?SJY5.U&V_O1ZLC?^._\ UJ +E%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1^%5$_TS4#)UAM\JO^TYZG\!Q^-7J],_/PHHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %, G # 2(  A$! Q$!_\0
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M5+5]0&E:1=WYC,@MXS(4!QNQVS2Z3?C5=(M+\1F,7$2R;"<[<CIF@"Y1110
M4444 %%%% !16/K>O+HMSIL+6YE^W7 @!#XV9QSTYZU<U348=)TRXOYU=HH%
MW,$&2?I0!<HJA'JJ3Z$-5MK>:9'@\Y(5'SMQD#'K4FFWCZAIT-T]M+;-(N3#
M*,,O/>@"W1110 4452U;5K/1+![V^E\N%>.F2Q[ #N: +M%<QIWC:TU&?R$T
M[48I'C:2 30;1-M!.%.>N!6SI&H/J>FQW<EG/:,^?W,XPPP<4 7J**Q;W7Q9
M^)M.T;[,7-XC/YN_&S )Z8YZ4 ;5%%% !116='JDCZ]+IIT^Y6..(2"[*_NV
M/' /KS^AH T:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XWXD:@UOX?CT^
M+>9K^41;8UW,4'+8'?L/QK"T34[:P^(<0M;2[M++4+=8-ES"8\R*, @=^@_[
MZKO[K1;*\U:TU*=&:YM 1"=QPN>IQZTFJ:'8ZP]J]W&Q>UD\V)E8J5;\/H/R
MH X2&*31O%:2>(8;QY+F]_T34(;DF/!/RH4S@#_/2I=+L$\4ZSKUSJFH74,E
MG<F*%8I]@@4$X;]/T-=/!X,T6#4$O!#*[QR&6..29F1&)SD*3CK2:AX)T+4M
M1>^N+9_.DQY@21E63Z@4 <Y/$=0\5^*[*::8P"Q1@%D(Y"J1C\1^IK"L]^B_
M# :E833I=7DOD2.).$7>WW1_">,9]Z]0AT2P@U2ZU%(C]HN8Q'+EB05   Q^
M JA:^"M"M+>[MX[5F@NAB2)Y"5'.1CTYH Y_0])U>QU^WFL["ZL=/DA9;C[1
M>K,&;!VN!GKG%5/#L3:-XEM;;7[>]75)Y'\F^6Y+Q7&>Q7.._P#+I76:=X.T
MG3+@30K<.RH8U$L[,%4C! &?2ET[P=H^F7T=Y#%*\L((A\Z9G$0/]T'I0!6^
M(7_(D:A_VS_]#6LGQ=-:)\,;>.X9/->"#R%)^8MA>1^&:[+4]-M=7T^6QO$+
MP2@!E#$'@Y'(]Q6-8^!/#UA<I<1V1DDCP4,TC.%QTP"<4 8=O)<0>-/"T%Q*
MZL=* ="Q +[&SD>O%4_[7N;2+QQ>6EPS/%,BQ,K;@F6*DCZ?TKM=;\,Z9X@,
M+7\+%X2=CHY5AGMD=J;8>%M'TV*\AMK-5AO%"S1$DJP QC!^IH XO0M,UB.\
MT;4+"PNXD?:UY/-?+(MPC 9;;GCN:U/BG9QS>%A<L7WP2J% 8A?F(!R._2MB
MP\%:-IUW#<0)<9A;=%&T[%$/J!FM;4]-M-7T^6QO8O,@D'S+G'3D$'L: .%U
MFU%E)X<\.V]U=0V%](7G?S3N?[OR[O3GI[U9T2)M#^(EQHMG<326#V@F:*20
MOY;Y'KT_^O6Z_@W1I-&CTN2!WMXW,B,TAWJWJ&JSHWAO3-!,KV4+"67_ %DL
MCEW;VR>U '/_ !*U#R](M=*C$C27\P#+$-SF-2"V .O.*R?#VJVUI\1)8K:U
MNK2RU*$*L=S"8_WB#C _ _BU=Y/HUE<:S;ZK*C-=6Z%(B6.%!SGCUY-)J6AV
M.JW-G<W4;&:SD\R%U8J0<@]NHX% 'F0M!K7A?Q!KU[J-RMZDLB!!+A54 80K
MZ'.,5H)/)HT7@S6C,R6CVZ6EP-QV@$<$CIW)_P" UU5QX$\/W5_/=RV9+SDL
MZ"0A"Q_BQZ\D_6KUUX;TR\T&+1IH6:SB"A%WG(V].: .%M[V&?1=7UO4I[[R
M=1OQ%;Q6LA#NJDX4>@/0_2I?#;7&G^-KG3TM[NQMI+ RFUN+CS2&!&&R"<5V
M<OAC29]"BT9[?_0XL%%#'<I'<'KGD_G4>G>$M)TR]^VV\4IN3&8FDDE9BX/K
MGO0!YK!83/\ #V37FU*^^V6T^V ><=J#> >/?<3GZ5T5Z\OB+Q=I6DWUS-%9
M-IZW)2*39YLA!ST_SP:ZI/"NE)H$FB+$_P!BD;<R^8<YR#U^H%)J?A/2-7BM
M4NH&W6J!(9$<JRJ.V1UH Y'Q(LMG>:%X=M9+N\LI#*707(5YL$X0OQP.F/ZT
MQAKWA[PWXAD,%Q:6A6/[&DEP)7BW,%;# D]#77S^$-%N-*M]->U(@MB6A*N0
MZ$G)(;.>34ECX7TNPM;JW6*29+L!9_/D9RX&<#GZF@#@+S1K;39O",\%_<3O
M=7,4DB22[E8DJ2X';KBNY\;_ /(F:I_UQ_J*@M? /A^SDAEBMI#+#*LL;M*Q
M*E>0/IGM6[J%C;ZG8365TI:"9=K@'!(^HH YVVD*?"]2CE7&EY!4X(^2N9@N
M9],M/!^NO<2>0P-K<[F)&&)P3],G\A766?@/0;!I&@@F'F1-$P,[$;6&#W]*
MO3>&=+N- 31)86:RCQM7>=PP<YS0!P,VJZ@OAKQ%XDMYI%:\NQ!;L&/R1!L9
M'IUQFM'0=*U>TUS3;JRT^ZM;)T(O&GO5E$P(X;&>O?C_ !KLX="TZ'1!HXME
M:Q"E/+8YR"<]?7/.:HZ9X.TG2KR*YMUN"\((B62=F5,C' )]#0!S/@;2SJ5W
M=ZG=7UV[6=](D$/F?(/4D=\Y_2K'Q**K+H#W/_'DMX#-GIVZ_AN_6NNTK1K+
M1HIX[)&19I3,^YB<L>O7Z5+J.G6FJV3V=] LT#]5;^8/8T 1:E<0C2IRDT>Y
MX',6&&3\I.5_#TKS$RW=QX3\)QI>SPR3WKQF57.X OC^1KNM.\#:%I<S306\
MAD*-&#)*S;588./3@FK">$])CM-/MEA?RK"7SH!YAX;.>?7F@#DO$>C?8=2\
M-:+9W]Y##+),K2>:2^&QGG\3^=-UO0H4\8>&]'BNKJ. 02+YJR?O,98D;O?I
M]*[N]T:RO]0LKZX1C/9L6A(8@ GU'?I1<:-976KVNJ2HQNK566)@Q  .<\=^
MIH \^L[Z\T"#QC96ES,\=B$:W,C;FC+$@D9]./RJ"]LO[%\.:+XALM2NGU*>
M2)I"TQ83;@25Q^E>B0^'].AO-0NA!N?4 %N [$JXP1C'XFLZR\":#87L=U%;
M.S1-NB225F1#G.0#0!S/B6WFL/$5UJFM6]Y<Z2Y003VMR5-IT'W0?7_/-7_-
MNKKQ]J\-G=,ADTH&!F8[58A<-C\:W+SP9HU]?R7=Q%,YD<221><WENP[E<XJ
MU+X=TV>^NKR2$F6ZM_LTHW$ Q\<8[=!0!R/@Y4TS7DT[4K2]MM9:%B9'N#)%
M<C/WNN,\?SKT.L72O"NEZ1>&[MTE>XV;!)-*SE5]!GI6U0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'U- &MYB?WU_.CS$_OK^=9.X^IHW'U- &MYB?WU_.CS$_OK^=9.X^IHW'U-
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MU [T27=M#*D4MQ$DC_=1G +?0=Z\^33K.+P'<W:0(+B&]/E38^>/;/M4*>H
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M?IWK3M]2,^MWECL016\$4RR@_>WY_3BI;?5M-NI7BM]0M970%F5)02 .I^E
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MXO*EACDC_N.H(_*I** &>5'L5/+78N,+C@8Z4NQ2X?:-P& V.<4ZB@ HHHH
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M$0#[XB;(<>O'.:W=-ACM?&VJQ01K%&]I!(RH, MEQG'K@"@#HB<4UGVJ68@
M#)-.-9&NSM]G2TC;$ERVT^R]S2D[*XXQYI6*%NYN[F:_?_EH=L8/9!T_.F2+
MN<L:MA B!%& H  J-DKBFN8]"+2*3(6X[59@G>$!<92G>63VILS06R;YY%5?
MYUGR7*;3T+$BP2@2 #(YS69+J$]WNCL4P@X:X?A1]/6D9Y]34Q6Z-%:G[TI&
M"P]!7&W5[=-<,$EV1(WEK$/Y5:CR*XZ5/VC<8O8VII%"&"!_D4\NW5F/5O\
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M@FBLFV3-+<B-G<#)5 1SCU..::WB2>YO;2VTFP6Z^U6@NU>27RPJ[L'/!_\
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MYG74+E"H'^HB/\(_O'W-;@44@P.*>.E:QCRJQSSFY.[#%%%%42%9U[_Q\?\
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M0!S5E*=7\6KJ-M!/':V]HT+2RQ-'YC,P.T!@"0,'GU-)XK@O(IK/4-.A>2X
MDM&"#)"R# 8^RL%-=-10!QECHTMGXD@TJ.W<:9;/]O20CY2WEA-N?7=N;%0)
M;W-OX9LI7MI_]&UEKB5%C)81^<_S;>I&"#]*[JB@#GM.C:7QCJ%[Y+B*2RMQ
M'(Z%<Y+DCGOTR*Q],L[F.'P\K6TJB'4;EF!0C8I\S!/H.1^==S10!Q0L)AX%
MU^$6LGG37%TZIL.Y\N=I [\8Q786V1:P[L[MBYSZXJ6B@##MH91XVOYC&XB:
MRA4.5^4D,^1GUJ;Q)9O>:+*T.!<VS+<P$]G0[A^>"/QK6JAJNF_VK:_9FNYX
M(6.)5A(!D4CE22,@'VP: .2GLKO6/#%UJ\44OGW]U%=>4@!?R(V&U0#P3M&[
M'<FK,/F.;W5+";4K[4(;)XXEN[;RT))SMQM7<<CI78QQI#$D4:A8T4*JCH .
M@IU '"V/GWGB/3;H2ZG=*MO.)9;FW\I$8J/E5=HQ^O:M7P])'H7@.TFNH9(A
M!!ODCV8;))XQZDFNEJ.:"*YB\N:-9$)!VL,C(.1^HH >IW*#@C(S@]12T44
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M37:)B>9561LGD+G''XFHI]+L[F_AOI(S]IA4HKJY7Y3V('4?6M86+]ROY_\
MUJ7[$_J/S_\ K4 8_P#9%C_9L&G^3_HL#(T:;CP5.5YZ]:AO/#VF7US)<3V[
M;Y<"79*R++C^\ <-^-;WV)_4?G_]:C[$_J/S_P#K4 4?)B\CR/+7RMNS9CY=
MN,8QZ8K*3POI"","WD81,&B#S.PB(.1MR?E_"NC^Q/ZC\_\ ZU'V)_4?G_\
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M6@!:**0L%ZD#)QS0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Y
MHYHHH 3%4[^P%\L(W[/+D$F<9SCM5VBDU?0:;3NBE_9X_O\ Z4?V>/[_ .E7
M:*GV<>Q?M9]RE_9X_O\ Z4?V>/[_ .E7:*/9Q[![67<I?V>/[_Z4?V>/[_Z5
M=HH]G'L'M9=RE_9X_O\ Z4?V>/[_ .E7:*/9Q[![6?<SY-,WQ.@EP6!&<=/U
MJU:VXM;6*!3D1J%SCK4U%-12V)E.4M&'-'-%%42'-'-%% !S1S110 <T<T44
M '-'-%% !S1S110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>18
<FILENAME>bivi-20190331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: bivi%2D20190331.xfr; Date: 2019%2D07%2D01T15:40:01Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:bivi="http://nanoantibiotics.com/20190331">
    <link:schemaRef xlink:href="bivi-20190331.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2017-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_StockOptionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_StockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_StockOptionThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_StockOptionFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_StockOptionFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_StockOptionSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_StockOptionSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_StockOptionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_StockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_StockOptionThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_StockOptionFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_StockOptionFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_StockOptionSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_StockOptionSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_StockOptionEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_StockOptionNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-03-31_us-gaap_StockOptionMember128077054">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2017-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2017-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2017-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-02to2018-07-03_us-gaap_SubsequentEventMember_custom_AcuitasGroupHoldingsLLCAndOtherPurchaserMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bivi:AcuitasGroupHoldingsLLCAndOtherPurchaserMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-02</xbrli:startDate>
        <xbrli:endDate>2018-07-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_StockOptionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_StockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_StockOptionThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_StockOptionFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_StockOptionFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_StockOptionSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_StockOptionSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-03-31_custom_StockOptionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-03-31_custom_StockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-03-31_custom_StockOptionThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-03-31_custom_StockOptionFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-03-31_custom_StockOptionFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-03-31_custom_StockOptionSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-03-31_custom_StockOptionSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-03-31_custom_StockOptionEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-03-31_custom_StockOptionNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_WarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:WarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_WarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:WarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_WarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:WarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_WarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:WarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <us-gaap:AssetsCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">5140</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">45800</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">1006614</us-gaap:AssetsCurrent>
    <us-gaap:Assets contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">2364209</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">2175491</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">2964272</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">470973</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">884207</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">179054</us-gaap:AccountsPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">630973</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">1238374</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">179054</us-gaap:LiabilitiesCurrent>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">3483134</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">4870475</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">9359780</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">1157317</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">111199</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">2785218</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">2364209</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">2175491</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">2964272</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2017-06-30" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2018-06-30" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2017-06-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2018-06-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2017-06-30" unitRef="Shares" decimals="INF">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2018-06-30" unitRef="Shares" decimals="INF">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2017-06-30" unitRef="Shares" decimals="INF">91925000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2018-06-30" unitRef="Shares" decimals="INF">98503199</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">316453673</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">-2434117</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-1330672</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">-1837081</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">-1858080</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">-621341</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-623615</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">-1869886</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">-412061</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">661999</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">504999</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">2795700</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">435001</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CommonStockValue contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">9192</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">9850</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">31645</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2017-06-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2018-06-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2017-06-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2018-06-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-06-30" unitRef="Shares" decimals="INF">91925000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-06-30" unitRef="Shares" decimals="INF">98503199</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">316453673</us-gaap:CommonStockSharesIssued>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">413234</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">350674</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">-382203</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">275283</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">40658</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-118616</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">925814</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">22940</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:Cash contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">5140</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">45800</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">971614</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">28080</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2016-06-30" unitRef="USD" decimals="0">123757</us-gaap:Cash>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">474955</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">832186</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">446071</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">555064</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2017-06-30" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2018-06-30" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-03-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">125000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">354167</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">229167</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">27972</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="From2018-07-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">187500</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2017-07-01to2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">6982</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">-2335009</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">-4769126</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">-6606207</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">2013357</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">1783980</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">1611947</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">345711</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">345711</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">345711</us-gaap:Goodwill>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">2359068</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">2129691</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">1957658</us-gaap:AssetsNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">35000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">893484</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">92052</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">63306</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">811203</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">229377</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">229377</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">172033</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">172033</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">370853</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">466354</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">732373</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">275116</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">311525</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">285392</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ProfessionalFees contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">1331142</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">503369</us-gaap:ProfessionalFees>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">129270</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">69122</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">936180</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">1401104</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">2372166</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">1553614</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">1840586</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">1848253</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">-2372166</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-1553614</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">-1840586</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">-1848253</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">40960</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestExpense contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">272</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">9828</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeOther contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">4</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">14</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">1036</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">1</us-gaap:InterestIncomeOther>
    <us-gaap:OtherExpenses contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">40956</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-222942</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">-52164</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">9827</us-gaap:OtherExpenses>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-07-01to2018-06-30" unitRef="USDPShares" decimals="INF">-0.03</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-07-01to2017-06-30" unitRef="USDPShares" decimals="INF">-0.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2018-07-01to2019-03-31" unitRef="USDPShares" decimals="INF">-0.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-07-01to2018-03-31" unitRef="USDPShares" decimals="INF">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-07-01to2018-06-30" unitRef="Shares" decimals="INF">95758079</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-07-01to2017-06-30" unitRef="Shares" decimals="INF">89391302</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2018-07-01to2019-03-31" unitRef="Shares" decimals="INF">313580066</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-07-01to2018-03-31" unitRef="Shares" decimals="INF">95014206</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">5150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-06-30_custom_StockOptionOneMember" unitRef="Shares" decimals="INF">3100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-06-30_custom_StockOptionTwoMember" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-06-30_custom_StockOptionThreeMember" unitRef="Shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-06-30_custom_StockOptionFourMember" unitRef="Shares" decimals="INF">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-06-30_custom_StockOptionFiveMember" unitRef="Shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-06-30_custom_StockOptionSixMember" unitRef="Shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-06-30_custom_StockOptionSevenMember" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-03-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">7250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-03-31_custom_StockOptionOneMember" unitRef="Shares" decimals="INF">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-03-31_custom_StockOptionTwoMember" unitRef="Shares" decimals="INF">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-03-31_custom_StockOptionThreeMember" unitRef="Shares" decimals="INF">3100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-03-31_custom_StockOptionFourMember" unitRef="Shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-03-31_custom_StockOptionFiveMember" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-03-31_custom_StockOptionSixMember" unitRef="Shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-03-31_custom_StockOptionSevenMember" unitRef="Shares" decimals="INF">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-03-31_custom_StockOptionEightMember" unitRef="Shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-03-31_custom_StockOptionNineMember" unitRef="Shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-03-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2018-07-01to2019-03-31_us-gaap_StockOptionMember128077054" unitRef="USDPShares" decimals="INF">0.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">344999</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">479999</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2018-07-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">445001</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <bivi:OptionVested contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">238165</bivi:OptionVested>
    <bivi:OptionVested contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">92051</bivi:OptionVested>
    <bivi:OptionVested contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:OptionVested contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">92051</bivi:OptionVested>
    <bivi:OptionVested contextRef="From2016-07-01to2017-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:OptionVested contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:OptionVested contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">238165</bivi:OptionVested>
    <bivi:OptionVested contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4748500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2017-07-01to2017-09-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2017-10-01to2017-12-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2018-01-01to2018-03-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2019-01-01to2019-03-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2017-07-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1500000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2017-10-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">150000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2018-01-01to2018-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2030000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1400000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">642850</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">49000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2018-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">475</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">642375</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2017-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-10-01to2017-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-01-01to2018-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2019-01-01to2019-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">150</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-10-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">15</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-01-01to2018-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">203</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">140</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="0">330000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">34500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">49000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-01-01to2018-03-31" unitRef="USD" decimals="0">242400</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">329850</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-10-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">34485</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-01-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">242197</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">48860</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-10-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-01-01to2018-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-07-01to2019-03-31_us-gaap_StockOptionMember128077054" unitRef="Shares" decimals="INF">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">575918</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">825918</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherInterestAndDividendIncome contextRef="From2017-07-01to2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherInterestAndDividendIncome contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">222928</us-gaap:OtherInterestAndDividendIncome>
    <us-gaap:OtherInterestAndDividendIncome contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">51400</us-gaap:OtherInterestAndDividendIncome>
    <us-gaap:OtherInterestAndDividendIncome contextRef="From2017-07-01to2018-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Liabilities contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">1206891</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">2064292</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">179054</us-gaap:Liabilities>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="From2017-07-01to2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">25000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">575918</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">575918</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">-2413122</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-1330672</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">-1788422</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">-1858080</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2016-07-01to2017-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-1330672</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-2413122</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2017-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2017-10-01to2017-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-01-01to2018-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2017-10-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-01-01to2018-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="0">-662841</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-502682</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">-848041</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2018-01-01to2018-03-31" unitRef="USD" decimals="0">-692557</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2017-10-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-01-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-662841</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2017-10-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-502682</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2018-01-01to2018-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-692557</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">-500510</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-10-01to2018-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-10-01to2018-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-10-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-439871</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2018-10-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-500510</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-848041</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2018-09-30" unitRef="USD" decimals="0">-439871</us-gaap:ProfitLoss>
    <bivi:DeemedDividend contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">-20995</bivi:DeemedDividend>
    <bivi:DeemedDividend contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividend contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">-48659</bivi:DeemedDividend>
    <bivi:DeemedDividend contextRef="From2017-07-01to2018-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2017-07-01to2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2018-07-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2017-07-01to2018-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4764999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1729699</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">444999</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">479999</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">477</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">479523</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-07-01to2017-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">172</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">444827</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2016-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">87160001</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2017-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">91925000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">98503199</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2017-06-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2018-06-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2017-09-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2017-12-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2018-03-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2018-09-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2019-03-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">94594091</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">94971364</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">97334697</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">315053673</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">315053673</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">316453673</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">1157317</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">111197</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">2785218</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">555442</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2016-06-30" unitRef="USD" decimals="0">1915939</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2016-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">8716</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">9193</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">9850</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">9460</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">9498</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">9734</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">31505</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">31505</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">31645</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2016-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2911560</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2016-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-1004337</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3483134</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-2335009</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4870474</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-4769126</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">1082229</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">791068</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4070619</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4282102</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4738797</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9251026</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9267310</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9359780</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-2997850</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-3500532</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-4193089</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-5257656</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-5758166</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-6606207</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">4024875</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">3540650</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <bivi:DeemedDividendsForRatchetAdjustmentToWarrants contextRef="From2017-07-01to2018-06-30" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividendsForRatchetAdjustmentToWarrants contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividendsForRatchetAdjustmentToWarrants contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">20995</bivi:DeemedDividendsForRatchetAdjustmentToWarrants>
    <bivi:DeemedDividendsForRatchetAdjustmentToWarrants contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-20995</bivi:DeemedDividendsForRatchetAdjustmentToWarrants>
    <bivi:DeemedDividendsForRatchetAdjustmentToWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividendsForRatchetAdjustmentToWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividendsForRatchetAdjustmentToWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">48659</bivi:DeemedDividendsForRatchetAdjustmentToWarrants>
    <bivi:DeemedDividendsForRatchetAdjustmentToWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-48659</bivi:DeemedDividendsForRatchetAdjustmentToWarrants>
    <bivi:DeemedDividendsForRatchetAdjustmentToWarrants contextRef="From2018-07-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2018-07-01to2019-03-31_us-gaap_StockOptionMember128077054" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">10</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1990</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfWarrantsForServices contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">12469</bivi:IssuanceOfWarrantsForServices>
    <bivi:IssuanceOfWarrantsForServices contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfWarrantsForServices contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">12469</bivi:IssuanceOfWarrantsForServices>
    <bivi:IssuanceOfWarrantsForServices contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfWarrantsForServices contextRef="From2018-01-01to2018-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfWarrantsForServices contextRef="From2018-01-01to2018-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfWarrantsForServices contextRef="From2018-01-01to2018-03-31" unitRef="USD" decimals="0">12469</bivi:IssuanceOfWarrantsForServices>
    <bivi:IssuanceOfWarrantsForServices contextRef="From2018-01-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">12469</bivi:IssuanceOfWarrantsForServices>
    <bivi:IssuanceOfWarrantsForServices contextRef="From2018-01-01to2018-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfWarrantsWithDebt contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">26519</bivi:IssuanceOfWarrantsWithDebt>
    <bivi:IssuanceOfWarrantsWithDebt contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfWarrantsWithDebt contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfWarrantsWithDebt contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">26519</bivi:IssuanceOfWarrantsWithDebt>
    <bivi:IssuanceOfWarrantsWithDebt contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">26519</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">51400</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2017-07-01to2018-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfShortTermDebt contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">35000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfShortTermDebt contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">244300</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="From2017-07-01to2018-03-31" unitRef="USD" decimals="0">10000</us-gaap:RepaymentsOfShortTermDebt>
    <bivi:ProceedsFromDemandPromissoryNote contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">250000</bivi:ProceedsFromDemandPromissoryNote>
    <bivi:ProceedsFromDemandPromissoryNote contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">100000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2017-07-01to2018-06-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%"&gt;&lt;b&gt;Background Information&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;BioVie Inc. (the &amp;#8220;Company&amp;#8221;) is a clinical-stage company pursuing the discovery,&#13;development, and commercialization of innovative drug therapies. The Company is currently focused on developing and commercializing&#13;BIV201, a novel approach to the treatment of ascites due to chronic liver cirrhosis. In March 2017, the Company received notification&#13;from the US Food and Drug Administration (FDA) that it could initiate a Phase 2a US clinical trial. In April the Company signed&#13;a Cooperative Research and Development Agreement (CRADA) with the McGuire Research Institute/VA in Richmond, VA, and began dosing&#13;patients with BIV201 in September 2017.&amp;#160;As of June 2018, three&amp;#160;patients had been treated with BIV201 therapy in this&#13;ongoing Phase 2a clinical trial.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;BIV201 has the potential to improve the health of thousands of patients suffering from&#13;life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has&#13;FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant&#13;unmet medical need. The FDA has never approved any drug specifically for treating ascites.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company&#13;acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing&#13;rights to its drug candidate. The Company and PharmaIN, Corp. (&amp;#8220;PharmaIN&amp;#8221;), LAT Pharma&amp;#8217;s former partner focused&#13;on the development of new modified drug candidates in the same therapeutic field but not including BIV201, agreed to pay royalties&#13;equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed&#13;to a third party, less than 5% of each company's net license revenues. The Company&amp;#8217;s relationship with PharmaIN could advance&#13;into a collaboration or be terminated. The Company has an issued US Patent covering the use of BIV201 for the treatment of ascites&#13;patients in the outpatient setting using ambulatory pump infusion, and has filed patent applications for its drug candidate in&#13;Japan, and Europe, and China.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s activities are subject to significant risks and uncertainties including&#13;failure to secure additional funding to properly execute the Company&amp;#8217;s business plan.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2018-07-01to2019-03-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 2%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&lt;b&gt;Background Information&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;BioVie Inc. (the &amp;#8220;Company&amp;#8221;)&#13;is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company&#13;is currently focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment&#13;of ascites due to chronic liver cirrhosis. The Company began dosing patients with BIV201 in September 2017 at the McGuire Research&#13;Institute Inc. in Richmond, VA. All six of the planned patients have been treated with BIV201 therapy in this Phase 2a clinical&#13;trial. In May 2019, the Company announced that the primary study objectives to assess the safety, tolerability, and pharmacokinetics&#13;(PK) of a continuous infusion of terlipressin over 28 days had been achieved. Detailed results will be presented to the Food &amp;#38;&#13;Drug Administration (&amp;#8220;FDA&amp;#8221;) in the first half of 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;BIV201 has the potential to improve&#13;the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic&#13;steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications,&#13;ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites.&#13;The Company has secured a US Patent covering the use of BIV201 for the treatment of ascites patients in the outpatient setting&#13;using ambulatory pump infusion, and has filed patent applications for its product candidate in Japan, and Europe, Hong Kong, and&#13;China. BIV201 also received Orphan Drug designation for hepatorenal syndrome (&amp;#8220;HRS&amp;#8221;) in November 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The BIV201 development program began&#13;at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The&#13;Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (&amp;#8220;PharmaIN&amp;#8221;),&#13;LAT Pharma&amp;#8217;s former partner focused on the development of new modified drug candidates in the same therapeutic field but&#13;not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development&#13;programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24,&#13;2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously&#13;paid the remaining balance due on a related debt. PharmaIN, Corp.&amp;#8217;s rights to our program remain unchanged.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The Company&amp;#8217;s activities&#13;are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the Company&amp;#8217;s&#13;business plan.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <bivi:LiquidityTextBlock contextRef="From2017-07-01to2018-06-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%"&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;We believe that our existing cash and cash equivalents, including the amounts received&#13;after the end of the fiscal year, will be sufficient to meet our operating and capital requirements for at least 12 months from&#13;the date of this report.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On July 3, 2018, the Company, entered into a Securities Purchase Agreement (the &amp;#8220;Purchase&#13;Agreement&amp;#8221;) with Acuitas Group Holdings, LLC (&amp;#8220;Acuitas&amp;#8221;) and certain other purchasers identified in the Purchase&#13;Agreement (together with Acuitas, the &amp;#8220;Purchasers&amp;#8221;) pursuant to which (i) the Purchasers agreed to purchase an aggregate&#13;of 2,133,332 shares of the Company&amp;#8217;s newly created Series A Convertible Preferred Stock (the &amp;#8220;Preferred Stock&amp;#8221;)&#13;at a price per share of $1.50 per share of Preferred Stock (the &amp;#8220;Initial Sale&amp;#8221;) and (ii) the Company will issue associated&#13;warrants (the &amp;#8220;Warrants&amp;#8221;) to purchase 213,333,200 shares of the Company&amp;#8217;s Class A Common Stock (the &amp;#8220;Common&#13;Stock&amp;#8221;), each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of&#13;$3.2 million.&lt;/p&gt;</bivi:LiquidityTextBlock>
    <bivi:LiquidityTextBlock contextRef="From2018-07-01to2019-03-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 2%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&lt;b&gt;Liquidity and Going Concern&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The Company&amp;#8217;s operations&#13;are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are&#13;not limited to: the results of clinical testing and trial activities of the Company&amp;#8217;s products, the Company&amp;#8217;s ability&#13;to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other&#13;companies, the price of, and demand for, Company products, the Company&amp;#8217;s ability to negotiate favorable licensing or other&#13;manufacturing and marketing agreements for its products, and the Company&amp;#8217;s ability to raise capital. The Company&amp;#8217;s&#13;financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization&#13;of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced losses since inception&#13;and has an accumulated deficit of approximately $6.6 million at March 31, 2019. In addition, the Company has not generated any&#13;revenues and no revenues are anticipated in the foreseeable future. The Company&amp;#8217;s future operations are dependent on the&#13;success of the Company&amp;#8217;s ongoing development and commercialization efforts, as well as continuing to secure additional financing.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2018, the Company completed&#13;a capital raise from Acuitas Group Holdings, LLC (&amp;#8220;Acuitas&amp;#8221;) and other purchasers and received net proceeds of $3.2&#13;million and has resumed further clinical development of BIV201. The Acuitas investment agreement also stipulated that if the clinical&#13;development of BIV201 continues, Acuitas may at its option invest up to an additional $3 million to fund operations in year two,&#13;less any federal or FDA grant funding received by the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The future viability of the Company&#13;is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources&#13;of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue&#13;these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to&#13;the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company&amp;#8217;s ability&#13;to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this&#13;uncertainty.&lt;/p&gt;</bivi:LiquidityTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2017-07-01to2018-06-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%"&gt;&lt;b&gt;Significant Accounting Policies&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity with accounting principles generally&#13;accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts&#13;and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues&#13;and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity with accounting principles&#13;generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported&#13;amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements&#13;and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Cash is maintained at financial institutions and, at times, balances may exceed&#13;federally insured limits. The Company has never experienced any losses related to these balances. All of the Company&amp;#8217;s cash&#13;balances were fully insured at June 30, 2018.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Financial Instruments&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s financial instruments include cash, accounts payable, related&#13;party loans and a demand promissory note. The carrying amounts of cash and accounts payable approximate their fair value, due&#13;to the short-term nature of these items.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Long-Term Notes Payable&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s long-term notes payable include accrued payroll to officers&#13;and accrued payments to third party consultants.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Research and development costs are charged to operations when incurred and are included&#13;in operating expenses. The Company expensed $370,853 and $466,354 for research and development for the years ended June 30, 2018&#13;and 2017, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Deferred income tax assets and liabilities arise from temporary differences associated&#13;with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates,&#13;which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current&#13;or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities&#13;not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary&#13;differences are expected to reverse.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company follows the provisions of FASB ASC 740-10 &amp;#8220;&lt;i&gt;Uncertainty in&#13;Income Taxes&lt;/i&gt;&amp;#8221; (ASC 740-10), January 1, 2007. The Company has not recognized a liability as a result of the implementation&#13;of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there&#13;are no unrecognized benefits at June 30, 2018 and since the date of adoption. The Company has not recognized interest expense&#13;or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize&#13;interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.&amp;#160; The Company&amp;#8217;s&#13;tax returns for the years ended June 30, 2015, 2016, 2017 and 2018 remain open to examination by taxing authorities.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Earnings (Loss) per Share&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Basic earnings per share are computed by dividing net income by the weighted average&#13;number of shares of common stock outstanding during the year. Diluted earnings per common share are computed by dividing net income&#13;by the weighted average number of shares of common stock outstanding and dilutive options outstanding during the year. For the&#13;years ended June 30, 2017 and 2018 all outstanding options have been excluded from the calculation of the diluted net loss per&#13;share since their effect was anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;The following potentially dilutive securities were excluded from the computation of diluted loss per share&#13;for the years ended June 30, 2017 and 2018:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Number of Shares (Thousands)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Number of Shares (Thousands)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 56%; text-align: center"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;6,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;4,774&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;10,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;9,924&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company has accounted for stock-based compensation under the provisions of FASB&#13;ASC 718 &amp;#8211; &amp;#8220;Stock Compensation&amp;#8221; which requires the use of the fair-value based method to determine compensation&#13;for all arrangements under which employees and others receive shares of stock or equity instruments (stock options and common&#13;stock purchase warrants). For employee awards, the fair value of each stock option award is estimated on the date of grant using&#13;the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free&#13;interest rate. For non-employees, the fair value of each stock option award is estimated on the measurement date using the Black-Scholes&#13;valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.&#13;For non-employees, the Company utilizes the graded vesting attribution method under which the entity treats each separately vesting&#13;portion (tranche) as a separate award and recognizes compensation cost for each tranche over its separate vesting schedule. Expected&#13;volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock&#13;options. For employee awards, the expected term of options granted is derived using the &amp;#8220;simplified method&amp;#8221; which&#13;computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the&#13;U.S. Treasury yield curve in effect at the time of grant for the period of the expected term.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Goodwill is recorded when the purchase price paid for an acquisition exceeds the fair&#13;value of net identified tangible and intangible assets acquired. The Company performs an annual impairment test of goodwill and&#13;further periodic tests to the extent indicators of impairment develop between annual impairment tests. The Company&amp;#8217;s impairment&#13;review process compares the fair value of the reporting unit to its carrying value, including the goodwill related to the reporting&#13;unit. To determine the fair value of the reporting unit, the Company may use various approaches including an asset or cost approach,&#13;market approach or income approach or any combination thereof. These approaches may require the Company to make certain estimates&#13;and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each time the&#13;Company tests goodwill for impairment and are typically developed as part of the Company&amp;#8217;s routine business planning and&#13;forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates&#13;could produce materially different results. The Company did not recognize any goodwill impairments for the years ended June 30th,&#13;2017 and June 30th, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Long-lived assets, including intangible assets, are reviewed for impairment whenever&#13;events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets&#13;to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows&#13;expected to be generated by the asset.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;If the carrying amount of an asset exceeds its undiscounted estimated future cash&#13;flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the&#13;asset exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected discounted&#13;cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported&#13;at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and&#13;liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability&#13;sections of the balance sheet.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Recent accounting pronouncements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company has reviewed recent accounting pronouncements issued by the FASB (including&#13;its EITF), the AICPA, and the SEC and did not or are not believed by management to have a material impact on the Company&amp;#8217;s&#13;financial statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2018-07-01to2019-03-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 2%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&lt;b&gt;Significant Accounting Policies&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;i&gt;Basis of Presentation &amp;#8211; Interim Financial&#13;Information&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The accompanying unaudited interim&#13;financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United&#13;State of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and with the instructions to Form 10-Q and Article&#13;10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information&#13;and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect&#13;all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair&#13;presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for&#13;the full year. The Condensed Balance Sheet at June 30, 2018 was derived from audited annual financial statements but does not contain&#13;all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included&#13;under the heading: &amp;#8220;Management&amp;#8217;s Discussion and Analysis of Financial Condition and Results of Operations&amp;#8221; should&#13;be read in conjunction with our Company&amp;#8217;s audited financial statements and related notes included in our Company&amp;#8217;s&#13;Form 10-K for the year ended June 30, 2018 filed with the SEC on October 5, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;For a summary of significant&#13;accounting policies, see the Company&amp;#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the&#13;SEC on October 5, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;i&gt;Net Loss per Common Share&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;Basic net loss per common share&#13;is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding&#13;during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares&#13;of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution&#13;that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures.&#13;Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The table below shows the number&#13;of outstanding stock options and warrants as of March 31, 2019 and June 30, 2018:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30, 2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;216,440,548&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,774,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;223,690,548&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;9,924,015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;i&gt;Recent accounting pronouncements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The Company considers the applicability&#13;and impact of all Accounting Standard Updates (&amp;#8220;ASU&amp;#8217;s&amp;#8221;). ASU&amp;#8217;s not discussed below were assessed and determined&#13;to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;In June 2018, the FASB issued&#13;ASU 2018-07, &amp;#8220;Compensation &amp;#8211; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting&amp;#8221;.&#13;This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment&#13;transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings&#13;as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair&#13;value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim&#13;periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on the&#13;financial statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <bivi:DemandNoteTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;b&gt;5. Demand Note&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On May 21, 2018, the Company received&#13;$250,000 in exchange for a promissory note from Acuitas Group Holding LLC. The promissory note carries 10% interest per year and&#13;has a maturity date of 10 business days of demand by Payee. The promissory note also has a provision that in the event of a superseding&#13;equity financing transaction, the Payor will receive 50% warrant coverage on same terms as if the superseding transactions occurs.&#13;On July 3, 2018, the Company entered into an equity financing transaction which resulted in Acuitas Group Holding LLC., receiving&#13;833,333 warrants that expire on July 3&lt;sup&gt;rd&lt;/sup&gt; 2024 with an exercise price of 1.8 cents per share. The Company valued the&#13;warrants at $29,666 using the Black Scholes Model and the following assumptions were used: volatility &amp;#8211; 169%; Term &amp;#8211;&#13;6 years; Risk Free Rate &amp;#8211; 2.96%; dividend rate &amp;#8211; 0.00%. Based on their relative fair value, the Company allocated&#13;$26,519 of the proceeds to the warrants, which was recorded as additional interest expense for the year ended June 30, 2018. As&#13;the promissory note was converted into common stock subsequent to June 30, 2018, the balance as of June 30, 2018 is classified&#13;as long term on the accompanying balance sheet.&lt;/p&gt;</bivi:DemandNoteTextBlock>
    <bivi:DemandNoteTextBlock contextRef="From2018-07-01to2019-03-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;b&gt;5. Renegotiated Debt&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On July 19, 2018, Geis-Hides&#13;Consulting LLC entered into an Accord and Debt Satisfaction Agreement with the Company in which the consulting firm agreed to release&#13;the Company from all liabilities arising from the Original Contract and Debt Repayment Plan dated December 15, 2013 totaling $132,000&#13;and received cash of $65,000 and 260,000 common shares in satisfaction. The common shares were valued at the market price on the&#13;date of settlement at $0.06 per common share. The gain of $51,400 on the settlement of debt was reflected on the Statements of&#13;Operations as &amp;#8220;other income&amp;#8221; for the nine-month period ended March 31, 2019.&lt;/p&gt;</bivi:DemandNoteTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;b&gt;6. Related Party Transactions&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Notes Payable&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;LAT Pharma was given a zero-interest bearing loan by the Company&amp;#8217;s CEO, Jonathan&#13;Adams in the amount of $5,000 in August 2015 and $5,000 in November 2015.&amp;#160; The total of $10,000 was outstanding when the&#13;Company merged with LAT Pharma. On June 16th, 2017, the Company was given an additional $25,000 zero-interest bearing loan by&#13;Jonathan Adams.&amp;#160; During the quarter ended December 31, 2017, the Company repaid the $35,000 outstanding balance of the loan.&#13;During the quarter ended March 31, 2018, the Company was given an additional $25,000 zero-interest bearing loan by Jonathan Adams.&#13;During the quarter ended June 30, 2018, the Company repaid the $25,000 outstanding balance of the loan. The outstanding balance&#13;of the loan was $35,000 as of June 30, 2017 and zero as of June 30, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On March 23, 2017, Barrett Ehrlich agreed to defer the payment of his consulting fee&#13;debt of $173,333 until&amp;#160;December 31, 2019, through the issuance of a Promissory note.&amp;#160; The promissory note does not carry&#13;any interest charge as long as the amount is paid in full before&amp;#160;December 31, 2019.&amp;#160; The consulting fee debt has thereby&#13;been reclassified from a current liability to a long-term liability on the balance sheet.&amp;#160;Any portion of the balance due&#13;under the note that remains unpaid after&amp;#160;December 31, 2019&amp;#160;will accrue interest at a rate of 5% per annum until paid&#13;in full.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On March 23, 2017, Elliot Ehrlich agreed to forgive 50% of his salary debt of $444,056.&amp;#160;&#13;The adjusted salary debt is $222,028.13.&amp;#160; Elliot Ehrlich also agreed to defer the payment of his salary debt of $222,028&#13;until&amp;#160;December 31, 2019, through the issuance of a Promissory note.&amp;#160; The promissory note does not carry any interest&#13;charge as long as the amount is paid in full before&amp;#160;December 31, 2019.&amp;#160; The salary debt has thereby been reclassified&#13;from a current liability to a long-term liability on the balance sheet and the salary debt forgiven has been reflected on the&#13;income statement as other income.&amp;#160;Any portion of the balance due under the note that remains unpaid after&amp;#160;December 31,&#13;2019&amp;#160;will accrue interest at a rate of 5% per annum until paid in full.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On March 23, 2017, Jonathan Adams agreed to defer the payment of his salary debt of&#13;$180,555 until&amp;#160;December 31, 2019, through the issuance of a Promissory note.&amp;#160; The promissory note does not carry any&#13;interest charge as long as the amount is paid in full before&amp;#160;December 31, 2019.&amp;#160; The salary debt has thereby been reclassified&#13;from a current liability to a long-term liability on the balance sheet.&amp;#160;Any portion of the balance due under the note that&#13;remains unpaid after&amp;#160;December 31, 2019&amp;#160;will accrue interest at a rate of 5% per annum until paid in full.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The outstanding balance of the long-term note payable was $575,917 as of June 30, 2017&#13;and $575,917 as of June 30, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Sale of Common Stock and Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In January 2018, the Company sold an aggregate of 333,333 shares of common stock and&#13;warrants to purchase 333,333 shares of common stock to a member of its board of directors for aggregate gross proceeds of $50,000.&#13;The purchase price for the common stock and warrants was $0.15 per share. The warrants are exercisable at an exercise price of&#13;$0.15 at any time from date of issuance until 7 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Common Stock issued for Services&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In January 2018, the Company issued 1,400,000 shares of common stock as compensation&#13;for the Board of Directors. The shares were valued at $0.15 per share which was the trading price on date of issuance, and the&#13;value of the compensation was $210,000.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2018-07-01to2019-03-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;b&gt;6. Related Party Transactions&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On July 9, 2018, Jonathan Adams&#13;(COO) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all&#13;liabilities including the original contract to defer payment of his accrued salary dated March 23, 2017, the promissory note issued&#13;by the Company to defer payment of accrued salary; and subsequent unpaid salary, totaling the amount of $534,722, and received&#13;cash of $25,694 in satisfaction. The gain of $509,028 on the settlement of debt was reflected in the additional paid in capital.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On July 9, 2018, Elliot Ehrlich&#13;(former CEO and shareholder) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release&#13;the Company from all liabilities including the original contract to defer payment of accrued salary dated March 23, 2017, totaling&#13;the amount of $222,028 the promissory note issued by the Company to defer payment of accrued salary; and received cash of $22,273&#13;and 222,028 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06&#13;per common share. The gain of $186,503 on the settlement of debt was reflected in the additional paid in capital.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On August 8, 2018, Barrett Ehrlich&#13;(Independent contractor, related party to Elliot Ehrlich and shareholder) on behalf of The Barrett Edge Inc. (&amp;#8220;Barrett&amp;#8221;)&#13;entered into an Accord and Debt Satisfaction Agreement with the Company in which Barrett agreed to release the Company from all&#13;liabilities including the original contract to defer payment of accrued consulting fees dated March 23, 2017, the promissory note&#13;issued by the Company to defer payment of accrued consulting fees; loan to the Company for $14,000, and subsequent unpaid consulting&#13;fees, totaling $543,014, and received cash of $131,333 and 493,333 common shares in satisfaction. The common shares were valued&#13;at the market price on the date of settlement at $0.13 per common share. The gain of $361,548 on the settlement of debt was reflected&#13;in the additional paid in capital.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;See note 8 for other related&#13;party transactions.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0"&gt;&lt;b&gt;7. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Office Lease&lt;/i&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On January 1, 2014, the Company executed a lease agreement with Cummings Properties&#13;for the Company&amp;#8217;s office of 270 square feet at 100 Cummings Center, Suite 247-C, Beverly, MA 01915. The lease is for a term&#13;of five years from January 1, 2014 to December 30, 2018 and requires monthly payments of $379. The Company notified the lessor&#13;that it will terminate the lease on December 30, 2018.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Employment Agreements&lt;/i&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On April 11, 2016, the Company entered into employment agreement with CEO Jonathan Adams.&#13;The Company&amp;#8217;s agreement provides for a three-year term with minimum annual base salary of $250,000 per year.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Challenge to US Patent&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On April 30, 2018, the Company received notice that Mallinckrodt Pharmaceuticals Ireland&#13;Limited had petitioned the US Patent and Trademark Office (USPTO) to institute an Inter Partes Review of BioVie&amp;#8217;s US Patent&#13;No. 9,655,945 titled &amp;#8220;Treatment of Ascites&amp;#8221; (the &amp;#8216;945 patent).&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and&#13;Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty&#13;and obviousness on the basis of prior art consisting of patents and printed publications. Although a petition for Inter Partes&#13;Review has been filed, grant of the petition by the PTAB is required for the proceeding to be instituted.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On August 15, 2018, BioVie submitted a Preliminary Response to the PTAB providing a&#13;rationale as to why, in the Company&amp;#8217;s opinion, Mallinckrodt&amp;#8217;s request to institute the IPR should not be granted.&#13;If he IPR is allowed to proceed, BioVie will seek to defend the &amp;#8216;945 patent and/or pursue a favorable settlement. As of&#13;June 30, 2018, no adjustments or accruals are reflected as the Company is unable to determine a likely outcome at this time.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;i&gt;Royalty Agreements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between&#13;LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous&#13;infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation; and The Barrett Edge, Inc.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between&#13;BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin&#13;products covered by US patent no. 9,655,645 and any future foreign issuances capped at significantly less than $500,000 per year.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company and PharmaIN, Corporation, LAT Pharma&amp;#8217;s former partner focused on&#13;the development of new modified drug candidates in the same therapeutic field but not including BIV201, agreed to pay royalties&#13;equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed&#13;to a third party, less than 5% of each company's net license revenues. The Company&amp;#8217;s relationship with PharmaIN could advance&#13;into a collaboration or be terminated. The Company has an issued US Patent covering the use of BIV201 for the treatment of ascites&#13;patients in the outpatient setting using ambulatory pump infusion, and has filed patent applications for its drug candidate in&#13;Japan, and Europe, and China.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2018-07-01to2019-03-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;b&gt;7. Commitments and Contingencies&lt;/b&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;i&gt;Office Lease&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On October 1, 2018, the Company&#13;executed a lease agreement with Acuitas Group Holdings, LLC (related party) for the Company&amp;#8217;s office at 11601 Wilshire Blvd&#13;Ste 1100, Los Angeles, CA 90025. The lease is a month-to-month lease that may be cancelled upon 30 days&amp;#8217; written notice and&#13;requires monthly payments of $1,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;i&gt;Challenge to US Patent&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On April 30, 2018, the Company&#13;received notice that Mallinckrodt Pharmaceuticals Ireland Limited had petitioned the US Patent and Trademark Office (USPTO) to&#13;institute an Inter Partes Review of BioVie&amp;#8217;s US Patent No. 9,655,945 titled &amp;#8220;Treatment of Ascites&amp;#8221; (the &amp;#8216;945&#13;patent). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the&#13;patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior&#13;art consisting of patents and printed publications.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On August 15, 2018, BioVie submitted&#13;a Preliminary Response to the PTAB providing a rationale as to why, in the Company&amp;#8217;s opinion, Mallinckrodt&amp;#8217;s request&#13;to institute the IPR should not be granted. On November 14, 2018, the PTAB granted institution of the IPR challenge after determining&#13;that there was a reasonable likelihood of success in proving that at least one of the Company&amp;#8217;s 14 claims was unpatentable.&#13;On March 7, 2019, we submitted a Patent Owner&amp;#8217;s Response and a Patent Owner&amp;#8217;s Contingent-Motion to Amend our patent&#13;claims, and Declaration of Dr. Jaime Bosch, MD, PhD, our medical expert. We are actively defending the &amp;#8216;945 patent and may&#13;explore the possibility of settlement with Mallinckrodt. However, there can be no assurance in that a favorable outcome will result,&#13;or if settlement is reached that the PTAB will accept it. Although the PTAB encourages settlement, in view of public-interest considerations,&#13;the board may continue the proceeding to a final written decision even if the parties settle. If the IPR is not terminated due&#13;to settlement, the PTAB is statutorily required to issue its final written decision in this case before November 14, 2019. As of&#13;March 31, 2019, no adjustments or accruals are reflected as the Company is unable to determine a likely outcome at this time.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;i&gt;Royalty Agreements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;Pursuant to the Agreement and&#13;Plan of Merger entered into on April 11, 2016 between LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low&#13;single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn&#13;Corporation; and The Barrett Edge, Inc.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The Company and PharmaIN Corporation,&#13;LAT Pharma&amp;#8217;s former partner focused on the development of new modified drug candidates in the same therapeutic field but&#13;not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development&#13;programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24,&#13;2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously&#13;paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;Pursuant to the Technology Transfer&#13;Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single&#13;digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped&#13;at a maximum of $200,000 per year.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;b&gt;8. Stockholders&amp;#8217; Equity&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;During the year ended June 30, 2017 and 2018, the Company issued stock options to consultants&#13;and board of directors for services provided to the Company.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The following is a summary of stock option activity for the years ended June 30, 2017&#13;and 2018.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Shares (Thousands)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Weighted-Average Exercise&#13;    Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Weighted Remaining Average&#13;    Contractual Term&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Options&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 46%"&gt;Outstanding at July 1, 2016&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;0.06&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;6.5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;0.24&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;4.0&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Outstanding at June 30, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.9&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(100)&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;0.02&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;5,150&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;0.12&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;5.8&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;4,150&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;0.13&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;4.8&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The following is a summary of stock options outstanding and exercisable by exercise&#13;price as of June 30, 2018.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Contract Life&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;0.06&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;31,00,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: center"&gt;6.5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;21,00,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.5&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.22&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.4&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;Total&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;51,50,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;41,50,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The fair value of options granted during the year ended June 30, 2018 was estimated&#13;using the Black Scholes Method and the following assumptions: volatility - 124.7% to 143.46%; Term &amp;#8211; 5 years; Risk Free&#13;Rate &amp;#8211; 2.45% to 2.61%; dividend rate &amp;#8211; 0.00%. The fair value of options granted during the year ended June 30, 2017&#13;was estimated using the Black Scholes Method and the following assumptions: volatility &amp;#8211; 136.8% to 143.1%; Term &amp;#8211;&#13;4 years; Risk Free Rate &amp;#8211; 0.53% to 1.4%; dividend rate &amp;#8211; 0.00%.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The compensation expense for the year ended June 30, 2018 includes $30,978 related to&#13;the stock options described above and an adjustment for year ended June 30, 2017 of $30,547. The adjustment was due to a correction&#13;made to the valuation of Stock Options issued to the Chief Operating Officer. The legal and professional expenses for the year&#13;ended June 30, 2018 includes $176,641 related to the stock options described above. The Company expects to recognize $11,486 of&#13;future expenses related to the vesting of stock options through April 11, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The compensation expense for the year ended June 30, 2017 includes $35,392 related to&#13;the stock options described above. The legal and professional expenses for the year ended June 30, 2017 includes $56,660 related&#13;to the stock options described above.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Extension of Maturity&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In November 2017, the Company extended the maturity date of stock options to acquire&#13;800,000 shares at exercise prices ranging from $0.21 to $0.25 issued to the board of directors between November 2016 and December&#13;2016 by 3 years. The Company recorded an incremental expense of $79,491 based on the increase in fair value of the options.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Offerings of Common Stock and Warrants&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Issuance of Shares for Cash&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In September 2016, the Company sold and issued an aggregate of 49,999 shares of common&#13;stock in a private placement transaction for aggregate gross proceeds of approximately $5,000. The purchase price for the common&#13;stock was $0.10 per share.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In October 2016, the Company sold and issued an aggregate of 225,000 shares of common&#13;stock and warrants to purchase 112,500 shares of common stock in a private placement transaction for aggregate gross proceeds&#13;of approximately $45,000. The purchase price for the common stock and warrants was $0.20 per share. The warrants are exercisable&#13;at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In November 2016, the Company sold and issued an aggregate of 250,000 shares of common&#13;stock and warrants to purchase 125,000 shares of common stock in a private placement transaction for aggregate gross proceeds&#13;of approximately $50,000. The purchase price for the common stock and warrants was $0.20 per share. The warrants are exercisable&#13;at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In December 2016, the Company sold and issued an aggregate of 100,000 shares of common&#13;stock and warrants to purchase 50,000 shares of common stock in a private placement transaction for aggregate gross proceeds of&#13;approximately $20,000. The purchase price for the common stock and warrants was $0.20 per share. The warrants are exercisable&#13;at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In January 2017,&amp;#160;the Company, entered into a common stock purchase agreement (the&#13;&amp;#8220;Purchase Agreement&amp;#8221;) with Aspire Capital Fund, LLC, an Illinois limited liability company (&amp;#8220;Aspire Capital&amp;#8221;)&#13;which provides that, on the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed&#13;to purchase up to an aggregate of $12.0 million of shares of the Company&amp;#8217;s common stock over the 30-month term of the Purchase&#13;Agreement (&amp;#8220;Aspire Equity Line&amp;#8221;). On execution of the Purchase Agreement, the Company agreed to sell to Aspire Capital&#13;1,000,000 shares of common stock and warrants to purchase 500,000 shares of common stock for proceeds of $200,000. The Warrant&#13;Shares will each have a five-year term and will be exercisable at $0.50 per share. Concurrently with entering into the Purchase&#13;Agreement, the Company also entered into a registration rights agreement with Aspire Capital (the &amp;#8220;Registration Rights Agreement&amp;#8221;),&#13;in which the Company agreed to file one or more registration statements, as permissible and necessary to register under the Securities&#13;Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;), registering the sale of the shares of the Company&amp;#8217;s common stock&#13;that have been and may be issued to Aspire Capital under the Purchase Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Under the Purchase agreement, after the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;)&#13;has declared effective the registration statement referred to above, on any trading day selected by the Company, the Company has&#13;the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a &amp;#8220;Purchase Notice&amp;#8221;), directing&#13;Aspire Capital (as principal) to purchase up to 100,000 shares of the Company&amp;#8217;s common stock per business day, up to $12.0&#13;million of the Company&amp;#8217;s common stock in the aggregate at a per share price (the &amp;#8220;Purchase Price&amp;#8221;) equal to&#13;the lesser of:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 15pt; text-align: right"&gt;&amp;#149;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the lowest sale price of the Company&amp;#8217;s common stock on the purchase date; or&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 15pt; text-align: right"&gt;&amp;#149;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the arithmetic average of the three (3) lowest closing sale prices for the Company&amp;#8217;s&#13;common stock during the twelve (12) consecutive trading days ending on the trading day immediately preceding the purchase date.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In addition, on any date on which the Company submits a Purchase Notice to Aspire&#13;Capital in an amount equal to 100,000 shares and the closing sale price of our stock is equal to or greater than $0.30 per share,&#13;the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase&#13;notice (each, a &amp;#8220;VWAP Purchase Notice&amp;#8221;) directing Aspire Capital to purchase an amount of stock equal to up to 30%&#13;of the aggregate shares of the Company&amp;#8217;s common stock traded on its principal market on the next trading day (the &amp;#8220;VWAP&#13;Purchase Date&amp;#8221;), subject to a maximum number of shares the Company may determine. The purchase price per share pursuant&#13;to such VWAP Purchase Notice is generally 95% of the volume-weighted average price for the Company&amp;#8217;s common stock traded&#13;on its principal market on the VWAP Purchase Date.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Purchase Price will be adjusted for any reorganization, recapitalization, non-cash&#13;dividend, stock split, or other similar transaction occurring during the period(s) used to compute the Purchase Price. The Company&#13;may deliver multiple Purchase Notices and VWAP Purchase Notices to Aspire Capital from time to time during the term of the Purchase&#13;Agreement, so long as the most recent purchase has been completed.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Purchase Agreement provides that the Company and Aspire Capital shall not affect&#13;any sales under the Purchase Agreement on any purchase date where the closing sale price of the Company&amp;#8217;s common stock is&#13;less than $0.10. There are no trading volume requirements or restrictions under the Purchase Agreement, and the Company will control&#13;the timing and amount of sales of the Company&amp;#8217;s common stock to Aspire Capital. Aspire Capital has no right to require any&#13;sales by the Company but is obligated to make purchases from the Company as directed by the Company in accordance with the Purchase&#13;Agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions on future funding, rights&#13;of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement. In consideration for entering&#13;into the Purchase Agreement, concurrently with the execution of the Purchase Agreement, the Company issued to Aspire Capital 2,400,000&#13;shares of the Company&amp;#8217;s common stock (the &amp;#8220;Commitment Shares&amp;#8221;). The Purchase Agreement may be terminated by&#13;the Company at any time, at its discretion, without any cost to the Company. Aspire Capital has agreed that neither it nor any&#13;of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of the Company&amp;#8217;s&#13;common stock during any time prior to the termination of the Purchase Agreement. Any proceeds that the Company receives under&#13;the Purchase Agreement are expected to be used for working capital and general corporate purposes.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In March 2017, the Company sold and issued an aggregate of 500,000 shares of common&#13;stock and warrants to purchase 250,000 shares of common stock in a private placement transaction for aggregate gross proceeds&#13;of approximately $100,000. The purchase price for the common stock and warrants was $0.20 per share. The warrants are exercisable&#13;at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In May 2017, the Company sold and issued an aggregate of 240,000 shares of common stock&#13;and warrants to purchase 120,000 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately&#13;$60,000. The purchase price for the common stock and warrants was $0.25 per share. The warrants are exercisable at an exercise&#13;price of $0.60 at any time from date of issuance until 5 years from the date of issuance. In August 2017, the Company issued an&#13;aggregate of 32,727 shares of common stock and 16,364 warrants to compensate these investors who purchased common stock at a $0.25&#13;share price in a Series C offering prior to a reduction in the offering price to $0.22 per share.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In July 2017 and August 2017, the Company sold and issued an aggregate of 886,364 shares&#13;of common stock and warrants to purchase 443,182 shares of common stock in a private placement transaction for aggregate gross&#13;proceeds of approximately $195,000. The purchase price for the common stock and warrants was $0.22 per share. The warrants are&#13;exercisable at an exercise price of $0.60 at any time from date of issuance until 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Between July 2017 and September 2017, the Company sold an aggregate of 250,000 shares&#13;of common stock in transactions under the Aspire Equity Line for aggregate gross proceeds of $50,000. The average purchase price&#13;for the common stock was $0.20 per share.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In October 2017, the Company sold and issued an aggregate of 159,091 shares of common&#13;stock and warrants to purchase 79,545 shares of common stock in a private placement transaction for aggregate gross proceeds of&#13;approximately $35,000. The purchase price for the common stock and warrants was $0.22 per share. The warrants are exercisable&#13;at an exercise price of $0.60 at any time from date of issuance until 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In November 2017, the Company also sold and issued an aggregate of 68,182 shares of&#13;common stock and warrants to purchase 34,091 shares of common stock in a private placement transaction for aggregate gross proceeds&#13;of approximately $15,000. The purchase price for the common stock and warrants was $0.22 per share. The warrants are exercisable&#13;at an exercise price of $0.60 at any time from date of issuance until 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In January 2018, the Company sold an aggregate of 333,333 shares of common stock and&#13;warrants to purchase 333,333 shares of common stock to a member of its board of directors for aggregate gross proceeds of $50,000.&#13;The purchase price for the common stock and warrants was $0.15 per share. The warrants are exercisable at an exercise price of&#13;$0.15 at any time from date of issuance until 7 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In June 2018, 100,000 shares of stock options were exercised for $2,000.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Issuance of Shares for Services&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In August 2017, the Company issued 1,500,000 shares of common stock to Aspire Capital&#13;in exchange for services. The shares were valued at $0.22 per share which was the trading price on date of issuance, and the value&#13;of the services were $330,000.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In November 2017, the Company issued 150,000 shares of common in exchange for services.&#13;The shares were valued at $0.23 per share which was the trading price on date of issuance, and the value of the services were&#13;$34,500.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In January 2018, The Company issued 30,000 shares of common stock in exchange for services.&#13;The shares were valued at $0.13 per share which was the trading price on date of issuance, and the value of the services were&#13;$3,900.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In January 2018, the Company issued 1,400,000 shares of common stock as compensation&#13;for the Board of Directors. The shares were valued at $0.15 per share which was the trading price on date of issuance, and the&#13;value of the compensation was $210,000.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In February 2018, the Company issued 600,000 shares of common stock in exchange for&#13;services. The shares were valued at $0.0475 per share which was the trading price on date of issuance, and the value of the services&#13;were $28,500.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In April 2018, the Company issued 300,000 shares of common in exchange for services.&#13;The shares were valued at $0.045 per share, and the value of the services were $13,500. In April 2018, the Company issued 150,000&#13;shares of common in exchange for services. The shares were valued at $0.024 per share which was the trading price on date of issuance,&#13;and the value of the services were $3,600.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In May 2018, the Company issued 250,000 shares of common in exchange for services. The&#13;shares were valued at $0.018 per share which was the trading price on date of issuance, and the value of the services were $4,500.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In May 2018, the Company issued 68,500 shares of common in exchange for services. The&#13;shares were valued at $0.10 per share which was the trading price on date of issuance, and the value of the services were $6,850.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In June 2018, the Company issued 300,000 shares of common in exchange for services.&#13;The shares were valued at $0.025 per share which was the trading price on date of issuance, and the value of the services were&#13;$7,500.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Issuance of Warrants for Cash&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In December 2017, the Company issued warrants to purchase 2,500,000 shares of common&#13;stock in a private placement transaction for aggregate gross proceeds of $100,000. The purchase price for the warrants were $0.04&#13;per warrant. The warrants are exercisable at an exercise price of $0.20 at any time from date of issuance until 7 years from the&#13;date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Issuance of Warrants for Services&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In January 2018, the Company issued warrants to purchase 105,000 shares of common stock&#13;in exchange for services. The warrants are exercisable at an exercise price of $0.15 any time from the date of issuance until&#13;7 years from the date of issuance. The warrants were valued at $9,444. The fair value of the warrants granted was estimated using&#13;the Black Scholes Method and the following assumptions: volatility &amp;#8211; 166.7%; Term &amp;#8211; 7 years; Risk Free Rate &amp;#8211;&#13;2.48%; dividend rate &amp;#8211; 0.00%&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In February 2018, the Company issued warrants to purchase 105,000 shares of common stock&#13;in a termination agreement. The warrants are exercisable at an exercise price of $0.15 any time from the date of issuance until&#13;7 years from the date of issuance. The warrants were valued at $3,025. The fair value of the warrants granted was estimated using&#13;the Black Scholes Method and the following assumptions: volatility &amp;#8211; 166.7%; Term &amp;#8211; 7 years; Risk Free Rate &amp;#8211;&#13;2.81%; dividend rate &amp;#8211; 0.00%&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Warrant Price Adjustment&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In December 2017, the Company issued warrants to purchase 2,500,000 shares of common&#13;stock in a private placement transaction for aggregate gross proceeds of $100,000. The warrants were exercisable at an exercise&#13;price of $0.20 at any time from date of issuance until 7 years from the date of issuance. The warrants have a down round feature&#13;that reduces the exercise price if the Company sells stock for a lower price. In January 2018, the Company sold shares at $0.15,&#13;which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants&#13;between the stated exercise price and the reduced exercise price and recorded $20,995 as a deemed dividend. The fair value of&#13;the warrants granted was estimated using the Black Scholes Method and the following assumptions: volatility &amp;#8211; 164.7%; Term&#13;&amp;#8211; 7 years; Risk Free Rate &amp;#8211; 2.47%; dividend rate &amp;#8211; 0.00%.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The following table summarizes the warrants that have been issued:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Weighted Average Remaining Life (Years)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 46%"&gt;Outstanding at June 30, 2016&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;50,00,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;11,73,864&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;0.51&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;3.5&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Outstanding at June 30, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,73,864&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,00,151&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.22&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(50,00,000)&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;47,74,015&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;0.29&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;5.5&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The following table summarizes the warrants by price:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Weighted Average Remaining Life (Years)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 26%; text-align: right"&gt;0.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 26%; text-align: right"&gt;30,43,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 26%; text-align: center"&gt;6.4&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,37,501&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3.5&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;0.60&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;6,93,181&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: Black 1pt solid"&gt;4.1&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;47,74,015&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: Black 2.5pt double"&gt;5.5&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2018-07-01to2019-03-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;b&gt;8. Equity Transactions&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The following table summarizes&#13;the activity relating to the Company&amp;#8217;s stock options for the nine months ended March 31, 2019:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-Average Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Remaining Average Contractual Term&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 44%; padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at June 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,100,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;88,370&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options Exercised or Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at March 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;166,175&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable at March 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The fair value of each option&#13;grant on the date of grant is estimated using the Black-Scholes Option &amp;#8211; Pricing model reflecting the following weighted-average&#13;assumptions:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life of options (In years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;69.77&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;69.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend Yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;Expected volatility is based&#13;on the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the&#13;expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures&#13;as they are incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The Company recorded stock-based&#13;compensation expense of $43,609 and $63,306 for the three-and nine-month periods ended March 31, 2019, respectively, and $152,062&#13;and $191,835 for the three-and nine-month periods ended March 31, 2018, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The fair value of options vested&#13;during the nine-month period ended March 31, 2019 and 2018, was $10,235 and $25,281 respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;As of March 31, 2019, there was&#13;approximately $1,555 of unrecognized compensation cost related to non-vested options granted which is expected to be recognized&#13;over a weighted-average period of 1 months.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The following is a summary of&#13;stock options outstanding and exercisable by exercise price as of March 31, 2019:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Contract Life&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;700,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;700,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,300,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,300,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,100,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,100,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;100,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;100,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;550,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;550,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;100,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;100,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.23&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.4&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;u&gt;Offerings of Common Stock&#13;and Warrants&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;i&gt;Issuance of Shares for Cash&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On July 3, 2018, BioVie Inc.,&#13;the Company, entered into a Securities Purchase Agreement (the &amp;#8220;Purchase Agreement&amp;#8221;) with Acuitas Group Holdings, LLC&#13;(&amp;#8220;Acuitas&amp;#8221;) and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the &amp;#8220;Purchasers&amp;#8221;)&#13;pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the Company&amp;#8217;s newly created Series&#13;A Convertible Preferred Stock (the &amp;#8220;Preferred Stock&amp;#8221;) at a price per share of $1.50 per share of Preferred Stock (the&#13;&amp;#8220;Initial Sale&amp;#8221;) and (ii) the Company will issue associated warrants (the &amp;#8220;Warrants&amp;#8221;) to purchase 213,333,200&#13;shares of the Company&amp;#8217;s Class A Common Stock (the &amp;#8220;Common Stock&amp;#8221;), each subject to the terms and conditions set&#13;forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. The Company received $160,000 of the $3.2 million&#13;in April and May 2018 as prepaid equity. Acuitas also received an additional 833,333 Warrants in connection with the payoff of&#13;a note issued by the Company in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition,&#13;Acuitas has the option to purchase up to an additional 200,000,000 shares of Common Stock at a price per share of $0.015, and associated&#13;warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale&#13;(the &amp;#8220;Subsequent Sale&amp;#8221;) in the event that the Company has not obtained $3,000,000 of funding through various non-dilutive&#13;grants prior to the one year anniversary of the closing of the Initial Sale.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;Each share of Preferred Stock&#13;automatically converted into 100 shares of Common Stock upon the filing with the Secretary of State of the State of Nevada of a&#13;Certificate of Amendment to the Company&amp;#8217;s Articles of Incorporation (the &amp;#8220;Amendment&amp;#8221;) on August 13, 2018 that&#13;increased the number of authorized shares of Common Stock to 800,000,000. The Amendment was approved by the written consent of&#13;the holders of more than a majority of the Company&amp;#8217;s issued and outstanding Common Stock on July 3, 2018 and was filed with&#13;the Secretary of State of the State of Nevada 20 calendar days following the distribution of the Company&amp;#8217;s Definitive Information&#13;that was filed with the Securities and Exchange Commission.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The purchase price of the Preferred&#13;Stock in the Initial Sale, the exercise price of the Warrants, and the Common Stock in the Subsequent Sale is subject to adjustment.&#13;In the event that Mallinckrodt Pharmaceuticals Ireland Limited prevails in any proceeding which results in the useful life of the&#13;Company&amp;#8217;s current intellectual property rights being reduced by more than 75 percent, then the price per share of Common&#13;Stock, the associated conversion ratio of the Preferred Stock, and the exercise price of the Warrants shall be retroactively adjusted&#13;to 50 percent of the then-effective price per share of Common Stock under the Purchase Agreement (for example, if the then-effective&#13;price per share of Common Stock is $0.015, then following such event, the price per share will be $0.0075). In this case, the Company&#13;may be required to issue additional shares of Common Stock, but in no event will the Company be required to pay cash, to reflect&#13;such lower price per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The Purchase Agreement contained&#13;customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties,&#13;the Company also disclosed customary information, including the following: (i) the existence of the Mallinckrodt Pharmaceuticals&#13;Ireland Limited petition before the US Patent Trial and Appeal Board, (ii) the current capitalization of the Company, (iii) the&#13;Company&amp;#8217;s obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be&#13;shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger,&#13;dated April 11, 2016, by and between LAT Pharma LLC and the Company, (iv) the Company&amp;#8217;s obligation to pay a low single digit&#13;royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to&#13;the Technology Transfer Agreement, dated July 25, 2016, by and between the Company and the University of Padova (Italy), and (v)&#13;certain recent issuances of Common Stock by the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;Pursuant to the Purchase Agreement,&#13;Terren Peizer, the Chairman of Acuitas, was appointed as a member of the Company&amp;#8217;s Board of Directors (the &amp;#8220;Board&amp;#8221;)&#13;and as the Chief Executive Officer of the Company, effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and&#13;the underlying common stock under the Purchase Agreement is exempt from registration under the Securities Act of 1933, as amended&#13;(the &amp;#8220;Securities Act&amp;#8221;), pursuant to the exemption for transactions by an issuer not involving any public offering under&#13;Section 4(a)(2) of the Securities Act.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;i&gt;Issuance of Shares for Services&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On January 2, 2019, the Company&#13;issued 1,400,000 shares of common stock as part of the annual board of director compensation. The share price on date of issuance&#13;was $0.035 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Issuance of Shares in Settlement&#13;of Debt&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;During the nine months ended&#13;March 31, 2019, the Company settled $1,475,765 of debt including $1,313,765 owed to related parties, by issuing 975,361 shares&#13;of common stock with a fair value of $1,150,135. See notes 5 and 6.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;i&gt;Issuance of Stock Options &lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On October 1, 2018, the Company&#13;issued stock options to purchase 100,000 shares of common stock to the Chief Financial Officer as part of her compensation. The&#13;stock options were issued and are exercisable at an exercise price of $0.07 at any time from date of issuance and expire in 5 years&#13;from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On October 13, 2018, the Company&#13;issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock&#13;options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On October 27, 2018, the Company&#13;issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock&#13;options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On November 10, 2018, the Company&#13;issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock&#13;options are exercisable at an exercise price of $0.05 at any time from date of issuance and expire in 5 years from the date of&#13;issuance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On January 19, 2019, the Company&#13;issued stock options to purchase 100,000 shares of common stock to each of five key employees or consultants and two company directors&#13;as part of his or her annual compensation, for an aggregate total of 700,000 stock options. The stock options are exercisable at&#13;an exercise price of $0.025 at any time from date of issuance until 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On March 11, 2019, the Company&#13;issued stock options to purchase 1,000,000 shares of common stock to an investor relations (IR) consultant. The stock options were&#13;issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;i&gt;Cashless exercise of warrant&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On August 4, 2018, the Company&#13;issued 2,241,913 shares of common stock pursuant to a cash less exercise of warrants to purchase 2,500,000 shares at an exercise&#13;price of $0.015 per share. As a result of the conversion of the Series A Preferred Stock in July 2018, the exercise of warrants&#13;to purchase 2,500,000 shares of common stock was reduced from $0.15 per share to $0.015 per share.&lt;br style="clear: both" /&gt;&#13;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;i&gt;Warrant Price Adjustment&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;In December 2017, the Company&#13;issued warrants to purchase 2,500,000 shares of common stock in a private placement transaction for aggregate gross proceeds of&#13;$100,000. The warrants were exercisable at an exercise price of $0.20 at any time from date of issuance until 7 years from the&#13;date of issuance. The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower&#13;price. In January 2018, the Company sold shares at $0.15, which therefore triggered the reduction in the strike price. The Company&#13;calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded&#13;$20,995 as a deemed dividend. In July 2018, the Company sold shares at $0.015, which therefore triggered the reduction in the strike&#13;price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise&#13;price and recorded $44,889 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;In January 2018, the Company&#13;issued warrants to purchase 210,000 shares of common stock in exchange for banking services which was recognized at fair value.&#13;The warrants were exercisable at an exercise price of $0.15 at any time from date of issuance until 7 years from the date of issuance.&#13;The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In July 2018,&#13;the Company sold shares at $0.015, which therefore triggered the reduction in the strike price. The Company calculated the difference&#13;in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $3,770 as a deemed&#13;dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"&gt;The following table summarizes&#13;the warrants that have been issued:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Remaining Life (Years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intrinsic Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 44%; padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at June 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,774,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.29&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;214,166,533&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.02&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,284,908&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.02&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding and exercisable at March 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;216,440,548&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,284,908&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;Of the above warrants, 1,173,864&#13;expire in fiscal year ending June 30, 2022, 556,818 expire in fiscal year ending June 30, 2023, and 214,709,866 expire in fiscal&#13;year ending June 30, 2025.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2017-07-01to2018-06-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 99%"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the&#13;carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. At June&#13;30, 2018, the Company has a Net Operating Loss (&amp;#8220;NOL&amp;#8221;) carryforward of approximately $1,800,000. The NOL expires during&#13;the years 2032 to 2037. Realization of any portion of the $832,186 of net deferred tax assets at June 30, 2018 is not considered&#13;more likely than not by management; accordingly, a valuation allowance has been established for the full amount. The valuation&#13;allowance as of June 30, 2018 was $832,186. The change in the valuation allowance during the year ended June 30, 2018 amounted&#13;to $357,231. The Company does not have any uncertain tax positions or events leading to uncertainty in a tax position. The Company&amp;#8217;s&#13;2015, 2016 and 2017 Corporate Income Tax Returns are subject to Internal Revenue Service examination.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On December 22, 2017, the Tax Cuts and Jobs Act (the &amp;#8220;Act&amp;#8221;) was signed into&#13;law. The Act decreases the U.S. corporate federal income tax rate from a maximum of 35% to a flat 21% effective January 1, 2018.&#13;The Act also includes a number of other provisions including, among others, the elimination of net operating loss carrybacks and&#13;limitations on the use of future losses, the repeal of the Alternative Minimum Tax regime and the repeal of the domestic production&#13;activities deduction. These provisions are not expected to have a material effect on the Corporation.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Given the significant complexity of the Act and anticipated additional implementation&#13;guidance from the Internal Revenue Service, further implications of the Act may be identified in future periods.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Significant components of the Company&amp;#8217;s deferred tax assets are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Since management of the Company believes that it is more likely than not that the net&#13;deferred tax assets will not provide future benefit, the Company has established a 100 percent valuation allowance on the net&#13;deferred tax assets as of June 30, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;&lt;b&gt;June 30, 2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;&lt;b&gt;June 30, 2017&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 56%; text-align: left"&gt;Tax loss carryforward&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5,55,064&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,46,071&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,277&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,735&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,57,845&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(8,32,186&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(4,74,955&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Reconciliation of the differences between income tax benefit computed at the federal&#13;and state statutory tax rates and the provision for income tax benefit for the years ended June 30, 2018 and 2017 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 56%; text-align: left"&gt;Income tax expense (benefit) at federal statutory rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;-39&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;-39&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;b&gt;10. Subsequent Events&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On July 3, 2018, BioVie, Inc., the Company, entered into a Securities Purchase Agreement&#13;(the &amp;#8220;Purchase Agreement&amp;#8221;) with Acuitas Group Holdings, LLC (&amp;#8220;Acuitas&amp;#8221;) and certain other purchasers identified&#13;in the Purchase Agreement (together with Acuitas, the &amp;#8220;Purchasers&amp;#8221;) pursuant to which (i) the Purchasers agreed to&#13;purchase an aggregate of 2,133,332 shares of the Company&amp;#8217;s newly created Series A Convertible Preferred Stock (the &amp;#8220;Preferred&#13;Stock&amp;#8221;) at a price per share of $1.50 per share of Preferred Stock (the &amp;#8220;Initial Sale&amp;#8221;) and (ii) the Company&#13;will issue associated warrants (the &amp;#8220;Warrants&amp;#8221;) to purchase 213,333,200 shares of the Company&amp;#8217;s Class A Common&#13;Stock (the &amp;#8220;Common Stock&amp;#8221;), each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate&#13;consideration of $3.2 million. Acuitas also received an additional 833,333 Warrants in connection with the payoff of a note issued&#13;by the Company in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas&#13;has the option to purchase up to an additional 200,000,000 shares of Common Stock at a price per share of $0.015, and associated&#13;warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial&#13;Sale (the &amp;#8220;Subsequent Sale&amp;#8221;) in the event that the Company has not obtained $3,000,000 of funding through various&#13;non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Each share of Preferred Stock automatically converted into 100 shares of Common Stock&#13;upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to the Company&amp;#8217;s Articles&#13;of Incorporation (the &amp;#8220;Amendment&amp;#8221;) on August 13, 2018 that increased the number of authorized shares of Common Stock&#13;to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of the Company&amp;#8217;s&#13;issued and outstanding Common Stock on July 3, 2018, and was filed with the Secretary of State of the State of Nevada 20 calendar&#13;days following the distribution of the Company&amp;#8217;s Definitive Information to be filed with the Securities and Exchange Commission.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;See the heading &amp;#8220;Series A Convertible Preferred Stock&amp;#8221; below for additional&#13;information related to the Preferred Stock. The purchase price of the Preferred Stock in the Initial Sale, the exercise price&#13;of the Warrants, and the Common Stock in the Subsequent Sale is subject to adjustment. First, in the event that the volume weighted&#13;average price of the Common Stock during the five-trading day period following July 3, 2018 is less than $0.015 per share, the&#13;price per share of Common Stock, the associated conversion ratio of the Preferred Stock, and the exercise price of the Warrants&#13;shall be retroactively adjusted to reflect such lower price. Second, in the event that Mallinckrodt Pharmaceuticals Ireland Limited&#13;prevails in any proceeding which results in the useful life of the Company&amp;#8217;s current intellectual property rights being&#13;reduced by more than 75 percent, then the price per share of Common Stock, the associated conversion ratio of the Preferred Stock,&#13;and the exercise price of the Warrants shall be retroactively adjusted to 50 percent of the then-effective price per share of&#13;Common Stock under the Purchase Agreement (for example, if the then-effective price per share of Common Stock is $0.015, then&#13;following such event, the price per share will be $0.0075). In each case, the Company may be required to issue additional shares&#13;of Common Stock, but in no event will the Company be required to pay cash, to reflect such lower price per share.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Purchase Agreement contained customary representations and warranties. In connection&#13;with the disclosure schedule associated with the representations and warranties, the Company also disclosed customary information,&#13;including the following: (i) the existence of the Mallinckrodt Pharmaceuticals Ireland Limited petition before the US Patent Trial&#13;and Appeal Board, (ii) the current capitalization of the Company, (iii) the Company&amp;#8217;s obligation to pay a royalty on the&#13;net sales of BIV201 (continuous infusion terlipressin) in the amount of five percent to be allocated four percent to LAT Pharma&#13;LLC members, 0.4 percent to PharmaIn Corporation and 0.6 percent to The Barrett Edge, Inc. pursuant to the Agreement and Plan&#13;of Merger, dated April 11, 2016, by and between LAT Pharma LLC and the Company, (iv) the Company&amp;#8217;s obligation to pay a royalty&#13;of five percent on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant&#13;to the Technology Transfer Agreement, dated July 25, 2016, by and between the Company and the University of Padova (Italy), and&#13;(v) certain recent issuances of Common Stock by the Company.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Pursuant to the Purchase Agreement, Terren Peizer, the Chairman of Acuitas, was appointed&#13;as a member of the Company&amp;#8217;s Board of Directors (the &amp;#8220;Board&amp;#8221;) and as the Chief Executive Officer of the Company,&#13;effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and the underlying common stock under the Purchase Agreement&#13;is exempt from registration under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;), pursuant to the exemption&#13;for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On July 9, 2018, Elliot Ehrlich entered into an Accord and Debt Satisfaction Agreement&#13;with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment&#13;of his accrued salary dated March 23, 2017 totaling the amount of $222,028.13 and received the settled sum of $22,203 and 222,028&#13;common shares in satisfaction. This settlement reduced the Company&amp;#8217;s debt by $222,028.13.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On July 9, 2018, Jonathan Adams entered into an Accord and Debt Satisfaction Agreement&#13;with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment&#13;of his accrued salary dated March 23, 2017 and subsequent unpaid salary, totaling the amount of $513,889, and received the settled&#13;sum of $25,694 in satisfaction. This settlement reduced the Company&amp;#8217;s debt by $513,889.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On July 19, 2018, Geis-Hides Consulting LLC entered into an Accord and Debt Satisfaction&#13;Agreement with the Company in which the consulting firm agreed to release the Company from all liabilities arising from the Original&#13;Contract and Debt Repayment Plan dated December 15, 2013 totaling $130,000 and received the settled sum of $65,000 and 260,000&#13;common shares in satisfaction. This settlement reduced the Company&amp;#8217;s debt by $130,000.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;As a result of the conversion of the Series A Preferred Stock in July 2018, the exercise&#13;of warrants to purchase 2,500,000 shares of common stock was reduced from $0.15 per share to $0.015 per share. On August 4, 2018,&#13;the Company issued 2,241,913 shares of common stock pursuant to a cash less exercise of warrants to purchase 2,500,000 shares&#13;at an exercise price of $0.015 per share.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On August 8, 2018, Barrett Ehrlich on behalf of The Barrett Edge Inc. (&amp;#8220;Barrett&amp;#8221;)&#13;entered into an Accord and Debt Satisfaction Agreement with the Company in which Barrett agreed to release the Company from all&#13;liabilities including the original contract to defer payment of Barrett&amp;#8217;s accrued salary dated March 23, 2017, loan to the&#13;Company for $14,000, and subsequent unpaid consulting fees, totaling $493,333, and received the settled sum of $131,333 and 493,333&#13;common shares in satisfaction. This settlement reduced the Company&amp;#8217;s debt by $507,333.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2018-07-01to2019-03-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;b&gt;9. Subsequent Events&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;In April 2019, to facilitate&#13;the Company&amp;#8217;s planned uplisting to the NASDAQ Stock Market and related potential future issuances and sales of equity securities&#13;for ordinary corporate finance and general corporate purposes and as recommended by the Board of Directors (&amp;#8220;Board&amp;#8221;),&#13;the Company&amp;#8217;s stockholders approved an amendment to the Company&amp;#8217;s Articles of Incorporation to effect a reverse split&#13;of its outstanding Class A common stock in the range of 50:1 to 200:1, as determined by the Board. Following that approval, the&#13;Company filed a Registration Statement on Form S-1 (Registration No. 333-231136) (the &amp;#8220;S-1 Registration Statement&amp;#8221;)&#13;pursuant to which it anticipates completing an offering of equity securities with proceeds sufficient to enable the launch and&#13;completion of the BIV201 Phase 2b study and fund internal operations for at least the next twelve months.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity with accounting principles generally&#13;accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts&#13;and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues&#13;and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2018-07-01to2019-03-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;i&gt;Basis of Presentation &amp;#8211; Interim Financial&#13;Information&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The accompanying unaudited interim&#13;financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United&#13;State of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and with the instructions to Form 10-Q and Article&#13;10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information&#13;and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect&#13;all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair&#13;presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for&#13;the full year. The Condensed Balance Sheet at June 30, 2018 was derived from audited annual financial statements but does not contain&#13;all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included&#13;under the heading: &amp;#8220;Management&amp;#8217;s Discussion and Analysis of Financial Condition and Results of Operations&amp;#8221; should&#13;be read in conjunction with our Company&amp;#8217;s audited financial statements and related notes included in our Company&amp;#8217;s&#13;Form 10-K for the year ended June 30, 2018 filed with the SEC on October 5, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;For a summary of significant&#13;accounting policies, see the Company&amp;#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the&#13;SEC on October 5, 2018.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity with accounting principles generally&#13;accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts&#13;of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the&#13;reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0"&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Cash is maintained at financial institutions and, at times, balances may exceed federally&#13;insured limits. The Company has never experienced any losses related to these balances. All of the Company&amp;#8217;s cash balances&#13;were fully insured at June 30, 2018.&amp;#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0"&gt;&lt;i&gt;Financial Instruments&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s financial instruments include cash, accounts payable, related party&#13;loans and a demand promissory note. The carrying amounts of cash and accounts payable approximate their fair value, due to the&#13;short-term nature of these items.&amp;#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LongTermDebtTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0"&gt;&lt;i&gt;Long-Term Notes Payable&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s long-term notes payable include accrued payroll to officers and&#13;accrued payments to third party consultants.&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0"&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Research and development costs are charged to operations when incurred and are included&#13;in operating expenses. The Company expensed $370,853 and $466,354 for research and development for the years ended June 30, 2018&#13;and 2017, respectively.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Deferred income tax assets and liabilities arise from temporary differences associated&#13;with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates,&#13;which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current&#13;or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities&#13;not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary&#13;differences are expected to reverse.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company follows the provisions of FASB ASC 740-10 &amp;#8220;&lt;i&gt;Uncertainty in Income&#13;Taxes&lt;/i&gt;&amp;#8221; (ASC 740-10), January 1, 2007. The Company has not recognized a liability as a result of the implementation of&#13;ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there&#13;are no unrecognized benefits at June 30, 2018 and since the date of adoption. The Company has not recognized interest expense&#13;or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize&#13;interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.&amp;#160; The Company&amp;#8217;s&#13;tax returns for the years ended June 30, 2015, 2016, 2017 and 2018 remain open to examination by taxing authorities.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0"&gt;&lt;i&gt;Earnings (Loss) per Share&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Basic earnings per share are computed by dividing net income by the weighted average&#13;number of shares of common stock outstanding during the year. Diluted earnings per common share are computed by dividing net income&#13;by the weighted average number of shares of common stock outstanding and dilutive options outstanding during the year. For the&#13;years ended June 30, 2017 and 2018 all outstanding options have been excluded from the calculation of the diluted net loss per&#13;share since their effect was anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;The following potentially dilutive securities were excluded from the computation of diluted loss per share&#13;for the years ended June 30, 2017 and 2018:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Number of Shares (Thousands)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Number of Shares (Thousands)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 56%; text-align: center"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;6,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;4,774&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;10,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;9,924&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2018-07-01to2019-03-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;i&gt;Net Loss per Common Share&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;Basic net loss per common share&#13;is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding&#13;during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares&#13;of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution&#13;that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures.&#13;Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The table below shows the number&#13;of outstanding stock options and warrants as of March 31, 2019 and June 30, 2018:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30, 2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;216,440,548&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,774,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;223,690,548&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;9,924,015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0"&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company has accounted for stock-based compensation under the provisions of FASB&#13;ASC 718 &amp;#8211; &amp;#8220;Stock Compensation&amp;#8221; which requires the use of the fair-value based method to determine compensation&#13;for all arrangements under which employees and others receive shares of stock or equity instruments (stock options and common&#13;stock purchase warrants). For employee awards, the fair value of each stock option award is estimated on the date of grant using&#13;the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free&#13;interest rate. For non-employees, the fair value of each stock option award is estimated on the measurement date using the Black-Scholes&#13;valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.&#13;For non-employees, the Company utilizes the graded vesting attribution method under which the entity treats each separately vesting&#13;portion (tranche) as a separate award and recognizes compensation cost for each tranche over its separate vesting schedule. Expected&#13;volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock&#13;options. For employee awards, the expected term of options granted is derived using the &amp;#8220;simplified method&amp;#8221; which&#13;computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the&#13;U.S. Treasury yield curve in effect at the time of grant for the period of the expected term.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0"&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Goodwill is recorded when the purchase price paid for an acquisition exceeds the fair&#13;value of net identified tangible and intangible assets acquired. The Company performs an annual impairment test of goodwill and&#13;further periodic tests to the extent indicators of impairment develop between annual impairment tests. The Company&amp;#8217;s impairment&#13;review process compares the fair value of the reporting unit to its carrying value, including the goodwill related to the reporting&#13;unit. To determine the fair value of the reporting unit, the Company may use various approaches including an asset or cost approach,&#13;market approach or income approach or any combination thereof. These approaches may require the Company to make certain estimates&#13;and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each time the&#13;Company tests goodwill for impairment and are typically developed as part of the Company&amp;#8217;s routine business planning and&#13;forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates&#13;could produce materially different results. The Company did not recognize any goodwill impairments for the years ended June 30th,&#13;2017 and June 30th, 2018.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0"&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Long-lived assets, including intangible assets, are reviewed for impairment whenever&#13;events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets&#13;to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows&#13;expected to be generated by the asset.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;If the carrying amount of an asset exceeds its undiscounted estimated future cash flows,&#13;an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the asset&#13;exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected discounted&#13;cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported&#13;at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and&#13;liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability&#13;sections of the balance sheet.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0"&gt;&lt;i&gt;Recent accounting pronouncements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company has reviewed recent accounting pronouncements issued by the FASB (including&#13;its EITF), the AICPA, and the SEC and did not or are not believed by management to have a material impact on the Company&amp;#8217;s&#13;financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2018-07-01to2019-03-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;i&gt;Recent accounting pronouncements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The Company considers the applicability&#13;and impact of all Accounting Standard Updates (&amp;#8220;ASU&amp;#8217;s&amp;#8221;). ASU&amp;#8217;s not discussed below were assessed and determined&#13;to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;In June 2018, the FASB issued&#13;ASU 2018-07, &amp;#8220;Compensation &amp;#8211; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting&amp;#8221;.&#13;This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment&#13;transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings&#13;as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair&#13;value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim&#13;periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on the&#13;financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0"&gt;The following potentially dilutive securities were excluded from the computation of diluted loss per share&#13;for the years ended June 30, 2017 and 2018:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Number of Shares (Thousands)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Number of Shares (Thousands)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 56%; text-align: center"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;6,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;4,774&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;10,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;9,924&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2018-07-01to2019-03-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The table below shows the number&#13;of outstanding stock options and warrants as of March 31, 2019 and June 30, 2018:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30, 2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;216,440,548&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,774,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;223,690,548&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;9,924,015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;b&gt;4. Intangible Assets&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The company&amp;#8217;s intangible assets consist of intellectual property acquired from&#13;LAT Pharma, Inc., and are amortized over their estimated useful lives as indicated below. The following is a summary of the intangible&#13;assets as of June 30, 2018 and 2017.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;June 30, 2018&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;June 30, 2017&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 56%; text-align: left"&gt;Intangible Assets subject to Amortization&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;22,93,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;22,93,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;5,09,790&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;2,80,413&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Intangible Assets (Net of Amortization&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;17,83,980&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;20,13,357&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Future expected Amortization of intangible assets is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;b&gt;Year Ending June 30,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 70%; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;2,29,377&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center"&gt;2020&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,29,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center"&gt;2021&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,29,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center"&gt;2022&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,29,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center"&gt;2023&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,29,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,37,095&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,83,980&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2018-07-01to2019-03-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;4. Intellectual&#13;Property&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Intellectual&#13;property, stated at cost, less accumulated amortization consists of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30, 2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intellectual Property&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,293,770&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,293,770&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;681,823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;509,790&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intellectual Property, Net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,611,947&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,783,980&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Amortization&#13;expense for the and nine-month periods ended March 31, 2019 and 2018 was $172,033. Estimated future&#13;amortization expense is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: bottom; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;Year ending June 2019 (remaining three months)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;57,344 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: bottom; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: bottom; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: bottom; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: bottom; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-bottom: 1pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-bottom: 1pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: bottom; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;637,095&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-bottom: 1pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-bottom: 2.5pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-bottom: 2.5pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: bottom; border-top: black 1pt solid; border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,611,947 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-bottom: 2.5pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0; text-align: justify"&gt;The following is a summary of the intangible&#13;assets as of June 30, 2018 and 2017.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;June 30, 2018&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;June 30, 2017&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 56%; text-align: left"&gt;Intangible Assets subject to Amortization&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;22,93,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;22,93,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;5,09,790&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;2,80,413&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Intangible Assets (Net of Amortization)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;17,83,980&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;20,13,357&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2018-07-01to2019-03-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Intellectual&#13;property, stated at cost, less accumulated amortization consists of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30, 2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intellectual Property&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,293,770&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,293,770&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;681,823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;509,790&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intellectual Property, Net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,611,947&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,783,980&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0; text-align: justify"&gt;Future expected Amortization of intangible assets is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;b&gt;Year Ending June 30,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 70%; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;2,29,377&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center"&gt;2020&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,29,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center"&gt;2021&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,29,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center"&gt;2022&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,29,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center"&gt;2023&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,29,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,37,095&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,83,980&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2018-07-01to2019-03-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Estimated future&#13;amortization expense is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: bottom; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;Year ending June 2019 (remaining three months)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;57,344 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: bottom; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: bottom; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: bottom; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: bottom; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-bottom: 1pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-bottom: 1pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: bottom; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;637,095&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-bottom: 1pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-bottom: 2.5pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-bottom: 2.5pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: bottom; border-top: black 1pt solid; border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt/115% Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,611,947 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-bottom: 2.5pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0; text-align: justify"&gt;Reconciliation of the differences between income tax benefit computed at the federal&#13;and state statutory tax rates and the provision for income tax benefit for the years ended June 30, 2018 and 2017 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 56%; text-align: left"&gt;Income tax expense (benefit) at federal statutory rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;-39&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;-39&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2017-07-01to2018-06-30">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;&lt;b&gt;June 30, 2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;&lt;b&gt;June 30, 2017&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 56%; text-align: left"&gt;Tax loss carryforward&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5,55,064&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,46,071&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,277&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,735&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,57,845&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(8,32,186&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(4,74,955&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1 contextRef="From2018-07-02to2018-07-03_us-gaap_SubsequentEventMember_custom_AcuitasGroupHoldingsLLCAndOtherPurchaserMember" unitRef="Shares" decimals="INF">213333200</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="From2018-07-02to2018-07-03_us-gaap_SubsequentEventMember_custom_AcuitasGroupHoldingsLLCAndOtherPurchaserMember" unitRef="USD" decimals="0">3200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-07-01to2018-06-30" unitRef="Shares" decimals="INF">9924015</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-07-01to2017-06-30" unitRef="Shares" decimals="INF">9924000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-07-01to2019-03-31" unitRef="Shares" decimals="INF">223690548</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">5150000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">5150000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-07-01to2019-03-31_us-gaap_StockOptionMember128077054" unitRef="Shares" decimals="INF">7250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">4774015</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">4774000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-07-01to2019-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">216440548</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">2013357</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">1783980</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">1611947</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">280413</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">509790</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">681823</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">2293770</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">2293770</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">2293770</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">637095</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">637095</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">57344</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2018-07-01to2019-03-31_us-gaap_StockOptionMember128077054" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2018-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2019-03-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2018-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">4150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2018-06-30_custom_StockOptionOneMember" unitRef="Shares" decimals="INF">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2018-06-30_custom_StockOptionTwoMember" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2018-06-30_custom_StockOptionThreeMember" unitRef="Shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2018-06-30_custom_StockOptionFourMember" unitRef="Shares" decimals="INF">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2018-06-30_custom_StockOptionFiveMember" unitRef="Shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2018-06-30_custom_StockOptionSixMember" unitRef="Shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2018-06-30_custom_StockOptionSevenMember" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-03-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">6250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-03-31_custom_StockOptionOneMember" unitRef="Shares" decimals="INF">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-03-31_custom_StockOptionTwoMember" unitRef="Shares" decimals="INF">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-03-31_custom_StockOptionThreeMember" unitRef="Shares" decimals="INF">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-03-31_custom_StockOptionFourMember" unitRef="Shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-03-31_custom_StockOptionFiveMember" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-03-31_custom_StockOptionSixMember" unitRef="Shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-03-31_custom_StockOptionSevenMember" unitRef="Shares" decimals="INF">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-03-31_custom_StockOptionEightMember" unitRef="Shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-03-31_custom_StockOptionNineMember" unitRef="Shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember">P5Y10M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-03-31_us-gaap_StockOptionMember128077054">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2017-07-01to2018-06-30_custom_StockOptionOneMember">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2017-07-01to2018-06-30_custom_StockOptionTwoMember">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2017-07-01to2018-06-30_custom_StockOptionThreeMember">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2017-07-01to2018-06-30_custom_StockOptionFourMember">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2017-07-01to2018-06-30_custom_StockOptionFiveMember">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2017-07-01to2018-06-30_custom_StockOptionSixMember">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2017-07-01to2018-06-30_custom_StockOptionSevenMember">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-03-31_custom_StockOptionOneMember">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-03-31_custom_StockOptionTwoMember">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-03-31_custom_StockOptionThreeMember">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-03-31_custom_StockOptionFourMember">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-03-31_custom_StockOptionFiveMember">P3Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-03-31_custom_StockOptionSixMember">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-03-31_custom_StockOptionSevenMember">P3Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-03-31_custom_StockOptionEightMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-03-31_custom_StockOptionNineMember">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember">P5Y</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember">P4Y</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2018-07-01to2019-03-31_us-gaap_StockOptionMember128077054">P4Y7M6D</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4 contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember">P5Y9M18D</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4 contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember">P5Y10M15D</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4 contextRef="From2018-07-01to2019-03-31_us-gaap_StockOptionMember128077054">P5Y3M18D</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-03-31_us-gaap_StockOptionMember128077054">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2018-06-30_custom_WarrantOneMember" unitRef="Shares" decimals="INF">3043333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2018-06-30_custom_WarrantTwoMember" unitRef="Shares" decimals="INF">1037501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2018-06-30_custom_WarrantThreeMember" unitRef="Shares" decimals="INF">693181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2018-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">4774015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2017-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">6173864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2016-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2019-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">216440548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="AsOf2018-06-30_custom_WarrantOneMember" unitRef="USDPShares" decimals="INF">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="AsOf2018-06-30_custom_WarrantTwoMember" unitRef="USDPShares" decimals="INF">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="AsOf2018-06-30_custom_WarrantThreeMember" unitRef="USDPShares" decimals="INF">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="AsOf2018-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="AsOf2017-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="AsOf2016-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="AsOf2019-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3 contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember">P5Y6M</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3 contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember">P0Y8M12D</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3 contextRef="From2018-07-01to2019-03-31_us-gaap_WarrantMember">P5Y3M18D</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3 contextRef="From2017-07-01to2018-06-30_custom_WarrantOneMember">P6Y4M24D</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3 contextRef="From2017-07-01to2018-06-30_custom_WarrantTwoMember">P3Y6M</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3 contextRef="From2017-07-01to2018-06-30_custom_WarrantThreeMember">P4Y1M6D</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">3600151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1173864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2018-07-01to2019-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">214166533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="From2018-07-01to2019-03-31_us-gaap_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue contextRef="From2018-07-01to2019-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue contextRef="From2018-07-01to2019-03-31_us-gaap_WarrantMember" unitRef="USDPShares" xsi:nil="true" />
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember">P6Y1M6D</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember">P3Y6M</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="From2018-07-01to2019-03-31_us-gaap_WarrantMember">P5Y3M18D</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember">P0Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2018-07-01to2019-03-31_us-gaap_WarrantMember">P5Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2017-07-01to2018-06-30" unitRef="Pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2016-07-01to2017-06-30" unitRef="Pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2017-07-01to2018-06-30" unitRef="Pure" decimals="INF">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2016-07-01to2017-06-30" unitRef="Pure" decimals="INF">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2017-07-01to2018-06-30" unitRef="Pure" decimals="INF">-0.39</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2016-07-01to2017-06-30" unitRef="Pure" decimals="INF">-0.39</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2017-07-01to2018-06-30" unitRef="Pure" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2016-07-01to2017-06-30" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="AsOf2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="AsOf2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">25149</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">257845</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">3735</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">19277</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <invest:InvestmentOptionsExercisePrice contextRef="From2017-07-01to2018-06-30_custom_StockOptionOneMember" unitRef="USDPShares" decimals="INF">0.06</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2017-07-01to2018-06-30_custom_StockOptionTwoMember" unitRef="USDPShares" decimals="INF">0.10</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2017-07-01to2018-06-30_custom_StockOptionThreeMember" unitRef="USDPShares" decimals="INF">0.20</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2017-07-01to2018-06-30_custom_StockOptionFourMember" unitRef="USDPShares" decimals="INF">0.21</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2017-07-01to2018-06-30_custom_StockOptionFiveMember" unitRef="USDPShares" decimals="INF">0.22</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2017-07-01to2018-06-30_custom_StockOptionSixMember" unitRef="USDPShares" decimals="INF">0.25</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2017-07-01to2018-06-30_custom_StockOptionSevenMember" unitRef="USDPShares" decimals="INF">0.23</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2018-07-01to2019-03-31_custom_StockOptionOneMember" unitRef="USDPShares" decimals="INF">0.03</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2018-07-01to2019-03-31_custom_StockOptionTwoMember" unitRef="USDPShares" decimals="INF">0.05</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2018-07-01to2019-03-31_custom_StockOptionThreeMember" unitRef="USDPShares" decimals="INF">0.06</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2018-07-01to2019-03-31_custom_StockOptionFourMember" unitRef="USDPShares" decimals="INF">0.07</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2018-07-01to2019-03-31_custom_StockOptionFiveMember" unitRef="USDPShares" decimals="INF">0.10</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2018-07-01to2019-03-31_custom_StockOptionSixMember" unitRef="USDPShares" decimals="INF">0.20</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2018-07-01to2019-03-31_custom_StockOptionSevenMember" unitRef="USDPShares" decimals="INF">0.21</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2018-07-01to2019-03-31_custom_StockOptionEightMember" unitRef="USDPShares" decimals="INF">0.22</invest:InvestmentOptionsExercisePrice>
    <invest:InvestmentOptionsExercisePrice contextRef="From2018-07-01to2019-03-31_custom_StockOptionNineMember" unitRef="USDPShares" decimals="INF">0.23</invest:InvestmentOptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0; text-align: justify"&gt;The following is a summary of stock option activity for the years ended June 30, 2017&#13;and 2018.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Shares (Thousands)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Weighted-Average Exercise&#13;    Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Weighted Remaining Average&#13;    Contractual Term&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Options&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 46%"&gt;Outstanding at July 1, 2016&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;0.06&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;6.5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;0.24&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;4.0&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Outstanding at June 30, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.9&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(100)&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;0.02&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;5,150&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;0.12&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;5.8&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;4,150&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;0.13&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;4.8&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2018-07-01to2019-03-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The following table summarizes&#13;the activity relating to the Company&amp;#8217;s stock options for the nine months ended March 31, 2019:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-Average Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Remaining Average Contractual Term&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 44%; padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at June 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,100,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;88,370&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options Exercised or Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at March 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;166,175&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable at March 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The fair value of each option&#13;grant on the date of grant is estimated using the Black-Scholes Option &amp;#8211; Pricing model reflecting the following weighted-average&#13;assumptions:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life of options (In years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;69.77&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;69.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend Yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember">&lt;p style="margin: 0; text-align: justify"&gt;The following table summarizes the warrants that have been issued:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Weighted Average Remaining Life (Years)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 46%"&gt;Outstanding at June 30, 2016&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;50,00,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;11,73,864&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;0.51&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;3.5&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Outstanding at June 30, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,73,864&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,00,151&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.22&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(50,00,000)&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;47,74,015&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;0.29&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;5.5&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2018-07-01to2019-03-31_us-gaap_WarrantMember">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"&gt;The following table summarizes&#13;the warrants that have been issued:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Remaining Life (Years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intrinsic Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 44%; padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at June 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,774,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.29&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;214,166,533&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.02&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,284,908&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.02&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding and exercisable at March 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;216,440,548&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,284,908&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2017-07-01to2018-06-30">&lt;p style="margin: 0; text-align: justify"&gt;The following is a summary of stock options outstanding and exercisable by exercise&#13;price as of June 30, 2018.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Contract Life&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;0.06&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;31,00,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: center"&gt;6.5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;21,00,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.5&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.22&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.4&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,00,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;Total&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;51,50,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;41,50,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2018-07-01to2019-03-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The following is a summary of&#13;stock options outstanding and exercisable by exercise price as of March 31, 2019:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Contract Life&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;700,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;700,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,300,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,300,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,100,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,100,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;100,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;100,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;550,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;550,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;100,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;100,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.23&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.4&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember">&lt;p style="margin: 0; text-align: justify"&gt;The following table summarizes the warrants by price:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Weighted Average Remaining Life (Years)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 26%; text-align: right"&gt;0.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 26%; text-align: right"&gt;30,43,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 26%; text-align: center"&gt;6.4&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,37,501&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3.5&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;0.60&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;6,93,181&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: Black 1pt solid"&gt;4.1&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;47,74,015&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: Black 2.5pt double"&gt;5.5&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">3040000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="From2017-07-01to2018-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPaidNet contextRef="From2018-07-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPaidNet contextRef="From2017-07-01to2018-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaidNet contextRef="From2018-07-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaidNet contextRef="From2017-07-01to2018-03-31" unitRef="USD" xsi:nil="true" />
    <bivi:ConversionOfPreferredSharesToCommonStock contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">3200000</bivi:ConversionOfPreferredSharesToCommonStock>
    <bivi:ConversionOfPreferredSharesToCommonStock contextRef="From2017-07-01to2018-03-31" unitRef="USD" xsi:nil="true" />
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">1150135</bivi:SettlementOfDebtByIssuanceOfCommonStock>
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2017-07-01to2018-03-31" unitRef="USD" xsi:nil="true" />
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">98</bivi:SettlementOfDebtByIssuanceOfCommonStock>
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1150037</bivi:SettlementOfDebtByIssuanceOfCommonStock>
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2018-09-30" unitRef="USD" decimals="0">1150135</bivi:SettlementOfDebtByIssuanceOfCommonStock>
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">224</bivi:CashlessExerciseOfWarrants>
    <bivi:CashlessExerciseOfWarrants contextRef="From2017-07-01to2018-03-31" unitRef="USD" xsi:nil="true" />
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">224</bivi:CashlessExerciseOfWarrants>
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-224</bivi:CashlessExerciseOfWarrants>
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">48659</bivi:DeemedDividendsForRatchetAdjustmentsToWarrants>
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2017-07-01to2018-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease contextRef="From2018-07-01to2019-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue contextRef="From2018-07-01to2019-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.02</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2018-06-30_us-gaap_StockOptionMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2019-03-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">166175</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2019-03-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">14284908</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="From2018-07-01to2019-03-31_us-gaap_StockOptionMember128077054" unitRef="USD" decimals="0">88370</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="From2018-07-01to2019-03-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">14284908</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">250000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <dei:EntityRegistrantName contextRef="From2018-07-01to2019-03-31">BIOVIE INC.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2018-07-01to2019-03-31">0001580149</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2018-07-01to2019-03-31">S-1/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2018-07-01to2019-03-31">2019-03-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2018-07-01to2019-03-31">true</dei:AmendmentFlag>
    <dei:EntityFilerCategory contextRef="From2018-07-01to2019-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="From2018-07-01to2019-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntitySmallBusiness contextRef="From2018-07-01to2019-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityExTransitionPeriod contextRef="From2018-07-01to2019-03-31">false</dei:EntityExTransitionPeriod>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">35000</us-gaap:OtherAssetsCurrent>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2018-07-01to2019-03-31" unitRef="USD" decimals="0">-35000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2017-07-01to2018-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2018-07-01to2019-03-31_us-gaap_StockOptionMember128077054" unitRef="USD" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2019-03-31_us-gaap_StockOptionMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfSharesInPrivatePlacementShares contextRef="From2017-07-01to2017-09-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <bivi:IssuanceOfSharesInPrivatePlacementShares contextRef="From2017-10-01to2017-12-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <bivi:IssuanceOfSharesInPrivatePlacementShares contextRef="From2018-01-01to2018-03-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <bivi:IssuanceOfSharesInPrivatePlacementShares contextRef="From2017-07-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1169091</bivi:IssuanceOfSharesInPrivatePlacementShares>
    <bivi:IssuanceOfSharesInPrivatePlacementShares contextRef="From2017-10-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">227273</bivi:IssuanceOfSharesInPrivatePlacementShares>
    <bivi:IssuanceOfSharesInPrivatePlacementShares contextRef="From2018-01-01to2018-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">333333</bivi:IssuanceOfSharesInPrivatePlacementShares>
    <bivi:IssuanceOfSharesInPrivatePlacementShares contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">2133332</bivi:IssuanceOfSharesInPrivatePlacementShares>
    <bivi:IssuanceOfSharesInPrivatePlacementShares contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2017-07-01to2017-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2017-10-01to2017-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2018-01-01to2018-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2017-07-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">117</bivi:IssuanceOfSharesInPrivatePlacement>
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2017-10-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">23</bivi:IssuanceOfSharesInPrivatePlacement>
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2018-01-01to2018-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">33</bivi:IssuanceOfSharesInPrivatePlacement>
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="0">245000</bivi:IssuanceOfSharesInPrivatePlacement>
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">50000</bivi:IssuanceOfSharesInPrivatePlacement>
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2018-01-01to2018-03-31" unitRef="USD" decimals="0">50000</bivi:IssuanceOfSharesInPrivatePlacement>
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2017-07-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">244883</bivi:IssuanceOfSharesInPrivatePlacement>
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2017-10-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">49977</bivi:IssuanceOfSharesInPrivatePlacement>
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2018-01-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">49967</bivi:IssuanceOfSharesInPrivatePlacement>
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2017-07-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2017-10-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2018-01-01to2018-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">3200000</bivi:IssuanceOfSharesInPrivatePlacement>
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3200000</bivi:IssuanceOfSharesInPrivatePlacement>
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfSharesInPrivatePlacement contextRef="From2018-07-01to2018-09-30" unitRef="USD" decimals="0">3200000</bivi:IssuanceOfSharesInPrivatePlacement>
    <us-gaap:ShareBasedCompensation contextRef="From2017-07-01to2017-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2017-10-01to2017-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2017-07-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2017-10-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="0">12752</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">27021</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">43609</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-03-31" unitRef="USD" decimals="0">152062</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-07-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">12752</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-10-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">27021</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">152062</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">43609</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-07-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2017-10-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">16285</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-10-01to2018-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-10-01to2018-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3412</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-10-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">16285</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-10-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2018-09-30" unitRef="USD" decimals="0">3412</us-gaap:ShareBasedCompensation>
    <bivi:IssuanceOfWarrantsInPrivatePlacement contextRef="From2017-10-01to2017-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfWarrantsInPrivatePlacement contextRef="From2017-10-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfWarrantsInPrivatePlacement contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">100000</bivi:IssuanceOfWarrantsInPrivatePlacement>
    <bivi:IssuanceOfWarrantsInPrivatePlacement contextRef="From2017-10-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">100000</bivi:IssuanceOfWarrantsInPrivatePlacement>
    <bivi:IssuanceOfWarrantsInPrivatePlacement contextRef="From2017-10-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:ConversionOfPreferredStockToCommonStockShares contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">-2133332</bivi:ConversionOfPreferredStockToCommonStockShares>
    <bivi:ConversionOfPreferredStockToCommonStockShares contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">213333200</bivi:ConversionOfPreferredStockToCommonStockShares>
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">-3200000</bivi:ConversionOfPreferredStockToCommonStock>
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">21333</bivi:ConversionOfPreferredStockToCommonStock>
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-21333</bivi:ConversionOfPreferredStockToCommonStock>
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <bivi:SettlementOfDebtByIssuanceOfCommonStockShares contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <bivi:SettlementOfDebtByIssuanceOfCommonStockShares contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">975361</bivi:SettlementOfDebtByIssuanceOfCommonStockShares>
    <bivi:CashlessExerciseOfWarrantsShares contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <bivi:CashlessExerciseOfWarrantsShares contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2241913</bivi:CashlessExerciseOfWarrantsShares>
    <dei:AmendmentDescription contextRef="From2018-07-01to2019-03-31">Updated to reflect changes incorporated subsequent to previous amendment</dei:AmendmentDescription>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>bivi-20190331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: bivi%2D20190331.xfr; Date: 2019%2D07%2D01T15:40:01Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanoantibiotics.com/role/DocumentAndEntityInformation" xlink:href="bivi-20190331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheets" xlink:href="bivi-20190331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheetsParenthetical" xlink:href="bivi-20190331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfOperation" xlink:href="bivi-20190331.xsd#StatementsOfOperation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementOfChangesInStockholdersEquity" xlink:href="bivi-20190331.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementOfCashFlows" xlink:href="bivi-20190331.xsd#StatementOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BackgroundInformation" xlink:href="bivi-20190331.xsd#BackgroundInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/Liquidity" xlink:href="bivi-20190331.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:href="bivi-20190331.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssets" xlink:href="bivi-20190331.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/DemandNote" xlink:href="bivi-20190331.xsd#DemandNote" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:href="bivi-20190331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:href="bivi-20190331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquity" xlink:href="bivi-20190331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxes" xlink:href="bivi-20190331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SubsequentEvents" xlink:href="bivi-20190331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:href="bivi-20190331.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:href="bivi-20190331.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:href="bivi-20190331.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquityTables" xlink:href="bivi-20190331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesTables" xlink:href="bivi-20190331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/LiquidityDetailsNarrative" xlink:href="bivi-20190331.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:href="bivi-20190331.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:href="bivi-20190331.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:href="bivi-20190331.xsd#IntangibleAssetsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquityDetails" xlink:href="bivi-20190331.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquityDetails2" xlink:href="bivi-20190331.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:href="bivi-20190331.xsd#EquityTransactionsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquityDetails4" xlink:href="bivi-20190331.xsd#StockholdersEquityDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails" xlink:href="bivi-20190331.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails2" xlink:href="bivi-20190331.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapNotesPayableRelatedPartiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfOperation" xlink:title="00000004 - Statement - STATEMENTS OF OPERATION (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInterestAndDividendIncome" xlink:label="loc_us-gaapOtherInterestAndDividendIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherExpenses" xlink:to="loc_us-gaapOtherInterestAndDividendIncome" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherExpenses" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherExpenses" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DeemedDividend" xlink:label="loc_biviDeemedDividend" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_biviDeemedDividend" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementOfCashFlows" xlink:title="00000006 - Statement - STATEMENT OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaapRepaymentsOfShortTermDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfShortTermDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ProceedsFromDemandPromissoryNote" xlink:label="loc_biviProceedsFromDemandPromissoryNote" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_biviProceedsFromDemandPromissoryNote" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BackgroundInformation" xlink:title="00000007 - Disclosure - Background Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/Liquidity" xlink:title="00000008 - Disclosure - Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssets" xlink:title="00000010 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/DemandNote" xlink:title="00000011 - Disclosure - Demand Note" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders' Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:title="00000019 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquityTables" xlink:title="00000020 - Disclosure - Stockholders' Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesTables" xlink:title="00000021 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/LiquidityDetailsNarrative" xlink:title="00000022 - Disclosure - Liquidity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:title="00000024 - Disclosure - Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:title="00000025 - Disclosure - Intangible Assets (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquityDetails" xlink:title="00000026 - Disclosure - Stockholders' Equity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquityDetails2" xlink:title="00000027 - Disclosure - Stockholders' Equity (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:title="00000028 - Disclosure - Equity Transactions (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquityDetails4" xlink:title="00000029 - Disclosure - Stockholders' Equity (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetails" xlink:title="00000030 - Disclosure - Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetails2" xlink:title="00000031 - Disclosure - Income Taxes (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>bivi-20190331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: bivi%2D20190331.xfr; Date: 2019%2D07%2D01T15:40:01Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanoantibiotics.com/role/DocumentAndEntityInformation" xlink:href="bivi-20190331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheets" xlink:href="bivi-20190331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheetsParenthetical" xlink:href="bivi-20190331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfOperation" xlink:href="bivi-20190331.xsd#StatementsOfOperation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementOfChangesInStockholdersEquity" xlink:href="bivi-20190331.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementOfCashFlows" xlink:href="bivi-20190331.xsd#StatementOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BackgroundInformation" xlink:href="bivi-20190331.xsd#BackgroundInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/Liquidity" xlink:href="bivi-20190331.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:href="bivi-20190331.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssets" xlink:href="bivi-20190331.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/DemandNote" xlink:href="bivi-20190331.xsd#DemandNote" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:href="bivi-20190331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:href="bivi-20190331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquity" xlink:href="bivi-20190331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxes" xlink:href="bivi-20190331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SubsequentEvents" xlink:href="bivi-20190331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:href="bivi-20190331.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:href="bivi-20190331.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:href="bivi-20190331.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquityTables" xlink:href="bivi-20190331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesTables" xlink:href="bivi-20190331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/LiquidityDetailsNarrative" xlink:href="bivi-20190331.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:href="bivi-20190331.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:href="bivi-20190331.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:href="bivi-20190331.xsd#IntangibleAssetsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquityDetails" xlink:href="bivi-20190331.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquityDetails2" xlink:href="bivi-20190331.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:href="bivi-20190331.xsd#EquityTransactionsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquityDetails4" xlink:href="bivi-20190331.xsd#StockholdersEquityDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails" xlink:href="bivi-20190331.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails2" xlink:href="bivi-20190331.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfOperation" xlink:title="00000004 - Statement - STATEMENTS OF OPERATION (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfSharesInPrivatePlacement" xlink:label="loc_biviIssuanceOfSharesInPrivatePlacement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfSharesInPrivatePlacement_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfSharesInPrivatePlacementShares" xlink:label="loc_biviIssuanceOfSharesInPrivatePlacementShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfSharesInPrivatePlacementShares_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfWarrantsInPrivatePlacement" xlink:label="loc_biviIssuanceOfWarrantsInPrivatePlacement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfWarrantsInPrivatePlacement_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_OptionVested" xlink:label="loc_biviOptionVested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviOptionVested_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfWarrantsForServices" xlink:label="loc_biviIssuanceOfWarrantsForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfWarrantsForServices_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfWarrantsWithDebt" xlink:label="loc_biviIssuanceOfWarrantsWithDebt_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfWarrantsWithDebt_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DeemedDividendsForRatchetAdjustmentToWarrants" xlink:label="loc_biviDeemedDividendsForRatchetAdjustmentToWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviDeemedDividendsForRatchetAdjustmentToWarrants_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ConversionOfPreferredStockToCommonStock" xlink:label="loc_biviConversionOfPreferredStockToCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviConversionOfPreferredStockToCommonStock_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ConversionOfPreferredStockToCommonStockShares" xlink:label="loc_biviConversionOfPreferredStockToCommonStockShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviConversionOfPreferredStockToCommonStockShares_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SettlementOfDebtByIssuanceOfCommonStock" xlink:label="loc_biviSettlementOfDebtByIssuanceOfCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSettlementOfDebtByIssuanceOfCommonStock_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SettlementOfDebtByIssuanceOfCommonStockShares" xlink:label="loc_biviSettlementOfDebtByIssuanceOfCommonStockShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSettlementOfDebtByIssuanceOfCommonStockShares_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_CashlessExerciseOfWarrants" xlink:label="loc_biviCashlessExerciseOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfWarrants_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_CashlessExerciseOfWarrantsShares" xlink:label="loc_biviCashlessExerciseOfWarrantsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfWarrantsShares_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_60" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementOfCashFlows" xlink:title="00000006 - Statement - STATEMENT OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BackgroundInformation" xlink:title="00000007 - Disclosure - Background Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/Liquidity" xlink:title="00000008 - Disclosure - Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssets" xlink:title="00000010 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/DemandNote" xlink:title="00000011 - Disclosure - Demand Note" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders' Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:title="00000019 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquityTables" xlink:title="00000020 - Disclosure - Stockholders' Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesTables" xlink:title="00000021 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/LiquidityDetailsNarrative" xlink:title="00000022 - Disclosure - Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_AcuitasGroupHoldingsLLCAndOtherPurchaserMember" xlink:label="loc_biviAcuitasGroupHoldingsLLCAndOtherPurchaserMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_biviAcuitasGroupHoldingsLLCAndOtherPurchaserMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_20" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:title="00000024 - Disclosure - Intangible Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:title="00000025 - Disclosure - Intangible Assets (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquityDetails" xlink:title="00000026 - Disclosure - Stockholders' Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionNineMember" xlink:label="loc_biviStockOptionNineMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionNineMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionEightMember" xlink:label="loc_biviStockOptionEightMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionEightMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionSixMember" xlink:label="loc_biviStockOptionSixMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSixMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionFiveMember" xlink:label="loc_biviStockOptionFiveMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFiveMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionFourMember" xlink:label="loc_biviStockOptionFourMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFourMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionThreeMember" xlink:label="loc_biviStockOptionThreeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionThreeMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionTwoMember" xlink:label="loc_biviStockOptionTwoMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionTwoMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionSevenMember" xlink:label="loc_biviStockOptionSevenMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSevenMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionOneMember" xlink:label="loc_biviStockOptionOneMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionOneMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_400" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_400" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_400" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_400" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_400" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_400" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_400" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_400" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_400" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_400" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_400" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_400" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3_400" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_400" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_400" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_400" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_400" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_400" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_400" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquityDetails2" xlink:title="00000027 - Disclosure - Stockholders' Equity (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionSixMember" xlink:label="loc_biviStockOptionSixMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSixMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionNineMember" xlink:label="loc_biviStockOptionNineMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionNineMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionEightMember" xlink:label="loc_biviStockOptionEightMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionEightMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionSevenMember" xlink:label="loc_biviStockOptionSevenMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSevenMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionFiveMember" xlink:label="loc_biviStockOptionFiveMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFiveMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionOneMember" xlink:label="loc_biviStockOptionOneMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionOneMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionTwoMember" xlink:label="loc_biviStockOptionTwoMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionTwoMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionThreeMember" xlink:label="loc_biviStockOptionThreeMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionThreeMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionFourMember" xlink:label="loc_biviStockOptionFourMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFourMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantThreeMember" xlink:label="loc_biviWarrantThreeMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_biviWarrantThreeMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantTwoMember" xlink:label="loc_biviWarrantTwoMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_biviWarrantTwoMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantOneMember" xlink:label="loc_biviWarrantOneMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_biviWarrantOneMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_investInvestmentOptionsExercisePrice_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_investInvestmentOptionsExercisePrice_530" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_530" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_530" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_530" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_530" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_530" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_530" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:title="00000028 - Disclosure - Equity Transactions (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionThreeMember" xlink:label="loc_biviStockOptionThreeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionThreeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionNineMember" xlink:label="loc_biviStockOptionNineMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionNineMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionEightMember" xlink:label="loc_biviStockOptionEightMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionEightMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionSevenMember" xlink:label="loc_biviStockOptionSevenMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSevenMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionSixMember" xlink:label="loc_biviStockOptionSixMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSixMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionFiveMember" xlink:label="loc_biviStockOptionFiveMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFiveMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionFourMember" xlink:label="loc_biviStockOptionFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionOneMember" xlink:label="loc_biviStockOptionOneMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionOneMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionTwoMember" xlink:label="loc_biviStockOptionTwoMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionTwoMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_investInvestmentOptionsExercisePrice_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_investInvestmentOptionsExercisePrice_400" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_400" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_400" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_400" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquityDetails4" xlink:title="00000029 - Disclosure - Stockholders' Equity (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantThreeMember" xlink:label="loc_biviWarrantThreeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_biviWarrantThreeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantOneMember" xlink:label="loc_biviWarrantOneMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_biviWarrantOneMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantTwoMember" xlink:label="loc_biviWarrantTwoMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_biviWarrantTwoMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_140" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_140" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetails" xlink:title="00000030 - Disclosure - Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetails2" xlink:title="00000031 - Disclosure - Income Taxes (Details 2)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>bivi-20190331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: bivi%2D20190331.xfr; Date: 2019%2D07%2D01T15:40:01Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionOneMember" xlink:label="bivi_StockOptionOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionOneMember" xlink:to="bivi_StockOptionOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionOneMember_lbl" xml:lang="en-US">StockOptionOneMember</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionTwoMember" xlink:label="bivi_StockOptionTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionTwoMember" xlink:to="bivi_StockOptionTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionTwoMember_lbl" xml:lang="en-US">StockOptionTwoMember</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionThreeMember" xlink:label="bivi_StockOptionThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionThreeMember" xlink:to="bivi_StockOptionThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionThreeMember_lbl" xml:lang="en-US">StockOptionThreeMember</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionFourMember" xlink:label="bivi_StockOptionFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionFourMember" xlink:to="bivi_StockOptionFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionFourMember_lbl" xml:lang="en-US">StockOptionFourMember</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionFiveMember" xlink:label="bivi_StockOptionFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionFiveMember" xlink:to="bivi_StockOptionFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionFiveMember_lbl" xml:lang="en-US">StockOptionFiveMember</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionSixMember" xlink:label="bivi_StockOptionSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionSixMember" xlink:to="bivi_StockOptionSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionSixMember_lbl" xml:lang="en-US">StockOptionSixMember</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionSevenMember" xlink:label="bivi_StockOptionSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionSevenMember" xlink:to="bivi_StockOptionSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionSevenMember_lbl" xml:lang="en-US">StockOptionSevenMember</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionEightMember" xlink:label="bivi_StockOptionEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionEightMember" xlink:to="bivi_StockOptionEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionEightMember_lbl" xml:lang="en-US">StockOptionEightMember</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionNineMember" xlink:label="bivi_StockOptionNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionNineMember" xlink:to="bivi_StockOptionNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionNineMember_lbl" xml:lang="en-US">StockOptionNineMember</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Capital in Excess of Par Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_AcuitasGroupHoldingsLLCAndOtherPurchaserMember" xlink:label="bivi_AcuitasGroupHoldingsLLCAndOtherPurchaserMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AcuitasGroupHoldingsLLCAndOtherPurchaserMember" xlink:to="bivi_AcuitasGroupHoldingsLLCAndOtherPurchaserMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_AcuitasGroupHoldingsLLCAndOtherPurchaserMember_lbl" xml:lang="en-US">Acuitas Group Holdings, LLC and Other Purchaser [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantOneMember" xlink:label="bivi_WarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_WarrantOneMember" xlink:to="bivi_WarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_WarrantOneMember_lbl" xml:lang="en-US">WarrantOneMember</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantTwoMember" xlink:label="bivi_WarrantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_WarrantTwoMember" xlink:to="bivi_WarrantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_WarrantTwoMember_lbl" xml:lang="en-US">WarrantTwoMember</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantThreeMember" xlink:label="bivi_WarrantThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_WarrantThreeMember" xlink:to="bivi_WarrantThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_WarrantThreeMember_lbl" xml:lang="en-US">WarrantThreeMember</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DocumentAndEntityInformationAbstract" xlink:label="bivi_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DocumentAndEntityInformationAbstract" xlink:to="bivi_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">OTHER ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets (Net of Amortization)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Related Party Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Payroll</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Demand Promissory Note</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl" xml:lang="en-US">Notes Payable, Related Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Long Term Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 300,000,000; 300,000,000 and 800,000,000 shares authorized; 98,503,199; 91,925,000 and 316,453,673 shares issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">REVENUE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Payroll expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">TOTAL OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">OTHER EXPENSE (INCOME)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInterestAndDividendIncome" xlink:label="us-gaap_OtherInterestAndDividendIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInterestAndDividendIncome" xlink:to="us-gaap_OtherInterestAndDividendIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherInterestAndDividendIncome_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">TOTAL OTHER EXPENSE (INCOME)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DeemedDividend" xlink:label="bivi_DeemedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividend" xlink:to="bivi_DeemedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DeemedDividend_lbl" xml:lang="en-US">Deemed dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO COMPANY STOCKHOLDERS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE, BASIC AND DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning Balance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of shares and warrants for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of shares and warrants for cash, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfSharesInPrivatePlacement" xlink:label="bivi_IssuanceOfSharesInPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfSharesInPrivatePlacement" xlink:to="bivi_IssuanceOfSharesInPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfSharesInPrivatePlacement_lbl" xml:lang="en-US">Issuance of shares in a private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfSharesInPrivatePlacementShares" xlink:label="bivi_IssuanceOfSharesInPrivatePlacementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfSharesInPrivatePlacementShares" xlink:to="bivi_IssuanceOfSharesInPrivatePlacementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfSharesInPrivatePlacementShares_lbl" xml:lang="en-US">Issuance of shares in a private placement, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of shares for services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of shares for services, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfWarrantsInPrivatePlacement" xlink:label="bivi_IssuanceOfWarrantsInPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfWarrantsInPrivatePlacement" xlink:to="bivi_IssuanceOfWarrantsInPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfWarrantsInPrivatePlacement_lbl" xml:lang="en-US">Issuance of warrants in a private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_OptionVested" xlink:label="bivi_OptionVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_OptionVested" xlink:to="bivi_OptionVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_OptionVested_lbl" xml:lang="en-US">Options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options for cash, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfWarrantsForServices" xlink:label="bivi_IssuanceOfWarrantsForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfWarrantsForServices" xlink:to="bivi_IssuanceOfWarrantsForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfWarrantsForServices_lbl" xml:lang="en-US">Issuance of warrants for services</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfWarrantsWithDebt" xlink:label="bivi_IssuanceOfWarrantsWithDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfWarrantsWithDebt" xlink:to="bivi_IssuanceOfWarrantsWithDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfWarrantsWithDebt_lbl" xml:lang="en-US">Issuance of warrants with debt</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DeemedDividendsForRatchetAdjustmentToWarrants" xlink:label="bivi_DeemedDividendsForRatchetAdjustmentToWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividendsForRatchetAdjustmentToWarrants" xlink:to="bivi_DeemedDividendsForRatchetAdjustmentToWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DeemedDividendsForRatchetAdjustmentToWarrants_lbl" xml:lang="en-US">Deemed dividends for ratchet adjustment to warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ConversionOfPreferredStockToCommonStock" xlink:label="bivi_ConversionOfPreferredStockToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConversionOfPreferredStockToCommonStock" xlink:to="bivi_ConversionOfPreferredStockToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ConversionOfPreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ConversionOfPreferredStockToCommonStockShares" xlink:label="bivi_ConversionOfPreferredStockToCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConversionOfPreferredStockToCommonStockShares" xlink:to="bivi_ConversionOfPreferredStockToCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ConversionOfPreferredStockToCommonStockShares_lbl" xml:lang="en-US">Conversion of preferred stock to common stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SettlementOfDebtByIssuanceOfCommonStock" xlink:label="bivi_SettlementOfDebtByIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SettlementOfDebtByIssuanceOfCommonStock" xlink:to="bivi_SettlementOfDebtByIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SettlementOfDebtByIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of shares in exchange for debt settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SettlementOfDebtByIssuanceOfCommonStockShares" xlink:label="bivi_SettlementOfDebtByIssuanceOfCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SettlementOfDebtByIssuanceOfCommonStockShares" xlink:to="bivi_SettlementOfDebtByIssuanceOfCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SettlementOfDebtByIssuanceOfCommonStockShares_lbl" xml:lang="en-US">Issuance of shares in exchange for debt settlement, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock option compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_CashlessExerciseOfWarrants" xlink:label="bivi_CashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CashlessExerciseOfWarrants" xlink:to="bivi_CashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_CashlessExerciseOfWarrants_lbl" xml:lang="en-US">Cashless exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_CashlessExerciseOfWarrantsShares" xlink:label="bivi_CashlessExerciseOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CashlessExerciseOfWarrantsShares" xlink:to="bivi_CashlessExerciseOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_CashlessExerciseOfWarrantsShares_lbl" xml:lang="en-US">Cashless exercise of warrants, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending Balance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash to cash used by operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Services paid with common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Increase in prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued Payroll</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used by operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US">Repayment of loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from issuance of preferred shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ProceedsFromDemandPromissoryNote" xlink:label="bivi_ProceedsFromDemandPromissoryNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ProceedsFromDemandPromissoryNote" xlink:to="bivi_ProceedsFromDemandPromissoryNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ProceedsFromDemandPromissoryNote_lbl" xml:lang="en-US">Proceeds from demand promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xml:lang="en-US">Proceeds from exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net decrease in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ConversionOfPreferredSharesToCommonStock" xlink:label="bivi_ConversionOfPreferredSharesToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConversionOfPreferredSharesToCommonStock" xlink:to="bivi_ConversionOfPreferredSharesToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ConversionOfPreferredSharesToCommonStock_lbl" xml:lang="en-US">Conversion of preferred shares to common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SettlementOfDebtByIssuanceOfCommonStock" xlink:to="bivi_SettlementOfDebtByIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_SettlementOfDebtByIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Settlement of debt by issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" xlink:label="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" xlink:to="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants_lbl" xml:lang="en-US">Deemed dividends for ratchet adjustments to warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_NotesToFinancialStatementsAbstract" xlink:label="bivi_NotesToFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_NotesToFinancialStatementsAbstract" xlink:to="bivi_NotesToFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Background Information</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_LiquidityTextBlock" xlink:label="bivi_LiquidityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LiquidityTextBlock" xlink:to="bivi_LiquidityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_LiquidityTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DemandNoteTextBlock" xlink:label="bivi_DemandNoteTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DemandNoteTextBlock" xlink:to="bivi_DemandNoteTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DemandNoteTextBlock_lbl" xml:lang="en-US">Demand Note</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:label="bivi_UnauditedInterimFinancialStatementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:to="bivi_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US">Unaudited Interim Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Long-Term Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings (Loss) per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent accounting pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureSignificantAccountingPoliciesTablesAbstract" xlink:label="bivi_DisclosureSignificantAccountingPoliciesTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureSignificantAccountingPoliciesTablesAbstract" xlink:to="bivi_DisclosureSignificantAccountingPoliciesTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureSignificantAccountingPoliciesTablesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Dilutive securities were excluded from the computation of diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureIntangibleAssetsTablesAbstract" xlink:label="bivi_DisclosureIntangibleAssetsTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIntangibleAssetsTablesAbstract" xlink:to="bivi_DisclosureIntangibleAssetsTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureIntangibleAssetsTablesAbstract_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Future expected Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock options activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of stock option plans by exercise price range</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of gross amounts of deferred tax assets and deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Reconciliation of the federal statutory income tax rate to income tax expense expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_lbl" xml:lang="en-US">Warrants to be Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Total Consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Dilutive Securities excluded from the Computation of Diluted Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureIntangibleAssetsDetailsAbstract" xlink:label="bivi_DisclosureIntangibleAssetsDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIntangibleAssetsDetailsAbstract" xlink:to="bivi_DisclosureIntangibleAssetsDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureIntangibleAssetsDetailsAbstract_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Intangible Assets subject to Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureIntangibleAssetsDetails2Abstract" xlink:label="bivi_DisclosureIntangibleAssetsDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIntangibleAssetsDetails2Abstract" xlink:to="bivi_DisclosureIntangibleAssetsDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureIntangibleAssetsDetails2Abstract_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Option Outstanding at beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Option Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Option Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Option Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Option Outstanding at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Option Excersiable at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding Weighted Average Exercise Price at the beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding Weighted Average Exercise Price at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Excersiable Weighted Average Exercise Price at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term at the beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Excerised</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Excersiable Weighted Average Remaining Contractual Term at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Options Exercised or Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="invest_InvestmentOptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="invest_InvestmentOptionsExercisePrice" xlink:to="invest_InvestmentOptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="invest_InvestmentOptionsExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Option Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Weighted Average Contractual Life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xml:lang="en-US">Option Excersiable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xml:lang="en-US">Warrant, Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Warrant, Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_lbl" xml:lang="en-US">Warrant, Weighted Average Contractual Life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Warrant Outstanding at the beginning of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Warrant Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Warrant Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Warrant Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Warrant Outstanding at the end of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2_lbl" xml:lang="en-US">Weighted Average Exercise Price at the beginning of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_3_lbl" xml:lang="en-US">Weighted Average Exercise Price at the end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Remaining Life at the beginning of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_lbl" xml:lang="en-US">Weighted Average Remaining Life, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_2_lbl" xml:lang="en-US">Weighted Average Remaining Life at the end of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax expense (benefit) at U.S. statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax expense (benefit), net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureIncomeTaxesDetails2Abstract" xlink:label="bivi_DisclosureIncomeTaxesDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIncomeTaxesDetails2Abstract" xlink:to="bivi_DisclosureIncomeTaxesDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DisclosureIncomeTaxesDetails2Abstract_lbl" xml:lang="en-US">Income Taxes Details 2</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Tax loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AcuitasGroupHoldingsLLCAndOtherPurchaserMember" xlink:to="bivi_AcuitasGroupHoldingsLLCAndOtherPurchaserMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_AcuitasGroupHoldingsLLCAndOtherPurchaserMember_doc" xml:lang="en-US">Acuitas Group Holding, LLC and Other Purchaser [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CashlessExerciseOfWarrants" xlink:to="bivi_CashlessExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_CashlessExerciseOfWarrants_doc" xml:lang="en-US">Cashless Exercise of Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CashlessExerciseOfWarrantsShares" xlink:to="bivi_CashlessExerciseOfWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_CashlessExerciseOfWarrantsShares_doc" xml:lang="en-US">Cashless Exercise of Warrants, Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConversionOfPreferredSharesToCommonStock" xlink:to="bivi_ConversionOfPreferredSharesToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ConversionOfPreferredSharesToCommonStock_doc" xml:lang="en-US">Conversion Of Preferred Shares To Common Stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConversionOfPreferredStockToCommonStock" xlink:to="bivi_ConversionOfPreferredStockToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ConversionOfPreferredStockToCommonStock_doc" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConversionOfPreferredStockToCommonStockShares" xlink:to="bivi_ConversionOfPreferredStockToCommonStockShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ConversionOfPreferredStockToCommonStockShares_doc" xml:lang="en-US">Conversion of preferred stock to common stock, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividend" xlink:to="bivi_DeemedDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_DeemedDividend_doc" xml:lang="en-US">Deemed Dividend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" xlink:to="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants_doc" xml:lang="en-US">Deemed Dividends for Ratchet Adjustments to Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividendsForRatchetAdjustmentToWarrants" xlink:to="bivi_DeemedDividendsForRatchetAdjustmentToWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_DeemedDividendsForRatchetAdjustmentToWarrants_doc" xml:lang="en-US">Deemed Dividends for Ratchet Adjustment to Warrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DemandNoteTextBlock" xlink:to="bivi_DemandNoteTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_DemandNoteTextBlock_doc" xml:lang="en-US">Demand Note [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfSharesInPrivatePlacement" xlink:to="bivi_IssuanceOfSharesInPrivatePlacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_IssuanceOfSharesInPrivatePlacement_doc" xml:lang="en-US">Issuance of preferred stock in a private placement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfSharesInPrivatePlacementShares" xlink:to="bivi_IssuanceOfSharesInPrivatePlacementShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_IssuanceOfSharesInPrivatePlacementShares_doc" xml:lang="en-US">Issuance of preferred stock in a private placement, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfWarrantsForServices" xlink:to="bivi_IssuanceOfWarrantsForServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_IssuanceOfWarrantsForServices_doc" xml:lang="en-US">Issuance of Warrants for Service</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfWarrantsInPrivatePlacement" xlink:to="bivi_IssuanceOfWarrantsInPrivatePlacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_IssuanceOfWarrantsInPrivatePlacement_doc" xml:lang="en-US">Issuance of warrants in a private placement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfWarrantsWithDebt" xlink:to="bivi_IssuanceOfWarrantsWithDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_IssuanceOfWarrantsWithDebt_doc" xml:lang="en-US">Issuance of Warrant with Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_LATPharmaIncMember" xlink:label="bivi_LATPharmaIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LATPharmaIncMember" xlink:to="bivi_LATPharmaIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_LATPharmaIncMember_doc" xml:lang="en-US">LAT Pharma, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LiquidityTextBlock" xlink:to="bivi_LiquidityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_LiquidityTextBlock_doc" xml:lang="en-US">Liquidity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_OptionVested" xlink:to="bivi_OptionVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_OptionVested_doc" xml:lang="en-US">Option Vested.</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_PrepaidServicesPaidWithCommonStockMember" xlink:label="bivi_PrepaidServicesPaidWithCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_PrepaidServicesPaidWithCommonStockMember" xlink:to="bivi_PrepaidServicesPaidWithCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_PrepaidServicesPaidWithCommonStockMember_doc" xml:lang="en-US">Prepaid Services Paid Common Stock Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ProceedsFromDemandPromissoryNote" xlink:to="bivi_ProceedsFromDemandPromissoryNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ProceedsFromDemandPromissoryNote_doc" xml:lang="en-US">Proceeds from Demand Promissory Note</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SettlementOfDebtByIssuanceOfCommonStock" xlink:to="bivi_SettlementOfDebtByIssuanceOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_SettlementOfDebtByIssuanceOfCommonStock_doc" xml:lang="en-US">Settlement Of Debt By Issuance Of Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SettlementOfDebtByIssuanceOfCommonStockShares" xlink:to="bivi_SettlementOfDebtByIssuanceOfCommonStockShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_SettlementOfDebtByIssuanceOfCommonStockShares_doc" xml:lang="en-US">Issuance of shares in exchange for debt settlement, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_doc" xml:lang="en-US">Per share weighted average intrinsic value of equity-based compensation awards excersied. Excludes stock and unit options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted, Weighted Average Remaining Contractual Terms</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Excerised, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionEightMember" xlink:to="bivi_StockOptionEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionEightMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionFiveMember" xlink:to="bivi_StockOptionFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionFiveMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionFourMember" xlink:to="bivi_StockOptionFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionFourMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionNineMember" xlink:to="bivi_StockOptionNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionNineMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionOneMember" xlink:to="bivi_StockOptionOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionOneMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionSevenMember" xlink:to="bivi_StockOptionSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionSevenMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionSixMember" xlink:to="bivi_StockOptionSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionSixMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionTenMember" xlink:label="bivi_StockOptionTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionTenMember" xlink:to="bivi_StockOptionTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionTenMember_doc" xml:lang="en-US">Stock Option Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionThreeMember" xlink:to="bivi_StockOptionThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionThreeMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionTwoMember" xlink:to="bivi_StockOptionTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionTwoMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:to="bivi_UnauditedInterimFinancialStatementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_UnauditedInterimFinancialStatementsPolicyTextBlock_doc" xml:lang="en-US">Unaudited Interim Financial Statements [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_WarrantOneMember" xlink:to="bivi_WarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_WarrantOneMember_doc" xml:lang="en-US">Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_WarrantThreeMember" xlink:to="bivi_WarrantThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_WarrantThreeMember_doc" xml:lang="en-US">Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_WarrantTwoMember" xlink:to="bivi_WarrantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_WarrantTwoMember_doc" xml:lang="en-US">Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInterestAndDividendIncome" xlink:to="us-gaap_OtherInterestAndDividendIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInterestAndDividendIncome_2_lbl" xml:lang="en-US">Other Interest and Dividend Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_2_lbl" xml:lang="en-US">Interest Income, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_2_lbl" xml:lang="en-US">Other Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_2_lbl" xml:lang="en-US">Repayments of Short-term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>bivi-20190331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: bivi%2D20190331.xfr; Date: 2019%2D07%2D01T15:40:01Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanoantibiotics.com/role/DocumentAndEntityInformation" xlink:href="bivi-20190331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheets" xlink:href="bivi-20190331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheetsParenthetical" xlink:href="bivi-20190331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfOperation" xlink:href="bivi-20190331.xsd#StatementsOfOperation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementOfChangesInStockholdersEquity" xlink:href="bivi-20190331.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementOfCashFlows" xlink:href="bivi-20190331.xsd#StatementOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BackgroundInformation" xlink:href="bivi-20190331.xsd#BackgroundInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/Liquidity" xlink:href="bivi-20190331.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:href="bivi-20190331.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssets" xlink:href="bivi-20190331.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/DemandNote" xlink:href="bivi-20190331.xsd#DemandNote" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:href="bivi-20190331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:href="bivi-20190331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquity" xlink:href="bivi-20190331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxes" xlink:href="bivi-20190331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SubsequentEvents" xlink:href="bivi-20190331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:href="bivi-20190331.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:href="bivi-20190331.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:href="bivi-20190331.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquityTables" xlink:href="bivi-20190331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesTables" xlink:href="bivi-20190331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/LiquidityDetailsNarrative" xlink:href="bivi-20190331.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:href="bivi-20190331.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:href="bivi-20190331.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:href="bivi-20190331.xsd#IntangibleAssetsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquityDetails" xlink:href="bivi-20190331.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquityDetails2" xlink:href="bivi-20190331.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:href="bivi-20190331.xsd#EquityTransactionsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StockholdersEquityDetails4" xlink:href="bivi-20190331.xsd#StockholdersEquityDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails" xlink:href="bivi-20190331.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails2" xlink:href="bivi-20190331.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DocumentAndEntityInformationAbstract" xlink:label="loc_biviDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesNoncurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapNotesPayableRelatedPartiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfOperation" xlink:title="00000004 - Statement - STATEMENTS OF OPERATION (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaapOtherExpensesAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInterestAndDividendIncome" xlink:label="loc_us-gaapOtherInterestAndDividendIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapOtherInterestAndDividendIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DeemedDividend" xlink:label="loc_biviDeemedDividend" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_biviDeemedDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfSharesInPrivatePlacement" xlink:label="loc_biviIssuanceOfSharesInPrivatePlacement" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfSharesInPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfSharesInPrivatePlacementShares" xlink:label="loc_biviIssuanceOfSharesInPrivatePlacementShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfSharesInPrivatePlacementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfWarrantsInPrivatePlacement" xlink:label="loc_biviIssuanceOfWarrantsInPrivatePlacement" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfWarrantsInPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_OptionVested" xlink:label="loc_biviOptionVested" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviOptionVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfWarrantsForServices" xlink:label="loc_biviIssuanceOfWarrantsForServices" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfWarrantsForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfWarrantsWithDebt" xlink:label="loc_biviIssuanceOfWarrantsWithDebt" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfWarrantsWithDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DeemedDividendsForRatchetAdjustmentToWarrants" xlink:label="loc_biviDeemedDividendsForRatchetAdjustmentToWarrants" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviDeemedDividendsForRatchetAdjustmentToWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ConversionOfPreferredStockToCommonStock" xlink:label="loc_biviConversionOfPreferredStockToCommonStock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviConversionOfPreferredStockToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ConversionOfPreferredStockToCommonStockShares" xlink:label="loc_biviConversionOfPreferredStockToCommonStockShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviConversionOfPreferredStockToCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SettlementOfDebtByIssuanceOfCommonStock" xlink:label="loc_biviSettlementOfDebtByIssuanceOfCommonStock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSettlementOfDebtByIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SettlementOfDebtByIssuanceOfCommonStockShares" xlink:label="loc_biviSettlementOfDebtByIssuanceOfCommonStockShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSettlementOfDebtByIssuanceOfCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_CashlessExerciseOfWarrants" xlink:label="loc_biviCashlessExerciseOfWarrants" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_CashlessExerciseOfWarrantsShares" xlink:label="loc_biviCashlessExerciseOfWarrantsShares" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementOfCashFlows" xlink:title="00000006 - Statement - STATEMENT OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaapRepaymentsOfShortTermDebt" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfShortTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ProceedsFromDemandPromissoryNote" xlink:label="loc_biviProceedsFromDemandPromissoryNote" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_biviProceedsFromDemandPromissoryNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_IssuanceOfWarrantsWithDebt" xlink:label="loc_biviIssuanceOfWarrantsWithDebt" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_biviIssuanceOfWarrantsWithDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ConversionOfPreferredSharesToCommonStock" xlink:label="loc_biviConversionOfPreferredSharesToCommonStock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_biviConversionOfPreferredSharesToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SettlementOfDebtByIssuanceOfCommonStock" xlink:label="loc_biviSettlementOfDebtByIssuanceOfCommonStock" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_biviSettlementOfDebtByIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_CashlessExerciseOfWarrants" xlink:label="loc_biviCashlessExerciseOfWarrants" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_biviCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" xlink:label="loc_biviDeemedDividendsForRatchetAdjustmentsToWarrants" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_biviDeemedDividendsForRatchetAdjustmentsToWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BackgroundInformation" xlink:title="00000007 - Disclosure - Background Information">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_NotesToFinancialStatementsAbstract" xlink:label="loc_biviNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/Liquidity" xlink:title="00000008 - Disclosure - Liquidity">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_NotesToFinancialStatementsAbstract" xlink:label="loc_biviNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_LiquidityTextBlock" xlink:label="loc_biviLiquidityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviNotesToFinancialStatementsAbstract" xlink:to="loc_biviLiquidityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssets" xlink:title="00000010 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/DemandNote" xlink:title="00000011 - Disclosure - Demand Note">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_NotesToFinancialStatementsAbstract" xlink:label="loc_biviNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DemandNoteTextBlock" xlink:label="loc_biviDemandNoteTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviNotesToFinancialStatementsAbstract" xlink:to="loc_biviDemandNoteTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:label="loc_biviUnauditedInterimFinancialStatementsPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_biviUnauditedInterimFinancialStatementsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureSignificantAccountingPoliciesTablesAbstract" xlink:label="loc_biviDisclosureSignificantAccountingPoliciesTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureSignificantAccountingPoliciesTablesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:title="00000019 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureIntangibleAssetsTablesAbstract" xlink:label="loc_biviDisclosureIntangibleAssetsTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsTablesAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsTablesAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquityTables" xlink:title="00000020 - Disclosure - Stockholders' Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureStockOptionsTablesAbstract" xlink:label="loc_biviDisclosureStockOptionsTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureStockOptionsTablesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesTables" xlink:title="00000021 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/LiquidityDetailsNarrative" xlink:title="00000022 - Disclosure - Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureLiquidityDetailsNarrativeAbstract" xlink:label="loc_biviDisclosureLiquidityDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLiquidityDetailsNarrativeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_AcuitasGroupHoldingsLLCAndOtherPurchaserMember" xlink:label="loc_biviAcuitasGroupHoldingsLLCAndOtherPurchaserMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_biviAcuitasGroupHoldingsLLCAndOtherPurchaserMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract" xlink:label="loc_biviDisclosureSignificantAccountingPoliciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureSignificantAccountingPoliciesDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:title="00000024 - Disclosure - Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureIntangibleAssetsDetailsAbstract" xlink:label="loc_biviDisclosureIntangibleAssetsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:title="00000025 - Disclosure - Intangible Assets (Details 2)">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureIntangibleAssetsDetails2Abstract" xlink:label="loc_biviDisclosureIntangibleAssetsDetails2Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquityDetails" xlink:title="00000026 - Disclosure - Stockholders' Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureStockOptionsDetailsAbstract" xlink:label="loc_biviDisclosureStockOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureStockOptionsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionNineMember" xlink:label="loc_biviStockOptionNineMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionEightMember" xlink:label="loc_biviStockOptionEightMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionSixMember" xlink:label="loc_biviStockOptionSixMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionFiveMember" xlink:label="loc_biviStockOptionFiveMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionFourMember" xlink:label="loc_biviStockOptionFourMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionThreeMember" xlink:label="loc_biviStockOptionThreeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionTwoMember" xlink:label="loc_biviStockOptionTwoMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionSevenMember" xlink:label="loc_biviStockOptionSevenMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionOneMember" xlink:label="loc_biviStockOptionOneMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquityDetails2" xlink:title="00000027 - Disclosure - Stockholders' Equity (Details 2)">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureStockOptionsDetailsAbstract" xlink:label="loc_biviDisclosureStockOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureStockOptionsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionSixMember" xlink:label="loc_biviStockOptionSixMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionNineMember" xlink:label="loc_biviStockOptionNineMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionEightMember" xlink:label="loc_biviStockOptionEightMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionSevenMember" xlink:label="loc_biviStockOptionSevenMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionFiveMember" xlink:label="loc_biviStockOptionFiveMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionOneMember" xlink:label="loc_biviStockOptionOneMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionTwoMember" xlink:label="loc_biviStockOptionTwoMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionThreeMember" xlink:label="loc_biviStockOptionThreeMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionFourMember" xlink:label="loc_biviStockOptionFourMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantThreeMember" xlink:label="loc_biviWarrantThreeMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_biviWarrantThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantTwoMember" xlink:label="loc_biviWarrantTwoMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_biviWarrantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantOneMember" xlink:label="loc_biviWarrantOneMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_biviWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_investInvestmentOptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_investInvestmentOptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:title="00000028 - Disclosure - Equity Transactions (Details 3)">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureStockOptionsDetailsAbstract" xlink:label="loc_biviDisclosureStockOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureStockOptionsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionThreeMember" xlink:label="loc_biviStockOptionThreeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionNineMember" xlink:label="loc_biviStockOptionNineMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionEightMember" xlink:label="loc_biviStockOptionEightMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionSevenMember" xlink:label="loc_biviStockOptionSevenMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionSixMember" xlink:label="loc_biviStockOptionSixMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionFiveMember" xlink:label="loc_biviStockOptionFiveMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionFourMember" xlink:label="loc_biviStockOptionFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionOneMember" xlink:label="loc_biviStockOptionOneMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_StockOptionTwoMember" xlink:label="loc_biviStockOptionTwoMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_investInvestmentOptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_investInvestmentOptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StockholdersEquityDetails4" xlink:title="00000029 - Disclosure - Stockholders' Equity (Details 4)">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureStockholdersEquityDetails3Abstract" xlink:label="loc_biviDisclosureStockholdersEquityDetails3Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureStockholdersEquityDetails3Abstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantThreeMember" xlink:label="loc_biviWarrantThreeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_biviWarrantThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantOneMember" xlink:label="loc_biviWarrantOneMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_biviWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_WarrantTwoMember" xlink:label="loc_biviWarrantTwoMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_biviWarrantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetails" xlink:title="00000030 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetails2" xlink:title="00000031 - Disclosure - Income Taxes (Details 2)">
      <link:loc xlink:type="locator" xlink:href="bivi-20190331.xsd#bivi_DisclosureIncomeTaxesDetails2Abstract" xlink:label="loc_biviDisclosureIncomeTaxesDetails2Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIncomeTaxesDetails2Abstract" xlink:to="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>bivi-20190331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: bivi%2D20190331.xfr; Date: 2019%2D07%2D01T15:40:01Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +K4ps7xRiXhun8uMYntcWaqCKcPtz5B3SZlBtWh1fTmKPy4m/ryBWSGkfwQ24coO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:bivi="http://nanoantibiotics.com/20190331" elementFormDefault="qualified" targetNamespace="http://nanoantibiotics.com/20190331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://nanoantibiotics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StatementsOfOperation" id="StatementsOfOperation">
	  <link:definition>00000004 - Statement - STATEMENTS OF OPERATION (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StatementOfChangesInStockholdersEquity" id="StatementOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StatementOfCashFlows" id="StatementOfCashFlows">
	  <link:definition>00000006 - Statement - STATEMENT OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/BackgroundInformation" id="BackgroundInformation">
	  <link:definition>00000007 - Disclosure - Background Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/Liquidity" id="Liquidity">
	  <link:definition>00000008 - Disclosure - Liquidity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IntangibleAssets" id="IntangibleAssets">
	  <link:definition>00000010 - Disclosure - Intangible Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/DemandNote" id="DemandNote">
	  <link:definition>00000011 - Disclosure - Demand Note</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000012 - Disclosure - Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000013 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000014 - Disclosure - Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000015 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000016 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000017 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
	  <link:definition>00000018 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
	  <link:definition>00000019 - Disclosure - Intangible Assets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000020 - Disclosure - Stockholders' Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000021 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/LiquidityDetailsNarrative" id="LiquidityDetailsNarrative">
	  <link:definition>00000022 - Disclosure - Liquidity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" id="SignificantAccountingPoliciesDetails">
	  <link:definition>00000023 - Disclosure - Significant Accounting Policies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
	  <link:definition>00000024 - Disclosure - Intangible Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" id="IntangibleAssetsDetails2">
	  <link:definition>00000025 - Disclosure - Intangible Assets (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
	  <link:definition>00000026 - Disclosure - Stockholders' Equity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
	  <link:definition>00000027 - Disclosure - Stockholders' Equity (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails3" id="EquityTransactionsDetails3">
	  <link:definition>00000028 - Disclosure - Equity Transactions (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StockholdersEquityDetails4" id="StockholdersEquityDetails4">
	  <link:definition>00000029 - Disclosure - Stockholders' Equity (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000030 - Disclosure - Income Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
	  <link:definition>00000031 - Disclosure - Income Taxes (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20190331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20190331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20190331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20190331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
    <element id="bivi_OptionVested" name="OptionVested" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DeemedDividend" name="DeemedDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DeemedDividendsForRatchetAdjustmentToWarrants" name="DeemedDividendsForRatchetAdjustmentToWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfWarrantsForServices" name="IssuanceOfWarrantsForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfWarrantsWithDebt" name="IssuanceOfWarrantsWithDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ProceedsFromDemandPromissoryNote" name="ProceedsFromDemandPromissoryNote" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_LiquidityTextBlock" name="LiquidityTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DemandNoteTextBlock" name="DemandNoteTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ConversionOfPreferredSharesToCommonStock" name="ConversionOfPreferredSharesToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SettlementOfDebtByIssuanceOfCommonStock" name="SettlementOfDebtByIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_CashlessExerciseOfWarrants" name="CashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" name="DeemedDividendsForRatchetAdjustmentsToWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfSharesInPrivatePlacementShares" name="IssuanceOfSharesInPrivatePlacementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfSharesInPrivatePlacement" name="IssuanceOfSharesInPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfWarrantsInPrivatePlacement" name="IssuanceOfWarrantsInPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ConversionOfPreferredStockToCommonStockShares" name="ConversionOfPreferredStockToCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ConversionOfPreferredStockToCommonStock" name="ConversionOfPreferredStockToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SettlementOfDebtByIssuanceOfCommonStockShares" name="SettlementOfDebtByIssuanceOfCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_CashlessExerciseOfWarrantsShares" name="CashlessExerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionOneMember" name="StockOptionOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionTwoMember" name="StockOptionTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionThreeMember" name="StockOptionThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionFourMember" name="StockOptionFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionFiveMember" name="StockOptionFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionSixMember" name="StockOptionSixMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionSevenMember" name="StockOptionSevenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionEightMember" name="StockOptionEightMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionNineMember" name="StockOptionNineMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_AcuitasGroupHoldingsLLCAndOtherPurchaserMember" name="AcuitasGroupHoldingsLLCAndOtherPurchaserMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_WarrantOneMember" name="WarrantOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_WarrantTwoMember" name="WarrantTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_WarrantThreeMember" name="WarrantThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_UnauditedInterimFinancialStatementsPolicyTextBlock" name="UnauditedInterimFinancialStatementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureSignificantAccountingPoliciesTablesAbstract" name="DisclosureSignificantAccountingPoliciesTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureIntangibleAssetsTablesAbstract" name="DisclosureIntangibleAssetsTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureStockOptionsTablesAbstract" name="DisclosureStockOptionsTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureLiquidityDetailsNarrativeAbstract" name="DisclosureLiquidityDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract" name="DisclosureSignificantAccountingPoliciesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureIntangibleAssetsDetailsAbstract" name="DisclosureIntangibleAssetsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureIntangibleAssetsDetails2Abstract" name="DisclosureIntangibleAssetsDetails2Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureStockOptionsDetailsAbstract" name="DisclosureStockOptionsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureStockholdersEquityDetails3Abstract" name="DisclosureStockholdersEquityDetails3Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureIncomeTaxesDetails2Abstract" name="DisclosureIncomeTaxesDetails2Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_LATPharmaIncMember" name="LATPharmaIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_PrepaidServicesPaidWithCommonStockMember" name="PrepaidServicesPaidWithCommonStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionTenMember" name="StockOptionTenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6808153776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOVIE INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001580149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Updated to reflect changes incorporated subsequent to previous amendment<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6808144832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 971,614<span></span>
</td>
<td class="nump">$ 45,800<span></span>
</td>
<td class="nump">$ 5,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other Assets</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">1,006,614<span></span>
</td>
<td class="nump">45,800<span></span>
</td>
<td class="nump">5,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>OTHER ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets (Net of Amortization)</a></td>
<td class="nump">1,611,947<span></span>
</td>
<td class="nump">1,783,980<span></span>
</td>
<td class="nump">2,013,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">345,711<span></span>
</td>
<td class="nump">345,711<span></span>
</td>
<td class="nump">345,711<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Fixed Assets</a></td>
<td class="nump">1,957,658<span></span>
</td>
<td class="nump">2,129,691<span></span>
</td>
<td class="nump">2,359,068<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">2,964,272<span></span>
</td>
<td class="nump">2,175,491<span></span>
</td>
<td class="nump">2,364,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable and accrued expenses</a></td>
<td class="nump">179,054<span></span>
</td>
<td class="nump">884,207<span></span>
</td>
<td class="nump">470,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related Party Loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued Payroll</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,167<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">179,054<span></span>
</td>
<td class="nump">1,238,374<span></span>
</td>
<td class="nump">630,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Demand Promissory Note</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Notes Payable, Related Parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">575,918<span></span>
</td>
<td class="nump">575,918<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Long Term Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">825,918<span></span>
</td>
<td class="nump">575,918<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">179,054<span></span>
</td>
<td class="nump">2,064,292<span></span>
</td>
<td class="nump">1,206,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000,000; 300,000,000 and 800,000,000 shares authorized; 98,503,199; 91,925,000 and 316,453,673 shares issued and outstanding, respectively</a></td>
<td class="nump">31,645<span></span>
</td>
<td class="nump">9,850<span></span>
</td>
<td class="nump">9,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">9,359,780<span></span>
</td>
<td class="nump">4,870,475<span></span>
</td>
<td class="nump">3,483,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(6,606,207)<span></span>
</td>
<td class="num">(4,769,126)<span></span>
</td>
<td class="num">(2,335,009)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">2,785,218<span></span>
</td>
<td class="nump">111,199<span></span>
</td>
<td class="nump">1,157,317<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 2,964,272<span></span>
</td>
<td class="nump">$ 2,175,491<span></span>
</td>
<td class="nump">$ 2,364,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6810569920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued</a></td>
<td class="nump">316,453,673<span></span>
</td>
<td class="nump">98,503,199<span></span>
</td>
<td class="nump">91,925,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">316,453,673<span></span>
</td>
<td class="nump">98,503,199<span></span>
</td>
<td class="nump">91,925,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6808577552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATION (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUE</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">172,033<span></span>
</td>
<td class="nump">172,033<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">732,373<span></span>
</td>
<td class="nump">275,116<span></span>
</td>
<td class="nump">370,853<span></span>
</td>
<td class="nump">466,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Payroll expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,525<span></span>
</td>
<td class="nump">285,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,331,142<span></span>
</td>
<td class="nump">503,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">936,180<span></span>
</td>
<td class="nump">1,401,104<span></span>
</td>
<td class="nump">129,270<span></span>
</td>
<td class="nump">69,122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">1,840,586<span></span>
</td>
<td class="nump">1,848,253<span></span>
</td>
<td class="nump">2,372,166<span></span>
</td>
<td class="nump">1,553,614<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(1,840,586)<span></span>
</td>
<td class="num">(1,848,253)<span></span>
</td>
<td class="num">(2,372,166)<span></span>
</td>
<td class="num">(1,553,614)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>OTHER EXPENSE (INCOME)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInterestAndDividendIncome', window );">Other Income</a></td>
<td class="num">(51,400)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(222,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">9,828<span></span>
</td>
<td class="nump">40,960<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="num">(1,036)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">TOTAL OTHER EXPENSE (INCOME)</a></td>
<td class="num">(52,164)<span></span>
</td>
<td class="nump">9,827<span></span>
</td>
<td class="nump">40,956<span></span>
</td>
<td class="num">(222,942)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">(1,788,422)<span></span>
</td>
<td class="num">(1,858,080)<span></span>
</td>
<td class="num">(2,413,122)<span></span>
</td>
<td class="num">(1,330,672)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividend', window );">Deemed dividend</a></td>
<td class="num">(48,659)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20,995)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS ATTRIBUTABLE TO COMPANY STOCKHOLDERS</a></td>
<td class="num">$ (1,837,081)<span></span>
</td>
<td class="num">$ (1,858,080)<span></span>
</td>
<td class="num">$ (2,434,117)<span></span>
</td>
<td class="num">$ (1,330,672)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">NET LOSS PER COMMON SHARE, BASIC AND DILUTED</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED</a></td>
<td class="nump">313,580,066<span></span>
</td>
<td class="nump">95,014,206<span></span>
</td>
<td class="nump">95,758,079<span></span>
</td>
<td class="nump">89,391,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInterestAndDividendIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after discount, accretion and premium amortization, of interest income and dividend income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInterestAndDividendIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873854&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873831&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6813863808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock Shares</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 30, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,716<span></span>
</td>
<td class="nump">$ 2,911,560<span></span>
</td>
<td class="num">$ (1,004,337)<span></span>
</td>
<td class="nump">$ 1,915,939<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Jun. 30, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,160,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares and warrants for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 477<span></span>
</td>
<td class="nump">479,523<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">479,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares and warrants for cash, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,764,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_OptionVested', window );">Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">92,051<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">92,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfWarrantsWithDebt', window );">Issuance of warrants with debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,330,672)<span></span>
</td>
<td class="num">(1,330,672)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jun. 30, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,193<span></span>
</td>
<td class="nump">3,483,134<span></span>
</td>
<td class="num">(2,335,009)<span></span>
</td>
<td class="nump">1,157,317<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Jun. 30, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfSharesInPrivatePlacement', window );">Issuance of shares in a private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">244,883<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">245,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfSharesInPrivatePlacementShares', window );">Issuance of shares in a private placement, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,169,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">329,850<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">330,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares for services, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,752<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(662,841)<span></span>
</td>
<td class="num">(662,841)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,460<span></span>
</td>
<td class="nump">4,070,619<span></span>
</td>
<td class="num">(2,997,850)<span></span>
</td>
<td class="nump">1,082,229<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Sep. 30, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">94,594,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 30, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,193<span></span>
</td>
<td class="nump">3,483,134<span></span>
</td>
<td class="num">(2,335,009)<span></span>
</td>
<td class="nump">1,157,317<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Jun. 30, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SettlementOfDebtByIssuanceOfCommonStock', window );">Issuance of shares in exchange for debt settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,858,080)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,734<span></span>
</td>
<td class="nump">4,738,797<span></span>
</td>
<td class="num">(4,193,089)<span></span>
</td>
<td class="nump">555,442<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Mar. 31, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">97,334,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 30, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,193<span></span>
</td>
<td class="nump">3,483,134<span></span>
</td>
<td class="num">(2,335,009)<span></span>
</td>
<td class="nump">1,157,317<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Jun. 30, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares and warrants for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">444,827<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">444,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares and warrants for cash, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,729,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">642,375<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">642,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares for services, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,748,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_OptionVested', window );">Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">238,165<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">238,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">1,990<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options for cash, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfWarrantsForServices', window );">Issuance of warrants for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,469<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfWarrantsWithDebt', window );">Issuance of warrants with debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,519<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividendsForRatchetAdjustmentToWarrants', window );">Deemed dividends for ratchet adjustment to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,995<span></span>
</td>
<td class="num">(20,995)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,413,122)<span></span>
</td>
<td class="num">(2,413,122)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,850<span></span>
</td>
<td class="nump">4,870,474<span></span>
</td>
<td class="num">(4,769,126)<span></span>
</td>
<td class="nump">111,197<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">98,503,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Sep. 30, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,460<span></span>
</td>
<td class="nump">4,070,619<span></span>
</td>
<td class="num">(2,997,850)<span></span>
</td>
<td class="nump">1,082,229<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Sep. 30, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">94,594,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfSharesInPrivatePlacement', window );">Issuance of shares in a private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">49,977<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfSharesInPrivatePlacementShares', window );">Issuance of shares in a private placement, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">227,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">34,485<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">34,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares for services, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfWarrantsInPrivatePlacement', window );">Issuance of warrants in a private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27,021<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(502,682)<span></span>
</td>
<td class="num">(502,682)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,498<span></span>
</td>
<td class="nump">4,282,102<span></span>
</td>
<td class="num">(3,500,532)<span></span>
</td>
<td class="nump">791,068<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">94,971,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfSharesInPrivatePlacement', window );">Issuance of shares in a private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">49,967<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfSharesInPrivatePlacementShares', window );">Issuance of shares in a private placement, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">242,197<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">242,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares for services, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfWarrantsForServices', window );">Issuance of warrants for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,469<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">152,062<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">152,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(692,557)<span></span>
</td>
<td class="num">(692,557)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,734<span></span>
</td>
<td class="nump">4,738,797<span></span>
</td>
<td class="num">(4,193,089)<span></span>
</td>
<td class="nump">555,442<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Mar. 31, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">97,334,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,850<span></span>
</td>
<td class="nump">4,870,474<span></span>
</td>
<td class="num">(4,769,126)<span></span>
</td>
<td class="nump">111,197<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">98,503,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfSharesInPrivatePlacement', window );">Issuance of shares in a private placement</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfSharesInPrivatePlacementShares', window );">Issuance of shares in a private placement, Shares</a></td>
<td class="nump">2,133,332<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividendsForRatchetAdjustmentToWarrants', window );">Deemed dividends for ratchet adjustment to warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">48,659<span></span>
</td>
<td class="num">(48,659)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ConversionOfPreferredStockToCommonStock', window );">Conversion of preferred stock to common stock</a></td>
<td class="num">$ (3,200,000)<span></span>
</td>
<td class="nump">$ 21,333<span></span>
</td>
<td class="num">(21,333)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ConversionOfPreferredStockToCommonStockShares', window );">Conversion of preferred stock to common stock, Shares</a></td>
<td class="num">(2,133,332)<span></span>
</td>
<td class="nump">213,333,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SettlementOfDebtByIssuanceOfCommonStock', window );">Issuance of shares in exchange for debt settlement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">1,150,037<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,150,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SettlementOfDebtByIssuanceOfCommonStockShares', window );">Issuance of shares in exchange for debt settlement, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">975,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,412<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="num">(224)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrantsShares', window );">Cashless exercise of warrants, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,241,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(439,871)<span></span>
</td>
<td class="num">(439,871)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 31,505<span></span>
</td>
<td class="nump">9,251,026<span></span>
</td>
<td class="num">(5,257,656)<span></span>
</td>
<td class="nump">4,024,875<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Sep. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">315,053,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,850<span></span>
</td>
<td class="nump">4,870,474<span></span>
</td>
<td class="num">(4,769,126)<span></span>
</td>
<td class="nump">111,197<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">98,503,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SettlementOfDebtByIssuanceOfCommonStock', window );">Issuance of shares in exchange for debt settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,788,422)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 31,645<span></span>
</td>
<td class="nump">9,359,780<span></span>
</td>
<td class="num">(6,606,207)<span></span>
</td>
<td class="nump">2,785,218<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Mar. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">316,453,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Sep. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 31,505<span></span>
</td>
<td class="nump">9,251,026<span></span>
</td>
<td class="num">(5,257,656)<span></span>
</td>
<td class="nump">4,024,875<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Sep. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">315,053,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,285<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(500,510)<span></span>
</td>
<td class="num">(500,510)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 31,505<span></span>
</td>
<td class="nump">9,267,310<span></span>
</td>
<td class="num">(5,758,166)<span></span>
</td>
<td class="nump">3,540,650<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">315,053,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">48,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares for services, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">43,609<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">43,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(848,041)<span></span>
</td>
<td class="num">(848,041)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 31,645<span></span>
</td>
<td class="nump">$ 9,359,780<span></span>
</td>
<td class="num">$ (6,606,207)<span></span>
</td>
<td class="nump">$ 2,785,218<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Mar. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">316,453,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_CashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless Exercise of Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_CashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_CashlessExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless Exercise of Warrants, Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_CashlessExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ConversionOfPreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred stock to common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ConversionOfPreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ConversionOfPreferredStockToCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred stock to common stock, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ConversionOfPreferredStockToCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DeemedDividendsForRatchetAdjustmentToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividends for Ratchet Adjustment to Warrant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DeemedDividendsForRatchetAdjustmentToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfSharesInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of preferred stock in a private placement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfSharesInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfSharesInPrivatePlacementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of preferred stock in a private placement, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfSharesInPrivatePlacementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfWarrantsForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Warrants for Service</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfWarrantsForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfWarrantsInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants in a private placement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfWarrantsInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfWarrantsWithDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Warrant with Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfWarrantsWithDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_OptionVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option Vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_OptionVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SettlementOfDebtByIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Debt By Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SettlementOfDebtByIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SettlementOfDebtByIssuanceOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares in exchange for debt settlement, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SettlementOfDebtByIssuanceOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6798539520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENT OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (1,788,422)<span></span>
</td>
<td class="num">$ (1,858,080)<span></span>
</td>
<td class="num">$ (2,413,122)<span></span>
</td>
<td class="num">$ (1,330,672)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash to cash used by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Services paid with common stock</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">642,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">172,033<span></span>
</td>
<td class="nump">172,033<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">51,400<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,519<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="nump">63,306<span></span>
</td>
<td class="nump">811,203<span></span>
</td>
<td class="nump">893,484<span></span>
</td>
<td class="nump">92,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Increase in prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="num">(35,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts Payable</a></td>
<td class="num">(382,203)<span></span>
</td>
<td class="nump">275,283<span></span>
</td>
<td class="nump">413,234<span></span>
</td>
<td class="nump">350,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued Payroll</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="nump">229,167<span></span>
</td>
<td class="nump">27,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used by operating activities</a></td>
<td class="num">(1,869,886)<span></span>
</td>
<td class="num">(412,061)<span></span>
</td>
<td class="num">(621,341)<span></span>
</td>
<td class="num">(623,615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of loan</a></td>
<td class="num">(244,300)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred shares</a></td>
<td class="nump">3,040,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ProceedsFromDemandPromissoryNote', window );">Proceeds from demand promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">445,001<span></span>
</td>
<td class="nump">344,999<span></span>
</td>
<td class="nump">479,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,795,700<span></span>
</td>
<td class="nump">435,001<span></span>
</td>
<td class="nump">661,999<span></span>
</td>
<td class="nump">504,999<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash</a></td>
<td class="nump">925,814<span></span>
</td>
<td class="nump">22,940<span></span>
</td>
<td class="nump">40,658<span></span>
</td>
<td class="num">(118,616)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, beginning of period</a></td>
<td class="nump">45,800<span></span>
</td>
<td class="nump">5,140<span></span>
</td>
<td class="nump">5,140<span></span>
</td>
<td class="nump">123,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, end of period</a></td>
<td class="nump">971,614<span></span>
</td>
<td class="nump">28,080<span></span>
</td>
<td class="nump">45,800<span></span>
</td>
<td class="nump">5,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfWarrantsWithDebt', window );">Issuance of warrants with debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,519<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ConversionOfPreferredSharesToCommonStock', window );">Conversion of preferred shares to common stock</a></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SettlementOfDebtByIssuanceOfCommonStock', window );">Settlement of debt by issuance of common stock</a></td>
<td class="nump">1,150,135<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="nump">224<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividendsForRatchetAdjustmentsToWarrants', window );">Deemed dividends for ratchet adjustments to warrants</a></td>
<td class="nump">$ 48,659<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_CashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless Exercise of Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_CashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ConversionOfPreferredSharesToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Preferred Shares To Common Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ConversionOfPreferredSharesToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DeemedDividendsForRatchetAdjustmentsToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividends for Ratchet Adjustments to Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DeemedDividendsForRatchetAdjustmentsToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfWarrantsWithDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Warrant with Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfWarrantsWithDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ProceedsFromDemandPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Demand Promissory Note</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ProceedsFromDemandPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SettlementOfDebtByIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Debt By Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SettlementOfDebtByIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6632241360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Background Information</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 2%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt/115% Times New Roman, Times, Serif"><b>1.</b></font></td>
    <td style="width: 98%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt/115% Times New Roman, Times, Serif"><b>Background Information</b></font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioVie Inc. (the &#8220;Company&#8221;)
is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company
is currently focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment
of ascites due to chronic liver cirrhosis. The Company began dosing patients with BIV201 in September 2017 at the McGuire Research
Institute Inc. in Richmond, VA. All six of the planned patients have been treated with BIV201 therapy in this Phase 2a clinical
trial. In May 2019, the Company announced that the primary study objectives to assess the safety, tolerability, and pharmacokinetics
(PK) of a continuous infusion of terlipressin over 28 days had been achieved. Detailed results will be presented to the Food &#38;
Drug Administration (&#8220;FDA&#8221;) in the first half of 2019.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BIV201 has the potential to improve
the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic
steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications,
ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites.
The Company has secured a US Patent covering the use of BIV201 for the treatment of ascites patients in the outpatient setting
using ambulatory pump infusion, and has filed patent applications for its product candidate in Japan, and Europe, Hong Kong, and
China. BIV201 also received Orphan Drug designation for hepatorenal syndrome (&#8220;HRS&#8221;) in November 2018.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The BIV201 development program began
at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The
Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (&#8220;PharmaIN&#8221;),
LAT Pharma&#8217;s former partner focused on the development of new modified drug candidates in the same therapeutic field but
not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development
programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24,
2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously
paid the remaining balance due on a related debt. PharmaIN, Corp.&#8217;s rights to our program remain unchanged.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company&#8217;s activities
are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the Company&#8217;s
business plan.</p><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 2%"><b>1.</b></td>
    <td style="width: 98%"><b>Background Information</b></td></tr>
</table>
<p style="margin: 0">&#160;</p>

<p style="margin: 0; text-align: justify">BioVie Inc. (the &#8220;Company&#8221;) is a clinical-stage company pursuing the discovery,
development, and commercialization of innovative drug therapies. The Company is currently focused on developing and commercializing
BIV201, a novel approach to the treatment of ascites due to chronic liver cirrhosis. In March 2017, the Company received notification
from the US Food and Drug Administration (FDA) that it could initiate a Phase 2a US clinical trial. In April the Company signed
a Cooperative Research and Development Agreement (CRADA) with the McGuire Research Institute/VA in Richmond, VA, and began dosing
patients with BIV201 in September 2017.&#160;As of June 2018, three&#160;patients had been treated with BIV201 therapy in this
ongoing Phase 2a clinical trial.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">BIV201 has the potential to improve the health of thousands of patients suffering from
life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has
FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant
unmet medical need. The FDA has never approved any drug specifically for treating ascites.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company
acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing
rights to its drug candidate. The Company and PharmaIN, Corp. (&#8220;PharmaIN&#8221;), LAT Pharma&#8217;s former partner focused
on the development of new modified drug candidates in the same therapeutic field but not including BIV201, agreed to pay royalties
equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed
to a third party, less than 5% of each company's net license revenues. The Company&#8217;s relationship with PharmaIN could advance
into a collaboration or be terminated. The Company has an issued US Patent covering the use of BIV201 for the treatment of ascites
patients in the outpatient setting using ambulatory pump infusion, and has filed patent applications for its drug candidate in
Japan, and Europe, and China.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company&#8217;s activities are subject to significant risks and uncertainties including
failure to secure additional funding to properly execute the Company&#8217;s business plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6632107696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_LiquidityTextBlock', window );">Liquidity</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 2%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt/115% Times New Roman, Times, Serif"><b>2.</b></font></td>
    <td style="width: 98%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt/115% Times New Roman, Times, Serif"><b>Liquidity and Going Concern</b></font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company&#8217;s operations
are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are
not limited to: the results of clinical testing and trial activities of the Company&#8217;s products, the Company&#8217;s ability
to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other
companies, the price of, and demand for, Company products, the Company&#8217;s ability to negotiate favorable licensing or other
manufacturing and marketing agreements for its products, and the Company&#8217;s ability to raise capital. The Company&#8217;s
financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization
of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced losses since inception
and has an accumulated deficit of approximately $6.6 million at March 31, 2019. In addition, the Company has not generated any
revenues and no revenues are anticipated in the foreseeable future. The Company&#8217;s future operations are dependent on the
success of the Company&#8217;s ongoing development and commercialization efforts, as well as continuing to secure additional financing.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2018, the Company completed
a capital raise from Acuitas Group Holdings, LLC (&#8220;Acuitas&#8221;) and other purchasers and received net proceeds of $3.2
million and has resumed further clinical development of BIV201. The Acuitas investment agreement also stipulated that if the clinical
development of BIV201 continues, Acuitas may at its option invest up to an additional $3 million to fund operations in year two,
less any federal or FDA grant funding received by the Company.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The future viability of the Company
is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources
of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue
these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to
the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company&#8217;s ability
to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this
uncertainty.</p><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 2%"><b>2.</b></td>
    <td style="width: 98%"><b>Liquidity</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">We believe that our existing cash and cash equivalents, including the amounts received
after the end of the fiscal year, will be sufficient to meet our operating and capital requirements for at least 12 months from
the date of this report.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On July 3, 2018, the Company, entered into a Securities Purchase Agreement (the &#8220;Purchase
Agreement&#8221;) with Acuitas Group Holdings, LLC (&#8220;Acuitas&#8221;) and certain other purchasers identified in the Purchase
Agreement (together with Acuitas, the &#8220;Purchasers&#8221;) pursuant to which (i) the Purchasers agreed to purchase an aggregate
of 2,133,332 shares of the Company&#8217;s newly created Series A Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;)
at a price per share of $1.50 per share of Preferred Stock (the &#8220;Initial Sale&#8221;) and (ii) the Company will issue associated
warrants (the &#8220;Warrants&#8221;) to purchase 213,333,200 shares of the Company&#8217;s Class A Common Stock (the &#8220;Common
Stock&#8221;), each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of
$3.2 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_LiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_LiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6637525472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 2%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt/115% Times New Roman, Times, Serif"><b>3.</b></font></td>
    <td style="width: 98%; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt/115% Times New Roman, Times, Serif"><b>Significant Accounting Policies</b></font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Basis of Presentation &#8211; Interim Financial
Information</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The accompanying unaudited interim
financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United
State of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article
10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect
all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair
presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for
the full year. The Condensed Balance Sheet at June 30, 2018 was derived from audited annual financial statements but does not contain
all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included
under the heading: &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; should
be read in conjunction with our Company&#8217;s audited financial statements and related notes included in our Company&#8217;s
Form 10-K for the year ended June 30, 2018 filed with the SEC on October 5, 2018.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">For a summary of significant
accounting policies, see the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the
SEC on October 5, 2018.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Net Loss per Common Share</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Basic net loss per common share
is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding
during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares
of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution
that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures.
Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The table below shows the number
of outstanding stock options and warrants as of March 31, 2019 and June 30, 2018:</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30, 2018</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of Shares</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of Shares</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 58%; padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock Options</font></td>
    <td style="width: 8%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,250,000</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 8%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,150,000</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">216,440,548</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,774,015</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>223,690,548</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>9,924,015</b></font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Recent accounting pronouncements</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company considers the applicability
and impact of all Accounting Standard Updates (&#8220;ASU&#8217;s&#8221;). ASU&#8217;s not discussed below were assessed and determined
to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In June 2018, the FASB issued
ASU 2018-07, &#8220;Compensation &#8211; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting&#8221;.
This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment
transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings
as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair
value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim
periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on the
financial statements.</p><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 2%"><b>3.</b></td>
    <td style="width: 98%"><b>Significant Accounting Policies</b></td></tr>
</table>
<p style="margin: 0">&#160;</p>

<p style="margin: 0"><i>Basis of Presentation</i></p>

<p style="margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0"><i>Use of Estimates</i></p>

<p style="margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0"><i>Cash</i></p>

<p style="margin: 0; text-align: justify">Cash is maintained at financial institutions and, at times, balances may exceed
federally insured limits. The Company has never experienced any losses related to these balances. All of the Company&#8217;s cash
balances were fully insured at June 30, 2018.&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><i>Financial Instruments</i></p>

<p style="margin: 0; text-align: justify">The Company&#8217;s financial instruments include cash, accounts payable, related
party loans and a demand promissory note. The carrying amounts of cash and accounts payable approximate their fair value, due
to the short-term nature of these items.&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><i>Long-Term Notes Payable</i></p>

<p style="margin: 0; text-align: justify">The Company&#8217;s long-term notes payable include accrued payroll to officers
and accrued payments to third party consultants.</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><i>Research and Development</i></p>

<p style="margin: 0; text-align: justify">Research and development costs are charged to operations when incurred and are included
in operating expenses. The Company expensed $370,853 and $466,354 for research and development for the years ended June 30, 2018
and 2017, respectively.</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><i>Income Taxes</i></p>

<p style="margin: 0; text-align: justify">Deferred income tax assets and liabilities arise from temporary differences associated
with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates,
which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current
or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities
not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary
differences are expected to reverse.&#160;</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company follows the provisions of FASB ASC 740-10 &#8220;<i>Uncertainty in
Income Taxes</i>&#8221; (ASC 740-10), January 1, 2007. The Company has not recognized a liability as a result of the implementation
of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there
are no unrecognized benefits at June 30, 2018 and since the date of adoption. The Company has not recognized interest expense
or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize
interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.&#160; The Company&#8217;s
tax returns for the years ended June 30, 2015, 2016, 2017 and 2018 remain open to examination by taxing authorities.</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><i>Earnings (Loss) per Share</i></p>

<p style="margin: 0; text-align: justify">Basic earnings per share are computed by dividing net income by the weighted average
number of shares of common stock outstanding during the year. Diluted earnings per common share are computed by dividing net income
by the weighted average number of shares of common stock outstanding and dilutive options outstanding during the year. For the
years ended June 30, 2017 and 2018 all outstanding options have been excluded from the calculation of the diluted net loss per
share since their effect was anti-dilutive.</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">The following potentially dilutive securities were excluded from the computation of diluted loss per share
for the years ended June 30, 2017 and 2018:</p>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>2017</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>2018</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Number of Shares (Thousands)</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Number of Shares (Thousands)</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%; text-align: center">Stock Options</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">4,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">5,150</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center; padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">6,174</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">4,774</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">10,174</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">9,924</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>



<p style="margin: 0">&#160;</p>

<p style="margin: 0"><i>Stock-based Compensation</i></p>

<p style="margin: 0; text-align: justify">The Company has accounted for stock-based compensation under the provisions of FASB
ASC 718 &#8211; &#8220;Stock Compensation&#8221; which requires the use of the fair-value based method to determine compensation
for all arrangements under which employees and others receive shares of stock or equity instruments (stock options and common
stock purchase warrants). For employee awards, the fair value of each stock option award is estimated on the date of grant using
the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free
interest rate. For non-employees, the fair value of each stock option award is estimated on the measurement date using the Black-Scholes
valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.
For non-employees, the Company utilizes the graded vesting attribution method under which the entity treats each separately vesting
portion (tranche) as a separate award and recognizes compensation cost for each tranche over its separate vesting schedule. Expected
volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock
options. For employee awards, the expected term of options granted is derived using the &#8220;simplified method&#8221; which
computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the
U.S. Treasury yield curve in effect at the time of grant for the period of the expected term.</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><i>Goodwill</i></p>

<p style="margin: 0; text-align: justify">Goodwill is recorded when the purchase price paid for an acquisition exceeds the fair
value of net identified tangible and intangible assets acquired. The Company performs an annual impairment test of goodwill and
further periodic tests to the extent indicators of impairment develop between annual impairment tests. The Company&#8217;s impairment
review process compares the fair value of the reporting unit to its carrying value, including the goodwill related to the reporting
unit. To determine the fair value of the reporting unit, the Company may use various approaches including an asset or cost approach,
market approach or income approach or any combination thereof. These approaches may require the Company to make certain estimates
and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each time the
Company tests goodwill for impairment and are typically developed as part of the Company&#8217;s routine business planning and
forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates
could produce materially different results. The Company did not recognize any goodwill impairments for the years ended June 30th,
2017 and June 30th, 2018.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0"><i>Impairment of Long-Lived Assets</i></p>

<p style="margin: 0; text-align: justify">Long-lived assets, including intangible assets, are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows
expected to be generated by the asset.&#160;</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">If the carrying amount of an asset exceeds its undiscounted estimated future cash
flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the
asset exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected discounted
cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported
at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and
liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability
sections of the balance sheet.</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><i>Recent accounting pronouncements</i></p>

<p style="margin: 0; text-align: justify">The Company has reviewed recent accounting pronouncements issued by the FASB (including
its EITF), the AICPA, and the SEC and did not or are not believed by management to have a material impact on the Company&#8217;s
financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6636826496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>4. Intellectual
Property</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Intellectual
property, stated at cost, less accumulated amortization consists of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30, 2018</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 58%; padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Intellectual Property</font></td>
    <td style="width: 8%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,293,770</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 8%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,293,770</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated Amortization</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">681,823</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">509,790</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Intellectual Property, Net</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,611,947</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,783,980</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Amortization
expense for the and nine-month periods ended March 31, 2019 and 2018 was $172,033. Estimated future
amortization expense is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td colspan="4" style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">Year ending June 2019 (remaining three months)</font></td>
    <td style="vertical-align: bottom; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;57,344 </font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; text-align: right; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">2020</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td colspan="4" style="vertical-align: bottom; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">2021</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td colspan="4" style="vertical-align: bottom; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">2022</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td colspan="4" style="vertical-align: bottom; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">2023</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td colspan="4" style="vertical-align: bottom; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">Thereafter</font></td>
    <td style="vertical-align: top; padding-bottom: 1pt; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 1pt; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td colspan="4" style="vertical-align: bottom; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;637,095</font></td>
    <td style="vertical-align: top; padding-bottom: 1pt; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: bottom; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 2.5pt; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 2.5pt; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td colspan="4" style="vertical-align: bottom; border-top: black 1pt solid; border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,611,947 </font></td>
    <td style="vertical-align: top; padding-bottom: 2.5pt; line-height: 107%">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><b>4. Intangible Assets</b></p>

<p style="margin: 0; text-align: justify">The company&#8217;s intangible assets consist of intellectual property acquired from
LAT Pharma, Inc., and are amortized over their estimated useful lives as indicated below. The following is a summary of the intangible
assets as of June 30, 2018 and 2017.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>June 30, 2018</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>June 30, 2017</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%; text-align: left">Intangible Assets subject to Amortization</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">22,93,770</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">22,93,770</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">5,09,790</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">2,80,413</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-bottom: 2.5pt">Intangible Assets (Net of Amortization</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">17,83,980</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">20,13,357</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>



<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Future expected Amortization of intangible assets is as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center"><b>Year Ending June 30,</b></td><td><b>&#160;</b></td>
    <td colspan="3"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 70%; text-align: center">2019</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">2,29,377</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center">2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,29,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,29,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,29,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,29,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,37,095</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,83,980</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6632298336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Demand Note<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DemandNoteTextBlock', window );">Demand Note</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><b>5. Renegotiated Debt</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 19, 2018, Geis-Hides
Consulting LLC entered into an Accord and Debt Satisfaction Agreement with the Company in which the consulting firm agreed to release
the Company from all liabilities arising from the Original Contract and Debt Repayment Plan dated December 15, 2013 totaling $132,000
and received cash of $65,000 and 260,000 common shares in satisfaction. The common shares were valued at the market price on the
date of settlement at $0.06 per common share. The gain of $51,400 on the settlement of debt was reflected on the Statements of
Operations as &#8220;other income&#8221; for the nine-month period ended March 31, 2019.</p><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><b>5. Demand Note</b></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On May 21, 2018, the Company received
$250,000 in exchange for a promissory note from Acuitas Group Holding LLC. The promissory note carries 10% interest per year and
has a maturity date of 10 business days of demand by Payee. The promissory note also has a provision that in the event of a superseding
equity financing transaction, the Payor will receive 50% warrant coverage on same terms as if the superseding transactions occurs.
On July 3, 2018, the Company entered into an equity financing transaction which resulted in Acuitas Group Holding LLC., receiving
833,333 warrants that expire on July 3<sup>rd</sup> 2024 with an exercise price of 1.8 cents per share. The Company valued the
warrants at $29,666 using the Black Scholes Model and the following assumptions were used: volatility &#8211; 169%; Term &#8211;
6 years; Risk Free Rate &#8211; 2.96%; dividend rate &#8211; 0.00%. Based on their relative fair value, the Company allocated
$26,519 of the proceeds to the warrants, which was recorded as additional interest expense for the year ended June 30, 2018. As
the promissory note was converted into common stock subsequent to June 30, 2018, the balance as of June 30, 2018 is classified
as long term on the accompanying balance sheet.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DemandNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Demand Note [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DemandNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6633962464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><b>6. Related Party Transactions</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 9, 2018, Jonathan Adams
(COO) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all
liabilities including the original contract to defer payment of his accrued salary dated March 23, 2017, the promissory note issued
by the Company to defer payment of accrued salary; and subsequent unpaid salary, totaling the amount of $534,722, and received
cash of $25,694 in satisfaction. The gain of $509,028 on the settlement of debt was reflected in the additional paid in capital.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 9, 2018, Elliot Ehrlich
(former CEO and shareholder) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release
the Company from all liabilities including the original contract to defer payment of accrued salary dated March 23, 2017, totaling
the amount of $222,028 the promissory note issued by the Company to defer payment of accrued salary; and received cash of $22,273
and 222,028 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06
per common share. The gain of $186,503 on the settlement of debt was reflected in the additional paid in capital.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On August 8, 2018, Barrett Ehrlich
(Independent contractor, related party to Elliot Ehrlich and shareholder) on behalf of The Barrett Edge Inc. (&#8220;Barrett&#8221;)
entered into an Accord and Debt Satisfaction Agreement with the Company in which Barrett agreed to release the Company from all
liabilities including the original contract to defer payment of accrued consulting fees dated March 23, 2017, the promissory note
issued by the Company to defer payment of accrued consulting fees; loan to the Company for $14,000, and subsequent unpaid consulting
fees, totaling $543,014, and received cash of $131,333 and 493,333 common shares in satisfaction. The common shares were valued
at the market price on the date of settlement at $0.13 per common share. The gain of $361,548 on the settlement of debt was reflected
in the additional paid in capital.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">See note 8 for other related
party transactions.</p><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><b>6. Related Party Transactions</b></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Notes Payable</i></p>

<p style="margin: 0; text-align: justify">LAT Pharma was given a zero-interest bearing loan by the Company&#8217;s CEO, Jonathan
Adams in the amount of $5,000 in August 2015 and $5,000 in November 2015.&#160; The total of $10,000 was outstanding when the
Company merged with LAT Pharma. On June 16th, 2017, the Company was given an additional $25,000 zero-interest bearing loan by
Jonathan Adams.&#160; During the quarter ended December 31, 2017, the Company repaid the $35,000 outstanding balance of the loan.
During the quarter ended March 31, 2018, the Company was given an additional $25,000 zero-interest bearing loan by Jonathan Adams.
During the quarter ended June 30, 2018, the Company repaid the $25,000 outstanding balance of the loan. The outstanding balance
of the loan was $35,000 as of June 30, 2017 and zero as of June 30, 2018.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On March 23, 2017, Barrett Ehrlich agreed to defer the payment of his consulting fee
debt of $173,333 until&#160;December 31, 2019, through the issuance of a Promissory note.&#160; The promissory note does not carry
any interest charge as long as the amount is paid in full before&#160;December 31, 2019.&#160; The consulting fee debt has thereby
been reclassified from a current liability to a long-term liability on the balance sheet.&#160;Any portion of the balance due
under the note that remains unpaid after&#160;December 31, 2019&#160;will accrue interest at a rate of 5% per annum until paid
in full.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On March 23, 2017, Elliot Ehrlich agreed to forgive 50% of his salary debt of $444,056.&#160;
The adjusted salary debt is $222,028.13.&#160; Elliot Ehrlich also agreed to defer the payment of his salary debt of $222,028
until&#160;December 31, 2019, through the issuance of a Promissory note.&#160; The promissory note does not carry any interest
charge as long as the amount is paid in full before&#160;December 31, 2019.&#160; The salary debt has thereby been reclassified
from a current liability to a long-term liability on the balance sheet and the salary debt forgiven has been reflected on the
income statement as other income.&#160;Any portion of the balance due under the note that remains unpaid after&#160;December 31,
2019&#160;will accrue interest at a rate of 5% per annum until paid in full.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On March 23, 2017, Jonathan Adams agreed to defer the payment of his salary debt of
$180,555 until&#160;December 31, 2019, through the issuance of a Promissory note.&#160; The promissory note does not carry any
interest charge as long as the amount is paid in full before&#160;December 31, 2019.&#160; The salary debt has thereby been reclassified
from a current liability to a long-term liability on the balance sheet.&#160;Any portion of the balance due under the note that
remains unpaid after&#160;December 31, 2019&#160;will accrue interest at a rate of 5% per annum until paid in full.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The outstanding balance of the long-term note payable was $575,917 as of June 30, 2017
and $575,917 as of June 30, 2018.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Sale of Common Stock and Warrants</i></p>

<p style="margin: 0; text-align: justify">In January 2018, the Company sold an aggregate of 333,333 shares of common stock and
warrants to purchase 333,333 shares of common stock to a member of its board of directors for aggregate gross proceeds of $50,000.
The purchase price for the common stock and warrants was $0.15 per share. The warrants are exercisable at an exercise price of
$0.15 at any time from date of issuance until 7 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Common Stock issued for Services</i></p>

<p style="margin: 0; text-align: justify">In January 2018, the Company issued 1,400,000 shares of common stock as compensation
for the Board of Directors. The shares were valued at $0.15 per share which was the trading price on date of issuance, and the
value of the compensation was $210,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6636801520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><b>7. Commitments and Contingencies</b>&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Office Lease&#160;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 1, 2018, the Company
executed a lease agreement with Acuitas Group Holdings, LLC (related party) for the Company&#8217;s office at 11601 Wilshire Blvd
Ste 1100, Los Angeles, CA 90025. The lease is a month-to-month lease that may be cancelled upon 30 days&#8217; written notice and
requires monthly payments of $1,000.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Challenge to US Patent</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On April 30, 2018, the Company
received notice that Mallinckrodt Pharmaceuticals Ireland Limited had petitioned the US Patent and Trademark Office (USPTO) to
institute an Inter Partes Review of BioVie&#8217;s US Patent No. 9,655,945 titled &#8220;Treatment of Ascites&#8221; (the &#8216;945
patent). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the
patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior
art consisting of patents and printed publications.</p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On August 15, 2018, BioVie submitted
a Preliminary Response to the PTAB providing a rationale as to why, in the Company&#8217;s opinion, Mallinckrodt&#8217;s request
to institute the IPR should not be granted. On November 14, 2018, the PTAB granted institution of the IPR challenge after determining
that there was a reasonable likelihood of success in proving that at least one of the Company&#8217;s 14 claims was unpatentable.
On March 7, 2019, we submitted a Patent Owner&#8217;s Response and a Patent Owner&#8217;s Contingent-Motion to Amend our patent
claims, and Declaration of Dr. Jaime Bosch, MD, PhD, our medical expert. We are actively defending the &#8216;945 patent and may
explore the possibility of settlement with Mallinckrodt. However, there can be no assurance in that a favorable outcome will result,
or if settlement is reached that the PTAB will accept it. Although the PTAB encourages settlement, in view of public-interest considerations,
the board may continue the proceeding to a final written decision even if the parties settle. If the IPR is not terminated due
to settlement, the PTAB is statutorily required to issue its final written decision in this case before November 14, 2019. As of
March 31, 2019, no adjustments or accruals are reflected as the Company is unable to determine a likely outcome at this time.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Royalty Agreements</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to the Agreement and
Plan of Merger entered into on April 11, 2016 between LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low
single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn
Corporation; and The Barrett Edge, Inc.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company and PharmaIN Corporation,
LAT Pharma&#8217;s former partner focused on the development of new modified drug candidates in the same therapeutic field but
not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development
programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24,
2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously
paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to the Technology Transfer
Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single
digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped
at a maximum of $200,000 per year.</p><span></span>
</td>
<td class="text"><p style="margin: 0"><b>7. Commitments and Contingencies</b></p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><i>Office Lease</i>&#160;</p>

<p style="margin: 0; text-align: justify">On January 1, 2014, the Company executed a lease agreement with Cummings Properties
for the Company&#8217;s office of 270 square feet at 100 Cummings Center, Suite 247-C, Beverly, MA 01915. The lease is for a term
of five years from January 1, 2014 to December 30, 2018 and requires monthly payments of $379. The Company notified the lessor
that it will terminate the lease on December 30, 2018.&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><i>Employment Agreements</i><b>&#160;</b></p>

<p style="margin: 0; text-align: justify">On April 11, 2016, the Company entered into employment agreement with CEO Jonathan Adams.
The Company&#8217;s agreement provides for a three-year term with minimum annual base salary of $250,000 per year.</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><i>Challenge to US Patent</i></p>

<p style="margin: 0; text-align: justify">On April 30, 2018, the Company received notice that Mallinckrodt Pharmaceuticals Ireland
Limited had petitioned the US Patent and Trademark Office (USPTO) to institute an Inter Partes Review of BioVie&#8217;s US Patent
No. 9,655,945 titled &#8220;Treatment of Ascites&#8221; (the &#8216;945 patent).</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and
Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty
and obviousness on the basis of prior art consisting of patents and printed publications. Although a petition for Inter Partes
Review has been filed, grant of the petition by the PTAB is required for the proceeding to be instituted.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On August 15, 2018, BioVie submitted a Preliminary Response to the PTAB providing a
rationale as to why, in the Company&#8217;s opinion, Mallinckrodt&#8217;s request to institute the IPR should not be granted.
If he IPR is allowed to proceed, BioVie will seek to defend the &#8216;945 patent and/or pursue a favorable settlement. As of
June 30, 2018, no adjustments or accruals are reflected as the Company is unable to determine a likely outcome at this time.</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><i>Royalty Agreements</i></p>

<p style="margin: 0; text-align: justify">Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between
LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous
infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation; and The Barrett Edge, Inc.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between
BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin
products covered by US patent no. 9,655,645 and any future foreign issuances capped at significantly less than $500,000 per year.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company and PharmaIN, Corporation, LAT Pharma&#8217;s former partner focused on
the development of new modified drug candidates in the same therapeutic field but not including BIV201, agreed to pay royalties
equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed
to a third party, less than 5% of each company's net license revenues. The Company&#8217;s relationship with PharmaIN could advance
into a collaboration or be terminated. The Company has an issued US Patent covering the use of BIV201 for the treatment of ascites
patients in the outpatient setting using ambulatory pump infusion, and has filed patent applications for its drug candidate in
Japan, and Europe, and China.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6638471056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><b>8. Equity Transactions</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Stock Options</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The following table summarizes
the activity relating to the Company&#8217;s stock options for the nine months ended March 31, 2019:</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-Average Exercise Price</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Remaining Average Contractual Term</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate Intrinsic Value</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 44%; padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at June 30, 2018</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,150,000</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.12</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.8</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,100,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.04</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.6</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">88,370</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options Exercised or Forfeited</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at March 31, 2019</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,250,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.10</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.3</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">166,175</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable at March 31, 2019</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,250,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.10</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.3</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The fair value of each option
grant on the date of grant is estimated using the Black-Scholes Option &#8211; Pricing model reflecting the following weighted-average
assumptions:</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="7" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31,</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 58%; padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected life of options (In years)</font></td>
    <td style="width: 8%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 8%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">69.77</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">69.66</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk free interest rate</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.60</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.59</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Dividend Yield</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Expected volatility is based
on the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the
expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures
as they are incurred.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company recorded stock-based
compensation expense of $43,609 and $63,306 for the three-and nine-month periods ended March 31, 2019, respectively, and $152,062
and $191,835 for the three-and nine-month periods ended March 31, 2018, respectively.</p>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The fair value of options vested
during the nine-month period ended March 31, 2019 and 2018, was $10,235 and $25,281 respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">As of March 31, 2019, there was
approximately $1,555 of unrecognized compensation cost related to non-vested options granted which is expected to be recognized
over a weighted-average period of 1 months.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The following is a summary of
stock options outstanding and exercisable by exercise price as of March 31, 2019:</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Contract Life</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 20%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.03</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 5%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 19%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">700,000</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 5%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 19%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.8</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 5%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 19%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">700,000</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.05</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,300,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.6</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,300,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.06</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,100,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6.9</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,100,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.07</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.5</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.10</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.8</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.20</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.5</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.21</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">550,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.1</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">550,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.22</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.0</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.23</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.4</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.25</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.6</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,250,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,250,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><u>Offerings of Common Stock
and Warrants</u></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Issuance of Shares for Cash</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 3, 2018, BioVie Inc.,
the Company, entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Acuitas Group Holdings, LLC
(&#8220;Acuitas&#8221;) and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the &#8220;Purchasers&#8221;)
pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the Company&#8217;s newly created Series
A Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;) at a price per share of $1.50 per share of Preferred Stock (the
&#8220;Initial Sale&#8221;) and (ii) the Company will issue associated warrants (the &#8220;Warrants&#8221;) to purchase 213,333,200
shares of the Company&#8217;s Class A Common Stock (the &#8220;Common Stock&#8221;), each subject to the terms and conditions set
forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. The Company received $160,000 of the $3.2 million
in April and May 2018 as prepaid equity. Acuitas also received an additional 833,333 Warrants in connection with the payoff of
a note issued by the Company in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition,
Acuitas has the option to purchase up to an additional 200,000,000 shares of Common Stock at a price per share of $0.015, and associated
warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale
(the &#8220;Subsequent Sale&#8221;) in the event that the Company has not obtained $3,000,000 of funding through various non-dilutive
grants prior to the one year anniversary of the closing of the Initial Sale.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Each share of Preferred Stock
automatically converted into 100 shares of Common Stock upon the filing with the Secretary of State of the State of Nevada of a
Certificate of Amendment to the Company&#8217;s Articles of Incorporation (the &#8220;Amendment&#8221;) on August 13, 2018 that
increased the number of authorized shares of Common Stock to 800,000,000. The Amendment was approved by the written consent of
the holders of more than a majority of the Company&#8217;s issued and outstanding Common Stock on July 3, 2018 and was filed with
the Secretary of State of the State of Nevada 20 calendar days following the distribution of the Company&#8217;s Definitive Information
that was filed with the Securities and Exchange Commission.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The purchase price of the Preferred
Stock in the Initial Sale, the exercise price of the Warrants, and the Common Stock in the Subsequent Sale is subject to adjustment.
In the event that Mallinckrodt Pharmaceuticals Ireland Limited prevails in any proceeding which results in the useful life of the
Company&#8217;s current intellectual property rights being reduced by more than 75 percent, then the price per share of Common
Stock, the associated conversion ratio of the Preferred Stock, and the exercise price of the Warrants shall be retroactively adjusted
to 50 percent of the then-effective price per share of Common Stock under the Purchase Agreement (for example, if the then-effective
price per share of Common Stock is $0.015, then following such event, the price per share will be $0.0075). In this case, the Company
may be required to issue additional shares of Common Stock, but in no event will the Company be required to pay cash, to reflect
such lower price per share.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Purchase Agreement contained
customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties,
the Company also disclosed customary information, including the following: (i) the existence of the Mallinckrodt Pharmaceuticals
Ireland Limited petition before the US Patent Trial and Appeal Board, (ii) the current capitalization of the Company, (iii) the
Company&#8217;s obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be
shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger,
dated April 11, 2016, by and between LAT Pharma LLC and the Company, (iv) the Company&#8217;s obligation to pay a low single digit
royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to
the Technology Transfer Agreement, dated July 25, 2016, by and between the Company and the University of Padova (Italy), and (v)
certain recent issuances of Common Stock by the Company.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to the Purchase Agreement,
Terren Peizer, the Chairman of Acuitas, was appointed as a member of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;)
and as the Chief Executive Officer of the Company, effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and
the underlying common stock under the Purchase Agreement is exempt from registration under the Securities Act of 1933, as amended
(the &#8220;Securities Act&#8221;), pursuant to the exemption for transactions by an issuer not involving any public offering under
Section 4(a)(2) of the Securities Act.</p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Issuance of Shares for Services</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On January 2, 2019, the Company
issued 1,400,000 shares of common stock as part of the annual board of director compensation. The share price on date of issuance
was $0.035 per share.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Issuance of Shares in Settlement
of Debt</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">During the nine months ended
March 31, 2019, the Company settled $1,475,765 of debt including $1,313,765 owed to related parties, by issuing 975,361 shares
of common stock with a fair value of $1,150,135. See notes 5 and 6.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Issuance of Stock Options </i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 1, 2018, the Company
issued stock options to purchase 100,000 shares of common stock to the Chief Financial Officer as part of her compensation. The
stock options were issued and are exercisable at an exercise price of $0.07 at any time from date of issuance and expire in 5 years
from the date of issuance.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 13, 2018, the Company
issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock
options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 27, 2018, the Company
issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock
options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On November 10, 2018, the Company
issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock
options are exercisable at an exercise price of $0.05 at any time from date of issuance and expire in 5 years from the date of
issuance.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On January 19, 2019, the Company
issued stock options to purchase 100,000 shares of common stock to each of five key employees or consultants and two company directors
as part of his or her annual compensation, for an aggregate total of 700,000 stock options. The stock options are exercisable at
an exercise price of $0.025 at any time from date of issuance until 5 years from the date of issuance.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On March 11, 2019, the Company
issued stock options to purchase 1,000,000 shares of common stock to an investor relations (IR) consultant. The stock options were
issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><i>Cashless exercise of warrant</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On August 4, 2018, the Company
issued 2,241,913 shares of common stock pursuant to a cash less exercise of warrants to purchase 2,500,000 shares at an exercise
price of $0.015 per share. As a result of the conversion of the Series A Preferred Stock in July 2018, the exercise of warrants
to purchase 2,500,000 shares of common stock was reduced from $0.15 per share to $0.015 per share.<br style="clear: both" />
</p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><i>Warrant Price Adjustment</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In December 2017, the Company
issued warrants to purchase 2,500,000 shares of common stock in a private placement transaction for aggregate gross proceeds of
$100,000. The warrants were exercisable at an exercise price of $0.20 at any time from date of issuance until 7 years from the
date of issuance. The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower
price. In January 2018, the Company sold shares at $0.15, which therefore triggered the reduction in the strike price. The Company
calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded
$20,995 as a deemed dividend. In July 2018, the Company sold shares at $0.015, which therefore triggered the reduction in the strike
price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise
price and recorded $44,889 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In January 2018, the Company
issued warrants to purchase 210,000 shares of common stock in exchange for banking services which was recognized at fair value.
The warrants were exercisable at an exercise price of $0.15 at any time from date of issuance until 7 years from the date of issuance.
The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In July 2018,
the Company sold shares at $0.015, which therefore triggered the reduction in the strike price. The Company calculated the difference
in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $3,770 as a deemed
dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The following table summarizes
the warrants that have been issued:</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted </b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of Shares</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Average Exercise Price</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Remaining Life (Years)</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Intrinsic Value</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 44%; padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at June 30, 2018</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,774,015</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.29</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.5</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">214,166,533</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.02</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.3</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">14,284,908</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(2,500,000</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.02</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding and exercisable at March 31, 2019</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">216,440,548</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.03</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.3</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">14,284,908</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Of the above warrants, 1,173,864
expire in fiscal year ending June 30, 2022, 556,818 expire in fiscal year ending June 30, 2023, and 214,709,866 expire in fiscal
year ending June 30, 2025.</p><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><b>8. Stockholders&#8217; Equity</b></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Stock Options</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">During the year ended June 30, 2017 and 2018, the Company issued stock options to consultants
and board of directors for services provided to the Company.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The following is a summary of stock option activity for the years ended June 30, 2017
and 2018.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><b>Shares (Thousands)</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><b>Weighted-Average Exercise
    Price</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><b>Weighted Remaining Average
    Contractual Term</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Options</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 46%">Outstanding at July 1, 2016</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">3,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">0.06</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">6.5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt">Granted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">1,000</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">0.24</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">4.0</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Outstanding at June 30, 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.9</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.0</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-bottom: 1pt">Options Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(100)</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">0.02</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2018</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">5,150</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">0.12</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">5.8</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt">Exercisable at June 30, 2018</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">4,150</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">0.13</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">4.8</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>



<p style="margin: 0; text-align: justify"></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The following is a summary of stock options outstanding and exercisable by exercise
price as of June 30, 2018.</p>
<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Exercise Price</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Outstanding</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Contract Life</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Exercisable</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">0.06</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">31,00,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: center">6.5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">21,00,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">$</td><td style="text-align: right">0.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,00,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">4.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,00,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,00,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">4.5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,00,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">$</td><td style="text-align: right">0.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">4.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,50,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,00,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">4.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,00,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">$</td><td style="text-align: right">0.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,00,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">4.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,00,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">$</td><td style="text-align: right">0.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,00,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,00,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">&#160;</td><td style="text-align: center">Total</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">51,50,000</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">41,50,000</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>



<p style="margin: 0; text-align: justify"></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The fair value of options granted during the year ended June 30, 2018 was estimated
using the Black Scholes Method and the following assumptions: volatility - 124.7% to 143.46%; Term &#8211; 5 years; Risk Free
Rate &#8211; 2.45% to 2.61%; dividend rate &#8211; 0.00%. The fair value of options granted during the year ended June 30, 2017
was estimated using the Black Scholes Method and the following assumptions: volatility &#8211; 136.8% to 143.1%; Term &#8211;
4 years; Risk Free Rate &#8211; 0.53% to 1.4%; dividend rate &#8211; 0.00%.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The compensation expense for the year ended June 30, 2018 includes $30,978 related to
the stock options described above and an adjustment for year ended June 30, 2017 of $30,547. The adjustment was due to a correction
made to the valuation of Stock Options issued to the Chief Operating Officer. The legal and professional expenses for the year
ended June 30, 2018 includes $176,641 related to the stock options described above. The Company expects to recognize $11,486 of
future expenses related to the vesting of stock options through April 11, 2019.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The compensation expense for the year ended June 30, 2017 includes $35,392 related to
the stock options described above. The legal and professional expenses for the year ended June 30, 2017 includes $56,660 related
to the stock options described above.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Extension of Maturity</i></p>

<p style="margin: 0; text-align: justify">In November 2017, the Company extended the maturity date of stock options to acquire
800,000 shares at exercise prices ranging from $0.21 to $0.25 issued to the board of directors between November 2016 and December
2016 by 3 years. The Company recorded an incremental expense of $79,491 based on the increase in fair value of the options.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Offerings of Common Stock and Warrants</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Issuance of Shares for Cash</i></p>

<p style="margin: 0; text-align: justify">In September 2016, the Company sold and issued an aggregate of 49,999 shares of common
stock in a private placement transaction for aggregate gross proceeds of approximately $5,000. The purchase price for the common
stock was $0.10 per share.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In October 2016, the Company sold and issued an aggregate of 225,000 shares of common
stock and warrants to purchase 112,500 shares of common stock in a private placement transaction for aggregate gross proceeds
of approximately $45,000. The purchase price for the common stock and warrants was $0.20 per share. The warrants are exercisable
at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In November 2016, the Company sold and issued an aggregate of 250,000 shares of common
stock and warrants to purchase 125,000 shares of common stock in a private placement transaction for aggregate gross proceeds
of approximately $50,000. The purchase price for the common stock and warrants was $0.20 per share. The warrants are exercisable
at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In December 2016, the Company sold and issued an aggregate of 100,000 shares of common
stock and warrants to purchase 50,000 shares of common stock in a private placement transaction for aggregate gross proceeds of
approximately $20,000. The purchase price for the common stock and warrants was $0.20 per share. The warrants are exercisable
at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In January 2017,&#160;the Company, entered into a common stock purchase agreement (the
&#8220;Purchase Agreement&#8221;) with Aspire Capital Fund, LLC, an Illinois limited liability company (&#8220;Aspire Capital&#8221;)
which provides that, on the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed
to purchase up to an aggregate of $12.0 million of shares of the Company&#8217;s common stock over the 30-month term of the Purchase
Agreement (&#8220;Aspire Equity Line&#8221;). On execution of the Purchase Agreement, the Company agreed to sell to Aspire Capital
1,000,000 shares of common stock and warrants to purchase 500,000 shares of common stock for proceeds of $200,000. The Warrant
Shares will each have a five-year term and will be exercisable at $0.50 per share. Concurrently with entering into the Purchase
Agreement, the Company also entered into a registration rights agreement with Aspire Capital (the &#8220;Registration Rights Agreement&#8221;),
in which the Company agreed to file one or more registration statements, as permissible and necessary to register under the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), registering the sale of the shares of the Company&#8217;s common stock
that have been and may be issued to Aspire Capital under the Purchase Agreement.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Under the Purchase agreement, after the Securities and Exchange Commission (the &#8220;SEC&#8221;)
has declared effective the registration statement referred to above, on any trading day selected by the Company, the Company has
the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a &#8220;Purchase Notice&#8221;), directing
Aspire Capital (as principal) to purchase up to 100,000 shares of the Company&#8217;s common stock per business day, up to $12.0
million of the Company&#8217;s common stock in the aggregate at a per share price (the &#8220;Purchase Price&#8221;) equal to
the lesser of:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right">&#149;</td><td style="width: 5pt"></td><td style="text-align: justify">the lowest sale price of the Company&#8217;s common stock on the purchase date; or</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: right">&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right">&#149;</td><td style="width: 5pt"></td><td style="text-align: justify">the arithmetic average of the three (3) lowest closing sale prices for the Company&#8217;s
common stock during the twelve (12) consecutive trading days ending on the trading day immediately preceding the purchase date.</td>
</tr></table>


<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In addition, on any date on which the Company submits a Purchase Notice to Aspire
Capital in an amount equal to 100,000 shares and the closing sale price of our stock is equal to or greater than $0.30 per share,
the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase
notice (each, a &#8220;VWAP Purchase Notice&#8221;) directing Aspire Capital to purchase an amount of stock equal to up to 30%
of the aggregate shares of the Company&#8217;s common stock traded on its principal market on the next trading day (the &#8220;VWAP
Purchase Date&#8221;), subject to a maximum number of shares the Company may determine. The purchase price per share pursuant
to such VWAP Purchase Notice is generally 95% of the volume-weighted average price for the Company&#8217;s common stock traded
on its principal market on the VWAP Purchase Date.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Purchase Price will be adjusted for any reorganization, recapitalization, non-cash
dividend, stock split, or other similar transaction occurring during the period(s) used to compute the Purchase Price. The Company
may deliver multiple Purchase Notices and VWAP Purchase Notices to Aspire Capital from time to time during the term of the Purchase
Agreement, so long as the most recent purchase has been completed.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Purchase Agreement provides that the Company and Aspire Capital shall not affect
any sales under the Purchase Agreement on any purchase date where the closing sale price of the Company&#8217;s common stock is
less than $0.10. There are no trading volume requirements or restrictions under the Purchase Agreement, and the Company will control
the timing and amount of sales of the Company&#8217;s common stock to Aspire Capital. Aspire Capital has no right to require any
sales by the Company but is obligated to make purchases from the Company as directed by the Company in accordance with the Purchase
Agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions on future funding, rights
of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement. In consideration for entering
into the Purchase Agreement, concurrently with the execution of the Purchase Agreement, the Company issued to Aspire Capital 2,400,000
shares of the Company&#8217;s common stock (the &#8220;Commitment Shares&#8221;). The Purchase Agreement may be terminated by
the Company at any time, at its discretion, without any cost to the Company. Aspire Capital has agreed that neither it nor any
of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of the Company&#8217;s
common stock during any time prior to the termination of the Purchase Agreement. Any proceeds that the Company receives under
the Purchase Agreement are expected to be used for working capital and general corporate purposes.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In March 2017, the Company sold and issued an aggregate of 500,000 shares of common
stock and warrants to purchase 250,000 shares of common stock in a private placement transaction for aggregate gross proceeds
of approximately $100,000. The purchase price for the common stock and warrants was $0.20 per share. The warrants are exercisable
at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In May 2017, the Company sold and issued an aggregate of 240,000 shares of common stock
and warrants to purchase 120,000 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately
$60,000. The purchase price for the common stock and warrants was $0.25 per share. The warrants are exercisable at an exercise
price of $0.60 at any time from date of issuance until 5 years from the date of issuance. In August 2017, the Company issued an
aggregate of 32,727 shares of common stock and 16,364 warrants to compensate these investors who purchased common stock at a $0.25
share price in a Series C offering prior to a reduction in the offering price to $0.22 per share.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In July 2017 and August 2017, the Company sold and issued an aggregate of 886,364 shares
of common stock and warrants to purchase 443,182 shares of common stock in a private placement transaction for aggregate gross
proceeds of approximately $195,000. The purchase price for the common stock and warrants was $0.22 per share. The warrants are
exercisable at an exercise price of $0.60 at any time from date of issuance until 5 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Between July 2017 and September 2017, the Company sold an aggregate of 250,000 shares
of common stock in transactions under the Aspire Equity Line for aggregate gross proceeds of $50,000. The average purchase price
for the common stock was $0.20 per share.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In October 2017, the Company sold and issued an aggregate of 159,091 shares of common
stock and warrants to purchase 79,545 shares of common stock in a private placement transaction for aggregate gross proceeds of
approximately $35,000. The purchase price for the common stock and warrants was $0.22 per share. The warrants are exercisable
at an exercise price of $0.60 at any time from date of issuance until 5 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In November 2017, the Company also sold and issued an aggregate of 68,182 shares of
common stock and warrants to purchase 34,091 shares of common stock in a private placement transaction for aggregate gross proceeds
of approximately $15,000. The purchase price for the common stock and warrants was $0.22 per share. The warrants are exercisable
at an exercise price of $0.60 at any time from date of issuance until 5 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In January 2018, the Company sold an aggregate of 333,333 shares of common stock and
warrants to purchase 333,333 shares of common stock to a member of its board of directors for aggregate gross proceeds of $50,000.
The purchase price for the common stock and warrants was $0.15 per share. The warrants are exercisable at an exercise price of
$0.15 at any time from date of issuance until 7 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In June 2018, 100,000 shares of stock options were exercised for $2,000.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Issuance of Shares for Services</i></p>

<p style="margin: 0; text-align: justify">In August 2017, the Company issued 1,500,000 shares of common stock to Aspire Capital
in exchange for services. The shares were valued at $0.22 per share which was the trading price on date of issuance, and the value
of the services were $330,000.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In November 2017, the Company issued 150,000 shares of common in exchange for services.
The shares were valued at $0.23 per share which was the trading price on date of issuance, and the value of the services were
$34,500.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In January 2018, The Company issued 30,000 shares of common stock in exchange for services.
The shares were valued at $0.13 per share which was the trading price on date of issuance, and the value of the services were
$3,900.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In January 2018, the Company issued 1,400,000 shares of common stock as compensation
for the Board of Directors. The shares were valued at $0.15 per share which was the trading price on date of issuance, and the
value of the compensation was $210,000.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In February 2018, the Company issued 600,000 shares of common stock in exchange for
services. The shares were valued at $0.0475 per share which was the trading price on date of issuance, and the value of the services
were $28,500.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In April 2018, the Company issued 300,000 shares of common in exchange for services.
The shares were valued at $0.045 per share, and the value of the services were $13,500. In April 2018, the Company issued 150,000
shares of common in exchange for services. The shares were valued at $0.024 per share which was the trading price on date of issuance,
and the value of the services were $3,600.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In May 2018, the Company issued 250,000 shares of common in exchange for services. The
shares were valued at $0.018 per share which was the trading price on date of issuance, and the value of the services were $4,500.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In May 2018, the Company issued 68,500 shares of common in exchange for services. The
shares were valued at $0.10 per share which was the trading price on date of issuance, and the value of the services were $6,850.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In June 2018, the Company issued 300,000 shares of common in exchange for services.
The shares were valued at $0.025 per share which was the trading price on date of issuance, and the value of the services were
$7,500.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Issuance of Warrants for Cash</i></p>

<p style="margin: 0; text-align: justify">In December 2017, the Company issued warrants to purchase 2,500,000 shares of common
stock in a private placement transaction for aggregate gross proceeds of $100,000. The purchase price for the warrants were $0.04
per warrant. The warrants are exercisable at an exercise price of $0.20 at any time from date of issuance until 7 years from the
date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Issuance of Warrants for Services</i></p>

<p style="margin: 0; text-align: justify">In January 2018, the Company issued warrants to purchase 105,000 shares of common stock
in exchange for services. The warrants are exercisable at an exercise price of $0.15 any time from the date of issuance until
7 years from the date of issuance. The warrants were valued at $9,444. The fair value of the warrants granted was estimated using
the Black Scholes Method and the following assumptions: volatility &#8211; 166.7%; Term &#8211; 7 years; Risk Free Rate &#8211;
2.48%; dividend rate &#8211; 0.00%</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In February 2018, the Company issued warrants to purchase 105,000 shares of common stock
in a termination agreement. The warrants are exercisable at an exercise price of $0.15 any time from the date of issuance until
7 years from the date of issuance. The warrants were valued at $3,025. The fair value of the warrants granted was estimated using
the Black Scholes Method and the following assumptions: volatility &#8211; 166.7%; Term &#8211; 7 years; Risk Free Rate &#8211;
2.81%; dividend rate &#8211; 0.00%</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Warrant Price Adjustment</i></p>

<p style="margin: 0; text-align: justify">In December 2017, the Company issued warrants to purchase 2,500,000 shares of common
stock in a private placement transaction for aggregate gross proceeds of $100,000. The warrants were exercisable at an exercise
price of $0.20 at any time from date of issuance until 7 years from the date of issuance. The warrants have a down round feature
that reduces the exercise price if the Company sells stock for a lower price. In January 2018, the Company sold shares at $0.15,
which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants
between the stated exercise price and the reduced exercise price and recorded $20,995 as a deemed dividend. The fair value of
the warrants granted was estimated using the Black Scholes Method and the following assumptions: volatility &#8211; 164.7%; Term
&#8211; 7 years; Risk Free Rate &#8211; 2.47%; dividend rate &#8211; 0.00%.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The following table summarizes the warrants that have been issued:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Number of Shares</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Weighted Average Exercise Price</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Weighted Average Remaining Life (Years)</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 46%">Outstanding at June 30, 2016</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">50,00,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">0.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt">Granted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">11,73,864</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">0.51</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">3.5</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Outstanding at June 30, 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,73,864</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.7</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,00,151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.1</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(50,00,000)</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">0.50</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2018</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">47,74,015</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">0.29</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">5.5</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>




<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The following table summarizes the warrants by price:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td colspan="3" style="text-align: center"><b>Weighted Average Exercise Price</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Number of Shares</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Weighted Average Remaining Life (Years)</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 1%; text-align: left">$</td><td style="width: 26%; text-align: right">0.15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: right">30,43,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: center">6.4</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,37,501</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3.5</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">0.60</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">6,93,181</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: center; border-bottom: Black 1pt solid">4.1</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; border-bottom: Black 2.5pt double">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">47,74,015</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: center; border-bottom: Black 2.5pt double">5.5</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>



<p style="margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6801300944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 1%"><b>9.</b></td>
    <td style="width: 99%"><b>Income Taxes</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Deferred income taxes reflect the net tax effects of temporary differences between the
carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. At June
30, 2018, the Company has a Net Operating Loss (&#8220;NOL&#8221;) carryforward of approximately $1,800,000. The NOL expires during
the years 2032 to 2037. Realization of any portion of the $832,186 of net deferred tax assets at June 30, 2018 is not considered
more likely than not by management; accordingly, a valuation allowance has been established for the full amount. The valuation
allowance as of June 30, 2018 was $832,186. The change in the valuation allowance during the year ended June 30, 2018 amounted
to $357,231. The Company does not have any uncertain tax positions or events leading to uncertainty in a tax position. The Company&#8217;s
2015, 2016 and 2017 Corporate Income Tax Returns are subject to Internal Revenue Service examination.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On December 22, 2017, the Tax Cuts and Jobs Act (the &#8220;Act&#8221;) was signed into
law. The Act decreases the U.S. corporate federal income tax rate from a maximum of 35% to a flat 21% effective January 1, 2018.
The Act also includes a number of other provisions including, among others, the elimination of net operating loss carrybacks and
limitations on the use of future losses, the repeal of the Alternative Minimum Tax regime and the repeal of the domestic production
activities deduction. These provisions are not expected to have a material effect on the Corporation.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Given the significant complexity of the Act and anticipated additional implementation
guidance from the Internal Revenue Service, further implications of the Act may be identified in future periods.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Significant components of the Company&#8217;s deferred tax assets are as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Since management of the Company believes that it is more likely than not that the net
deferred tax assets will not provide future benefit, the Company has established a 100 percent valuation allowance on the net
deferred tax assets as of June 30, 2018.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><b>June 30, 2018</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><b>June 30, 2017</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%; text-align: left">Tax loss carryforward</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,55,064</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,46,071</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,277</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,735</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,57,845</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,149</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-bottom: 1pt">Valuation Allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(8,32,186</td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(4,74,955</td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>



<p style="margin: 0; text-align: justify"></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Reconciliation of the differences between income tax benefit computed at the federal
and state statutory tax rates and the provision for income tax benefit for the years ended June 30, 2018 and 2017 is as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2018</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2017</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%; text-align: left">Income tax expense (benefit) at federal statutory rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">34</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">34</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">-39</td><td style="text-align: left; padding-bottom: 1pt">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">-39</td><td style="text-align: left; padding-bottom: 1pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6632241360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><b>9. Subsequent Events</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In April 2019, to facilitate
the Company&#8217;s planned uplisting to the NASDAQ Stock Market and related potential future issuances and sales of equity securities
for ordinary corporate finance and general corporate purposes and as recommended by the Board of Directors (&#8220;Board&#8221;),
the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Articles of Incorporation to effect a reverse split
of its outstanding Class A common stock in the range of 50:1 to 200:1, as determined by the Board. Following that approval, the
Company filed a Registration Statement on Form S-1 (Registration No. 333-231136) (the &#8220;S-1 Registration Statement&#8221;)
pursuant to which it anticipates completing an offering of equity securities with proceeds sufficient to enable the launch and
completion of the BIV201 Phase 2b study and fund internal operations for at least the next twelve months.</p><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><b>10. Subsequent Events</b></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On July 3, 2018, BioVie, Inc., the Company, entered into a Securities Purchase Agreement
(the &#8220;Purchase Agreement&#8221;) with Acuitas Group Holdings, LLC (&#8220;Acuitas&#8221;) and certain other purchasers identified
in the Purchase Agreement (together with Acuitas, the &#8220;Purchasers&#8221;) pursuant to which (i) the Purchasers agreed to
purchase an aggregate of 2,133,332 shares of the Company&#8217;s newly created Series A Convertible Preferred Stock (the &#8220;Preferred
Stock&#8221;) at a price per share of $1.50 per share of Preferred Stock (the &#8220;Initial Sale&#8221;) and (ii) the Company
will issue associated warrants (the &#8220;Warrants&#8221;) to purchase 213,333,200 shares of the Company&#8217;s Class A Common
Stock (the &#8220;Common Stock&#8221;), each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate
consideration of $3.2 million. Acuitas also received an additional 833,333 Warrants in connection with the payoff of a note issued
by the Company in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas
has the option to purchase up to an additional 200,000,000 shares of Common Stock at a price per share of $0.015, and associated
warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial
Sale (the &#8220;Subsequent Sale&#8221;) in the event that the Company has not obtained $3,000,000 of funding through various
non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Each share of Preferred Stock automatically converted into 100 shares of Common Stock
upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to the Company&#8217;s Articles
of Incorporation (the &#8220;Amendment&#8221;) on August 13, 2018 that increased the number of authorized shares of Common Stock
to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of the Company&#8217;s
issued and outstanding Common Stock on July 3, 2018, and was filed with the Secretary of State of the State of Nevada 20 calendar
days following the distribution of the Company&#8217;s Definitive Information to be filed with the Securities and Exchange Commission.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">See the heading &#8220;Series A Convertible Preferred Stock&#8221; below for additional
information related to the Preferred Stock. The purchase price of the Preferred Stock in the Initial Sale, the exercise price
of the Warrants, and the Common Stock in the Subsequent Sale is subject to adjustment. First, in the event that the volume weighted
average price of the Common Stock during the five-trading day period following July 3, 2018 is less than $0.015 per share, the
price per share of Common Stock, the associated conversion ratio of the Preferred Stock, and the exercise price of the Warrants
shall be retroactively adjusted to reflect such lower price. Second, in the event that Mallinckrodt Pharmaceuticals Ireland Limited
prevails in any proceeding which results in the useful life of the Company&#8217;s current intellectual property rights being
reduced by more than 75 percent, then the price per share of Common Stock, the associated conversion ratio of the Preferred Stock,
and the exercise price of the Warrants shall be retroactively adjusted to 50 percent of the then-effective price per share of
Common Stock under the Purchase Agreement (for example, if the then-effective price per share of Common Stock is $0.015, then
following such event, the price per share will be $0.0075). In each case, the Company may be required to issue additional shares
of Common Stock, but in no event will the Company be required to pay cash, to reflect such lower price per share.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Purchase Agreement contained customary representations and warranties. In connection
with the disclosure schedule associated with the representations and warranties, the Company also disclosed customary information,
including the following: (i) the existence of the Mallinckrodt Pharmaceuticals Ireland Limited petition before the US Patent Trial
and Appeal Board, (ii) the current capitalization of the Company, (iii) the Company&#8217;s obligation to pay a royalty on the
net sales of BIV201 (continuous infusion terlipressin) in the amount of five percent to be allocated four percent to LAT Pharma
LLC members, 0.4 percent to PharmaIn Corporation and 0.6 percent to The Barrett Edge, Inc. pursuant to the Agreement and Plan
of Merger, dated April 11, 2016, by and between LAT Pharma LLC and the Company, (iv) the Company&#8217;s obligation to pay a royalty
of five percent on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant
to the Technology Transfer Agreement, dated July 25, 2016, by and between the Company and the University of Padova (Italy), and
(v) certain recent issuances of Common Stock by the Company.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Pursuant to the Purchase Agreement, Terren Peizer, the Chairman of Acuitas, was appointed
as a member of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and as the Chief Executive Officer of the Company,
effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and the underlying common stock under the Purchase Agreement
is exempt from registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to the exemption
for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On July 9, 2018, Elliot Ehrlich entered into an Accord and Debt Satisfaction Agreement
with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment
of his accrued salary dated March 23, 2017 totaling the amount of $222,028.13 and received the settled sum of $22,203 and 222,028
common shares in satisfaction. This settlement reduced the Company&#8217;s debt by $222,028.13.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On July 9, 2018, Jonathan Adams entered into an Accord and Debt Satisfaction Agreement
with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment
of his accrued salary dated March 23, 2017 and subsequent unpaid salary, totaling the amount of $513,889, and received the settled
sum of $25,694 in satisfaction. This settlement reduced the Company&#8217;s debt by $513,889.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On July 19, 2018, Geis-Hides Consulting LLC entered into an Accord and Debt Satisfaction
Agreement with the Company in which the consulting firm agreed to release the Company from all liabilities arising from the Original
Contract and Debt Repayment Plan dated December 15, 2013 totaling $130,000 and received the settled sum of $65,000 and 260,000
common shares in satisfaction. This settlement reduced the Company&#8217;s debt by $130,000.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">As a result of the conversion of the Series A Preferred Stock in July 2018, the exercise
of warrants to purchase 2,500,000 shares of common stock was reduced from $0.15 per share to $0.015 per share. On August 4, 2018,
the Company issued 2,241,913 shares of common stock pursuant to a cash less exercise of warrants to purchase 2,500,000 shares
at an exercise price of $0.015 per share.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On August 8, 2018, Barrett Ehrlich on behalf of The Barrett Edge Inc. (&#8220;Barrett&#8221;)
entered into an Accord and Debt Satisfaction Agreement with the Company in which Barrett agreed to release the Company from all
liabilities including the original contract to defer payment of Barrett&#8217;s accrued salary dated March 23, 2017, loan to the
Company for $14,000, and subsequent unpaid consulting fees, totaling $493,333, and received the settled sum of $131,333 and 493,333
common shares in satisfaction. This settlement reduced the Company&#8217;s debt by $507,333.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6797290000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Basis of Presentation &#8211; Interim Financial
Information</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The accompanying unaudited interim
financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United
State of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article
10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect
all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair
presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for
the full year. The Condensed Balance Sheet at June 30, 2018 was derived from audited annual financial statements but does not contain
all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included
under the heading: &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; should
be read in conjunction with our Company&#8217;s audited financial statements and related notes included in our Company&#8217;s
Form 10-K for the year ended June 30, 2018 filed with the SEC on October 5, 2018.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">For a summary of significant
accounting policies, see the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the
SEC on October 5, 2018.</p><span></span>
</td>
<td class="text"><p style="margin: 0"><i>Basis of Presentation</i></p>

<p style="margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0"><i>Use of Estimates</i></p>

<p style="margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0"><i>Cash</i></p>

<p style="margin: 0; text-align: justify">Cash is maintained at financial institutions and, at times, balances may exceed federally
insured limits. The Company has never experienced any losses related to these balances. All of the Company&#8217;s cash balances
were fully insured at June 30, 2018.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0"><i>Financial Instruments</i></p>

<p style="margin: 0; text-align: justify">The Company&#8217;s financial instruments include cash, accounts payable, related party
loans and a demand promissory note. The carrying amounts of cash and accounts payable approximate their fair value, due to the
short-term nature of these items.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0"><i>Long-Term Notes Payable</i></p>

<p style="margin: 0; text-align: justify">The Company&#8217;s long-term notes payable include accrued payroll to officers and
accrued payments to third party consultants.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0"><i>Research and Development</i></p>

<p style="margin: 0; text-align: justify">Research and development costs are charged to operations when incurred and are included
in operating expenses. The Company expensed $370,853 and $466,354 for research and development for the years ended June 30, 2018
and 2017, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0"><i>Income Taxes</i></p>

<p style="margin: 0; text-align: justify">Deferred income tax assets and liabilities arise from temporary differences associated
with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates,
which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current
or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities
not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary
differences are expected to reverse.&#160;</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company follows the provisions of FASB ASC 740-10 &#8220;<i>Uncertainty in Income
Taxes</i>&#8221; (ASC 740-10), January 1, 2007. The Company has not recognized a liability as a result of the implementation of
ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there
are no unrecognized benefits at June 30, 2018 and since the date of adoption. The Company has not recognized interest expense
or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize
interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.&#160; The Company&#8217;s
tax returns for the years ended June 30, 2015, 2016, 2017 and 2018 remain open to examination by taxing authorities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) per Share</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Net Loss per Common Share</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Basic net loss per common share
is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding
during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares
of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution
that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures.
Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The table below shows the number
of outstanding stock options and warrants as of March 31, 2019 and June 30, 2018:</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30, 2018</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of Shares</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of Shares</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 58%; padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock Options</font></td>
    <td style="width: 8%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,250,000</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 8%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,150,000</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">216,440,548</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,774,015</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>223,690,548</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>9,924,015</b></font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><p style="margin: 0"><i>Earnings (Loss) per Share</i></p>

<p style="margin: 0; text-align: justify">Basic earnings per share are computed by dividing net income by the weighted average
number of shares of common stock outstanding during the year. Diluted earnings per common share are computed by dividing net income
by the weighted average number of shares of common stock outstanding and dilutive options outstanding during the year. For the
years ended June 30, 2017 and 2018 all outstanding options have been excluded from the calculation of the diluted net loss per
share since their effect was anti-dilutive.</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">The following potentially dilutive securities were excluded from the computation of diluted loss per share
for the years ended June 30, 2017 and 2018:</p>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>2017</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>2018</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Number of Shares (Thousands)</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Number of Shares (Thousands)</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%; text-align: center">Stock Options</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">4,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">5,150</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center; padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">6,174</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">4,774</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">10,174</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">9,924</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0"><i>Stock-based Compensation</i></p>

<p style="margin: 0; text-align: justify">The Company has accounted for stock-based compensation under the provisions of FASB
ASC 718 &#8211; &#8220;Stock Compensation&#8221; which requires the use of the fair-value based method to determine compensation
for all arrangements under which employees and others receive shares of stock or equity instruments (stock options and common
stock purchase warrants). For employee awards, the fair value of each stock option award is estimated on the date of grant using
the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free
interest rate. For non-employees, the fair value of each stock option award is estimated on the measurement date using the Black-Scholes
valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.
For non-employees, the Company utilizes the graded vesting attribution method under which the entity treats each separately vesting
portion (tranche) as a separate award and recognizes compensation cost for each tranche over its separate vesting schedule. Expected
volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock
options. For employee awards, the expected term of options granted is derived using the &#8220;simplified method&#8221; which
computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the
U.S. Treasury yield curve in effect at the time of grant for the period of the expected term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0"><i>Goodwill</i></p>

<p style="margin: 0; text-align: justify">Goodwill is recorded when the purchase price paid for an acquisition exceeds the fair
value of net identified tangible and intangible assets acquired. The Company performs an annual impairment test of goodwill and
further periodic tests to the extent indicators of impairment develop between annual impairment tests. The Company&#8217;s impairment
review process compares the fair value of the reporting unit to its carrying value, including the goodwill related to the reporting
unit. To determine the fair value of the reporting unit, the Company may use various approaches including an asset or cost approach,
market approach or income approach or any combination thereof. These approaches may require the Company to make certain estimates
and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each time the
Company tests goodwill for impairment and are typically developed as part of the Company&#8217;s routine business planning and
forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates
could produce materially different results. The Company did not recognize any goodwill impairments for the years ended June 30th,
2017 and June 30th, 2018.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0"><i>Impairment of Long-Lived Assets</i></p>

<p style="margin: 0; text-align: justify">Long-lived assets, including intangible assets, are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows
expected to be generated by the asset.&#160;</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">If the carrying amount of an asset exceeds its undiscounted estimated future cash flows,
an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the asset
exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected discounted
cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported
at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and
liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability
sections of the balance sheet.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Recent accounting pronouncements</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company considers the applicability
and impact of all Accounting Standard Updates (&#8220;ASU&#8217;s&#8221;). ASU&#8217;s not discussed below were assessed and determined
to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In June 2018, the FASB issued
ASU 2018-07, &#8220;Compensation &#8211; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting&#8221;.
This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment
transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings
as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair
value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim
periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on the
financial statements.</p><span></span>
</td>
<td class="text"><p style="margin: 0"><i>Recent accounting pronouncements</i></p>

<p style="margin: 0; text-align: justify">The Company has reviewed recent accounting pronouncements issued by the FASB (including
its EITF), the AICPA, and the SEC and did not or are not believed by management to have a material impact on the Company&#8217;s
financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6801329424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureSignificantAccountingPoliciesTablesAbstract', window );"><strong>Disclosure Significant Accounting Policies Tables Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive securities were excluded from the computation of diluted loss per share</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The table below shows the number
of outstanding stock options and warrants as of March 31, 2019 and June 30, 2018:</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30, 2018</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of Shares</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of Shares</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock Options</font></td>
    <td style="width: 8%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,250,000</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 8%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,150,000</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">216,440,548</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,774,015</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>223,690,548</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>9,924,015</b></font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><p style="margin: 0">The following potentially dilutive securities were excluded from the computation of diluted loss per share
for the years ended June 30, 2017 and 2018:</p>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>2017</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>2018</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Number of Shares (Thousands)</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Number of Shares (Thousands)</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%; text-align: center">Stock Options</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">4,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">5,150</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center; padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">6,174</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">4,774</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">10,174</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">9,924</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureSignificantAccountingPoliciesTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureSignificantAccountingPoliciesTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6792815440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureIntangibleAssetsTablesAbstract', window );"><strong>Disclosure Intangible Assets Tables Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Intellectual
property, stated at cost, less accumulated amortization consists of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30, 2018</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 58%; padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Intellectual Property</font></td>
    <td style="width: 8%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,293,770</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 8%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,293,770</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated Amortization</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">681,823</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">509,790</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Intellectual Property, Net</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,611,947</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,783,980</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify">The following is a summary of the intangible
assets as of June 30, 2018 and 2017.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>June 30, 2018</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>June 30, 2017</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%; text-align: left">Intangible Assets subject to Amortization</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">22,93,770</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">22,93,770</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">5,09,790</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">2,80,413</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-bottom: 2.5pt">Intangible Assets (Net of Amortization)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">17,83,980</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">20,13,357</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future expected Amortization of intangible assets</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Estimated future
amortization expense is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td colspan="4" style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">Year ending June 2019 (remaining three months)</font></td>
    <td style="vertical-align: bottom; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;57,344 </font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; text-align: right; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">2020</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td colspan="4" style="vertical-align: bottom; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">2021</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td colspan="4" style="vertical-align: bottom; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">2022</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td colspan="4" style="vertical-align: bottom; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">2023</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td colspan="4" style="vertical-align: bottom; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377</font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">Thereafter</font></td>
    <td style="vertical-align: top; padding-bottom: 1pt; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 1pt; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td colspan="4" style="vertical-align: bottom; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;637,095</font></td>
    <td style="vertical-align: top; padding-bottom: 1pt; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: bottom; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 2.5pt; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 2.5pt; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td colspan="4" style="vertical-align: bottom; border-top: black 1pt solid; border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt/115% Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,611,947 </font></td>
    <td style="vertical-align: top; padding-bottom: 2.5pt; line-height: 107%">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify">Future expected Amortization of intangible assets is as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center"><b>Year Ending June 30,</b></td><td><b>&#160;</b></td>
    <td colspan="3"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 70%; text-align: center">2019</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">2,29,377</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center">2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,29,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,29,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,29,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,29,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,37,095</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,83,980</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureIntangibleAssetsTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureIntangibleAssetsTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6643136112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options activity</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The following table summarizes
the activity relating to the Company&#8217;s stock options for the nine months ended March 31, 2019:</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-Average Exercise Price</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Remaining Average Contractual Term</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate Intrinsic Value</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 44%; padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at June 30, 2018</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,150,000</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.12</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.8</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,100,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.04</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.6</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">88,370</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options Exercised or Forfeited</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at March 31, 2019</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,250,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.10</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.3</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">166,175</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable at March 31, 2019</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,250,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.10</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.3</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The fair value of each option
grant on the date of grant is estimated using the Black-Scholes Option &#8211; Pricing model reflecting the following weighted-average
assumptions:</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="7" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31,</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 58%; padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected life of options (In years)</font></td>
    <td style="width: 8%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 8%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">69.77</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">69.66</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk free interest rate</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.60</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.59</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Dividend Yield</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify">The following is a summary of stock option activity for the years ended June 30, 2017
and 2018.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><b>Shares (Thousands)</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><b>Weighted-Average Exercise
    Price</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><b>Weighted Remaining Average
    Contractual Term</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Options</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 46%">Outstanding at July 1, 2016</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">3,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">0.06</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">6.5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt">Granted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">1,000</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">0.24</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">4.0</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Outstanding at June 30, 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.9</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.0</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-bottom: 1pt">Options Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(100)</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">0.02</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2018</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">5,150</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">0.12</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">5.8</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt">Exercisable at June 30, 2018</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">4,150</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">0.13</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">4.8</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of stock option plans by exercise price range</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The following is a summary of
stock options outstanding and exercisable by exercise price as of March 31, 2019:</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Contract Life</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 20%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.03</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 5%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 19%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">700,000</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 5%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 19%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.8</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 5%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 19%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">700,000</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.05</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,300,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.6</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,300,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.06</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,100,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6.9</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,100,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.07</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.5</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.10</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.8</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.20</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.5</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.21</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">550,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.1</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">550,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.22</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.0</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.23</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.4</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.25</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.6</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,250,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,250,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify">The following is a summary of stock options outstanding and exercisable by exercise
price as of June 30, 2018.</p>
<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Exercise Price</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Outstanding</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Contract Life</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Exercisable</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">0.06</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">31,00,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: center">6.5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">21,00,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">$</td><td style="text-align: right">0.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,00,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">4.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,00,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,00,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">4.5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,00,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">$</td><td style="text-align: right">0.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">4.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,50,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,00,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">4.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,00,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">$</td><td style="text-align: right">0.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,00,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">4.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,00,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">$</td><td style="text-align: right">0.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,00,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,00,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">&#160;</td><td style="text-align: center">Total</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">51,50,000</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">41,50,000</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options activity</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The following table summarizes
the warrants that have been issued:</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted </b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of Shares</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Average Exercise Price</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Remaining Life (Years)</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Intrinsic Value</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 44%; padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at June 30, 2018</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,774,015</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.29</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.5</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">214,166,533</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.02</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.3</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">14,284,908</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(2,500,000</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.02</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding and exercisable at March 31, 2019</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">216,440,548</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.03</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.3</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">14,284,908</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify">The following table summarizes the warrants that have been issued:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Number of Shares</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Weighted Average Exercise Price</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Weighted Average Remaining Life (Years)</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 46%">Outstanding at June 30, 2016</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">50,00,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">0.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt">Granted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">11,73,864</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">0.51</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">3.5</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Outstanding at June 30, 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,73,864</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.7</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,00,151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.1</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(50,00,000)</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">0.50</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2018</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">47,74,015</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">0.29</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">5.5</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of stock option plans by exercise price range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify">The following table summarizes the warrants by price:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td colspan="3" style="text-align: center"><b>Weighted Average Exercise Price</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Number of Shares</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Weighted Average Remaining Life (Years)</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 1%; text-align: left">$</td><td style="width: 26%; text-align: right">0.15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: right">30,43,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: center">6.4</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,37,501</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3.5</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">0.60</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">6,93,181</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: center; border-bottom: Black 1pt solid">4.1</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; border-bottom: Black 2.5pt double">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">47,74,015</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: center; border-bottom: Black 2.5pt double">5.5</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6794438624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of gross amounts of deferred tax assets and deferred tax liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom; background-color: white"><td style="padding-bottom: 1pt"></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><b>June 30, 2018</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><b>June 30, 2017</b></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%; text-align: left">Tax loss carryforward</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,55,064</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,46,071</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,277</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,735</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,57,845</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,149</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-bottom: 1pt">Valuation Allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(8,32,186</td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(4,74,955</td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of the federal statutory income tax rate to income tax expense expense</a></td>
<td class="text"><p style="margin: 0; text-align: justify">Reconciliation of the differences between income tax benefit computed at the federal
and state statutory tax rates and the provision for income tax benefit for the years ended June 30, 2018 and 2017 is as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2018</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2017</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%; text-align: left">Income tax expense (benefit) at federal statutory rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">34</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">34</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">-39</td><td style="text-align: left; padding-bottom: 1pt">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">-39</td><td style="text-align: left; padding-bottom: 1pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6801234480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liquidity (Details Narrative) - Acuitas Group Holdings, LLC and Other Purchaser [Member] - Subsequent Event [Member]<br></strong></div></th>
<th class="th">
<div>Jul. 03, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1', window );">Warrants to be Issued | shares</a></td>
<td class="nump">213,333,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total Consideration | $</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bivi_AcuitasGroupHoldingsLLCAndOtherPurchaserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bivi_AcuitasGroupHoldingsLLCAndOtherPurchaserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6797235584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive Securities excluded from the Computation of Diluted Loss Per Share</a></td>
<td class="nump">223,690,548<span></span>
</td>
<td class="nump">9,924,015<span></span>
</td>
<td class="nump">9,924,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive Securities excluded from the Computation of Diluted Loss Per Share</a></td>
<td class="nump">216,440,548<span></span>
</td>
<td class="nump">4,774,015<span></span>
</td>
<td class="nump">4,774,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive Securities excluded from the Computation of Diluted Loss Per Share</a></td>
<td class="nump">7,250,000<span></span>
</td>
<td class="nump">5,150,000<span></span>
</td>
<td class="nump">5,150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6799621392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureIntangibleAssetsDetailsAbstract', window );"><strong>Disclosure Intangible Assets Details Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible Assets subject to Amortization</a></td>
<td class="nump">$ 2,293,770<span></span>
</td>
<td class="nump">$ 2,293,770<span></span>
</td>
<td class="nump">$ 2,293,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">681,823<span></span>
</td>
<td class="nump">509,790<span></span>
</td>
<td class="nump">280,413<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 1,611,947<span></span>
</td>
<td class="nump">$ 1,783,980<span></span>
</td>
<td class="nump">$ 2,013,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureIntangibleAssetsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureIntangibleAssetsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6808475456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details 2) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureIntangibleAssetsDetails2Abstract', window );"><strong>Disclosure Intangible Assets Details 2Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">2019</a></td>
<td class="nump">$ 57,344<span></span>
</td>
<td class="nump">$ 229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2020</a></td>
<td class="nump">229,377<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2021</a></td>
<td class="nump">229,377<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2022</a></td>
<td class="nump">229,377<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive', window );">2023</a></td>
<td class="nump">229,377<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">637,095<span></span>
</td>
<td class="nump">637,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 1,611,947<span></span>
</td>
<td class="nump">$ 1,783,980<span></span>
</td>
<td class="nump">$ 2,013,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureIntangibleAssetsDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureIntangibleAssetsDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6811012448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionNineMember', window );">StockOptionNineMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at end of year</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable at end of year</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term at the beginning</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionEightMember', window );">StockOptionEightMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at end of year</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable at end of year</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term at the beginning</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at beginning of year</a></td>
<td class="nump">5,150,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option Granted</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at end of year</a></td>
<td class="nump">7,250,000<span></span>
</td>
<td class="nump">5,150,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable at end of year</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="nump">4,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding Weighted Average Exercise Price at the beginning</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ .10<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="nump">.15<span></span>
</td>
<td class="nump">.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding Weighted Average Exercise Price at the end</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
<td class="nump">$ .10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Excersiable Weighted Average Exercise Price at the end</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term at the beginning</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 10 months 15 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Granted</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4', window );">Weighted Average Remaining Contractual Term at the end</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 10 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Excersiable Weighted Average Remaining Contractual Term at the end</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding at beginning of period</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Granted</a></td>
<td class="nump">88,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options Exercised or Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding at end of period</a></td>
<td class="nump">166,175<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSixMember', window );">StockOptionSixMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at beginning of year</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at end of year</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable at end of year</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term at the beginning</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFiveMember', window );">StockOptionFiveMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at beginning of year</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at end of year</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable at end of year</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term at the beginning</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFourMember', window );">StockOptionFourMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at beginning of year</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at end of year</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable at end of year</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term at the beginning</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionThreeMember', window );">StockOptionThreeMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at beginning of year</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at end of year</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable at end of year</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term at the beginning</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTwoMember', window );">StockOptionTwoMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at beginning of year</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at end of year</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable at end of year</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term at the beginning</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSevenMember', window );">StockOptionSevenMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at beginning of year</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at end of year</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable at end of year</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term at the beginning</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionOneMember', window );">StockOptionOneMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at beginning of year</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at end of year</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable at end of year</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term at the beginning</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards vested. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6816108368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Warrant, Exercise Price</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrant, Shares issued</a></td>
<td class="nump">216,440,548<span></span>
</td>
<td class="nump">4,774,015<span></span>
</td>
<td class="nump">6,173,864<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3', window );">Warrant, Weighted Average Contractual Life</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=bivi_WarrantThreeMember', window );">WarrantThreeMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Warrant, Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrant, Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3', window );">Warrant, Weighted Average Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=bivi_WarrantTwoMember', window );">WarrantTwoMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Warrant, Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrant, Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3', window );">Warrant, Weighted Average Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=bivi_WarrantOneMember', window );">WarrantOneMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Warrant, Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrant, Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,043,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3', window );">Warrant, Weighted Average Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSixMember', window );">StockOptionSixMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">7,250,000<span></span>
</td>
<td class="nump">5,150,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 10 months 15 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="nump">4,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionNineMember', window );">StockOptionNineMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionEightMember', window );">StockOptionEightMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSevenMember', window );">StockOptionSevenMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFiveMember', window );">StockOptionFiveMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionOneMember', window );">StockOptionOneMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTwoMember', window );">StockOptionTwoMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionThreeMember', window );">StockOptionThreeMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFourMember', window );">StockOptionFourMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of the option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Footnote 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted average intrinsic value of equity-based compensation awards not vested. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=bivi_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=bivi_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=bivi_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=bivi_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=bivi_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=bivi_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6799767184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details 3) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionThreeMember', window );">StockOptionThreeMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionNineMember', window );">StockOptionNineMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionEightMember', window );">StockOptionEightMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSevenMember', window );">StockOptionSevenMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSixMember', window );">StockOptionSixMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFiveMember', window );">StockOptionFiveMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFourMember', window );">StockOptionFourMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionOneMember', window );">StockOptionOneMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTwoMember', window );">StockOptionTwoMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">7,250,000<span></span>
</td>
<td class="nump">5,150,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 10 months 15 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="nump">4,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of the option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Footnote 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6799765376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrant Outstanding at the beginning of the year</a></td>
<td class="nump">4,774,015<span></span>
</td>
<td class="nump">6,173,864<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Warrant Granted</a></td>
<td class="nump">214,166,533<span></span>
</td>
<td class="nump">3,600,151<span></span>
</td>
<td class="nump">1,173,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Warrant Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease', window );">Warrant Exercised</a></td>
<td class="num">(2,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrant Outstanding at the end of year</a></td>
<td class="nump">216,440,548<span></span>
</td>
<td class="nump">4,774,015<span></span>
</td>
<td class="nump">6,173,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Weighted Average Exercise Price at the beginning of the year</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">0.22<span></span>
</td>
<td class="nump">0.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Weighted Average Exercise Price at the end of year</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Life at the beginning of the year</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1', window );">Weighted Average Remaining Life, Granted</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3', window );">Weighted Average Remaining Life at the end of year</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate Intrinsic Value, Granted</a></td>
<td class="nump">$ 14,284,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding at end of period</a></td>
<td class="nump">$ 14,284,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=bivi_WarrantThreeMember', window );">WarrantThreeMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrant Outstanding at the beginning of the year</a></td>
<td class="nump">693,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrant Outstanding at the end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Weighted Average Exercise Price at the beginning of the year</a></td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Weighted Average Exercise Price at the end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3', window );">Weighted Average Remaining Life at the end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=bivi_WarrantOneMember', window );">WarrantOneMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrant Outstanding at the beginning of the year</a></td>
<td class="nump">3,043,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrant Outstanding at the end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,043,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Weighted Average Exercise Price at the beginning of the year</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Weighted Average Exercise Price at the end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3', window );">Weighted Average Remaining Life at the end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=bivi_WarrantTwoMember', window );">WarrantTwoMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrant Outstanding at the beginning of the year</a></td>
<td class="nump">1,037,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrant Outstanding at the end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Weighted Average Exercise Price at the beginning of the year</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Weighted Average Exercise Price at the end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3', window );">Weighted Average Remaining Life at the end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted average intrinsic value of equity-based compensation awards excersied. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted average intrinsic value of equity-based compensation awards forfeited. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted average intrinsic value of equity-based compensation awards granted. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted average intrinsic value of equity-based compensation awards not vested. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards vested. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=bivi_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=bivi_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=bivi_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=bivi_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=bivi_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=bivi_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6634299968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax expense (benefit) at U.S. statutory rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax expense (benefit), net of federal benefit</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Change in valuation allowance</a></td>
<td class="num">(39.00%)<span></span>
</td>
<td class="num">(39.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6794261488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Tax loss carryforward</a></td>
<td class="nump">$ 555,064<span></span>
</td>
<td class="nump">$ 446,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">19,277<span></span>
</td>
<td class="nump">3,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">257,845<span></span>
</td>
<td class="nump">25,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">(832,186)<span></span>
</td>
<td class="num">(474,955)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !)HX4X?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ $FCA3B?HAPZ"    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MKC_\KL*N,W9O_['Q1;"IX===-%]02P,$%     @ $FCA3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M(PTUG@@,9S2TZRL&[+@M5[P=7*QX)E8D7Q,0^H_J8?!_8GEP_>")?I"B9T5
M.)^*AH4G&H,T8BI,=;.FQLYSM>)9;QZ<KU K%9C&$X7AC0J0KBO4RKRM\;E)
MKE;"?%=C13#@?06FJ<"T@?0S0C;>PQ'+>>#8?RY8 NM[R-1(0!@ TO? S<-
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M53\-#M[WF[NW'[;]U^/IVU.#9/_ZX6.O/QQWSY</5EN^?;K;[?\ 4$L#!!0
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M:N.FUW:NI@Z8 B/[T-QD_L,4?P%02P,$%     @ $FCA3J,T?\S- 0  ;00
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MP^REV-[L,W8)0A/F.&*2!>8ZG2$,Y><:R5J-8_*.G_R#GZYZ3",__</CS;K
M;E5@%P5V_VWR/08G^Z\B;'&J"FP3Y\F1TO0ZSO(B.X_L;1)OY3=\G/=';ANA
M'3D;CW<;;Z VQ@-:V5SA$+7XQ.9 0NW#]B/N[3AH8^!--[TA-C_DXA=02P,$
M%     @ $FCA3D7@24#+ 0  ;00  !D   !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL?51A;YT@%/TKA!]0?.BZ[D5-^M[2;,F6O'19^YFG5R4%L8#/[M\/
MT%IG7;\(]W+.X5S@F@Y*/YD&P*(7*5J3X<;:;D^(*1J0S%RI#EJW4BDMF76A
MKHGI-+ RD*0@-(JNB62\Q7D:<B>=IZJW@K=PTLCT4C+]YP!"#1G>X=?$/:\;
MZQ,D3SM6PR^PO[N3=A&954HNH35<M4A#E>';W?Z8>'P /' 8S&*.?"5GI9Y\
M\+W,<.0-@8#">@7FA@L<00@OY&P\3YIXWM(3E_-7];M0NZOES P<E7CDI6TR
M?(-1"17KA;U7PS>8ZOF$T53\#[B <'#OQ.U1*&'"%Q6]L4I.*LZ*9"_CR-LP
M#N,*_3+1M@ET(M"9<!-]2(@G0KPBD-%9*/4KLRQ/M1J0'B^K8_Y-[/:Q.\S"
M)\/9A357K7'92TZC74HN7FC"'$8,76!6B.-[Q'4\0X@S,+N@6RX.]!V?KG;8
M0/QGAWBSSCCPXW_JI-L"R:9 $@22#P]J"Q.O"MG")"LC9'%[$G0='KI!A>K;
MT&2+[-Q+MS3<_AM\;,2?3->\->BLK'M#X:8KI2PX*]&5>]V-Z_TY$%!9/_WL
MYGKL@#&PJIN:F\Q_F/PO4$L#!!0    ( !)HX4Y+:43F=P(  !\)   9
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M_8BA"TQXC3A\1-Q%,X18 [,+NN5B3S_PZ6J'#<1_=H@VZXP\/[KBA]L"\:9
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M/N#>IN%(AC?#-/=T?GSU7U!+ P04    "  2:.%.T!2K)S<"  # !@  &0
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MHGO,'+%U(/ <LG- R 1!VN-D-'(:C2P?SXRF;@'L%,!6@,P$LD6E R:VF';
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M.MUW33ZKYNK[6O#E:O'>&C*:3:_A-QHV5&Q=A1)7R:)QX.H%1UYLN-.>6ST
MA1A*=D!"0\FC*Q$BPHX*F"[1&:#;/J3' $$#Y!@0PLKFIM<L.\VYTT1?(BO:
M+1+9([=#(FGE9%PS"$G"D"0(R1J^3:]1-YUPIH@B28D5EZND.*:(66[O7)UB
ML4B4/>2N3D;='PY1P1 5"-$:D W01,H*#MFQ'-XAC6<\8NAL# PH;""!!I+I
M.;I-P*SQ=+*$G2RG9\UVZ8[Q4K"$X7Y8A D730_>%HFX9XHP#TD9Z"?VF( 8
M?& \(/-&%%2P#%.,N1ASDV]$M]EGD8AEY$L_!AY#Q'/2#T2,//U@"C&$H<1C
M E<Y0Z7GI%^!]#-?_G&%,E2B3OYC)_\B(G&;O&%?N)@9JF8G_TBT]/2#ZYF!
M@F:^30"N5 Z*D"(+LT9D+7SV;@&*/(/$<3US4,]D+]5&-%C8AJN+<6A2-W0)
M\X$#/I"]U"(1(]L?)/+E!T.$ XB0O2AR%R(X/Y.ZH4N8-=S%"%>^J#!&.,"(
M.^KNIB+F$H4%=A\,"'= 2!%(U",0BK']#,>HXP!U[DQR17QI[]>@R-Z'HNZ\
M'F-F<L!,=[JYS%1X8%PA60,S= K#E;O<Y(G/!.8F!]QTH;=$///056"Z"D17
M>V8;46@="HQ.@=!ISRX@XHEGS1>8AP+QT)X31A0<DN?&#]SY)1ZT"$PG 38Y
MSD@+>%_'/1UAAHD0A@D7)&PL+9@C(H0C0,03S\V"P-4O0JI?N$4]&A*N:0'V
M0KZM@\ U+4)J6L":MK>;6.6I?,*53R&53V[E2T1.I!M),F%"4 @AD(C;M]10
MY+GM(HP1"L$(N1C!^0&ZL?Q@W!#87#%/R9#G25,(;@CAQIZ#4.1C$F$F40B3
MR/>PQG;H<^PBS"X*81<2L=CV!VUO/$L98<!1".#(!1S.S^= 2!B$A$#HN:,F
M#$(* 2$AQ+G/.Z'*4Q(2@U"&@%"Z@(M1DH%.C&598A+*$!(BD?UP>XM$7F<P
M"64(":5+.)P@L/$:31!&H00H]"V $J-0AJ!0PL?NT@YJ')A#;SS/RT-0* 'B
M!,SR)#.'/F$6RA 6(E%D/WI!(NYAH<0LE"$LE(!Q.$&3T!SZA&$H$0Q]XXYA
M*$-@*"<P9V*"NT+/+QJ8A2J$A6J:<>:'C<_=-RK,0A7"0B3B]BQ$(N9YH*DP
M"U4("]4TXXQ#G[L+59B%"FT+/4NRPBQ4(2Q4D(4]Y:]_]C81-O+5B,)L5"%L
M5)/;/^,00./(,Q[E^>TO!(U(Q):V/PB-/F<P&E4(&M7D]L_X \B(\K.X.4R0
MZ_*U.]E1S?;%V[EN?TV_N7H]/?+ V\,(UO4MN]OU9T!^FNF/I/R1EJ^G<S5[
M+NJZR+L#"2]%4>O&S>A+,XQ'G1ZN'S+]4K=OX^9]V1\%Z3_4Q<4<<UE<S]JL
M_P=02P,$%     @ $FCA3@]BF(RW!   1QP  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&ULE9GKCN(X$(5?)<H#=.*R$Z %2 WT:%?:E5JSVIW?:3 7
M32YL$IK9M]]</!FPCX.[?S0DG*H<5^S/3CR_%N7WZBAE[?W(TKQ:^,>Z/C\'
M0;4]RBRIGHJSS)M?]D69)75S6!Z"ZES*9-<%96E 81@'67+*_>6\._=6+N?%
MI4Y/N7PKO>J294GYWTJFQ77A,__GB:^GP[%N3P3+^3DYR+]D_??YK6R.@B'+
M[I3)O#H5N5?*_<)_8<^O41?0*?XYR6MU\]UKF_)>%-_;@]]W"S]L'<E4;NLV
M1=)\?,BU3-,V4^/C7Y74'Z[9!MY^_YG]2]?XIC'O22771?KMM*N/"W_J>SNY
M3RYI_;6X_B95@R+?4ZW_0W[(M)&W3IIK;(NTZOY[VTM5%YG*TEC)DA_]YRGO
M/J_]+R)283B 5  - 12/!G 5P%T#A H00P";C 9$*B#Z%2"Z\O9M[XJY2>ID
M.2^+JU?V_>&<M-V./4?-[=JV)[N[T_W6U+-JSGXLN1#SX*--I#2K7D,W&G:O
M6)N*F ^2H#$PN"#D8D5&/&E7  I^+]D B=:25U/">8B-<E@NWB40MPF(X00"
M)A!F A%J]>XULTZ3=YKP*8RU@B 182<1=!(!)]I]7?6:^.8BG(7MGV;&U-&]
M[,Y/#/W$P(_6"U9 0WI/ 1HVPT8FT,@$&-'ZVFIB-A@6!NA&"C.%?J:&'YI:
M$LQ@@IE#GYNA[F09PRS$* D=>I02N5:$6:C%'#H+$-%46*X#N?3"R*$O*)%S
MDS!9F(D6FD:6%)@MS 4N#(+#0@Z&T<%<V,%,*+"QLF J,!<L !%-8\MU\*!G
M+J.>F<-YM$EX/#-S0'.RW6D\HIG+D&9P3!M3]V=&/N&13RXCG\R1'T4 F4@W
M4F3"A" 70B 1Z1,M%$TL9C!&R 4C9&($UP?HQNJ#<4-@)<-L=QWCAEQP0^/K
M%-4D*+(,"<),(A<FT<.%BC+TN04-87:1"[N0B G=#Q+9ZH,!1RZ HX?K%>7G
M<^L:PB D $)FP39A$)(+" DA3N<@%-GF18XYR%TXR!_RK3<$=&.3#<<<Y"X<
M1"(VT?T 46A93G',0>["0?Z0;\J/J1NMC^6!#G%P:DF!.<A=.,CA0]TDO/O3
M^R0,LCUO<LQ%[L)%_G"MI@R9.FV.NK>$N<A=N(A$-\]QR@]Z(+29P5SD+ESD
M#Q=^RH^I&ZT/YB)'"T1;G\1<Y"Y<Y AY(=?;!%463 L,1N$"1F$";X**#'3Z
M6XE[3YB,PH6,2*2_55HCD=4,)J-P(:,PB8<+!!Y(1PN$T2C0RR[+$E%8WG8Y
MO>Z":(ST1B&5[=4;1J%P0:$ *.2PRH"%8T7&+!0N+$2B4%]$(Q%9YF>!62A<
M6"@ "W&!  S'"H1A*,#KK]BR]!48A@+!T+CO,W-P$7K^ L*( >$&"$4("O4*
MA#P<J52$(1LAR.I="8AH-M6:"$7:W+M!E[,ZQ@B.$(+U_J9$M]6)X8T!0L'0
M[!O<;(YDLCQT.U65MRTN>=WN#MR<'7;#7JC=7-'.K]GSIM_3^I6FWV+[,RD/
MI[SRWHNZ+K)N@V5?%+5L?(9/#3B.,MD-!ZG<U^W72?.][+>V^H.Z.*MMNV#8
M.US^#U!+ P04    "  2:.%.V##,DR@$  !,%   &0   'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6R56-N.FT@0_17$^P;ZPL4CV](,:+4K)=(HJ]U]9NRV
MC0*T%_ X^?MPZ7BA^N X\S! ^U37Z:+J5-/KJZZ_-">E6N=K653-QCVU[?G)
M\YK=2959\T&?5=7]<M!UF;7=8WWTFG.MLOU@5!8>]_W0*[.\<K?K8>RUWJ[U
MI2WR2KW63G,IRZS^]J(*?=VXS/TQ\#D_GMI^P-NNS]E1_:7:O\^O=??DW6;9
MYZ6JFEQ73JT.&_>9/:4B[ T&Q#^YNC:3>Z=?RIO67_J'/_<;U^\9J4+MVGZ*
MK+N\JT0513]3Q^,_,ZE[\]D;3N]_S/[[L/AN,6]9HQ)=_)OOV]/&C5UGKP[9
MI6@_Z^L?RBPH<!VS^H_J714=O&?2^=CIHAG^.[M+T^K2S-)1*;.OXS6OANMU
M_"5DQ@P;<&/ ;P8\N&L@C(%XU$ : WDS8-$0K7$I0VS2K,VVZUI?G7I\O>>L
MSR+V)+OH[_K!(=C#;UUXFF[T?2MDL/;>^XD,YF7$\ F&S1&)C0C%#>)U!&XL
M.&+QPBU[3CP A)A#4@"1F(2 H1"#O9S:!SZ>0,()I#6!D"&)Y8@)!TPU8&04
M29^1F"<V+F21B$-)%FWC G_XP\0#2#P Q"-"/+ <<299& :"O(?$1HK0[U9(
MDB:U<8PL<48]A-1#0#TFU &&K"X)+2Z_W8UC!,E$@,R*D(EL3SRXXRF&GF+;
MTR171T\Q>&.AE'Y  Y382)B4J8VC23FCOH+45X Z28V7$;.:./(_<!+)!($H
MX_N8&5OF8X'T;5E8<:J0(ZB_3!SY5,0PC!-8BF&3(,UY+P@[ W&V> ,0+0V#
MH6P6R$!]?V8<!-%J,_PG09Q[PB+.;!47@:">!$@+G^H81-$L3"%J*3JX;S#0
M. )).0.0D)0R BV1P;V @6806*\*@/R0DD$SA31\ ,06](3A%L" O@>T?2&0
MS1B :(Q3"%J*,>X3##2*@'8M PJF_5'R6*[\>,$9;A4,] I&!=> ?L$9%G<&
MU%V$> J.!9?;@FMOHPQHUHI6@L4+&LFQ1G*DD:2-)@;TL"NL@-Q60+OM&=!<
M2Y:BA_6//Z!_"4>:M>0':Q9'FD5;!P+QA7T.QW+$@3Z(A9SD6!\XVB-:"67O
M (4OA1!+WS&XLCFJ;"NC[#W@?5^XL#G:!%HI%8-7S1;DBN.BYFC+9N44VFHM
M.1*X] 4H?2NI$$BL%OS@NA>@[B?[GOD4N)X%J&<KJ0QH]HGCBRCP%[1#+'R8
MHIJF265 C_O"=2U07=.D,J"']CP"U[5 FP.:4P;TF!]<_.*!S4&"0-8FQ)L<
MJ92J/@['58VSTY>J[8\=)J.W([%GWA_)D/&$/:7CP=;_TXSG;)^R^IA7C?.F
MVU:7P[',0>M6=1R[=;O.267[VT.A#FU_&W7W]7B^-3ZT^FS.[KS; >+V.U!+
M P04    "  2:.%.;PE?DPX"  #\!0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S,"YX;6Q]5.V.FS 0?!7$ YP#!M)$!.F2JFJE5HJN:OO;@>5#9V-J.^'Z
M]K4-QQ%B\0?;ZYG961MOVG/Q*FL Y;TQVLJ#7RO5[1&2>0V,R"?>0:MW2BX8
M47HI*B0[ :2P)$91N-DDB)&F];/4QLXB2_E5T::%L_#DE3$B_AV!\O[@!_Y[
MX*6I:F4"*$L[4L%/4+^ZL] K-*D4#8-6-KSU!)0'_SG8G[8&;P&_&^CE;.Z9
M2BZ<OYK%M^+@;XPAH) KHT#T<(,34&J$M(V_HZ8_I33$^?Q=_8NM7==R(1).
MG/YI"E4?_$^^5T!)KE2]\/XKC/7$OC<6_QUN0#7<.-$Y<DZE_7KY52K.1A5M
MA9&W86Q:._;#3KP;:6Y".!+"B1 DJP0\$O '(;+%#\YLJ9^)(EDJ>.^)X;(Z
M8OZ)8(_U8>8F:,_.[NEJI8[>,ASO4G0S0B/F.&#"&2;!$P1I^2E'Z,IQ#!_X
M(;Y/<7) (G<*["P#6SZ>\8/=SBT0.04B*Q#-SR'9+,[!A0D6A:QC[HS$3B.Q
M0R!<&'%AEB>ZCKDSDCB-) Z!:&'$A8D71M8Q=T:V3B/;!X'=\F8>(7B[L+$*
M&5R@V:-A("K;7Z27\VNKS,\YBTXM[#DTCVX1/^K6-G2B#YFA+_X@HFI:Z5VX
MTD_:/KR2<P7:X>9)7UFM6_&TH% J,]WJN1@:TK!0O!M[+9H:?O8?4$L#!!0
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MJ6YUM)/&WF]_"X]2&K!VR8,]ZLJ^R]-"P-&X*;-S-;Q.P\+(;GQXT?3ZE_\
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M U2\S>(RSB*]_:%8Q[/D/_X B%@D^4/RAY]TS>0T#\R=9TV[-[?Q-HUOT@6
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M6UZG-;<ON7;@EO5>74^OS]\!B;[2EV_TY8?SC]/KB\OW^S'-7G]OV;+"4R]
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MM3+(\@"7012!R[N!45!@1K$!YWXW^WF; O<RUE=UL2HVZ6:[D2N##S^FLWN
MQWFD?YUV]'2QT$7Z!0\6OP<Y?[4BHBJSWL=PSC=)LN)M)?-@'7SVCSCLYAY.
M_,,]4IJ^NWFUR>%H.S YR&F/)*)%-)'9*TP',#9#W_^][ %TCF4,-+K8;.?
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M!6(0R%OH?G=&72=^^!&]?O*_FF^M#X!I10<@=4'K:5RU;EJU6_&>2U,M2^/
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M)B!9!%4YE"7A_5$T/AW6$VI'04'HZ/9/]B:A1L]L[ G;J0+).:;B;O3Y?;Y
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M9!2=(O>N<G3%4F3C"\#5L0@<_AP47,//;% _UBN(5UN\K:JH0J6=@UII,-9
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M14[;PKLKA'A'O/<8Z8R-VAYA<ZU2:+9YBOL<1:7@;/=P9/^PX=G1R#QT?]@
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M14C"0S7L8!2@[5FVDL#VQ2-#,B$)67U6I;A?U71L&-U?PJT@D%5R9LI=,$*
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M,<6#PY6',6A\@0O,.M/8C2!=+Y+RG3 =J+NMHD8*85T.-3\4-O'_?;K9J@;
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M]J'O+6FLV./,5C2D,:N[9$:<[6 P$&;63LK,SIL4L<;]J?;]#5YL?[IN?^H
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M+4@=$UCSD$V\X\Y0R29[W6B <CH?+OXXQOZ#I^@_[&%5#>5VB%LK-V/&[D9
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M1T-M5DS][+7ERT(*&]:6>ET=Y >%$.X0R3#1 RPJ-HJZ)%$.HR&(D).> E#
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M!31.B9A0E":1$--2DVZ)*\!_FB.EM]>+;6'B=21\ GYFSNE D*X"EFI/&.4
M<MY>YX0ZC_HQ3188:P]"F:?)BW&8:G=:RA(*UF99P2XJII&?LVQ.Z0WV'VGA
M"DQ^MHDOI=[(&(]ATHMG0'BYI)889@M+-5RC !*S7"$@5T>&JPR4RLK0F+GI
MCVM0$/:%_H""9F5O%MPDQAN3 1]1&<_"; 3-;J9$$1\)B*WX5N%"8#><(D3N
MW8RS$[TAQ1AE33GUDX86+VLQ=&\I4/S3Y#-G-16,L+%AHM5BH<XFOUVEY)A
MS+7&53&0AM$Z=M.E%#X[EL*Q8*$^/]YG^FI2#7)]R>=E&RX0FB!ZR+>X$#DR
M;T5*&E:;'[0KE>/_Q*U'ES>F\!?>8)+=FA):WJ2X'M-RUU^G<>:8Z'?KK5!E
MIXY;MM1S(8/U+9ID(N,^";PG9A7-?B(DF7SCI)$@&::FTEZT$T.AO32*4W%
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MV3<?DF.C';E&#H=2Y7 3?SGBKR3RQ)B*5>RP)[E+65BR\38N'LX0UCEKFAT
MUTRZUTJ%(7_OHJQ6%GV3./:(L2].1W++,%.0Q<2$GQLD,2GP+H.1RW+;A1;>
M-LHY+R<EN8-BNHU#T]0:(JG-'Q"+Z^1494#6Q3QNB65>2AI::OVH\'XB/$54
M%$< -K@C!'Y1>&NC4;^*&-U3EHH(4/FN+R7]1,0&PM!#>TX*A8+SB^LW1XS
MTXNS#U-G3L(82#;YLY"*_$(BB$6,GH=UO.NJ_#KZ4B/3[W<\._,*KI'*5;,*
MO +UNX;@$;2IS%E9@2DS0&F[+^L%V,MC]2\OW].]?/]RY#S!D>.5/Q:9=@^L
MJG[T!#RJ?+S7I5YX)6^4*7D3F7XS,8=]12P, U5D]LF!HRCH&D,RY7%8KN0*
M>;1#O3^Y_F#J[1Q@<M_I $ZZZ_];3;WII_[TXY->=-(?Z%'W-)J<=NN'C:A!
MQ('N1>->+SH=3NC?DY-!='K2?0X"I$48;$]\R]Z!:BZ\;6!WTEZ!NPH,7@&K
M8/\'V!? '9CY=_.!C2(^*3C<DVXT[ UJ)CM\S\*0_R&V?>E-(CDSF HP8! -
M1I.J'],#S#>L#EN).5@*&E'+1HW]8@Y*ZK8*(-*4O"Z5Q_Z+9"MP[2T6MD_U
M86Y[PFSNT=3.E6EQMZ-)-!@.@<;TX;#ZI]%@,L$_>OX???^/@?WC&BV1\2VP
M;3T>3.#$L76,@[[]8G>?>G2U&S[W-@S@I6C3C%EFV=W@KU[P5S_X:^#^\G<8
MN2U: *EU6DMMOW_3Y^R#;2*+/@25N"^W3'@L?Q&B9[FCD&(]A3]ET[=7RKNV
MU+6=T;"C%9I+&3B$*87D[0=E6(AI.W2\JSF4:T=DWC0YZDB\*.!X:LOQ I;F
MZ0HC:GZE=N"M79>L8$!=EWI]/>J<N/KWMN-3/^IY'::ZP.(Z8_CGR0G<:-?N
MY]SV88>C>)/EMPFE2U3+ZE=^*2^RQ!"<($.K!+;;&2"5&2._':GSL$-=Z>-Q
M_<=F#=?U_FB^5<5^L%JW>]K2Y<SZX/EHK-Z-]XHOLD]: NXJE:ULP-"Q"6;R
M>Z(Y;LDX2DS2^%IM!3L#E8<7*Q:0CO1(C]Q[GKMU?-J93/1W^/_CL?Y.40NU
MJD-;][&CU7>ZUQEAC?[7)KSR+^1/Q"?POQ=@D6$D@,'%G<*>"=T^Z:@:P:X1
MU=0N5%-E5#/@7D6LA>E;,]8#ARQC/>Z,7"LV^Z"/6-1M;\,V#.'VU!L&@%I+
M/[)1IPX'#WNF!5NWOU\+-B(&'B$H(U:I89M[>P [.6EE[\&EH@N)8E]+Y1(H
M;N?K(4B%=+D<2^?WLZRNH4Y1JW:44R5*?1E4DA7_/+6.\XZ0FL)U!WHBI!3/
M3/[-CT9PK0/[<.S^4@)( TN&QYU31Y3Y\43W[+<C[3]"V)%' YASY#U"GFX?
MC<R_^5%/CT;FD?VWDI9_/?M5-Y@+6;]]- P''-EE "FQRV ]R9%X1Z]?F)CL
M#0K*!X52.YR6BZ]T$=P!"6,$,'N?</CF+WMID0<IHZAT;9%WV_VH=''1R#QT
M?]BK<U]V=3 GR6WVX; T[,@M:(#W%P47..K9.>V_RA3!=,?]W^_(BKA?W\(]
M)+9=;3GMS52NR(I-5;M @U!6WQKR:5*7M;?XO2YKI*X>T%B0<4:#@:'C(O@,
MH_[),#KMGMBVF_L(61YO</5KRBRB22@KH4M5SO(-2D+IRJM]#D;_JP_K/T ?
MUA>_MW^B9JU[*:?<<MM+8ZWMOT;.1>]WSQV\UPWH-E/1/WVSMAH'3TWSMFI+
MLW+'RDWF_V2,1/+_>]W#O]K&_4.VC7N;_FV;SLF>]!J]MHM"OT>"A%Z)(WW<
MVKD)#^62W/RV,Y(58^#3<B^J)A'G)] 2.[HK]6$_7;W6AP='G'O0("R9.)<+
M]BG^'UW_-@MA9T$_GO^C#Y[LU9.#P>.HG\AZXKS25%4/SEGHP3'I5)3\^:$A
M9_0GW\'2>( U1FAOS7*B3W*?&%AH\I_L;6,O?]AD6J\IVY!N$HGPJ\Q&/HG]
M3T'WO_8<^DT'@6)>];=^M^:W7LUO_9K?!C7V63$7[V<8WGWW]!T#U?MTE3!8
ME5\2H"M)1FC> NA%4MGPP?D7+,B0&I&XY8,6L:5BS!7*;^,NRF,-A'H/C9VY
M/\36(=4VF&[KYSA[_=YEM/V.) AI:3D8D5$;CTTTD<KS-GVZ)!GN.J4##4KT
MSFL(!XV:%@ZB9.6G_O#)H[_DQ@'8*NGY'C@^?Y21@->I 2_@^W7@9=[K=>V+
MH]H7Q_+B6-[["MQHO*"AS#$Q:QFWK;GAZQ= VI;S'.PXS];;>];,C5ZA5K3F
M *Y*8D\;1C<Y?YZ](*&D]4MI'L4SLK40PZOT2RLI; 34P7Y YDWU!IAZ^UR[
ML,P?+-OF]8,-=RS</._Q\]WKOD8?=_U<XPK:[V8_UY^S]H4_X12N,%&A_4S;
MMSE\.ON\;!(<6J42EL4.]/<-LC3H71UK/FJ0_Z,2W6Y\[<J5X*CBG7VKT4B-
MU 3M)TW$JPFR3NS%]6L/469N@2?S1A.(R//&*QCO>9WMYU@5=W8R@UU'5Y41
M*TMB>+GV Y8M\ S:@:<=\H8M$K$QPY=(;FW$<JTH*]\W< 3S6"R1S8\;1*&6
MY3U%OMXA+;9N<+<85[^UO46N9V@)9-S\JEV$8S5*4N.]B.B>*VW9:R,7;UQ9
M:'8UJE]%A6PR2U$>=&B3JC"08:?;+4<Q_,3FJAJCH!V^R8I5H:9UP[=:N,HO
M'PY.<8S*KFO/IMT84&,0KCO+BGVXQ1A1&YOW4Y-IN/Q>C66X_$J#0=B]]GU1
M;'[ZOU!+ P04    "  2:.%.A\%?4$H"  "$"P  #0   'AL+W-T>6QE<RYX
M;6S55FUKVS 0_BM"':.%4=M)F]+5-FR%PF KA>;#OA7%/ML"O7BRG#G]]9,L
MOR0>Z]:L&\V7Z.XYW7./7IQ36.D-@_L"0*.&,U%%N-"Z?.]Y55( )]6I+$&8
M2"85)]JX*O>J4@%)*YO$F3?S_87'"14X#D7-;[BN4")KH2-\-D#(Y5_+%"+\
M</SV6RWUU1ODQJ-W1T?^P\G5%#]N R<8.8Y/:82#Q1GV_ISTU/=_36R#$_+S
MYY(_S3ZE7SR3_BGR"?6%I?:Z_8_#3(KQ&.;8 :8VX8#6A$7XFC"Z4M1F9813
MMG'PS *)9%(A;<[?: LL4CVZ<. \>S4Z'DZ%5&UM5\']KKKIDT#O68&4L4'@
M##L@#DNB-2AQ8YQV<@O^%$*=O=R41F&NR":8G>,QH1U,D954*:BA3(![* X9
M9%:.HGEA1RU+SP:UEMP8*26Y%*35T&=TAJ%-@+%[^]U\S7:XFPRY.?9(?(RL
MBMXTJ^[,\=3\5O(VF^/>IMV/%Y5T+?7'VBQ'M+Z].W"G(*--ZS?9(,"PD[)D
MFP^,YH*#6\QO"P9[%HQ#TM=!A53TT?#9JY(8 !1&:U":)MO(=T7*)32ZOTY-
MMJ_FV0%J?NE]SD& (FQ;M+G[KWF7_[-BVV'^6G/[MS)5_((BYQ>O7Z/MI@<@
M<G$((@_@N.>7_UBCU[7&K?Z[TWT'%*UJRC05G=J"IBDX/?;Y$^%;^_)B.SUP
M;,*&7I.5>1+O\)O<%#)2,WUGE]@&(SS:GZWP8#',6@X4$1[M+Y#2FE^V!<=W
M=_P#4$L#!!0    ( !)HX4XB :AM4 ,  !L5   /    >&PO=V]R:V)O;VLN
M>&ULQ9A-<]HP$$#_BL:7TDO!AM D$S)#P0E,*3 Q38\=80O08$M$$OGZ]5V9
MD,BMN].+TI.Q)*3GM59/\L6#5-NEE%OR6.1"]X*-,;OS9E.G&U90_4GNF(":
ME50%-7"KUDV]4XQF>L.8*?)FU&IUFP7E(KB\./8U5TWW1AJ6&BX%%-J"6\X>
M]%N]O244&MRS!5WV@E9 Z-[(*YX;IH;4L&LE]SLNUKT@#,B**VT2.W;9LN""
M%_R99>6=WLB'D53\60I#\R15,L_+?]F*\D\P@GXMN67*\+32T-#E#0767M!M
M08?W7/,ES[EYZ@7E[YP%\!1-YS'*.!ROAR">JW\)HURM>,J&,MT73)A#'!7+
M[>A";_A.!T30@O6"8Q-"149B88"&C,6A*VAKGP6&'F>'YS(0L3=8HLXY5*AQ
M%EIP?Y!?^I/^=!"39!3'BX0TO@NZS[AAV4>'+T+XHO_%1QISJAS(-@+9]@N9
M+/J+^%L\!<#9%9G-XYO^8CR;'FD=R X"V7DG2,LX&/6GUW%"QE.2+&:#KZ.9
M WF"0)Z\)V0_&9&KR>Q'4A/)+@+9]3PG:;I=P^(&:5V?SY\1ML]^V2;\;L\A
M09X<G%,$Y]3S^^1KP:$MA66PGZ80,P-&('.9\Y0S[4">(9!G?B''8!VQMF.2
MOM9@!7=I;F%K<\LOV!!Z@$DV!1&[2*@N//OBQA:RC,#:"SI;*"HT+3<)E:!A
MP@@]&V,@BX(;VTB7YAW(<LXQ\=N$"S%AA+Z-862ZW<@\8TI_(#'D;"5C0\P3
MH6=1C$4J"T86]+$:+TP+H6\O[)>:W>WM;BJ^MZ_6!<-4$'IV ;K _8Q<3,P*
MH6<MX)AM%Q.S1>A9%W^LQ*0!._^<:7<W&F*J"#V[HBYQZR CS!N19V^X&5P+
MAQDD\FR0UQT*:0R9H3S79$J5HO8@68%$3QV>)8+G2\?%Q#02>=9(3;Z\Q+02
M2<PFD7>;_ V11!5(3"^1;[W49G5=*#'71+Y=@U$2US41YIK(LVM>P-R]X1ME
MNQ)-S#61[Z,)&LU*BF/"B;P?3MRUO&9*MC'3M-_5-+6)W<9DTRYETSQ^C,O8
MB@N63:%O#>4IS=.Y(O9R.%9T3JS\5_L\'T#93$PD+3^?V3Z.WR4O?P%02P,$
M%     @ $FCA3I "W&=R 0  LA,  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<\78S6J#0!2&X5L)7D#&<R:_)6;53;9M;V P$Y7XQ\R4)G=?ZZ8&
MDCE=A*\;191S7A >Q-V;K4VHNM:75>]GEZ9N?9:4(?0O2OF\M(WQ\ZZW[7#G
MU+G&A.'2%:HW^=D45G&:KI2;SDCVN^G,V>&8)>YPI&3V85QA0Y:H2ZV^.G?V
MI;7!J_%$\V'!\,BUMW]9WYU.56Y?N_RSL6VX4_&[(%'W@S@>Q/ @'0_2\*!%
M/&@!#UK&@Y;PH%4\: 4/6L>#UO"@33QH P_:QH.V\"!*!1E3?)*$-5YK$K@F
MO-<D@$UXL4D@F_!FDX VX=4F@6W"NTT"W(27FP2Z"6\W"7@37F\6]&:\WBSH
MS?_PK2U];./U9D%OQNO-@MZ,UYL%O1FO-PMZ,UYO%O1FO-XLZ,UXO5G0F_%Z
M:T%OC==;"WIKO-YZHK<OC;/']^"JMO#/+KD9_K!F K</U]H^/V.<^G#_1.DP
M;+%J/#[]M8Q3?R+4S2^Z_3=02P,$%     @ $FCA3JZN;4B, 0  710  !,
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M2+Z,6>SKL_:OXO0'4$L! A0#%     @ $FCA3A\CSP/     $P(   L
M         ( !     %]R96QS+RYR96QS4$L! A0#%     @ $FCA3B?HAPZ"
M    L0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"
M% ,4    "  2:.%."]\6F>\    K @  $0              @ &9 0  9&]C
M4')O<',O8V]R92YX;6Q02P$"% ,4    "  2:.%.F5R<(Q &  "<)P  $P
M            @ &W @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M !)HX4XBW0;'+0(  $X'   8              "  ?@(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    "  2:.%.]T%0+14$   X$P  &
M            @ %;"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ $FCA3I)3"+YN @  0PD  !@              ( !I@\  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !)HX4XV?"@)200  ' 3
M   8              "  4H2  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    "  2:.%.&-6X IP+  #I30  &               @ ')%@
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ $FCA3M5#6Z$K
M!0  V!D  !@              ( !FR(  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( !)HX4ZL.NP;S $  &T$   8              "
M ?PG  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  2:.%.
M^30_2LH!  !M!   &               @ '^*0  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ $FCA3MWS#=O- 0  ;00  !@
M     ( !_BL  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M !)HX4[^3VIDR@$  &T$   9              "  0$N  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ $FCA3A^U </, 0  ;00  !D
M             ( ! C   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    "  2:.%.U='?1,T!  !M!   &0              @ $%,@  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( !)HX4Z]?YOGRP$
M &T$   9              "  0DT  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ $FCA3J,T?\S- 0  ;00  !D              ( !
M"S8  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  2:.%.
M+B'MQ[@!  #4 P  &0              @ $/.   >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( !)HX4Y%X$E RP$  &T$   9
M      "  ?XY  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ $FCA3DMI1.9W @  'PD  !D              ( ! #P  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  2:.%.@7AK8<H!  !M!
M&0              @ &N/@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( !)HX4[)/^7>X@$  /8$   9              "  :]   !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ $FCA3N-'BB3^
M 0  Y 4  !D              ( !R$(  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    "  2:.%.@[J-J<4!   Y!   &0
M@ ']1   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !)H
MX4X 'B(LI@$  (@#   9              "  ?E&  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ $FCA3M 4JR<W @  P 8  !D
M         ( !UD@  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    "  2:.%.!UWW> L"  ##!0  &0              @ %$2P  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( !)HX4XV\\KB0 (  *T'
M   9              "  89-  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ $FCA3@\L,?2F!0  62,  !D              ( !_4\
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  2:.%.PM\J
MJ[,%  !W(P  &0              @ ':50  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( !)HX4X/8IB,MP0  $<<   9
M  "  <1;  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M$FCA3M@PS),H!   3!0  !D              ( !LF   'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    "  2:.%.;PE?DPX"  #\!0  &0
M            @ $190  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( !)HX4ZH>CF$& (   D&   9              "  59G  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ $FCA3AFSK+.D:0
MX;4! !0              ( !I6D  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!
M A0#%     @ $FCA3H?!7U!* @  A L   T              ( !>],  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  2:.%.(@&H;5 #   ;%0  #P
M        @ 'PU0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ $FCA3I "
MW&=R 0  LA,  !H              ( !;=D  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ $FCA3JZN;4B, 0  710  !,
M     ( !%]L  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "@ * #*"@
&U-P

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>137</ContextCount>
  <ElementCount>242</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>20</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - STATEMENTS OF OPERATION (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StatementsOfOperation</Role>
      <ShortName>STATEMENTS OF OPERATION (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StatementOfChangesInStockholdersEquity</Role>
      <ShortName>STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - STATEMENT OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StatementOfCashFlows</Role>
      <ShortName>STATEMENT OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Background Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/BackgroundInformation</Role>
      <ShortName>Background Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Demand Note</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/DemandNote</Role>
      <ShortName>Demand Note</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IntangibleAssets</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/StockholdersEquity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IncomeTaxes</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Liquidity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/LiquidityDetailsNarrative</Role>
      <ShortName>Liquidity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/Liquidity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IntangibleAssetsTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Intangible Assets (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IntangibleAssetsDetails2</Role>
      <ShortName>Intangible Assets (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IntangibleAssetsTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/StockholdersEquityTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Stockholders' Equity (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StockholdersEquityDetails2</Role>
      <ShortName>Stockholders' Equity (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/StockholdersEquityTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Equity Transactions (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactionsDetails3</Role>
      <ShortName>Equity Transactions (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Stockholders' Equity (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StockholdersEquityDetails4</Role>
      <ShortName>Stockholders' Equity (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/StockholdersEquityTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IncomeTaxesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bivi-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IncomeTaxesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bivi-20190331.xml</File>
    <File>bivi-20190331.xsd</File>
    <File>bivi-20190331_cal.xml</File>
    <File>bivi-20190331_def.xml</File>
    <File>bivi-20190331_lab.xml</File>
    <File>bivi-20190331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001520138-19-000217-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001520138-19-000217-xbrl.zip
M4$L#!!0    ( !)HX4ZJU$S:^;X  $/("  1    8FEV:2TR,#$Y,#,S,2YX
M;6SLO6MSVTBR(/I](_8_X'K=NW8$)1-\TYZ9#?G5HSEN6]=R]^S>+R<@LBCA
M- AP %"RYM???%05"B!( B1(@A+GQ)FQ"* J*S,K7Y65^9?__7/J6?<BC-S
M_^L+^[SYPA+^*!B[_NU?7_Q^?79Q_>'R\H7UO__VW_^;!?_YR_]S=F9]=H4W
M?FM]#$9GE_XD>&=]=:;BK?6K\$7HQ$'XSOK#\>;X2_#9]41H?0BF,T_$ A[P
M3&^MSGFK.[;.S@J,^X?PQT'X^_=+/>Y=',_>OGGS\/!P[@?WSD,0_AF=CX)B
MPUT'\W D]%@W[KW[2^MCJVD/F^VV??YS O!_=&)XA+_!HV8?_\O^87??=IIO
MF_;_5W">V(GGD9ZG^;,I_\.?_^7G3>BY;_&_+:"!'[W]&;E_?6$L[:%]'H2W
M;UK-IOWF__SVY7IT)Z;.F>M'L>./Q OUE>?Z?^9]9P^'PS?T5+VZ\"9.KN9H
MO\''-TZ4C(P KGA_ 1)X.H[U!^;+W3?\,/6JF_MJCU]UU:MCD7DO$J/SV^#^
M#3R ]^W!6=,^:]OJ]5!,EH+<>P-/U8MN%'1:=G_5^O@-]<$\.KMUG)G^8.)$
M-_2R?) ###P) T]$N=_0DYR/_,#WY]-\N,9Q^"9^G(DW\-(9O"5"=Z2_6_]1
M^@.  7_.AXZ>Y$ W"N9^'#[FDT0^Q,_ZZ<]<_UY$<?Y7_ P_:J<_BL)X$3;X
M,0<LW,7Z7=_Q \>/W1LWB-T12H;I&[6_7ZB=B]S^-J(]]5U,+-HH;^^(?7"P
MLT0@1.,7\C$BY:\O(A>EV0OKC1J*=_(H\&/Q,[;<\5]?7$3?)HR$WEF[J>;4
MKPH +G[4O^K?W3$^F;@@,@DRD2*HPM>'R_]X\3>0(W9WT+0[P[^\R7Z<3/<F
M=SXYVPR8(1CG0$'[.OY;L@ ]A7R2'3\UDOI1XF,MD@;'CJ3!'I T/&NVSQ+N
M/3XDR07L!DF?PV#*W(IB)PZ.EJL *6&,QL??DN6HD9)G"Y^!@:0^RC"C>E(I
MGGL&GH]3Q*7PW-L$S_T]X'E@X/DX!4 *SX--\)R1&SO!<T9N'#N>-Y4;N\-S
MHNF/$+=I3;\[)2:1U#M*@6H@J;<'<TA*W_^4KM=_7L?!Z,]OL]@-_-_$]$:$
M!T-?LB7%[508Z]:/Q@#,SYGGCMR88;7&+KS) 1BYH+<? 3OW3NS>BTO 7SC'
MH;Z[T9\7/]WHQ=_46PO+_LN;W!E,Z-[D@W=,KL*)[/4A^SZ<G]Z)['4C^SZ$
MO-KMHWD4!U.3ZM]\\1P(CW&HMWG+?N+[?3GA?SP$SY'P>MG/E_!WH7B6>]Y8
M^+,E_N=@'CY'VB?K?KZD!U0]2]+K=3];TE^[/Y\CY?6RGR_AQ;UX%H[= NF3
MA3]QXLNH_LFCKX]'O],#V@S93QY]C3SZPQ+^Y-$_5\*?//KG2_R31_]\27_R
MZ)\KZ4\>_7,E_,FC?[[$_^3>WL7/D?C&PI\M\;^ZS].Q3];]5$F_/.?^%-4[
M<%3O:&\1G#BG3IQS3/<BEG..W1HT^_UFMW-BH?VS4&VO?*P2/A^"Z11,=T3D
MTQ ^>!-=X/>?_C4'N/$V?N##GU&:=1;6?9(^95GG8CQV<>LYWI7CCB_]#\[,
MC1WO6;'12AR<6*HL2WT7L0/.Q/B3$_JN?QL]*U[*7_R)B<IZ8B>55@>55EM7
M;!7KG%1:G57:4;+42:752Z4=!1/!/X8F$UV%8B+"4(R?GU;+6_KQ,9 DZ(X9
MR&XF#&2WS$C1B8'JQ$!$I[(,1 3==:C1SI0&.3%0#1E(TJFT"MMYH'%H,% V
M5GUBH/HPT' 3!MIW<:*L#71RZ^O .D=I_9Q8IQZL<X1VSXEUZL Z1VGQG%BG
M#JQS3+;.D=7!.UK#X+CQ7%,MFB,*CQG/M94;.=;*,>.YMJI]E2]Z.B=\<N>$
MA_913RQ5;Y:JJ=9=Y;N>6*K.+%5;Q;?*ISVQ5)U9JK8VZRI;ZI0@\P029 YM
M/9V8J&Y,=(3VTHF)ZL5$M;60!H8D&AQ_2'&PR68=[&>SFGFUIY3(FN:3;'3S
M<; 'DR%GHYX8J)8,=(02Z'2^6P_6.4+9<V*=>K#.$4J=4P2NSA&XHY1&)Y:J
M-TL=H90ZA5)J%THY/KET8J*Z,5%-)=&J$\L3$]6+B6I[1IFCSHX[J%LWB;^D
MP>W)%SZ0+WS@-N8GNA^>[H?H8WZB^^'IOH^V9]G]?CIO.>AYRX%W_8GZ=:'^
MGO;^Z;"^EM3/).KMB/JGD_:Z4C\5C-F5Y#\5?JDE]0=[Z(YR2M.J,?5W+OE/
M.5;UI?[N)?^IY%==J;^/OEBG>EWUB_,<PMH_T;T.=-^_G7^B^^'I?@@+_T3W
M6M!][[;]B>YUH/O^K?H3W0]/]WW8\]D\C5.6<,VRA/><OY'EAU-BW<$3ZPZ<
MP7.2"/65"/LXXS]U[ZNS1#A$EL=)(M17(NPC[^/4_*S.$F&/F3]'ECE_F)#Y
M,2-I]W&'4\W=X]$MASAG.O%#G?EA_^=/)WZH+S\<XESJQ ^UYH>]GU>=^*'.
M_+#_<ZP3/]27'PZ1KW:*5=0I5G$(C^+$ ?7B@/W[$"<.J!,'',)K.'% S3A@
M[W["B0/JQ0'[]PQ.'% G#MB'+W"<]9X.(RB/&4D[E"6I*F(M544,_MW6<N5Z
M?A.)?\UQ"][#?_$6^L_1/(J#Z7]>C&!7.M&O83"?_3V K09[[\N7#Q?^^%M\
M)\*K>3BZ<R(1/A%AE$;%C\>92(NA7%RMET)E8/@N/)"(XRLGC!]_A(X?.2.,
MA43O'\TG#-:->^^^+4>B?8O,G.IO+3U#T>IOR*_)]#ON!);-%OFG$P(9XB?"
MX<74;6K-!V69C?I^95)*=L(RO73SN!/+U(9E>ANVBMLYRYBU/+/6_8EE#J^8
M:EC^-4\Q2=.,[OQ\FZ%Q\,T73X-Q/@*N[IW8O1>78 :'<QSJNQO]:9@[><L^
M::C->>?'0_ <>4<O^\0[6_#.72B>I>0Q%G[BG\WYYW,P?R*1@W+LDZS[Q#U;
M< ]@^UERCU[WB7LVYYYK]^=S9!Z][!/O;,$[XE[XSY)[DH6?^*=HB.?DK]?*
M7Z]MK*<8[YS\]1/O;,P[)W_]Q#];\,_)7S]QSQ;<<_+73]RS,?><_/43[VS,
M.R=__<0_6_#/)_?V[HFD9I3C'V/A)_[9G'^^NL\SX).L^\0]JPJ328Z1^5!/
M)CJX)@V,N"6[YGTSRH%*T:4I_F1B>B4H?K" 7CTH_G0B<65H?K@PW(%+3I[2
M>Y\VO4\W .I#[WV4&,Z6G3_1^W#TWD>1^=-UC?K0>Z=7K]?G 9V\M%/RSZ9,
M<W+T3DQ3GFE.ON*S9YRY[S+7_'[]<8$)IL*)YJ'XFQL%G9;=?POOJ,'4H_04
M.-J2\:_OG%!$2Z>02*"7-IX#X+M:,L\8.&"<@UO\]NM\*D(G#G(J*Y3 01;&
MO%&-23\*/YBZ_KIIU^,E.V_>P.IY"@L%$'H%TZPAV0S^69Q@NA)G%(DX^C /
M0]A!EN3,[V*2]7M?6/@U/4 &M<9BY$X=+_KKB^:+OW7M#NR$W"%+SS<H,%\'
MI%EE$TIC<^6$=K/9Z]F=4E-NBLQ6N]=I-8?9N8I/4@2#L(&ZG:&]^21%L-8:
MPDKZK;63C$;!'#3$E?/HW'AB2U[L])O#?MN8,W?TS6$H@MW! "C8WQT,A5BV
M/VQV.V5A^.(Z-Z[GQJ[85B;TVFDZ+(Z\V=Q%\&^WVH-VOU/]Y)L@?OW<2ZHA
M&XT_-R5"NS-HVVV3"]9.50UPA:3XH-_L]+O[!ZX(%8?M[K _:&X#'/UX%WAC
M$49L#6]*1MON]MNV(5 6A]YL\D*;"?XS'%8_=R$-TA]T6_:@S.3&=KOPQ]71
M8$$MKYNH"L V4N7[ &PC]5\6L*M03 1(3'Z5_8F+>7P7A.Z_Q;@8(:478D!V
M^?4S&73TGP2XU9-M#]HB*6L#VB(Q]PC:MWF,T5TL:K<51=< 94Q3 52%B;E7
MJ K3<7.H#'57Z7YL-Q=8:\546T)5F'I[A:HP]0;50E75!AS:PU9W-51E&*NJ
M'3@<=)OME &S2[ *$[%M]SK==L_TD,K ]57$E_XHF(HO093VSY<'G5<JZ[-6
MI]VQ31LS-47I^7.*)ZZ>WVZWFSW36MAN_IRTW37S@\?8'-A5S9_!?Y'YNX.F
MZ7"LF_^#$]U=A0'&$<?O'W^/!#@EWV88Z01^N1C%[CU96I4P1Z\%7F0:-P6G
MKQ;PTES5 [/=[AX>\ W8L3<<#'J'A[PT(W?L5K.W2U[Y[/J./ZJ<R7L]T!+#
MM7#GS%XMW&5YO-OLU +NLBS>Z@^[_6;S\("7Y?!.&\R<]0Q> &Y#X__A>'.Q
M:6P"3:]<.X)&W636(AL&+:MJ9RW"-F0X%9\V[=^4Q?+/R'WKN]Y?7\3A7+RP
MWFPX^A)L5C3Z$JR5&_W*";^%='@_IHFN1$A&:&%D72WS-<]3FZ78K-7!FHOZ
MFL*:2\@]PLHS74;1?$MO?DU\@6?8#I:J(C!5P%)5W"4?E@6WL ("%?#5MP:F
M2@]]:V J]<OSH0%G+11.)#X*_M]+/W/D6H61VK';+?,\;^VDE4!9UB0% ZG7
MWSN4I7VL]J#5:K;W#699<[/5[[8&VT")QNF%/\;_P7.6>\?#?+PKRDS+#E8)
MCS9[7>/(KLST58->/@H%?K?=JP?P9?D91/K S%$Z).REF;PU-%/(M@6]FD0V
M'*GHZ!NDK949OA#]^W8O2_\2X*^G43H^66;X7K&DG7ZWOWK\C])H^N'\Y%PR
MM&X=3,NX\+S@ ?SMC7WH3K\S[!J.98&I*H*N4$99NV6;T< JH-,1. PP?W#"
M\'$2A ]..-XX=;'3Z37[]@HHET]9,;1%<-KM@IG2J01:PT3<J2-M>GP%YJP(
MS-(^]&' +.T^;PGFI^G,"QZ%D%W[JDN=M#.^V=J)*H&LR)9I=SMVK[\%9(O&
MZ_(AJK!%P:Y( 5QF_JIA+VN,MOI#\SSTD* 7,$77A1LKIOSZ--Q!OVMNHFK1
M=Q6*F>../_V<"7]CKZD\RM9/6Y;)>L/!2AY+SYB%,-NT&3S1^71.Z 1MBA>Y
M-I6!9ZTV'K,80:'U<U4#7:$#\4Z_-[1;O?U#5RBPT>LU>ZD+".6AN_1CQ[]U
M;SS!MM!7$7_Z.?+FF(SR:Q",'US/VSB5MFD#<5-2>?UD50%8*.6Y/V@/!\W#
M %CHCD'/MH>=+3&X+1G;G6[?-DRH3>8I9'14,$^AD\6"\T@,!_YH.S.OU>X.
MFSTC4I8=>).)BV6,MX:]Q<M?VTU<B&V'W7XJ-KANXH]S\2,PNF)O;UNWTZ;U
M\@FV V5#C5]ND@TM,67WO!<^R/Z8<O'1OWD/"G^,%[9!TU,HH0H#?#!L=P:=
M18]A[>250EW6*AJVFMW6H8$N&__M80;EH8$N:Z8/;#MU!K,QU!?3 /;+O^G9
MMTE6'U;D2[;[YJW.E3-N#U]I?W'/\)7E3[L/E&[O#[[2'N-6\'T7D7#"$1Y;
M?!3WP@MF5 5C*P<QK;GZS4&W;=KT*R;<&KJRS-?I]=KFK=?=0E>6]?KM5KN_
M-]QM<,)KV[T-H?OBW 0AO"FMABH9SK:[+>-$)'^FS>$I+=^ _<T\QV+P7(7!
M1$01W=S]+*J)*H+[:ML= Y3L))L 43[OM]WN#8O#<"T\#[U!4*RAXP'>+L93
MUW>C.*1JWQ4R#K@7K;YA9!>;N3IXR\? [%;K<."6/N=O]^S! =%;6J]VFK;=
M[&P+L#Z-D\^KL>G:_9;=,V3OPBP;@5&6 ^UNMYTZNZ\&C-(6VJ#3[ XJQT;Y
MT'UGT#)-G>)@5'TI;BE[++^:51"6\JE)2WED:U@VN)VTC%&VAF6#BW/+N&4Y
M+&#,BU!$59KGG>:PEXX8FS-L $ !!EE_@+1VEO*W=EI5+K(LM8>#UJ#T_,P'
MW^([$59"Z44 C!DV!**TQM@)%*451K/=VP4<I35&*2#HQRJM"-C[75,8FN.7
MGKRT8FAA\F2KJNE+ZX(N:,A.5;-O( _Z!>=69Y\JG>>]$[DC=+%=;QYG;@T4
MY8-EV45GS?-44'/UU!5 NI9I5D%J[Q/2M?Q5&TC7\N(J2%L;0_I/@2W9Q/CB
M'LR86_%UCI5POTWH4Z,BQ-;LN^PV3K??'33[1F!A,X!VMZS5O+ZL:,JP/;3;
M)EGJMJS5&V/I=:4V)I6;+DK=UK5Z&RWEPJ;=:34K7U;^6=(%UJ.^I;+5[Q^3
M5ZZ<1_SI E-^N=V=69*%(5AQ#JU;21C]\F21[[7K[V0K_%0.^$$PDVV:M %F
MNG;W*6(FVVYF \RTGS;/+#;=3!IT%)"3SPPW21^*]3OJN:'&Z+:P%CFM9X:<
MS\$\+,PX3U(2K\"->U^8;YZ;O-%=[$];:E5O^F<JC+/-U3:P;OJM)REMEK<4
M+V'=])\TTVQEW-CMYX:;,M;-$S6+EV.GC'GS['!3PKQYVFKJ9-Z404TI\^:9
M*?%/&+0\"9Q\Y'QUBYLXQ[RK,J'K3S]%.'(C<16Z*\N5%+*65QQ#G=N[P=>J
MY=0(BV5BS2L+1=BMYXS&,H'IU?4V>L\9C64\X-7<> 2;.EHS[Z_8_C6Z]+F@
M5V%4KNBGN[6H[); :G7+JQEF<T[6M\9LJW/";.[A_G+,VJU!L]]O=CN%16L]
M<'P5!B,AQA&N&6ND8A6R;Y-ES?@VO97429>[7SMI)5"6O@[7'QX R@K*]%1!
MP_45]#O=3/'J@MBA]N',IW^(:-.LO84[( .[!_)_8?!2LVYRQ=S>P:1:K!CH
MRQ/8RUEAZYF7M,K,AV*_2,D6PMD!9E:9)[NER:J9-Z=)-=MC%6S;$44K/L0J
ME^;^. ]A'%9@K#3Y]\]!>"W">U!=1=.^"U%NB5[N]#N#5 FR<A#N=GWPCZ&Y
MOG0]^J5+W <1[&8"I-TR+:7:  G<86<47OV '!I 9FW.V@"YBB<WV'/VPL'$
MP??<<G;>>'WU6=ZJC;#!\EK-=KW6MVH/;4*^SC[8DZK6;JKQ5M^4[[1239]*
M 5 Y]&6O*G6&17"_)^ +^$P;2M^MR%_<5,WXN]V:(K8B*Q@XOWT<:]RI-;T9
MB"6-S7T!N+&AN1\ MS R]P/@%@;FX7FPG'RSZZ/U-K4H\Q95ES5M:D;FU19N
MUV51F]J.N15TZK*HG"VU.EQ?S* _W-Y95Q*X/L#G\-/QF+LY.WSU/NZT.O6!
M?I4BV=RF;+>&-?*F5NF5+=;8Z0R.0LUL$2#OM.QAORYK7*5U-E]C9S#HU8A3
ME^_&VG@_RS=334!<M1DJ G'+]*1T)L*O8?&J;MM<-+*KOFB4LXP#86K3_)Z5
M^<I/$E-;Y^LL"W!7G>-= &5&8Z/MFU9T^]VA;91@RQU\8P@*=11H[1*"#=-F
MJ/*4*CU&Y4?NW;'PQUR%;,/0>_63EB\IWQJ:!?=6S[@]?&4C^MBOM;D_\"J(
MV2_K<E:J/6"S-S#;MZSH7+9FND+I4<U>IY6JN[WQ=,6Z! R;9B'Y%;.9:6-&
MTY3'C^(FWM&6*SMEZ0V7;D^S:KHL:%^#6*@6X.D6,M5+_2)S505?H5:N!X1O
M\T3+B1M75ZFX8[=35<R3\<O-7+XN,;:=Z5<P<_DJQ/W!H%/%FC>H.=Q--\.N
M$-O;)PMN/W6I0,'NP"CFANZ('7>2Q[G]U'LDS?:GS#N24;L^6UXW^VX/CM=*
MR9V>"J^>?=='OIO3?>=;<HM3U]U1?,=3;W6$63FM5TN77J\UZ-A5")=R9X1G
MW6:K-ZA JI4]WSL;= ;-*E9<]FSNK#=L=<W^O;N0XWO5<Q6=?.UNG^\1C,H.
MD'8GZS<Q/G8H'K:"JRKIL?UQSF[V^,# UZ"8.&UV[0I<JT':>MVSD9BS[/T:
MB4O7OG-K9?G"=V\H+5WU7N7X<@SL5YTLQ<8F J'3'@[ZE5@;R]&SF0"M1EZL
MTGN;P%6A=9:EX[:$HAN;'X68"GWH44T0LCD<JINBZ>%+SKQ%[ZN",Y0.-G8&
MO>ZPBK55<(CT'4NNS3>^TK/-\!5T)5LU? 45#$H@I\)+-WS>_U4\T*-*8[U+
MKQ?WTI4PBD%6W7HJOBYM]UO#WL[60WE199>SIHA%(?2G)ZX,VFT+DAP<VHTO
MFA7,M-SO(K;(K.P/NZV"=Q;VNZ;=YRGN1+SDI12T#H7?W5Q&!-&3ZGM7GS55
MF#AJ5J<K4IAP Y4#9G*OF:I$M##S1J!5H-V']C"3"U(-:!4H:KRTT+93RF0G
M6*NJ1L4F:-GGW+LJQ5)L[MU46"F(\YW4)"DX]\%P7C(<6.G<NZH#LPF?;R)Z
M.MUAISG<@<#>NC++L#/LV^U>MA)C%0)[VZHCPWZ[W>FEKBA5!=JV!&W;W6:W
MW>NWJX=M:XKN#+8*"LFT[5ZG-&PXP5W@C448??K7W(T?+_V1-\=7KX*0KAW$
M<>C>S&-,@?P18-HC !\&G@>OJ$3IC;.6[6Z_;6>-UJW!V=\BB\0$;/C/PE7
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M#6;$DDM8D3,54IJ)>0S[#%X&'7$SCU'KP%LRX\K2R@_E^1@7#[Z%%0:/(!I
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M.B(DWWU6P\I1!9P7]507O5.VF[3/_QM8=2A<TZ$(F#) =3;F6 +!$;K I(_
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M<X>IHHX=S(,>6!7:="2C8#K4D\!#(J1 4\(J^)&..&FJI$RBO.V"'!2Y4["
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M,21KB65N=*O.;\DM&$(;.:C<60-+&A 6G G,NF+QR2.N4D1M1A),XS4J]MP
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MVZH31WO0:W2;[:>S4>3AT4!ME4R(F_?*I<\=RJGBJN2\(&SH$CHS4ES  ]G
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MPS P!=T_!9?"Y(Y=,=_8PZ.@ _2_"!X=V-Y++95MF?8*L>[P_1'$3A)!0&%
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M< &-I/DS)IFDN<R2HN ?SLR1PWR:8[R&__WA#G"0&](K%Y>K/JJW]^/W$M'
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M2Q7[KF0D:(_UG0;G?.&-\[13\:M/5 6RVFRO7=T[76A)5-F1<+40&Y5[EI1
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M4_VX"W%%_:B"[W-WX9\QH$%NO=\<8$954K*R HV71KE^1&BVJ77,2.?^\ Q
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M5U.EMYHFF1W!3F8Q-=#L]*N@0?Z>8*N1%$%K4%]YQ(4_EB*_O0SY6PBB9L?
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MENXQFZQ_T'C9VHS.PESYY+TF?GH3<3Z/6Z9[P!<*[UU^NC"7EOW\/D,A7HS
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MF4QB7V$\TBB3-A*I]UMUQ2ZB#%_[),KC+3:5 *8B8(@EV"O]+<=\9(U)R!(
M6;UGI> L4D^&I,SHTD(P1W/IKAWVING[A$.*V)8YM6R&8@AU=0L)JN41^O4
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MJ*1GVC\?+#O*S2FQ+3JPC_JX:\ZF[SH,$ ,412"H)N#4\%T(DCU84ROJ:)D
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MSJ-<<U;%V:PY)P%%[38#W=YPTAGTQTV==8)VAW8 CJ/7*_AD5K,X, :=!NM
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MO_K2A.F0!*$->04<T.2MG\9Y(2E2K@$UN =,Y<;/@5?>*H5?<;.\(80$_A[
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M3L,AMJ86S#N2WIVEK[!":#RR:5$:=[Q6T])O3<MAIJ77=.8=2>^J-BT_8U8
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M#7CDK3%Y15HP7G= %$.0=BJAPL:YUI"M#/$CA-%3J#*>ID"J._R545,V@W$
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M?\]HIY?KXBU_,:&$P^01Z^[A'(]_L4F>^[@O^H#_MV#NPJ[\!5!+ P04
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M(7PFPW+S%K J+#**X"T;9)HDQ-P(\I/!C6G-D>8EJ%=GD@D0;]DJ 6$<V+D
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MN)Y^+N@SO8)"&_HNANE*E%QV\ =+C%:@9()@!C,=.OGK KFS0=],KLZFG\=
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MO/:\C_-!@[=R)XPO(P#>H7F&<4,= 'X%07/W6K'(NTI/VNUU$>\0COXV,S*
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M7/6[//FVA35ODEL!OR(WW/-G&I@R$LS!]\ F0BT)B#"4/C@G=#(8@2IB<)M
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M<EE).QU72P-L+0U(92-M%\M:IN#5GR[)O\C/Q4_D_]!1COSR_P%02P,$%
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M7M[2%3G[^(*&=R1\\MRF&U7-,- 1X9UL6$+QH$:VF"C?!EKA.- AXMUL9-;
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MO0<&;<JTP?8M*/*.%2T] KSWPRBVG3+8FZ1R*>4ZG,]#,F?8ENW +"5&8;)
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M,S,Q+GAS9%!+ 0(4 Q0    ( !)HX4[=!>?V% P  -61   5
M  "  5+*  !B:79I+3(P,3DP,S,Q7V-A;"YX;6Q02P$"% ,4    "  2:.%.
M@NVF0#,3   :9P$ %0              @ &9U@  8FEV:2TR,#$Y,#,S,5]D
M968N>&UL4$L! A0#%     @ $FCA3L-5[J0N-0  $$<# !4
M ( !_^D  &)I=FDM,C Q.3 S,S%?;&%B+GAM;%!+ 0(4 Q0    ( !)HX4Z6
MMYZPDR,  *"7 @ 5              "  6 ? 0!B:79I+3(P,3DP,S,Q7W!R
;92YX;6Q02P4&      8 !@"* 0  )D,!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
